{
    "1": {
        "question": "<div class=\"qtext\"><p>A 32-year-old man presents to the hospital with fever, chills, and bloody diarrhea. He recently returned from Thailand. He has no significant past medical history and takes no prescribed or over-the-counter medications. He reports that he was vaccinated for <em>Meningococcus</em> 1 month before his trip.</p>\n<p>His BP is 168/96 mm Hg, heart rate is 102/min, and temperature is 39.2°C. The remainder of the physical examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; border-collapse: collapse; width: 74%; margin-right: calc(26%);\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 20%;\"><strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">Hemoglobin</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">8.8 g/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">14–18</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">Platelet count</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">92,000/µL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">150,000–450,000</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">Reticulocyte count</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">3.6%</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">0.5–1.5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">4.4 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">0.7–1.3</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">Haptoglobin</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">25 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">83–267</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">Lactate dehydrogenase</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">644 IU/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">80–225</td>\n</tr>\n</tbody>\n</table>\n<p>A peripheral blood smear shows numerous schistocytes.</p>\n<p><strong><b>Which ONE of the following is the BEST next step in diagnosis or management?</b></strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Stool polymerase chain reaction (PCR) forE. coliO157:H7"
            },
            {
                "label": "B.",
                "text": "Eculizumab"
            },
            {
                "label": "C.",
                "text": "Kidney biopsy"
            },
            {
                "label": "D.",
                "text": "Vitamin B12level"
            },
            {
                "label": "E.",
                "text": "Plasma exchange"
            }
        ],
        "correct_answer": "Stool polymerase chain reaction (PCR) forE. coliO157:H7",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with bloody diarrhea and evidence of hemolytic uremic syndrome (HUS), the most appropriate next step is to send a stool PCR for identification of <em>Escherichia coli </em>O157:H7.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Differentiating between Shiga toxin–producing <em>E. coli</em>–associated HUS and atypical HUS (aHUS) is important for both immediate management and prognostication purposes. The patient described in this case has findings suggesting microangiopathic hemolytic anemia (MAHA) with a low haptoglobin, increased lactate dehydrogenase, and schistocytes on peripheral blood smear. The combination of MAHA, thrombocytopenia, and AKI supports a diagnosis of thrombotic microangiopathy (TMA). The presence of bloody diarrhea is not pathognomonic and can be seen in either Shiga toxin–producing <em>E. coli</em> HUS or atypical HUS. Ruling out an <em>E. coli</em> O157:H7 infection via PCR testing of a stool sample should be the initial step in this patient, who has a clinical exposure history. If PCR testing is positive, then supportive care with fluid resuscitation and managing complications related to AKI should be provided.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Complement pathway evaluation and treatment with eculizumab can be considered if Shiga toxin–producing <em>E. coli</em> HUS has been excluded. Ideally, thrombotic thrombocytopenic purpura (TTP) would also be ruled out by confirming normal ADAMTS13 levels. Interestingly, diarrhea may be present in up to 50% of cases of complement-mediated TMA in adults. This point emphasizes the need to perform stool PCR testing as the initial evaluation. Because stool PCR results are not yet known, initiating eculizumab therapy would not be appropriate at this time, although may be beneficial if aHUS is diagnosed.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">As the cause of AKI is most likely TMA, a kidney biopsy would not be indicated as a first step, nor would biopsy help differentiate among the different causes of TMA. Additionally, performing a kidney biopsy in a patient with ongoing hemolysis and thrombocytopenia is high risk and should only be undertaken with careful consideration of risks and benefits.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Severe cobalamin (vitamin B<sub>12</sub>) deficiency can present with a condition called “pseudo-TMA,” caused by decreased platelet production and abnormally-appearing RBCs due to deficiency of B<sub>12</sub> substrate. These fragmented products can cause endothelial and organ damage. Cobalamin deficiency is diagnosed with serum assays for vitamin B<sub>12  </sub>and methylmalonic acid (MMA) and may be distinguished from true TMA by assaying reticulocyte counts, which will be elevated in true TMA and &lt;3% in B<sub>12</sub> deficiency. In addition to schistocytes, the peripheral blood smear may also demonstrate anisocytes, poikilocytes, and hypersegmented neutrophils. The diagnosis of cobalamin deficiency–mediated pseudo-TMA should only be made after TTP and Shiga toxin–producing <em>E. coli</em> HUS have been ruled out. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Plasma exchange is used to treat TTP, and works by removing the autoantibodies to ADAMTS13 while replacing the deficient protein. Although plasma exchange is frequently done empirically while awaiting ADAMTS13 levels in cases in which the most likely diagnoses are either TTP or aHUS, it is an invasive procedure that would not be indicated for suspected cases of <em>E. coli</em> HUS such as this one. </p>\n</div>",
        "references": [
            "Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea.Clin Infect Dis65(12): e45.80, 2017",
            "McKee RS, Tarr, PI, Dietzen DJ, et al. Clinical and laboratory predictors of shiga toxin-producingEscherichia coliinfection in children with bloody diarrhea.J Pediatric Infect Dis Soc7(3): e116–e22, 2018",
            "Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial ahus and their impact on clinical phenotype.Clin J Am Soc Nephrol5(10): 1844–1859, 2010",
            "Grangé S, Bekri S, Artaud-Macari E, et al. Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency.Lancet386(9997): 1011–1012, 2015"
        ]
    },
    "2": {
        "question": "<div class=\"qtext\"><p>A 63-year-old man with a history of CKD stage 3, type 2 diabetes mellitus, and congestive heart failure with preserved ejection fraction presents to the emergency department with a 3-day history of nausea, vomiting, and malaise. He receives most of his care at another health system and is unable to provide a current medication list.</p>\n<p>Physical examination reveals a BP of 121/71 mm Hg, heart rate of 92/min, respiratory rate of 26/min, and temperature of 37.3°C. His abdomen is soft and nontender, and the remainder of the examination is normal. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136–145 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.6 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Chloride</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">99 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">98–106 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">12 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28  </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Glucose</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">161 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">70–99, fasting</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.0 mg/dL (baseline)</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7­–1.3</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Lipase</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">33 IU/mL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">10–140 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Lactic acid</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.6 mmol/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7–2.1</td>\n</tr>\n</tbody>\n</table>\n<p></p>\n<p>Urinalysis reveals 3+ ketones and 2+\n    glucose but is otherwise normal.</p>\n<p></p>\n<p><strong>Which ONE of the following medications is MOST LIKELY to be the cause of this patient’s clinical presentation?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Metformin"
            },
            {
                "label": "B.",
                "text": "Canagliflozin"
            },
            {
                "label": "C.",
                "text": "Sitagliptin"
            },
            {
                "label": "D.",
                "text": "Semaglutide"
            },
            {
                "label": "E.",
                "text": "Glipizide"
            }
        ],
        "correct_answer": "Canagliflozin",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has euglycemic diabetic ketoacidosis (DKA) most likely caused by the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Euglycemic DKA (eDKA) is defined by high anion gap metabolic acidosis, ketosis, and lack of hyperglycemia (serum glucose ≤200 mg/dL). This patient meets the diagnostic criteria for eDKA with a high anion gap metabolic acidosis and ketonuria, which indicates underlying ketosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Typically, underutilization of gluconeogenesis by the liver or increased urinary excretion of glucose causes eDKA. There are many potential causes of eDKA, including pregnancy, fasting, glycogen storage diseases, liver disease, alcohol use, and pancreatitis. SGLT2 inhibitors, such as canagliflozin, have also been associated with an increased risk of eDKA. The risk of eDKA with SGLT2 inhibitor use is low but elevated compared with placebo. The pathophysiology of eDKA in patients receiving SGLT2 inhibitors is complex but may involve the use of lower insulin doses in patients receiving SGLT2 inhibitors, with insufficient suppression of lipolysis, promotion of glucagon secretion, and decreased renal clearance of ketone bodies.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Metformin is more commonly associated with lactic acidosis. The lactic acid in this case was normal, making metformin a less likely culprit.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Semaglutide and sitagliptin have not been independently associated with eDKA. Both have been associated with pancreatitis, but the serum lipase was normal in this case.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Glipizide is not independently associated with the development of eDKA.</p>\n</div>",
        "references": [
            "Barski L, Eshkoli T, Brandstaetter E, et al. Euglycemic diabetic ketoacidosis.Eur J Intern Med63: 9–14, 2019",
            "Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors.Diabetes Care38(9): 1638–1642, 2015",
            "Schwetz V, Eisner F, Schilcher G, et al. Combined metformin-associated lactic acidosis and euglycemic ketoacidosis.Wien Klin Wochenschr129(17–18): 646–649, 2017",
            "Poulose V. An unusual case of metformin associated lactic acidosis.Med J Malaysia57(2): 209–210, 2002",
            "Shetty R, Basheer FT, Poojari PG, et al. Adverse drug reactions of GLP-1 agonists: A systematic review of case reports.Diabetes Metab Syndr16(3): 102427, 2022",
            "Plosker G. Sitagliptin: A review of its use in patients with type 2 diabetes mellitus.Drugs74(2): 223–242, 2014",
            "Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis.J Clin Endocrinol Metab100(8): 2849–2852, 2015"
        ]
    },
    "3": {
        "question": "<div class=\"qtext\"><p>A 56-year-old woman with a history of gout presents to the nephrology clinic for follow-up of nephrolithiasis. She had her first kidney stone approximately 10 years ago and has had two additional stones since that time. She was recently seen in the emergency department with flank pain and hematuria and was found to have a 4-mm kidney stone that she passed spontaneously. Stone analysis revealed 100% uric acid. She was diagnosed with gout 15 years ago; she has a gout flare approximately once every 3 years. </p>\n<p>Her BP is 121/76 mm Hg, heart rate is 76/min, and body mass index (BMI) is 36 kg/m<sup>2</sup>. She appears well, and physical examination is normal. Her laboratory evaluation is below:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                143 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.9 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                102 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Total CO<sub>2</sub> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">     BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                18 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.9 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">      Uric acid\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–7.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>24-Hour Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Volume\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.4 L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                96 mEq\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Calcium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                195 mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;250\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Oxalate\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25 mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Citrate\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                283 mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                250–1000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Uric acid\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                700 mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                250–750 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  pH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.4\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5–8.0\n            </td>\n</tr>\n</tbody>\n</table><strong>\n<p>In addition to increased fluid intake, which ONE of the following is the MOST appropriate treatment for this patient’s recurrent nephrolithiasis?</p></strong></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Potassium\ncitrate"
            },
            {
                "label": "B.",
                "text": "Probenecid"
            },
            {
                "label": "C.",
                "text": "Allopurinol"
            },
            {
                "label": "D.",
                "text": "Sodium\nbicarbonate"
            },
            {
                "label": "E.",
                "text": "Dietary sodium restriction"
            }
        ],
        "correct_answer": "Potassium\ncitrate",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with recurrent uric acid stones and an acidic urine, the most appropriate treatment is to alkalinize the urine with potassium citrate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The primary driver of uric acid stone formation is a low urine pH, so urinary alkalinization should be prescribed to all patients with uric acid stones as first-line treatment, in addition to increased fluid intake. High urinary uric acid concentration may be a secondary factor in the pathogenesis of uric acid stones.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Potassium citrate is a commonly used and well-tolerated alkalinizing agent. It should be used to target a urine pH of 6–7 to ensure maximum solubility of uric acid as urate anion. Higher urine pH may predispose patients to calcium phosphate stone formation. Atlhough sodium bicarbonate may also be used as a urine alkalinizing agent, the sodium load associated with its administration may predispose patients to increased calcium excretion, which may promote the formation of calcium-containing stones. Moreover, bicarbonate salts do not replace citrate, which is a powerful anti-lithogenic agent irrespective of urine pH and which is borderline low in this patient.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Serum uric acid–lowering therapy (such as allopurinol and febuxostat) may be used in patients with gout and uric acid nephrolithiasis. These treatments are typically reserved for patients with frequent gout flares or tophaceous gout, as no strong evidence exists that these medications decrease stone formation despite decreasing uricosuria. In patients requiring uric acid–lowering therapy, febuxostat may be preferred because it reduces uricosuria more than allopurinol and may be used at lower eGFR, although it is more expensive.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Probenecid is used to treat gout and hyperuricemia. However, it works by blocking uric acid reabsorption in the proximal tubule, increasing the uric acid concentration in the urine, which may worsen uricosuria and uric acid nephrolithiasis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Besides increasing fluid intake, reducing dietary sodium intake is one of the most effective means of preventing recurrent nephrolithiasis, especially in patients with calcium-based stones. The postulated pathophysiology involves increased urinary sodium promoting increased calcium excretion. This patient’s stones are 100% uric acid, although in many cases, mixed stones containing both uric acid and calcium may occur. Moreover, the 24-hour urine sodium, assuming sodium balance, reflects sodium intake that is very close to goal at (96 mEq/day × 23.1 mg/mEq =) 2.2 g/day.</p>\n</div>",
        "references": [
            "Kenny JES, Goldfarb DS: Update on the pathophysiology and management of uric acid renal stones.Curr Rheumatol Rep12(2): 125–129, 2010",
            "Canales BK, Sharma N, Yuzhakov SV, et al: Long-term recurrence rates in uric acid stone formers with or without medical management.Urology131: 46–52, 2019",
            "Goldfarb DS, MacDonald PA, Gunawardhana L, Chefo S, McLean L: Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones.Clin J Am Soc Nephrol8(11): 1960–1967, 2013",
            "Mehta TH, Goldfarb DS: Uric acid stones and hyperuricosuria.Adv Chronic Kidney Dis19(6): 413–418, 2012",
            "Trinchieri A, Montanari E: Biochemical and dietary factors of uric acid stone formation.Urolithiasis46(2): 167–172, 2018"
        ]
    },
    "4": {
        "question": "<div class=\"qtext\"><p>A 55-year-old man presents to the nephrology clinic for evaluation of 3 weeks of sudden-onset, progressively worsening anasarca. He also reports diffuse edema and foamy urine. His past medical history is notable for CKD stage 2 attributed to hypertension and type 2 diabetes, diagnosed 3 years ago, without evidence of retinopathy or neuropathy. He does not have any rashes or joint pain. His medications include metformin and hydrochlorothiazide. He does not take NSAIDs or other over-the-counter medications.</p>\n<p>His BP is 142/74 mm Hg, and heart rate is 68/min. His physical examination is notable for periorbital edema, 3+ pitting edema of both lower extremities to the thighs bilaterally, and presacral edema.</p>\n<p>Laboratory data are as follows: </p>\n<table>\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>8 Months Ago</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Today </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range </strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<span>Serum </span>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.9 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Hemoglobin A1<sub>c </sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.4%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.6\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.0–5.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Albumin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.9 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.8 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Urine, random\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Albumin-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12 mg/g\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6456 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;30\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Protein-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.16 mg/mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.2 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.2\n            </td>\n</tr>\n</tbody>\n</table>\n<p>A urinalysis is notable for 3+ protein and 2+ blood. The urine sediment shows 1 fatty cast/HPF and 3–4 non-dysmorphic RBCs/HPF.</p>\n<p><strong><strong>Which ONE of the following is the BEST next step\n            in managemen</strong>t?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Perform kidney biopsy"
            },
            {
                "label": "B.",
                "text": "Perform cystoscopy"
            },
            {
                "label": "C.",
                "text": "Obtain echocardiogram"
            },
            {
                "label": "D.",
                "text": "Prescribe empagliflozin"
            },
            {
                "label": "E.",
                "text": "Prescribe lisinopril"
            }
        ],
        "correct_answer": "Perform kidney biopsy",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Kidney biopsy is the next best step in the management of this patient with diabetes and new-onset nephrotic range proteinuria. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">According to a retrospective study published in 2020, duration of diabetes of &lt;5 years, the absence of proliferative diabetic retinopathy, and the presence of hematuria are independent predictors of non-diabetic renal disease (NDRD). A kidney biopsy is not mandatory for confirming diabetic nephropathy (DN) but should be considered when patients present with atypical features of DN and NDRD is suspected, as a diagnosis of NDRD may present an opportunity for curative management, such as the addition of immunosuppression, or the diagnosis of another condition, such as malignancy. In this series, membranous nephropathy was the most common cause of NDRD, followed by focal segmental glomerulosclerosis, crescentic glomerulonephritis, IgA nephropathy, and chronic tubulointerstitial nephritis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although a urologic process should be considered in a patient &gt;50 years old with hematuria, a glomerular cause of hematuria is much more likely in this case, so cystoscopy would not be the next best step in management. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Anasarca is common in conditions such as congestive heart failure, but the severity of AKI with nephrotic-range proteinuria and hematuria make a primary cardiac condition less likely, so echocardiography would be unlikely to be diagnostic. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ACEIs (lisinopril) and sodium-glucose cotransporter-2 inhibitors (empagliflozin) decrease proteinuria and attenuate progression of both diabetic kidney disease and some types of NDRD. However, these agents would not act immediately, and definitive diagnosis with kidney biopsy is indicated for diagnosis, prognosis, and ultimately disease-specific management.</p>\n</div>",
        "references": [
            "Hsieh JT, Chang FP, Yang AH, et al. Timing of kidney biopsy in type 2 diabetic patients: A stepwise approach.BMC Nephrology21: 131, 2020",
            "Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease.N Engl J Med383(15): 1436–1446, 2020"
        ]
    },
    "5": {
        "question": "<div class=\"qtext\"><p>A 52-year-old woman with a 1-year history of ulcerative colitis is referred to nephrology clinic after hematuria and proteinuria were incidentally found on her urinalysis. She had a normal urinalysis 2 years ago. She otherwise feels well and reports that her ulcerative colitis has gone into remission since she was prescribed infliximab 1 year ago.</p>\n<p>Her creatinine level is 1.8 mg/dL (baseline 1.1, reference range 0.5–1.1), and fecal calprotectin, used to monitor gastrointestinal inflammation, is 14 μg/mg (reference range 10–50). A urinalysis shows 10–15 RBC/HPF, and the urine protein-to-creatinine ratio is 1.2 mg/mg (reference range &lt;0.2). </p>\n<p>A kidney biopsy shows mesangial expansion in 40% of the glomeruli with mild endocapillary proliferation. No crescents are seen. There is no significant interstitial fibrosis or tubular atrophy. IF shows 3+ IgA and 1+ C3 complement mesangial staining. Mesangial deposits are seen on EM.</p>\n<p><strong>Which ONE of the following is the next best step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe lisinopril"
            },
            {
                "label": "B.",
                "text": "Prescribe prednisone and cyclophosphamide"
            },
            {
                "label": "C.",
                "text": "Prescribe mycophenolate mofetil (MMF)"
            },
            {
                "label": "D.",
                "text": "Change infliximab to vedolizumab"
            },
            {
                "label": "E.",
                "text": "Prescribe budesonide"
            }
        ],
        "correct_answer": "Change infliximab to vedolizumab",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with presumed IgA nephropathy secondary to the tumor necrosis factor (TNF)-α inhibitor infliximab should be changed to an alternative ulcerative colitis regimen.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There have been numerous case reports demonstrating the development of IgA nephropathy in patients prescribed TNF-α inhibitor therapy for rheumatologic disorders and inflammatory bowel disease (IBD). The pathophysiology of TNF-α inhibitors causing IgA nephropathy has not yet been elicited. One theory is that anti-drug antibodies cross-react with aberrant IgA molecules and form complexes that deposit in the mesangium. In case reports examining TNF-α inhibitor-related IgA nephropathy, most patients improved with discontinuation of the agent alone.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">IBD itself is associated with secondary IgA nephropathy. Budesonide is newly approved by the US Food and Drug Administration (FDA) for primary, but not secondary, IgA nephropathy at risk of progression. It has been shown in a randomized controlled trial to reduce proteinuria and preserve kidney function at 12 months. All patients in the trial were already prescribed stable doses of renin-angiotensin-aldosterone system blockers. Budesonide may also be used to treat active IBD, but with this patient’s low calprotectin level and lack of symptoms, she is likely in remission from IBD, so escalating IBD therapy is not needed. Moreover, prescription of budesonide would not obviate the need to discontinue infliximab as the most likely cause of IgA nephropathy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient may benefit from ACEI and/or MMF therapy if proteinuria does not resolve with discontinuation of infliximab, but the offending agent should be stopped first.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cyclophosphamide with glucocorticoids is generally reserved for patients with IgA nephropathy with rapidly progressive glomerulonephritis (RPGN). RPGN can be defined as a &gt;50% decline in kidney function in 3 months or less and the presence of crescents on kidney biopsy. This patient did not have crescents on kidney biopsy, so cyclophosphamide would not be warranted. Regardless, the offending agent should be stopped before initiating other therapies. </p>\n</div>",
        "references": [
            "Strobel T, Ahmed W, De la Sancha C, et al. IgA nephropathy in the setting of anti-TNF-α therapy for inflammatory bowel disease.ACG Case Rep J7(9): e00462, 2020",
            "Bhagat Singh AK, Jeyaruban AS, Wilson GJ, et al. Adalimumab induced IgA nephropathy.BMJ Case Rep12(3): e226442, 2019",
            "Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.Nephrol Dial Transplant20(7): 1400–1406, 2005",
            "Di Lernia V. IgA nephropathy during treatment with TNF-alpha blockers: Could it be predicted? Med Hypotheses 107: 12–13, 2017",
            "Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: Early treatment is a must.Autoimmun Rev13: 723–729, 2014",
            "Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.Kidney Int103(2): 391–402, 2023",
            "Hou F F, Xie D, Wang J, Xu X et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial.JAMA Netw Open6(2): e2254054, 2023"
        ]
    },
    "6": {
        "question": "<div class=\"qtext\"><p>A 62-year-old man with a past medical history of type 2 diabetes and ESRD receiving PD presents to the outpatient PD clinic to discuss the results of his peritoneal equilibration test (PET). Over the last few months, his weight has increased by 5 kg, and he has noticed increased swelling in his legs. His current PD prescription is CCPD, with four exchanges over 9 hours using 2 L dialysate. He alternates between 1.5% and 2.5% dextrose solutions. He urinates approximately 250 mL/day.</p>\n<p>On examination, BP is 160/90 mm Hg, and he has 2+ edema of his legs. The remainder of his examination is unremarkable.</p>\n<p>His PET results show a dialysate-to-plasma creatinine ratio of 0.9.</p>\n<p><strong>Which ONE of the following changes to the patient’s PD regimen is MOST appropriate?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase to six exchanges and add a daytime dwell with 7.5% icodextrin"
            },
            {
                "label": "B.",
                "text": "Increase dialysis time to 10 hours and change to all\n2.5% dextrose dialysate"
            },
            {
                "label": "C.",
                "text": "Increase fill volume to 2.5 L and change to all 2.5%\ndextrose dialysate"
            },
            {
                "label": "D.",
                "text": "Decrease to three exchanges and change to all 2.5% dextrose\ndialysate"
            },
            {
                "label": "E.",
                "text": "Change modality to CAPD with all 2.5% dextrose dialysate"
            }
        ],
        "correct_answer": "Increase to six exchanges and add a daytime dwell with 7.5% icodextrin",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This high (rapid) transporter would benefit from an increase in the number of exchanges and the addition of a long, daytime dwell with 7.5% icodextrin. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The PET is done to determine the characteristics of an individual’s peritoneal membrane. Dialysate is infused into the patient’s peritoneum for 2–4 hours, after which the effluent is drained and assayed for concentrations of glucose, urea, and creatinine. These values are compared against the plasma concentrations of the same substances to determine the dialysate-to-plasma (D/P) ratio. Patients with a high D/P creatinine ratio of urea or creatinine (0.81–1.03) are classified as “high transporters,” meaning that substances are rapidly transported through the peritoneal membrane. This implies rapid equilibration of small solutes between the dialysate and the blood. Patients who are fast transporters also rapidly absorb glucose from the dialysate, leading to a loss of the osmotic gradient that drives ultrafiltration earlier in the dwell, and have been shown to have less ultrafiltration than patients with other peritoneal membrane transport types. These patients often struggle with fluid retention and BP control. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There are several management strategies for patients with rapid transport characteristics who present with inadequate fluid removal and volume overload. Increasing the number of exchanges will decrease the dwell time, leading to maintenance of the osmotic gradient for more time during each exchange. Additionally, adding a daytime dwell with icodextrin can improve fluid removal. Icodextrin, a high-molecular-weight glucose polymer, is absorbed much more slowly through the peritoneum, leading to sustained ultrafiltration regardless of transport status. One study found that ultrafiltration with icodextrin outperformed 4.25% dextrose in high and high-average transporters. A combined strategy, using shorter dwell times and icodextrin daytime dwells, would be the best management option for this patient. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Increasing the dialysate fill volume can be a useful strategy to increase small molecule clearance in patients who are low or average transporters but would not improve ultrafiltration in this patient. Similarly, switching to all 2.5% dialysate will help with ultrafiltration, but patients who are fast transporters will still equilibrate their osmotic gradient prior to the end of the dwell and risk fluid retention. Decreasing the number of exchanges, and a change to CAPD that leads to a lengthening of the duration of each dwell, will worsen fluid retention. Adding time to dwells would not assist in fluid removal in rapid transporters such as this patient</p>\n</div>",
        "references": [
            "Agrawal A, Nolph K. Management of high peritoneal transporters.Peritoneal Dial Int20(2): 160–165, 2000",
            "Li PKT, Chow KM. Maximizing the success of peritoneal dialysis in high transporters.Peritoneal Dial Int27: 148–152, 2006",
            "Finkelstein F, Healy H, Abu-Alfa A, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration.J Am Soc Nephrol16(4): 546–554, 2005",
            "Guest, Stephen: Peritoneal Permeability Tests. In:Handbook of Peritoneal Dialysis,2nded., 2014, pp 23-26"
        ]
    },
    "7": {
        "question": "<div class=\"qtext\"><p>A 51-year-old man with ESRD due to focal segmental glomerulosclerosis treated with HD is evaluated in the dialysis unit. His current HD prescription is 4.5 hours thrice weekly with blood flow rate of 500 mL/min and dialysate flow rate of 800 mL/min. His medications include lisinopril, carvedilol, famotidine, and sevelamer with meals. He receives calcitriol and epoetin alfa with each HD treatment. He feels well and is adherent to his HD treatments and medications.</p>\n<p>On examination, his BP is 142/84 mm Hg, and heart rate is 68/min. His lungs are clear to auscultation, and he has a well-functioning arteriovenous fistula.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                68 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.1 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alkaline phosphatase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                169 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30–120\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                PTH, intact\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                698 pg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                130–585 (dialysis patients)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Kt/V, single-pool\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.23\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &gt;1.2\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>In addition to counseling on a low phosphorus diet, which ONE of the following is the BEST next step in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Change calcitriol to doxercalciferol"
            },
            {
                "label": "B.",
                "text": "Prescribe cinacalcet"
            },
            {
                "label": "C.",
                "text": "Change sevelamer to sucroferric oxyhydroxide"
            },
            {
                "label": "D.",
                "text": "Prescribe tenapanor"
            },
            {
                "label": "E.",
                "text": "Reduce calcitriol dose"
            }
        ],
        "correct_answer": "Prescribe cinacalcet",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with hyperphosphatemia and secondary hyperparathyroidism should be prescribed cinacalcet. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The KDOQI goal for phosphorus in patients with ESRD is 3.5–5.5 mg/dL, due to associations of phosphorus levels &gt;6.5 mg/dL with higher mortality. However, guidelines note that in studies of patients with ESRD, treatment of hyperphosphatemia with dietary modification or phosphate binders has failed to show a reduction in morbidity or mortality. KDIGO recommends lowering phosphorus levels to closer to the normal range. Initial therapy for hyperphosphatemia consists of dietary phosphate restriction and oral phosphate binder therapy. This patient also has secondary hyperparathyroidism, and the elevated alkaline phosphatase suggests that his hyperphosphatemia is in part due to PTH-stimulated phosphorus release from bone. Intact PTH levels &gt;600 pg/mL are significantly associated with hyperphosphatemia, and treatment of hyperparathyroidism with a calcimimetic such as cinacalcet is expected to lower the secretion of PTH without increasing intestinal phosphorus absorption.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sucroferric oxyhydroxide is an intestinal phosphate binder with comparable efficacy to sevelamer. Although pill burden with this drug may be decreased, the patient already reports excellent medication adherence, and control of phosphorus would not be expected to be improved by switching to this binder.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Tenapanor, a drug approved for the treatment of irritable bowel syndrome and constipation, is an inhibitor of gastrointestinal sodium/hydrogen exchanger-3 (NHE3) that reduces paracellular phosphate absorption in the intestine. Randomized controlled trials of the drug in patients with CKD and ESRD demonstrated a dose-dependent reduction in serum phosphorus in patients randomized to tenapanor compared with placebo. One study evaluating the addition of tenapanor or placebo to oral phosphate binders showed a reduction in serum phosphorus of 0.86 mg/dL in patients receiving combination therapy compared to 0.19 mg/dL in patients receiving phosphate binders alone. Notably, trials have not compared tenapanor with phosphate binders directly. Additionally, although tenapanor has been shown to reduce phosphorus levels in patients receiving dialysis, it would not affect PTH-mediated phosphorus release from bone. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Calcitriol and vitamin D analogs are used for the treatment of secondary hyperparathyroidism. Although active vitamin D therapy has been shown to be effective to reduce PTH, these agents increase gastrointestinal absorption of calcium and phosphorus, which may lead to hypercalcemia and hyperphosphatemia. KDIGO guidelines recommend reduction or discontinuation of vitamin D therapy in the setting of hypercalcemia or hyperphosphatemia. Switching therapy from calcitriol to doxercalciferol would be inappropriate given the patient’s hyperphosphatemia. Although lowering calcitriol dosage would be indicated to avoid stimulating gastrointestinal phosphorus absorption, this change could worsen secondary hyperparathyroidism and the associated phosphorus release from bone. </p>\n</div>",
        "references": [
            "Streja E, Lau WL, Goldstein L, et al. Hyperphosphatemia is a combined function of high PTH and high dietary protein intake in dialysis patients.Kidney Int Suppl3(5): 462–468, 2013",
            "Block GA, Rosenbaum DP, Yan A, Chertow GM. Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: A randomized phase 3 trial.J Am Soc Nephrol30: 641–652, 2019",
            "Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disease Disorder (CKD-MBD) Guideline Update: What’s changed and why it matters.Kidney Int92: 26–36, 2017"
        ]
    },
    "8": {
        "question": "<div class=\"qtext\"><p>A 72-year-old man is evaluated in the ICU for AKI. Yesterday, a CT scan with iodinated contrast showed acute pancreatitis without necrosis, and he was treated with lactated Ringer’s solution and hydromorphone IV. An indwelling urinary catheter was placed overnight, with 75 mL urine recorded over the last 8 hours.</p>\n<p>On examination, he is afebrile with a BP of 86/57 mm Hg and a heart rate of 126/min while receiving norepinephrine and vasopressin IV. His oxygen saturation is 94% while receiving 80% inspired oxygen. His jugular venous pressure is elevated, lungs demonstrate bilateral crackles, and cardiac examination shows a hyperdynamic left ventricle. The abdomen is soft but distended and tender over the epigastrium with markedly diminished bowel sounds. Hands are warm with a capillary refill of &lt;1 second, and there is symmetric peripheral edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Admission</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Current</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.4 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.6\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                57\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.4\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Lactic acid\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7 mmol/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–2.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Arterial blood gas</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     pH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.38\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.38–7.44\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     pCO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24 mm Hg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38–42\n            </td>\n</tr>\n</tbody>\n</table>\n<p>A transduced bladder pressure is normal. A chest x-ray shows bilateral diffuse infiltrates.</p>\n<p>Furosemide 1 mg/kg (120 mg) IV is administered over 40 minutes with a subsequent urine output of 110 mL over 2 hours.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Furosemide infusion"
            },
            {
                "label": "B.",
                "text": "Isotonic sodium bicarbonate bolus"
            },
            {
                "label": "C.",
                "text": "Acetazolamide"
            },
            {
                "label": "D.",
                "text": "Sodium zirconium cyclosilicate"
            },
            {
                "label": "E.",
                "text": "Continuous venovenous hemofiltration (CVVH)"
            }
        ],
        "correct_answer": "Continuous venovenous hemofiltration (CVVH)",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with AKI who has shown a poor urinary response to the furosemide stress test (FST) should be initiated on renal replacement therapy (RRT), such as CVVH.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has AKI stage 2 likely due to ischemic acute tubular necrosis (ATN) in the setting of pancreatitis and shock. The FST entails administration of furosemide (1 mg/kg IV in furosemide-naïve patients and 1.5 mg/kg IV in patients who have been exposed to furosemide within the previous 7 days) to euvolemic patients with AKI stage 1 or 2. Urine output of &lt;200 mL over the subsequent 2 hours indicates FST non-responsiveness and has been found to predict progression to AKI stage 3, the need for RRT, and higher mortality. In this case, the combination of the low probability of reversal of AKI suggested by the FST, the evolving hyperkalemia, and the progressive hypoxemia with volume overload refractory to diuretic therapy are indications to initiate RRT.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A continuous IV infusion of furosemide would most likely be ineffective in a patient who did not respond to a high-dose furosemide IV bolus. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although the BICAR-ICU trial showed improved survival and reduced need for RRT when sodium bicarbonate IV was used to treat severe metabolic acidosis in patients with severe AKI, this patient’s pH is &gt;7.2, and he is volume-overloaded, hypoxemic, and unresponsive to high-dose furosemide. He would probably not tolerate sodium bicarbonate IV, nor would such therapy be likely to obviate the need for RRT.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The addition of acetazolamide to loop diuretic therapy in patients with acute decompensated heart failure was found to augment decongestion in a multicenter, randomized controlled trial. However, acetazolamide would be unlikely to correct the numerous metabolic abnormalities and volume overload in this patient with lactic acidosis, severe AKI, diuretic unresponsiveness, and hypotension.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sodium zirconium cyclosilicate can acutely lower serum potassium levels over the course of several hours but may be ineffective in patients with reduced bowel motility or ileus, which is suggested in this case. Additionally, this therapy would not assist with management of metabolic acidosis and volume overload.</p>\n</div>",
        "references": [
            "Chawla LS, Davison DL, Brasha-Mitchell E, et al. Development and standardization of a furosemide stress test to predict the severity of acute kidney injury.Crit Care17(5): R207, 2013",
            "Lumlertgul N, Peerapornratana S, Trakarnvanich, et al. Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST Trial).Crit Care22(1): 101, 2018",
            "Koyner JL, Davison DL, Brasha-Mitchell E, et al. Furosemide stress test and biomarkers for the prediction of AKI severity.J Am Soc Nephrol. 26(8): 2023–2031, 2015",
            "Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for patients with severe metabolic acidemia in the intensive care unit (BICAR-ICU): A multicentre, open-label randomised controlled, phase 3 trial.”Lancet392(10141): 31–40, 2018",
            "Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload.New Engl J Med387(13): 1185–1195, 2022"
        ]
    },
    "9": {
        "question": "<div class=\"qtext\"><p>A 72-year-old man is evaluated in the nephrology clinic for a rising creatinine level. His past medical history includes CKD stage 3, diabetes mellitus, coronary artery disease, hyperlipidemia, hypertension, and peripheral arterial disease. He has a 50-pack-year smoking history and currently smokes one pack per day.</p>\n<p>Two weeks ago, he underwent a femoral-approach cardiac catheterization with placement of a drug-eluting coronary artery stent for unstable angina. His current medications include carvedilol, atorvastatin, lisinopril, low-dose aspirin, clopidogrel, and chlorthalidone. His discharge BP was 130/70 mm Hg.</p>\n<p>His BP is currently 176/91 mm Hg. The remainder of his physical examination is normal except for a new skin rash (see photo below). </p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b1q8.png\" width=\"50%\"/>\n<figcaption><em>Image courtesy of Lawrence B. Stack, MD, Thomas F. Frist Jr. College of Medicine, Belmont University</em></figcaption>\n</figure>\n<p>Laboratory results are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width:25%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width:25%;\">\n<strong>Current</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width:25%;\">\n<strong>2 Weeks Ago</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width:25%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11.2\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelet count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                220,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                187,000\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Eosinophils\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0–6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                97 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                36\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.7\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                C3 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                89 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100–233 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                C4 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                27 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–48 \n            </td>\n</tr>\n</tbody>\n</table>\n<p>A urinalysis and kidney ultrasound are normal.</p>\n<p><strong>Which ONE of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Contrast-associated AKI"
            },
            {
                "label": "B.",
                "text": "Acute interstitial nephritis"
            },
            {
                "label": "C.",
                "text": "Atheroembolic renal disease"
            },
            {
                "label": "D.",
                "text": "Cryoglobulinemic vasculitis"
            },
            {
                "label": "E.",
                "text": "Thrombotic microangiopathy"
            }
        ],
        "correct_answer": "Atheroembolic renal disease",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient most likely has atheroembolic AKI secondary to atheroembolic renal disease (AERD).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">AERD is part of a multisystem disorder caused by the occlusion of small arteries by cholesterol crystal emboli released from eroded atherosclerotic plaques. Damage may also be induced by the inflammatory response to these crystals. AERD can occur spontaneously (23.5%) or after angiographic/surgical procedures (76.5%). The recognized risk factors include male sex, age &gt;60 years, peripheral arterial disease, smoking, and underlying CKD. Anticoagulation and thrombolysis may also play a role in this disorder by destabilizing eroded atherosclerotic plaques. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most common triggering event for AERD is cardiac catheterization through the femoral artery. A common clinical triad consists of the following sequence: (1) a recognized precipitating event, (2) acute/subacute kidney injury, and (3) signs of peripheral emboli. Examination clues include “blue toe syndrome” (shown in the above image), livedo reticularis, and Hollenhorst plaques of the central retinal artery. Urine sediment is often bland. Peripheral eosinophilia and hypocomplementemia may be present. Mesenteric involvement is common and may present as pancreatitis, intestinal ischemia, or gastrointestinal bleed. Neurologic manifestations include transient ischemic attack and retinal ischemia. Fever, myalgia, and anorexia may also occur. Biopsy of a skin lesion or kidney may show pathognomonic biconvex, needle-shaped clefts within the occluded vessel, which represent cholesterol crystals dissolved during specimen processing. Treatment is supportive, including BP control and use of statins, which may reduce risk of death and dialysis dependence by 50%. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Contrast-associated AKI is unlikely to cause severe AKI that persists 2 weeks after exposure to iodinated contrast and would not cause blue toe syndrome.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute interstitial nephritis (AIN) is most often caused by drug exposure and can also be associated with fever, rash, and peripheral eosinophilia. Although bland urine does not definitively exclude AIN, urinalysis often shows numerous WBCs and WBC casts. Blue toe syndrome is not characteristic of the rash associated with AIN.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cryoglobulinemia can cause AKI with hypocomplementemia and cutaneous manifestations (including livedo reticularis, Raynaud phenomenon, and acrocyanosis). However, urinalysis usually shows proteinuria and hematuria. The most common cutaneous manifestation is erythematous macules and purpuric papules of the lower extremities (“palpable purpura”). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Thrombotic microangiopathy has been described within 2 weeks of initiating clopidogrel after percutaneous coronary intervention and may cause AKI, but it would be an unlikely diagnosis without evidence of microangiopathic hemolytic anemia and thrombocytopenia.</p>\n</div>",
        "references": [
            "Thadhani RI, Camargo CA Jr, Xavier RJ, et al. Atheroembolic renal failure after invasive procedures. Natural history based on 52 histologically proven cases.Medicine(Baltimore)74: 350–358, 1995",
            "Scolari F, Tardanico R, Zani R, et al. Cholesterol crystal embolism: A recognizable cause of renal disease.Am J Kidney Dis36(6): 1089–1109, 2000",
            "Scolari F, Ravani P, Gaggi R, et al. The challenge of diagnosing atheroembolic renal disease: Clinical features and prognostic factors.Circulation116: 298–304, 2007",
            "Bennet CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel.N Eng J Med342(24): 1773–1777, 2000"
        ]
    },
    "10": {
        "question": "<div class=\"qtext\"><p>A 54-year-old man with ESRD due to IgA nephropathy is seen 5 days after having been admitted to the hospital with 1 week of low back pain and fevers and was diagnosed with methicillin-resistant <em>Staphylococcus aureus</em> bacteremia. Since admission, he has received vancomycin IV. An evaluation for the source of the bacteremia has been unrevealing, and he reports ongoing back pain and fevers.</p>\n<p>The primary team is concerned for osteomyelitis and has ordered an MRI of the lumbar spine with IV gadobutrol, a non-ionic, macrocylic, gadolinium-based contrast agent. </p>\n<p>Relevant laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                13,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000‒11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Serum\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                137 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136‒145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.9 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5‒5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                21 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23‒28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                65 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7‒1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0‒4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Lactate\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.9 mmol/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7‒2.1\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which one of the following is the next BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Proceed with MRI"
            },
            {
                "label": "B.",
                "text": "Change contrast to gadodiamide"
            },
            {
                "label": "C.",
                "text": "Change MRI to CT scan with iodinated contrast"
            },
            {
                "label": "D.",
                "text": "Proceed with MRI followed by three consecutive daily HD sessions"
            },
            {
                "label": "E.",
                "text": "Administer isotonic IV fluids for at least 8 hours before MRI followed\nby HD immediately thereafter"
            }
        ],
        "correct_answer": "Proceed with MRI",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in management is to proceed with contrast MRI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has bacteremia without a clear source, for which an MRI with gadolinium is scheduled to evaluate for osteomyelitis of the lumbar spine. Gadolinium is a rare earth element that normally binds to chelators in patients with normal kidney function and is then excreted relatively unaltered by the kidneys. However, in the setting of significantly impaired kidney function, gadolinium eventually dissociates from these chelators and can then bind to anions such as phosphate. These insoluble precipitates may then deposit in various tissues, such as the skin and subcutaneous tissues, leading to a disease known as nephrogenic systemic fibrosis (NSF). NSF may cause rapidly progressive joint stiffness, painful skin tightening reminiscent of scleroderma, sclerosis of the pericardium and peritoneum, and increased mortality.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although HD has historically been used to remove at least some gadolinium and thereby reduce the risk of NSF, recent data have suggested that the risk of NSF is extremely low in patients receiving group II macrocyclic gadolinium-based contrast agents, such as gadobutrol. As such, the American College of Radiology and National Kidney Foundation recommend that in patients who are already receiving dialysis, elective MRI tests be performed, ideally before regularly scheduled dialysis, although such timing is not mandatory. Daily HD should not be initiated in patients receiving group II agents but may be considered in patients receiving group I, linear, gadolinium-based contrast agents, including gadodiamide, which confer a higher risk of NSF, or group III agents, for which there are limited data available. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There are no data to support the prophylactic use of IV fluids before an MRI with gadolinium.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although a CT scan with iodinated contrast could be considered as an alternative imaging modality, the sensitivity and specificity of contrast-enhanced MRI to diagnose osteomyelitis is greater than that of CT. Because the risk of NSF is so low and the importance of diagnosing life-threatening osteomyelitis is so high, MRI would be the more appropriate diagnostic test.</p>\n</div>",
        "references": [
            "Weinreb JC, Rodby RA, Yee J, et al. Use of intravenous gadolinium-based contrast media in patients with chronic kidney disease: Consensus statements from the American College of Radiology and the National Kidney Foundation.Kidney Med3(1): 142–150, 2020",
            "American College of Radiology Manual on Contrast Media. ACR Committee on Drugs and Contrast Media.https://www.acr.org/-/media/acr/files/clinical-resources/contrast_media.pdf.  Accessed January 28, 2023"
        ]
    },
    "11": {
        "question": "<div class=\"qtext\"><p>A 64-year-old woman with hypertension, chronic obstructive pulmonary disease, and CKD stage 4 due to type 2 diabetes is seen in the emergency department for 3 days of worsening left calf pain and swelling. She has chronic exertional dyspnea and an occasionally productive cough that are at baseline. The remainder of the review of systems is unrevealing. She has no history of major bleeding complications. She works as a farmer and lives about an hour from the nearest laboratory.</p>\n<p>Her medications include losartan, amlodipine, hydrochlorothiazide, sodium bicarbonate, fluticasone-salmeterol, and insulin glargine. She has plans to pursue arteriovenous fistula creation if her CKD progresses.</p>\n<p>On examination, she is afebrile, with BP of 146/90 mm Hg and heart rate of 104/min. Her weight is 74 kg. She has expiratory wheezing and 2+ left lower extremity edema with only trace right lower extremity edema and no surrounding erythema.</p>\n<p>Laboratory data in the emergency department are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000‒11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.5 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelet count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                200,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Serum\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136‒145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.9 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5‒5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">     Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23‒28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                45 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.5 mg/dL (baseline)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7‒1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                123 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99, fasting\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0‒4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                International normalized ratio (INR)</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.9\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.8–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Activated partial thromboplastin time\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                33 s\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25–35\n            </td>\n</tr>\n</tbody>\n</table>\n<p>EKG shows sinus tachycardia without any ST changes. Chest x-ray is notable for hyperinflation without opacities. Doppler ultrasound reveals a partially occlusive acute thrombus in the left distal popliteal vein.</p>\n<p><strong>Which ONE of the following is the BEST management plan for this patient?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Heparin IV and warfarin"
            },
            {
                "label": "B.",
                "text": "Dabigatran"
            },
            {
                "label": "C.",
                "text": "Apixaban"
            },
            {
                "label": "D.",
                "text": "Fondaparinux"
            },
            {
                "label": "E.",
                "text": "Compression stockings"
            }
        ],
        "correct_answer": "Apixaban",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in the management of this patient with CKD stage 4 and an acute deep vein thrombosis is to prescribe apixaban and discharge the patient from the emergency department with close outpatient follow-up.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">While warfarin or dose-adjusted low-molecular-weight heparin has typically been used for anticoagulation in patients with advanced CKD (eGFR &lt;30 mL/min/1.73 m<sup>2</sup>), recent systematic reviews of patients with significant CKD or ESRD have found similar efficacy and safety with direct oral anticoagulants (DOACs) and warfarin in patients with acute venous thromboembolism (VTE) and nonvalvular atrial fibrillation. As such, the FDA has extended the use of apixaban to patients with nonvalvular atrial fibrillation and VTE who are receiving dialysis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this patient could be prescribed warfarin with unfractionated heparin bridging, this approach would require hospitalization for a patient who could otherwise be safely managed as an outpatient. Long-term warfarin anticoagulation would also require frequent blood monitoring, which may be difficult in a patient who does not have laboratory services within close proximity. Regular INR measurement may also cause damage to peripheral veins in a patient considering arteriovenous fistula creation in the future.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Of the DOACs, dabigatran is the most dependent on renal clearance and would thus be a less preferred option compared with apixaban in this patient with advanced CKD. Likewise, elimination of fondaparinux is prolonged in patients with decreased kidney function and is thus best avoided in patients with eGFR &lt;30 mL/min/1.73 m<sup>2</sup>.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Anticoagulation is indicated for this patient with a deep vein thrombosis without major contraindications, so compression stockings alone would be inappropriate.</p>\n</div>",
        "references": [
            "Chen HY, Ou SH, Huang CW, et al. Efficacy and safety of direct oral anticoagulants vs wafarin in patients with chronic kidney disease and dialysis patients: A systematic review and meta-analysis.Clin Drug Investig41(4): 341–351, 2021",
            "Cheung CYS, Parikh J, Farrell A, et al. Direct oral anticoagulant use in chronic kidney disease and dialysis patients with venous thromboembolism: A systematic review of thrombosis and bleeding outcomes.Ann Pharmacother.55(6): 711–722, 2021",
            "Fatima H, Nwankwo I, Anam M, et al. Safety and efficacy of apixaban vs warfarin in patients with stage 4 and 5 chronic kidney disease: A systematic review.Cureus14(10): e30230, 2022",
            "Bristol-Myers Squibb Company. ELIQUIS (apixaban) package insert. Reference ID: 3961165.https://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed January 30, 2023"
        ]
    },
    "12": {
        "question": "<div class=\"qtext\"><p>A 42-year-old man with ESRD develops sudden-onset abdominal pain, nausea, chest pain, and dyspnea during his outpatient HD treatment. </p>\n<p>On physical examination, his BP is 100/50 mm Hg, and heart rate is 110/min. He appears to be in distress. A port wine color is noted in the venous blood circuit. </p>\n<p>Laboratory data after the event are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range </strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.2 g/dL (8.7, 1 month ago)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelets \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                160,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<span>Serum</span>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                138 mEq\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.5 mEq/L (4.3, 1 month ago)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.2 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Direct bilirubin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.1–0.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Indirect bilirubin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.2–0.7\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Lactate dehydrogenase \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                450 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                80–225\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Haptoglobin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                42 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                83–267\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong style=\"font-size: 0.9375rem; font-style: normal;\">Which ONE of the following is the MOST likely cause of this patient’s clinical presentation and laboratory findings?</strong><br/></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Chloramine contamination"
            },
            {
                "label": "B.",
                "text": "Aluminum toxicity"
            },
            {
                "label": "C.",
                "text": "Air entry into the dialysis circuit"
            },
            {
                "label": "D.",
                "text": "Type A dialyzer reaction"
            },
            {
                "label": "E.",
                "text": "Type B dialyzer reaction"
            }
        ],
        "correct_answer": "Chloramine contamination",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of this patient’s hypotension and hemolysis is chloramine contamination.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Chloramine is a disinfectant added to city water systems. Chloramine is normally removed by carbon tanks in HD water treatment systems. However, in cases of carbon tank malfunction or exhaustion (excess load of chloramine beyond the capacity of the carbon tanks), chloramine contamination can occur with entry into the blood of patients receiving HD. Chloramine contamination most commonly presents as hemolysis and methemoglobinemia. Clinical symptoms of severe acute hemolysis can include chest pain, abdominal pain, nausea, and vomiting. Laboratory manifestations of hemolytic anemia include elevated lactate dehydrogenase, decreased haptoglobin, and elevated indirect bilirubin. Peripheral smears may show the presence of Heinz bodies. If acute hemolysis is suspected during HD, dialysis should be stopped, both blood lines should be clamped, and blood should not be returned to the patient because of the risk of precipitating life-threatening hyperkalemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Aluminum toxicity can cause osteomalacia and encephalopathy. The accumulation of aluminum in bone marrow can cause microcytic anemia that is resistant to iron supplementation but does not cause hemolytic anemia. Rates of aluminum toxicity have decreased significantly because of the elimination of aluminum from dialysate water by reverse osmosis, deionization systems, and ion exchange resins, as well as decreased use of aluminum-based phosphate binders.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Air entry into the dialysis circuit can cause venous air embolism, which can present with chest pain, dyspnea, hypotension, and tachycardia in the case of pulmonary embolism or stroke symptoms in the case of cerebrovascular embolism. Hemolysis is not a feature of venous air embolism. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Type A dialyzer reactions are IgE-mediated and typically occur within 5–20 minutes of HD initiation. Type A reactions present clinically with pruritis, urticaria, bronchospasm, and in severe cases, anaphylaxis. Type B reactions are complement-mediated and occur later, usually 15–30 minutes after dialysis initiation. Type B reactions may present with chest and back pain but are less severe than type A reactions. Neither type A nor type B reactions are associated with hemolysis. </p>\n</div>",
        "references": [
            "Chuang PH, Tsai KF, Wang IK, et al. Blood aluminum levels in patients with hemodialysis and peritoneal dialysis.Int J Environ Res Public Health19(7): 3885, 2022",
            "Pérez-García R, Rodríguez-Benítez P. Chloramine, a sneaky contaminant of dialysate.Nephrol Dialysis Transplant14(11): 2579–2582, 1999",
            "Saha M, Allon M. Diagnosis, treatment, and prevention of hemodialysis emergencies.Clin J Am Soc Nephrol12(2): 357, 2017",
            "Sam R, Haghighat L, Kjellstrand CM, et al. Hemolysis during hemodialysis.Handbook of Dialysis Therapy. 2008: 457"
        ]
    },
    "13": {
        "question": "<div class=\"qtext\"><p>A 71-year-old man with ESRD attributed to diabetes and hypertension and treated with HD for 8 years undergoes abdominal US to evaluate abdominal pain. He describes the abdominal pain as dull, aching, and poorly localized toward the left side. He is anuric. His vital signs are normal, and an abdominal examination is unremarkable.</p>\n<p>On abdominal US, the right and the left kidneys both measure 11.1 cm and contain numerous cysts, the largest of which measures 3.8 cm and contains internal septations &gt;1 mm in width. A representative image of the left kidney is shown below.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b1q12.png\" width=\"50%\"/>\n<figcaption><em>Image courtesy of Clay Block, MD, MS, FASN, Dartmouth Hitchcock Medical Center</em></figcaption>\n</figure>\n<p><strong>Which ONE of the following is the next best step in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Genetic testing"
            },
            {
                "label": "B.",
                "text": "Contrast-enhanced MRI"
            },
            {
                "label": "C.",
                "text": "Left nephrectomy"
            },
            {
                "label": "D.",
                "text": "Repeat ultrasound in\n6 months"
            },
            {
                "label": "E.",
                "text": "No additional management"
            }
        ],
        "correct_answer": "Contrast-enhanced MRI",
        "abim_content_category": "Tubular, Interstitial and Cystic Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in managing this patient with abdominal pain and a kidney cyst larger than 3 cm with internal septations is to obtain cross-sectional imaging by CT or MRI.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acquired cystic kidney disease (ACKD) is defined as the presence of multiple, bilateral kidney cysts in the setting of advanced CKD. The cysts can range in size and character from simple and small (&lt;0.5 cm) to large and complex (&gt;3 cm with internal hemorrhage, septae, nodules, calcifications, or solid components). ACKD is frequently observed in patients with ESRD but can occur earlier during kidney function decline; the prevalence is reported to reach 80% after 10 years of dialysis. Most patients are asymptomatic, and ACKD is found incidentally or via screening. Occasionally, patients may present with hematuria, flank pain, or infection. The differential diagnosis includes ADPKD, autosomal dominant tubulointerstitial kidney disease (ADTKD), von Hippel-Lindau syndrome (VHL), and tuberous sclerosis complex (TSC).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most serious complication of ACKD is renal cell carcinoma (RCC), which occurs in up to 7% of the patients with ACKD. Larger cysts (&gt;3 cm) and those with complex features should be further categorized by either CT or MRI with contrast to delineate benign versus malignant features. Although there has been concern regarding the development of nephrogenic systemic fibrosis (NSF) after exposure to gadolinium-based MRI contrast, newer gadolinium contrast agents have generated so few reports of NSF that the American College of Radiology and the National Kidney Foundation have issued consensus statements advising that the risk of delaying the study is likely greater than the risk of contrast administration.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ACKD can be distinguished from ADPKD by the absence of nephromegaly or cysts in other organs, such as the liver or pancreas. ACKD can be distinguished from ADTKD, VHL, or TSC by the absence of family history and other clinical features of these syndromes. Genetic testing could be useful in those cases that are not clinically determinable but would not obviate the need for additional imaging.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Nephrectomy would be premature because the identified cyst has not been characterized adequately. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Repeat US at 6 months or no additional testing or management are not the best strategies to evaluate this cyst with concerning features. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The role of screening for ACKD in patients with CKD or ESRD is controversial. Many transplant programs screen candidates every 5 years and continue to screen those with ACKD even after transplantation, as these individuals have an even higher risk of progression to RCC.</p>\n</div>",
        "references": [
            "Rahbari-Oskoui F, O'Neill WC. Diagnosis and management of acquired cystic kidney disease and renal tumors in ESRD patients.Semin Dial30(4): 373–379, 2017",
            "Narasimhan N, Golper TA, Wolfson M, et al. Clinical characteristics and diagnostic considerations in acquired renal cystic disease.Kidney Int30(5): 748–752, 1986",
            "Weinreb JC, Rodby RA, Yee J, et al. Use of intravenous gadolinium-based contrast media in patients with kidney disease: Consensus statements from the American College of Radiology and the National Kidney Foundation.Radiology298(1): 28–35, 2021"
        ]
    },
    "14": {
        "question": "<div class=\"qtext\"><p>A 47-year-old woman with a past medical history of type 2 diabetes, hypertension, and previous urinary tract infections presents to clinic with right-sided flank pain, anorexia, malaise, fatigue, and unintentional weight loss. Her diabetes and hypertension have been well controlled, and she has no history of cardiac disease.</p><p>On examination, BP is 121/82 mm Hg, heart rate is 82/min, respiratory rate is 14/min, and temperature is 38°C. She is mildly pale and appears chronically ill. Her heart, lungs, and extremities are normal. A tender mass is present on the right side of her abdomen and flank. </p>\n<p>Laboratory results are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.2 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelet count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                265,000/μL\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Erythrocyte sedimentation rate\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                35 mm/h</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                21 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.2 mg/dL (baseline)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Uric acid\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–7.0 \n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis: specific gravity, 1.020; pH 8; leukocyte esterase positive; glucose 2+. Microscopy shows WBCs too numerous to count. Urine culture is pending. </p>\n<p>A coronal CT scan of her right kidney is shown below:</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b1q13.png\" width=\"50%\"/>\n<figcaption><em>Image courtesy of Ferreira et al. Kidney360 2(8): 1392, 2021</em></figcaption>\n</figure>\n<p>The left kidney is radiographically normal.</p>\n<p><strong>In addition to empiric antibiotics, which ONE of the following is the next best step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Acetohydroxamic\nacid"
            },
            {
                "label": "B.",
                "text": "Extracorporeal\nshockwave lithotripsy"
            },
            {
                "label": "C.",
                "text": "Percutaneous cyst\ndrainage and biopsy"
            },
            {
                "label": "D.",
                "text": "En bloc nephrectomy"
            },
            {
                "label": "E.",
                "text": "Percutaneous\nnephrostomy tubes"
            }
        ],
        "correct_answer": "En bloc nephrectomy",
        "abim_content_category": "Tubular, Interstitial, and Cystic disorders.",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">En bloc nephrectomy is the best treatment for this patient with clinical and radiographic features of xanthogranulomatous pyelonephritis (XGP).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">XGP is a rare complication of chronic pyelonephritis in which there is massive destruction of the kidney by granulomatous tissue. The lesions contain lipid-laden macrophages, which accounts for the yellow color of the involved sites. It remains uncertain why lipid accumulates in this lesion. It most often occurs in middle-aged women with recurrent urinary tract infections. Staghorn (struvite) calculi may be present. Additional risk factors include diabetes, immunodeficiency, and urinary tract anatomic anomaly or obstruction. The presenting symptoms are flank pain, fever, malaise, anorexia, and weight loss. Inflammatory markers are often elevated. Urine culture usually reveals <em>Escherichia coli</em> or <em>Proteus</em>, although other bacteria may be found. The diagnosis is established by imaging, with CT a scan as the preferred diagnostic tool.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Characteristically, as in this case, kidney tissue is replaced by rounded, low-density areas that are surrounded by a contrast-enhanced rim, resulting in a multi-loculated appearance. These findings resemble the appearance of the paw print of a bear and are known as “bear paw sign” (asterisk in image). The abnormalities correspond to dilated calyces lined with necrotic xanthogranulomatous tissue extending into the renal parenchyma. The condition is almost always unilateral and is associated with virtually complete destruction of renal parenchyma. Occasionally the process may involve adjacent structures, and amyloidosis is a rare complication. The optimal treatment consists of en bloc nephrectomy following initial treatment with antibiotics. In the case of bilateral disease, which is rare, partial nephrectomy can be attempted, but total nephrectomy is often needed, followed by the initiation of dialysis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The differential diagnosis includes tuberculosis, inflammatory conditions such as malakoplakia, and renal cell cancers (including clear cell and sarcomatoid types), but aspiration and biopsy are unlikely to yield definitive results, making surgical resection the preferred approach.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Antibiotics are useful to control infection pre- and peri-operatively but do not cure the underlying inflammatory process, and even prolonged courses do not obviate the need for surgery.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Staghorn calculi often develop in the context of chronic infection by urea-splitting organisms. Even in the absence of xanthogranulomatous inflammation, surgical lithotomy is the preferred approach. Extracorporeal shock wave lithotripsy (ESWL) is associated with incomplete dissolution and retained fragments. Acetohydroxamic acid (AHA) is an oral urease inhibitor that can be used as adjunctive therapy for patients with persistent stone fragments or who are poor surgical candidates. Neither ESWL nor AHA would address the xanthogranulomatous inflammation. This patient does not have radiologic evidence of hydronephrosis or urinary obstruction, so percutaneous nephrostomy tubes would not provide benefit.</p>\n</div>",
        "references": [
            "Parsons MA, Harris SC, Longstaff AJ, et al. Xanthogranulomatous pyelonephritis: A pathological, clinical and aetiological analysis of 87 cases.Diag Histopathol6: 203, 1983",
            "Chuang CK, Lai MK, Chang PL, et al. Xanthogranulomatous pyelonephritis: Experience in 36 cases.J Urol147: 333–336, 1992",
            "Ferreira F, Relvas M, Vale L. Unusual findings in a patient with abdominal pain and kidney dysfunction.Kidney3602: 1392–1393, 2021",
            "Terry RS, Preminger GM. Metabolic evaluation and medical management of staghorn calculi.Asian J Urol7(2): 122–129, 2020",
            "Garrido-Abad P, Rodriguez-Cabello MA, Vera-Beron R, et al. Bear paw sign: Xanthogranulomatous pyelonephritis.J Radiol Case Rep12(11): 18–24, 2018"
        ]
    },
    "15": {
        "question": "<div class=\"qtext\"><p>A 44-year-old woman with a history of class III lupus nephritis presented to the hospital with worsening shortness of breath and a BP of 220/110 mm Hg, despite adherence to all antihypertensive medications and mycophenolate mofetil. Further imaging revealed a large pericardial effusion. She underwent a kidney biopsy that showed diffuse, proliferative (class IV) lupus nephritis, and was initiated on high-dose pulse steroids and cyclophosphamide IV.</p>\n<p>She now returns to the clinic 4 weeks later for follow-up and her second cyclophosphamide dose. </p>\n<p>On examination, her BP is 140/90 mm Hg. She has no murmurs. Lungs are clear to auscultation in all fields. Her abdomen is soft and nontender. She has 1+ lower extremity edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><b>At Diagnosis (4 Weeks Ago)</b></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Two Weeks Ago</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong>  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7600/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2900</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Neutrophils\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                65%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                52</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                50–70\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Lymphocytes\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30–45 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Monocytes\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0–6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelet count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                233,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                220,000\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Serum\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     BUN \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                86 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                80\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.3 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.0 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.2\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis reveals 15 RBC/HPF and &gt;500 mg/dL of protein.</p>\n<p><strong>Which ONE of the following is the next best step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Reduce cyclophosphamide dose"
            },
            {
                "label": "B.",
                "text": "Change cyclophosphamide to oral"
            },
            {
                "label": "C.",
                "text": "Change cyclophosphamide to rituximab"
            },
            {
                "label": "D.",
                "text": "Change cyclophosphamide to mycophenolate mofetil"
            },
            {
                "label": "E.",
                "text": "Repeat kidney biopsy"
            }
        ],
        "correct_answer": "Reduce cyclophosphamide dose",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with severe SLE and cyclophosphamide-induced leukopenia, the dose of cyclophosphamide should be reduced.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient is being treated with cyclophosphamide for severe, organ-threatening exacerbation of SLE based on a landmark trial published in 1996. Initial dosing of the drug is done based on body surface area, and age and underlying kidney function are also usually taken into consideration. In this patient with AKI, subsequent doses should be based on both the response to therapy and nadir of the WBC count. Thus, it is important to check a complete blood count with differential 10–14 days after the initial dose. Based on the developing lymphopenia in this patient, the subsequent dose of cyclophosphamide should be decreased to minimize the risk of serious infections. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Transition to PO cyclophosphamide would not be appropriate in this case. Generally, use of PO cyclophosphamide increases the total exposure to drug and subsequently increases the risk of toxicity. IV dosing minimizes drug exposure while maintaining efficacy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In a study of 144 patients with either class III or IV lupus nephritis, participants who received rituximab in combination with mycophenolate mofetil did not have a significant increase in the likelihood of partial or complete remission compared with patients receiving mycophenolate mofetil alone. Use of rituximab should be considered in patients unable to tolerate mycophenolate mofetil or cyclophosphamide and could also be considered in those with resistant disease, but should not be considered for initial monotherapy. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mycophenolate mofetil is commonly used in the management of lupus nephritis. In this patient with severe disease who had a lupus flare with new-onset class IV lupus nephritis while receiving mycophenolate mofetil, restarting the drug as the primary immunosuppressive agent would not be appropriate. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">As this patient’s kidney function is improving and the patient is early in her treatment course, a repeat kidney biopsy would not be indicated at this time.</p>\n</div>",
        "references": [
            "Gourley MF, Austin HA III, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial.Ann Intern Med125(7): 549–557, 1996",
            "Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study.Arthritis Rheum64(4): 1215–1226, 2012"
        ]
    },
    "16": {
        "question": "<div class=\"qtext\"><p>A 37-year-old man with no significant past medical history is referred to nephrology clinic for evaluation of hypercalcemia. His serum calcium level has ranged from 10.7 to 11.3 mg/dL for the past year. Today, he feels well and has no complaints. He cannot provide any family history as he is adopted. Review of systems is negative. He denies taking any over-the-counter or prescription medications. Physical examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Serum</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.5 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">26 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7–1.3</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Calcium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">11.2 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8.6–10.2</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  PTH, intact</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">64 pg/mL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">10–65</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  25-Hydroxyvitamin D</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">35 ng/mL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">30–60</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Urine calcium-to-creatinine ratio</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.005</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;0.14 </td>\n</tr>\n</tbody>\n</table>\n<p>Kidney ultrasound is normal.</p>\n<p><strong>Which ONE of the following is the MOST likely cause of this patient’s hypercalcemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Heterozygous inactivating\nmutation of theCASRgene"
            },
            {
                "label": "B.",
                "text": "Germline inactivating\nmutation of theMEN1gene"
            },
            {
                "label": "C.",
                "text": "Germline inactivating\nmutation of theHRPT2gene"
            },
            {
                "label": "D.",
                "text": "Homozygous inactivating\nmutation of theCASRgene"
            },
            {
                "label": "E.",
                "text": "Parathyroid adenoma"
            }
        ],
        "correct_answer": "Heterozygous inactivating\nmutation of theCASRgene",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with mild to moderate hypercalcemia and an elevated PTH level most likely has a heterozygous inactivating mutation of the calcium-sensing receptor (<em>CASR) </em>gene, causing familial hypocalciuric hypercalcemia (FHH). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The pathophysiology of FHH involves a heterozygous inactivating mutation of the <em>CASR</em> gene. Normally, when serum calcium is transiently elevated, the CASR<em> </em>regulates calcium balance by inhibiting PTH secretion from the parathyroid gland and inducing calcium excretion by the kidney. Inactivating mutations affecting the CASR result in inappropriate PTH secretion and reduced renal calcium excretion in the setting of elevated serum calcium. Patients with FHH have a markedly decreased urine calcium-to-creatinine ratio (&lt;0.01) due to the inactivating mutation of the <em>CASR</em> gene. Because the patient presented in the case had a calcium-to-creatinine ratio of 0.005, his presentation is consistent with FHH. FHH is a benign condition that requires no specific treatment other than avoiding parathyroidectomy caused by misdiagnosis of primary hyperparathyroidism.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary hyperparathyroidism, typically from a parathyroid adenoma, is a far more common cause of hypercalcemia and an elevated PTH level than FHH, and it is crucial to distinguish between FHH and primary hyperparathyroidism prior to referring the patient for parathyroid surgery. In ambiguous cases, genetic testing is recommended to distinguish this condition from FHH.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Inactivating germline mutation of the <em>MEN1 </em>tumor suppressor gene is the cause of multiple endocrine neoplasia type 1 (MEN1), which can present with hyperparathyroidism and hypercalcemia. However, MEN1 also affects the pituitary gland and pancreas or duodenum, and there is no history to suggest that these organs are involved in this case. Inactivating germline mutations of the <em>HRPT2/CDC73 </em>gene causes hyperparathyroidism jaw tumor syndrome, which causes ossifying fibromas in the mandible and maxilla and cysts in the kidneys. Homozygous inactivating mutations of the <em>CASR</em> gene cause severe hyperparathyroidism in the neonate and would present with severe hypercalcemia, very high PTH levels, and life-threatening complications shortly after birth.  </p>\n</div>",
        "references": [
            "Toka HR, Al-Romaih K, Koshy JM, et al: Deficiency of the calcium-sensing receptor in the kidney causes parathyroid hormone-independent hypocalciuria.J Am Soc Nephrol23(11): 1879–1890, 2012",
            "Kos CH, Karaplis AC, Peng JB, et al: The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest111(7): 1021–1028, 2003",
            "Kantham L, Quinn SJ, Egbuna OI, et al: The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion.Am J Physiol Endocrinol Metab297(4): E915–E923, 2009",
            "Riccardi D, Brown EM: Physiology and pathophysiology of the calcium-sensing receptor in the kidney.Am J Physiol Renal Physiol298(3): F485–F499, 2010",
            "Pollak MR, Brown EM, Chou Y-HW, et al: Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.Cell75(7): 1297–1303, 1993",
            "Weaver TD, Shakir MKM, Hoang TD: Hyperparathyroidism-jaw tumor syndrome.Case Rep Oncol14(1): 29‒33, 2021",
            "Thompson R, Landry CS: Multiple endocrine neoplasia 1: a broad overview.Ther Adv Chronic Dis2021 Aug 12;12:20406223211035288, 2021"
        ]
    },
    "17": {
        "question": "<div class=\"qtext\"><p>A 70-year-old man with a past medical history of hypertension,  type 2 diabetes, ischemic stroke, and mild dementia was admitted to the hospital 5 days ago with altered mental status and fever. Urinalysis, chest x-ray, and blood cultures did not yield a source of infection. There have been no changes in his medications. For the last 5 days, his mental status has precluded him from taking food or drink by mouth. Over the last 24 hours, he has received a total of 4 L of 5% dextrose in water to treat new-onset hypernatremia.</p>\n<p>On examination, his BP is 110/65 mm Hg, his heart rate is 90/min, his temperature is 38.5°C, and he weighs 70 kg. He is confused and unable to answer questions. His oral mucosa is dry, and his cardiopulmonary and abdominal examinations are unremarkable. There is no edema of his lower extremities.</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width:20%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width:20%;\">\n<strong>Admission (5 Days Ago)</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width:20%;\"><strong>One Day Ago</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width:20%;\">\n<strong>Current</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width:20%;\">\n<strong>Reference Range </strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                147 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                159\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                145\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                18 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                31\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                21\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.9 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.8 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                123 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                132 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                170 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99, fasting\n            </td>\n</tr>\n</tbody>\n</table>\n<p>A nasogastric (NG) tube is placed, and enteral nutrition is initiated.</p>\n<p><strong>Which ONE of the following is the most appropriate next step in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Normal saline 1\nL IV"
            },
            {
                "label": "B.",
                "text": "Normal saline 100\nmL/h IV"
            },
            {
                "label": "C.",
                "text": "Free water flushes via nasogastric tube"
            },
            {
                "label": "D.",
                "text": "Hypertonic saline 25 mL/h IV"
            },
            {
                "label": "E.",
                "text": "Desmopressin subcutaneously"
            }
        ],
        "correct_answer": "Free water flushes via nasogastric tube",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with rapidly corrected hypernatremia who is unable to drink, free water flushes should be initiated by nasogastric (NG) tube. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has hypernatremia most likely because of his inability to drink water and ongoing free water losses from fever. There has been no change in his ability to access water, and he will need continued water supplementation to make up for ongoing losses.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypernatremia is a common problem in hospitalized elderly patients. In a hypernatremic patient, it is important to calculate the free water deficit (FWD) using the following formula: </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">FWD = % body water × weight (kg) × [(current sodium – goal sodium)/goal sodium]</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this elderly man, the percentage of body water is approximately 50%. Yesterday, with his serum sodium of 159 mEq/L and the target sodium (successfully achieved) of 145 mEq/L, his FWD was 0.5 × 70 × [(159 – 145)/145] = 3.4 L.</p>\n<p>The patient received 4 L of free water, which decreased his sodium to 145 mEq/L. This is a change of 14 mEq/L in 24 hours, equivalent to a rate of change of 0.6 mEq/L/hour. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There are currently no guidelines regarding sodium correction rate in hypernatremia. Generally, a recommended rate of correction of &lt;0.5 mEq/L/hour and &lt;10 mEq/L/day has been recommended for chronic (&gt;48 hours) hypernatremia based on data in pediatric patients to avoid cerebral edema, seizure, and permanent neurologic damage from rapid correction. However, a retrospective trial of 449 adult patients was performed to evaluate the safety of rapid correction of hypernatremia (&gt;0.5 mEq/L/hour). This study showed a shorter hospital stay in patients who received rapid correction and no statistically significant increase in mortality or neurologic complications. Another retrospective study of 131 patients showed that hypernatremia correction within 72 hours using a correction rate of &lt;0.5 mEq/L/hour was associated with a higher mortality rate. Thus, in patients with hypernatremia, and in contrast to hyponatremia, correction to goal should be undertaken in a timely fashion. Once goal sodium levels are achieved, maintenance with either enteral or IV free water should be undertaken. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">As this patient does not show evidence of volume depletion, giving isotonic saline, either by bolus or IV infusion, is not the next best step. The infusion of isotonic fluid in a patient with a negative water balance may cause or worsen hypernatremia.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Giving 3% saline to correct the normalized serum sodium is not appropriate. As stated above, the rapid correction of hypernatremia is not associated with significant mortality or neurologic complications and may be of clinical benefit.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Desmopressin, a vasopressin analog, is prescribed for patients with central diabetes insipidus. This patient is unlikely to have diabetes insipidus, and the addition of desmopressin will not treat the underlying problem, which is a lack of free water intake.</p>\n</div>",
        "references": [
            "Chauhan K, Pattharanitima P, Patel N, et al. Rate of correction of hypernatremia and health outcomes in critically ill patients.Clin J Am Soc Nephrol14(5): 656–663, 2019",
            "Alshayeb HM, Showkat A, Babar F, et al. Severe hypernatremia correction rate and mortality in hospitalized patients.Am J Med Sci341(5): 356–360, 2011",
            "Bataille S, Baralla C, Torro D, et al. Undercorrection of hypernatremia is frequent and associated with mortality.BMC Nephrol15: 37, 2014"
        ]
    },
    "18": {
        "question": "<div class=\"qtext\"><p>A 56-year-old woman with CKD stage 5 due to ADPKD, anemia attributed to CKD, hypothyroidism, breast cancer, and a lower extremity deep venous thrombosis 3 months ago presents for routine follow-up. The patient’s breast cancer was discovered on a screening mammogram done as part of her evaluation for a kidney transplant 3 years ago. She was treated with lumpectomy, radiation, and tamoxifen, which is planned to continue for an additional 2 years. She denies shortness of breath, palpitations, postural dizziness, or uremic symptoms, although she has limited some activities because of fatigue. Medications include iron, sodium bicarbonate, levothyroxine, and apixaban.</p>\n<p>On examination, BP is 138/73 mm Hg, and heart rate is 90/min. Cardiopulmonary examinations are normal, and she does not have asterixis.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                eGFR\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14 mL/min/1.73 m<sup>2</sup>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≥60\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.8 g/dL (3 months ago, 8.2)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Iron saturation\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">31%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20–50\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Ferritin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                492 ng/nL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11–307\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Vitamin B<sub>12</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                812 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                200–800\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Folate\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.7 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.8–9.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Thyroid-stimulating hormone\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.8 µU/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–4.0\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the most appropriate NEXT STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Observation"
            },
            {
                "label": "B.",
                "text": "Erythropoietin"
            },
            {
                "label": "C.",
                "text": "Blood transfusion"
            },
            {
                "label": "D.",
                "text": "Iron sucrose"
            },
            {
                "label": "E.",
                "text": "Roxadustat"
            }
        ],
        "correct_answer": "Observation",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Observation is the most appropriate next step in management for this patient with stable anemia and active malignancy treated with curative chemotherapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Erythropoiesis-stimulating agents (ESAs) reduce the need for blood transfusions, improve quality of life and exercise tolerance, and may improve left ventricular hypertrophy (LVH). Observational data from the oncology literature have shown that ESA use is associated with increased risk of cancer and poorer outcomes, including increased mortality. These observations came from trials in the early 2000s that targeted normal hemoglobin levels (13–16 g/dL). Erythropoietin promotes proliferation, migration, and differentiation of vascular endothelial cells into vascular tubes and new blood vessels (angiogenesis), which promotes tumor growth. Increased mortality observed with ESAs may be limited to patients with specific malignancies, including head, neck, and breast cancers. A Cochrane review showed statistically significant mortality increases in patients treated to hemoglobin &gt;12 g/dL but not those treated to lower hemoglobin levels. ESA use is also associated with higher rates of thromboembolic and cerebrovascular events in patients with cancer.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">KDIGO guidelines for the management of anemia in patients with CKD and cancer suggest caution when using ESAs in patients with active malignancy or with a history of malignancy. The guidelines strongly advise against raising hemoglobin to a normal level. They recommend using ESAs “with great caution, if at all, if cure is the anticipated outcome.” In this patient, who is asymptomatic with a stable hemoglobin level over the last 3 months, observation would be the best option.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The American Society of Clinical Oncology (ASCO) does not address ESA use in patients with cancer and CKD. Their guidelines only target patients with chemotherapy-associated anemia and recommend that ESAs should not be prescribed to patients with chemotherapy-associated anemia whose cancer treatment is curative in intent.    </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hypoxia-inducible factor-prolyl hydroxylase inhibitors, such as roxadustat, are undergoing active investigation as substitutes for ESAs in some circumstances. These agents have not been studied in patients who have cancer and CKD. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Blood transfusion would not be indicated in an asymptomatic patient with stable anemia, such as this one. Similarly, iron sucrose would not be indicated in this patient in the absence of iron deficiency.</p>\n</div>",
        "references": [
            "Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer.Cochrane Database of Syst Rev12: CD003407, 2012",
            "Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or darbepoetin for patients with cancer: Meta-analysis based on individual patient data.Cochrane Database Syst Rev3: CD007303, 2009",
            "Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group M. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. 2016;https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf. Accessed April 20, 2023",
            "Bohlius J. Management of cancer associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical guideline update.http://www.bloodadvances.org/content/3/8/1197?sso-checked=true. Accessed April 17, 2023"
        ]
    },
    "19": {
        "question": "<div class=\"qtext\"><p>A 47-year-old man with type 1 diabetes and hypertension presents to the emergency department feeling ill. He is confused, but able to report that he went out with his friends the night before to celebrate a recent job promotion. His medications include insulin, hydrochlorothiazide, simvastatin, lisinopril, and low-dose aspirin.</p>\n<p>On examination, BP is 110/60 mm Hg, heart rate is 105/min, and respiratory rate is 22/min, with oxygen saturation of 98% while breathing room air. He is lethargic and oriented to self only. His oral mucosa appears dry, his lungs are clear, and his heart is tachycardic. The remainder of his examination is normal.</p>\n<p>Laboratory results are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.0 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Chloride \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">     Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Albumin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.0 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Arterial blood gas</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     pH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.38\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.38–7.44\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     pCO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30 mm Hg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38–42\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     pO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                90 mm Hg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                75–100\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the most likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "High anion gap metabolic acidosis and metabolic\nalkalosis"
            },
            {
                "label": "B.",
                "text": "No acid base disorder is present"
            },
            {
                "label": "C.",
                "text": "Non-anion gap metabolic acidosis and respiratory\nalkalosis"
            },
            {
                "label": "D.",
                "text": "High anion gap metabolic acidosis, metabolic\nalkalosis, and respiratory alkalosis"
            },
            {
                "label": "E.",
                "text": "Non-anion gap metabolic acidosis with\nappropriate respiratory compensation"
            }
        ],
        "correct_answer": "High anion gap metabolic acidosis, metabolic\nalkalosis, and respiratory alkalosis",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely diagnosis in this patient is a high anion gap (AG) metabolic acidosis, a metabolic alkalosis, and a respiratory alkalosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">To determine a patient’s acid-base status, the first step is to evaluate the patient’s blood pH, total CO<sub>2</sub>, and pCO<sub>2</sub>. In this patient, the serum total CO<sub>2</sub> and pH are normal, but the pCO<sub>2</sub> is lower than normal range, suggesting a respiratory disorder or respiratory compensation for a masked metabolic disorder.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next step involves calculating the AG, using the following formula: </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">AG = sodium – (total CO<sub>2</sub> + chloride).   </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The AG in this patient is 13, which is within the typical normal range for most laboratories (7–13). However, because albumin is the anion that comprises the largest portion of the AG, patients with hypoalbuminemia can appear to have a falsely low AG. The AG can be corrected for the serum albumin using the following formula:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">(AG)<sub>corrected</sub> = (AG)<sub>uncorrected</sub> + 2.5 × (4.4 – [albumin]). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">After making the above calculation, the corrected AG is elevated at 19. Thus, the patient has a high AG metabolic acidosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next step requires calculation of the delta-delta gap to determine whether there are other disorders masked by the AG metabolic acidosis. The delta-delta gap calculation is based on the principle that, in the presence of a high AG metabolic acidosis, the decrease in serum bicarbonate should be directly proportional to the increase in AG. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The delta-delta gap is calculated as follows: </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">(corrected AG – normal AG)/(normal total CO<sub>2</sub> – measured total CO<sub>2</sub>). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, the delta-delta gap is: (19 – 10)/(24 – 23) = 9. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">When the delta-delta gap is &gt;2 in the setting of an AG metabolic acidosis, the serum bicarbonate is higher than expected for the calculated AG, so there must be a coexisting metabolic alkalosis or, less commonly, a respiratory acidosis. Conversely, when the delta-delta gap is &lt;1, the serum bicarbonate is lower than expected, which implies a coexisting non-AG metabolic acidosis or respiratory alkalosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, the delta-delta gap is 9, indicating a combined AG metabolic acidosis and metabolic alkalosis (or respiratory acidosis, but see below), which may be attributed to vomiting in the setting of diabetic ketoacidosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The last step is to determine whether there is adequate respiratory compensation for the metabolic acidosis. Winter’s formula is the most commonly used formula to make this determination and can be calculated as follows:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">pCO<sub>2</sub> expected = (1.5 × total CO<sub>2</sub>) + 8 ± 2</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">If the serum total CO<sub>2</sub> is is 10–40 mm Hg, another method to determine the expected pCO<sub>2</sub> is to add 15 to the total CO<sub>2</sub>. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, Winter’s formula yields an expected pCO<sub>2</sub> of 42 ± 2 mm Hg, and the alternative method yields an expected pCO<sub>2 </sub>of 38 mm Hg. Because the measured pCO<sub>2</sub> is less than expected by either method, it can be concluded that this patient also has a respiratory alkalosis in addition to his metabolic derangements. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Therefore, the overall acid-base disorder is a high AG metabolic acidosis, metabolic alkalosis, and respiratory alkalosis.</p>\n</div>",
        "references": [
            "Mehta AN, Emmett M. Approach to acid-base disorders. In:National Kidney Foundation’s Primer on Kidney Disease, 8th ed., edited by Gilbert S. Philadelphia: Elsevier and National Kidney Foundation; 2023: 123–132",
            "Fenves AZ, Emmett M. Approach to patients with high anion gap metabolic acidosis: Core curriculum 2021.Am J Kidney Dis78(4): 590–600, 2021",
            "Adrogue, HJ, Tucker BM, Madias NE. Clinical approach to assessing acid-base status: Physiological vs Stewart.Adv Chronic Kidney Dis29(4): 343–354, 2022"
        ]
    },
    "20": {
        "question": "<div class=\"qtext\"><p>A 57-year-old man with type 2 diabetes, hypertension, and CKD stage 3 presents for a routine follow-up visit. He was last seen 5 months ago and, at that time, was noted to have a BP of 145/85 mm Hg. He was advised to continue his current BP medications, monitor his daily BP, and lower his dietary sodium intake. His current medications include metformin, dapagliflozin, and maximal doses of losartan, carvedilol, and chlorthalidone.</p>\n<p>On examination, BP is 112/68 mm Hg, and heart rate is 65/min. He has trace to 1+ bilateral lower extremity edema. The remainder of his examination is normal, other than mild loss of sensation in his feet bilaterally.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                142 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.3 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">     Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                28 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.9 mg/dL (baseline)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine, random</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Albumin-to-creatinine ratio \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                200 mg/g\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;30\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Protein-to-creatinine ratio \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.35 mg/mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.2\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Echocardiogram shows mild left ventricular hypertrophy but is otherwise normal.</p>\n<p><strong>Which ONE of the following is the best next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe finerenone"
            },
            {
                "label": "B.",
                "text": "Prescribe spironolactone"
            },
            {
                "label": "C.",
                "text": "Replace losartan with\n finerenone"
            },
            {
                "label": "D.",
                "text": "Prescribe torsemide"
            },
            {
                "label": "E.",
                "text": "Prescribe lisinopril"
            }
        ],
        "correct_answer": "Prescribe finerenone",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A non-steroidal mineralocorticoid receptor antagonist (ns-MRA), such as finerenone, should be prescribed in this patient with diabetic kidney disease (DKD) and ongoing proteinuria.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has ongoing proteinuria despite maximal therapy with an ARB and a sodium-glucose transporter-2 inhibitor (SGLT2i). The recently published KDIGO guidelines, influenced by the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) and Finerenone in Reducing Cardiovascular Mortality and Morbidity in DKD (FIGARO-DKD) trials, suggest prescribing an ns-MRA to those patients who have ongoing proteinuria despite use of a renin-angiotensin-aldosterone inhibitor (RASi). The FIGARO-DKD trial showed a significantly decreased incidence of kidney failure, eGFR decline, or death from kidney causes and improved cardiovascular outcomes. Notably, most of the patients in these trials were not prescribed an SGLT2i. Nonetheless, the authors of the KDIGO guidelines believe the benefits of these two classes of medications are likely to be additive and suggest the addition of ns-MRA after maximizing RASi and SGLT2i in patients with albuminuria without hyperkalemia. Because ns-MRAs do not bind to the glucocorticoid receptor, they are unlikely to affect BP and are preferred in patients who qualify for additional anti-proteinuric therapy but whose BP is controlled or low, as in this patient.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Spironolactone, a steroidal MRA (sMRA), is recommended as fourth-line therapy in patients with resistant hypertension. sMRAs have not been studied in large-scale clinical trials for improving CKD or cardiovascular outcomes and thus are only recommended in patients with heart failure, hyperaldosteronism, or resistant hypertension. As this patient has controlled BP and no evidence of heart failure on echocardiogram, spironolactone would not be the next best step.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Finerenone has only been studied in patients who were already receiving a RASi. Thus, replacing losartan with finerenone is not indicated. A loop diuretic such as torsemide may help with this patient’s edema but would not address his ongoing proteinuria. Additionally, it would likely worsen his hypokalemia. As this patient is already receiving an ARB, the addition of lisinopril is not recommended.</p>\n</div>",
        "references": [
            "Rossing P, Caramori L, Chan M, et al.KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease.Kidney Int102(5): S1–S127, 2022",
            "de Boer IH, Kamlesh K, Tami S, et al. Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).Kidney Int102(5): 974–989, 2022",
            "Rossing P, Caramori LM, Chan JCN, et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: An update based on rapidly emerging new evidence.Kidney Int102(5): 990–999, 2022"
        ]
    },
    "21": {
        "question": "<div class=\"qtext\"><p>A 57-year-old man with CKD stage 3 and hypertension presents to clinic for further evaluation of poorly controlled BP. For the past several years, his BP has been at goal, but over the last 6 months, his ambulatory and in-office readings have been elevated. He reports adherence to his medications and to a low-sodium diet. Prior to this consultation, his primary care physician ordered an echocardiogram, which was normal except for mild left ventricular hypertrophy. His current medications are chlorthalidone 25 mg once daily, lisinopril 40 mg once daily, and amlodipine 10 mg once daily. He does not smoke or take NSAIDs or other over-the-counter medications.</p>\n<p>On examination, BP ranges from 150–170/85–95 mm Hg, with no discrepancy between limbs. His heart rate is 84/min. His body mass index is 27 kg/m<sup>2</sup>. His pulses are equal, and his cardiac examination is within normal limits. He has no abdominal bruits or edema. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                142 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.2 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.7 mg/dL (baseline)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Aldosterone \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7 ng/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≤30 (low sodium diet, supine)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Renin activity \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2 ng/ml/hr\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.9–4.5 (low sodium diet)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Albumin-to-creatinine ratio, random</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150 mg/g\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;30\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Sodium, 24-hour\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                84 mEq\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the most appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Spironolactone"
            },
            {
                "label": "B.",
                "text": "Reduce dietary sodium"
            },
            {
                "label": "C.",
                "text": "Weight loss"
            },
            {
                "label": "D.",
                "text": "Hydralazine"
            },
            {
                "label": "E.",
                "text": "Carvedilol"
            }
        ],
        "correct_answer": "Spironolactone",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with resistant hypertension, the most appropriate next step is to add a mineralocorticoid receptor antagonist (MRA) such as spironolactone to the patient’s antihypertensive regimen.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Resistant hypertension is defined as a BP above goal (systolic BP &gt;130 mm Hg in a patient with CKD) despite at least three antihypertensive agents, including at least one diuretic. It is important to confirm medication adherence and elevated BP in an ambulatory setting in a patient who is believed to have “resistant hypertension.” Clinical trials have shown that patients with resistant hypertension respond favorably to the addition of spironolactone compared with other classes of antihypertensives, which is recognized in the KDIGO 2021 guidelines. Furthermore, this patient has persistent albuminuria despite the use of an ACEI, and the addition of an MRA may provide anti-proteinuric benefit. A diagnosis of primary aldosteronism is not required to obtain benefit from MRA prescription in resistant hypertension.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Reducing dietary sodium can be a helpful lifestyle modification in patients with hypertension, but this patient is already consuming a low-sodium diet, and his urinary sodium excretion (84 mEq/day, or &lt;2 g/day) confirms adherence. Further reductions in dietary sodium are not expected to be helpful. Weight loss may be a useful adjunctive strategy to manage BP, but this method is unlikely to be effective in the immediate term, and this patient already has evidence of end-organ damage. Prescribing an MRA is anticipated to have immediate benefits for BP control.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Prescribing hydralazine, a direct-acting vasodilator, would not be the next best step in management, as it would not confer the additional anti-proteinuric or cardioprotective benefit of an MRA. Carvedilol, a combination α-β antagonist, may be considered in a patient with established heart failure, but this patient has normal cardiac function by echocardiogram.</p>\n</div>",
        "references": [
            "Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial.Lancet386: 2059–2068, 2015",
            "Nishizaka M, Konishi Z, Mohammad A, et al. Efficacy of low-dose spironolactone in subjects with resistant hypertension.Am J Hypertens16(11): 925–930, 2003",
            "Nagarajan N, Jalal D. Resistant hypertension: Diagnosis and management.Adv Chronic Kidney Dis26(2): 99–109, 2019",
            "Ku E, Lee BJ, Wei J, et al. Hypertension in CKD: Core curriculum 2019.Am J Kidney Dis74(1): 120–131, 2019",
            "Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.Kidney Int99(3S): S1–S87, 2021"
        ]
    },
    "22": {
        "question": "<div class=\"qtext\"><p>A 67-year-old woman with a history of small cell lung cancer is seen in clinic. Her main complaint is fatigue, which coincides with her cancer therapy initiation. She reports decreased appetite and nausea but no fevers or diarrhea. Other past medical history includes hypertension and hypothyroidism. Her chemotherapeutic regimen is atezolizumab, carboplatin, and etoposide. Her medications also include amlodipine, atorvastatin, and levothyroxine.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\"><strong>Six Months Ago</strong> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\"><strong>Two Months Ago</strong> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\"><strong>Current</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 20%;\"><strong>Reference Range</strong> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Sodium </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">130 mEq/L </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">132 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">131</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136–145 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Potassium </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.1 mEq/L </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.3 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.0</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Chloride </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">97 mEq/L </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">99 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">100</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">98–106 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Total CO<sub>2</sub> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">24 mEq/L </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">24</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28  </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">BUN </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">12 mg/dL </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">10 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">11</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Creatinine </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.5 mg/dL </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.6 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.6</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.5–1.1 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Thyroid-stimulating hormone</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.2 µU/mL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.5–4.0</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which of the following complications of hyponatremia is MOST LIKELY? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increased cancer mortality"
            },
            {
                "label": "B.",
                "text": "Seizures"
            },
            {
                "label": "C.",
                "text": "Intestinal dysmotility"
            },
            {
                "label": "D.",
                "text": "Symptomatic hypothyroidism"
            },
            {
                "label": "E.",
                "text": "Hip fracture"
            }
        ],
        "correct_answer": "Hip fracture",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with mild, chronic hyponatremia is at greatest risk for hip fracture. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hyponatremia is frequently seen in patients with lung cancer, with a prevalence range of 3%–46% and a mean of 24% in those with small cell lung cancer, although recent studies have not distinguished patients with mild, apparently asymptomatic hyponatremia from those with more profound and symptomatic values.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although individuals with mild hyponatremia may appear asymptomatic, sophisticated testing reveals myriad subtle symptoms, including decreased attention and reaction time, decreased steadiness, and gait instability. Hyponatremic patients are also at increased risk for osteoporosis-dependent and -independent fractures.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">One retrospective cohort study examined ~1400 women with bone mineral density testing. After adjusting for age, CKD stage, osteoporosis risk factors, and osteoporosis treatment, those with hyponatremia (&lt;135 mEq/L) had a 2.25-fold increased risk of fracture compared with those with eunatremia. In another cohort study of &gt;5200 subjects, those with hyponatremia (&lt;136 mEq/L) had a higher relative risk of both vertebral (1.61) and non-vertebral fractures (1.34) compared with those with eunatremia after adjustment for age, sex, body mass index, disability index, use of diuretics, use of psychiatric medications, prevalent diabetes mellitus, and recent falls. Finally, a cohort study of &gt;31,000 people showed a higher prevalence of hip fracture in those with hyponatremia (&lt;135 mEq/L). After adjustment, those with prolonged hyponatremia (&gt;90 days) had a 4.52-fold increased risk of hip fracture compared with those who were eunatremic.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">With respect to cancer outcomes, the data are mixed. A recent meta-analysis and systemic review of &gt;12,000 patients with small cell and non-small cell lung cancer showed higher mortality in patients with hyponatremia, but of the 26 studies reviewed, 15 found that hyponatremia was an independent prognostic factor and 8 concluded that hyponatremia was not an independent prognostic factor. Overall, hyponatremia did correlate with lung cancer outcome in a large Danish registry. Those patients with hyponatremia and small cell lung cancer had a 1.21-fold increased risk of overall mortality. However, when the authors stratified by degree of hyponatremia, those patients with small cell lung cancer and mild hyponatremia (130–134 mEq/L) did not have a statistically significantly worse outcome compared with those with eunatremia. For patients with non-small cell lung cancer, even mild hyponatremia conferred a higher mortality. Thus, although there may be a relationship between mild hyponatremia and cancer outcomes, the correlation is much stronger for hyponatremia and fractures.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although acute, severe hyponatremia may present with seizures, there are no data showing that this is a concern with mild, chronic hyponatremia. Similarly, no data implicate mild, chronic hyponatremia with intestinal dysmotility or worsening hypothyroidism.</p>\n</div>",
        "references": [
            "Kinsella S, Moran S, Sullivan MO, et al. Hyponatremia independent of osteoporosis is associated with fracture occurrence.Clin J Am Soc Nephrol5(2): 275–280, 2010",
            "Hoorn EJ, Rivadeneira F, van Meurs JB, et al. Mild hyponatremia as a risk factor for fractures: The Rotterdam Study.J Bone Miner Res26(8): 1822–1828, 2011",
            "Ayus JC, Fuentes NA, Negri AL, et al. Mild prolonged chronic hyponatremia and risk of hip fracture in the elderly.Nephrol Dial Transplant31(10): 1662–1669, 2016",
            "Sandfeld-Paulsen B, Aggerholm-Pedersen N, Winther-Larsen A. Hyponatremia in lung cancer: Incidence and prognostic value in a Danish population-based cohort study.Lung Cancer153: 42–48, 2021",
            "Bartalis E, Gergics M, Tinusz B, et al. Prevalence and prognostic significance of hyponatremia in patients with lung cancer: Systematic review and meta-analysis.Front Med (Lausanne)8: 671951, 2021"
        ]
    },
    "23": {
        "question": "<div class=\"qtext\"><p>A 67-year-old woman with a history of type 2 diabetes, hypertension, heart failure with reduced ejection fraction, and ESRD treated with HD for 10 years presents to her scheduled HD session. Her current HD access is a tunneled central venous catheter, which was recently replaced in the setting of <em>Staphylococcus aureus</em> bacteremia. Ninety minutes into her HD treatment, she reports new-onset chest pain and dyspnea.</p>\n<p>On examination, her BP is 86/53 mm Hg, heart rate is 128/min, and oxygen saturation is  85% while breathing room air. Her mental status is decreased compared with previously, and she has cyanosis and a continuous holosystolic murmur. The HD technician reports foam in the venous blood line.</p>\n<p><strong>Which ONE of the following is the most likely diagnosis in this patient?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Type A dialyzer reaction"
            },
            {
                "label": "B.",
                "text": "Type B dialyzer reaction"
            },
            {
                "label": "C.",
                "text": "Air embolism"
            },
            {
                "label": "D.",
                "text": "Acute coronary syndrome"
            },
            {
                "label": "E.",
                "text": "Chloramine contamination"
            }
        ],
        "correct_answer": "Air embolism",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely diagnosis in this patient with acute hypoxia and a new murmur is air embolism.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Air embolism is an uncommon complication of HD. Possible mechanisms of air entry into a patient’s bloodstream include inadequate priming of the dialyzer, inappropriate administration of medications, or defects in the tubing or arterial blood needle. If a considerable volume of air enters the circuit, it will be detected by a sensor and the blood pump will stop; this safety mechanism makes air embolism during dialysis very rare. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Clinical manifestations are related to the migration of air emboli to the pulmonary circulation and include hypotension, tachycardia, hypoxemia, and cardiac arrest. If there is a paradoxical air embolism from the right heart to the left heart via an anatomical cardiac defect, the symptoms and signs will depend on the site of end-organ damage. Altered mental status and neurologic deficits would be expected if air emboli migrate to the cerebral arteries. A distinctive splashing murmur may be present if air migrates to the cardiac chambers.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, poor management of the central venous catheter and the tubing connections may have precipitated air entry. Foam may be seen in the venous blood lines or the dialyzer and is a helpful sign for diagnosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Treatment includes providing supplemental oxygen, managing hypotension with fluids and vasopressors, terminating HD without returning blood, placing the patient on their left side in Trendelenburg position, and cardiorespiratory support, if needed.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A type A dialyzer reaction occurs early during the treatment (first 30 minutes) and manifests as pruritus, bronchospasms, chest pain, hypotension, and cardiac arrest if not treated. Type B reactions occur &gt;30 minutes after HD initiation, but symptoms are milder. Type B reactions would not be associated with severe hypotension, tachycardia, altered mental status, cyanosis, and foam in the venous blood line, as in this case.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Chloramine contamination is a result of inadequate water treatment that manifests as hemolytic anemia. Frequently, numerous patients in a dialysis shift will be affected by contaminated dialysate water. Commonly, a \"port wine” appearance of the blood in the venous line will provide a clue to the presence of hemolysis. In this case, only one patient was affected, and symptoms were not related to hemolysis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute coronary syndrome is unlikely with the presence of foam in the venous blood line.  </p>\n</div>",
        "references": [
            "Wong SS, Kwaan HC, Ing TS. Venous air embolism related to the use of central catheters revisited: With emphasis on dialysis catheters.Clin Kidney J10(6): 797–803, 2017",
            "Greenberg K, Choi MJ. Hemodialysis emergencies: Core curriculum 2021.Am J Kidney Dis77(5): 796–809, 2021",
            "Baines R. Air embolism associated with central venous hemodialysis catheters.UHL Renal Guideline.https://secure.library.leicestershospitals.nhs.uk/PAGL/Shared Documents/Air Embolism Associated With Central Venous Haemodialysis Catheters of Haemodialysis UHL Renal Guideline.pdf. Accessed January 2020"
        ]
    },
    "24": {
        "question": "<div class=\"qtext\"><p>A 58-year-old man with hepatocellular cancer presents the emergency department with a new rash on his ears and legs. He underwent hepatic artery embolization 6 days ago. In addition to the rash, he also reports occasional fever, tenderness in his legs, arthralgias, and nose bleeds. Past medical history includes CKD stage 2, hepatitis C, hypertension, type 2 diabetes, and peripheral neuropathy. His medications include insulin, lisinopril, simvastatin, and aspirin, as well as cabozantinib for hepatocellular carcinoma. He reports occasional use of cocaine and daily use of NSAIDs since his embolization.</p>\n<p>On examination, BP is 164/97 mm Hg, heart rate is 76/min, and he is afebrile. He has nasal septal deviation, his right ear has necrotic lesions (see image below), and he has a maculopapular rash on his shins bilaterally. Legs are tender to palpation.</p>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b1q25.png\" width=\"50%\"/>\n<figcaption><em>Image courtesy McGrath et al, Clin J Am Soc Nephrol 6: 2799, 2011</em></figcaption>\n</figure>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.1 mg/dL (baseline, 1.5)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatine kinase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                112 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                55–170 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                C3\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                99 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100–233 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                C4\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–48 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Cryoglobulins\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hepatitis C antibody\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Positive\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Anti-MPO IgG\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Positive\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Anti-PR3 IgG\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Positive\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ANA\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1:1280\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≤1:40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Anti-double-stranded DNA antibody</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis reveals 2+ protein and 1+ blood, and microscopy shows 15–30 RBCs/HPF, some dysmorphic, with no WBCs or casts.</p>\n<p>Kidney biopsy reveals moderate tubular atrophy and interstitial fibrosis, cellular crescents with segmental fibrinoid necrosis, mesangial hypercellularity, and no electron-dense deposits on EM.</p>\n<p><strong>Which ONE of the following is the MOST LIKELY cause of this patient’s clinical presentation?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Cocaine"
            },
            {
                "label": "B.",
                "text": "Hepatitis C"
            },
            {
                "label": "C.",
                "text": "Lupus"
            },
            {
                "label": "D.",
                "text": "Paraneoplastic syndrome"
            },
            {
                "label": "E.",
                "text": "Cabozantinib"
            }
        ],
        "correct_answer": "Cocaine",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely diagnosis is ANCA-associated vasculitis from cocaine adulterated with levamisole. </p>\n<p>The prevalence of levamisole-adulterated cocaine has been increasing in the United States since 2005 and is currently estimated at 70–80% of the product entering the country. Although the reason for its use as an adulterant is unknown, some have speculated that it potentiates the dopaminergic effects of cocaine in the central nervous system. Levamisole is an anti-helminthic agent that is sometimes used as a steroid-sparing agent in childhood nephrotic syndrome due to its immunomodulatory effects. The mechanism by which levamisole-adulterated cocaine causes vasculitis or glomerulonephritis is unclear, but use of the drug has been associated with the development of autoantibodies. It has been hypothesized that priming of neutrophils by levamisole leads to translocation of ANCA antigens to the cell surface, leading to binding of autoantibodies and increased adherence and migration of neutrophils through the endothelium. Release of reactive oxidative species and neutrophil degranulation products also play a role in causing small vessel destruction. </p>\n<p>Patients present with constitutional symptoms, cutaneous leukocytoclastic vasculitis, head and neck involvement, arthritis, and a pulmonary-renal syndrome. Autoantibody patterns such as double positivity for myeloperoxidase (MPO) and proteinase 3 (PR3) in combination with a positive ANA and other serologies are clues to this drug-induced vasculitis. Low complement levels have also been observed.</p>\n<p>The kidney biopsy findings in this patient are consistent with ANCA-associated vasculitis rather than the other options. Findings in lupus nephritis include mesangial and endocapillary hypercellularity and subendothelial immune deposits (wire loop lesions). In hepatitis C-associated cryoglobulinemic glomerulonephritis, the biopsy would be expected to show subendothelial immune complex deposits. Paraneoplastic MPGN is quite rare and does not usually manifest as a systemic vasculitis. It has been more commonly reported in association with lymphoproliferative disorders. Cabozantinib, a tyrosine-kinase inhibitor of vascular endothelial growth factor, would more commonly cause thrombotic microangiopathy.</p>\n</div>",
        "references": [
            "Nolan A, Kuang-Yu J. Pathologic manifestations of levamisole-adulterated cocaine exposure.Diagn Pathol10: 48, 2015",
            "Munoz-Vahos CH, Herrera-Uribe S, Arbelaez-Cortes A, et al. Clinical profile of levamisole-adulterated cocaine-induced vasculitis/vasculopathy: A 30-case series.J Clin Rheumatol25(3): e16–e26, 2019",
            "Cambier JF, Ronco P. Onconephrology: Glomerular disease with cancer.Clin J Am Soc Nephrol7(10): 1701–1712, 2012",
            "Fogo AB, Lusco MA, Najafian B, et al. AJKD atlas of renal pathology: Cryoglobulinemic glomerulonephritis.Am J Kidney Dis67(2): e5–e7, 2016",
            "Hachiya A, Karasawa M, Imaizumi T, et al. The ISN/RPS 2016 classification predicts renal prognosis in patients with first-onset class III/IV lupus nephritis.Sci Rep11(1): 1525, 2021",
            "McGrath MM, Isakova T, Rennke HG, et al. Contaminated cocaine and antineurtrophil cytoplasmic antibody-associated disease.Clin J Am Soc Nephrol6: 2799–2805, 2011"
        ]
    },
    "25": {
        "question": "<div class=\"qtext\"><p>A 71-year-old man presents to the nephrology clinic for the evaluation of recent-onset nephrotic syndrome. He has a past medical history of CKD stage 3 attributed to hypertension, bladder cancer, and rheumatic heart disease, for which he has undergone mechanical mitral valve replacement. He complains of worsening edema and dyspnea on exertion over the last month. His medications include hydrochlorothiazide, losartan, and warfarin.</p>\n<p>On examination, BP is 112/84 mm Hg, and heart rate is 85/min. Heart auscultation is unremarkable aside from a metallic click from his prosthetic valve. His lungs are clear to auscultation. Significant bilateral peripheral edema is present.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><span>Serum</span></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">     Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.5 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7–1.3 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">     Albumin</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.9 g/dL </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.5 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">     Total cholesterol</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">440 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;200, desirable</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">     Anti-phospholipase A2 receptor antibody titer</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">182 RU/mL (relative units)</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;14 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">     Urine albumin-to-creatinine ratio</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8240 mg/g</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;30</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Kidney biopsy"
            },
            {
                "label": "B.",
                "text": "Lisinopril"
            },
            {
                "label": "C.",
                "text": "Rituximab"
            },
            {
                "label": "D.",
                "text": "Prednisone"
            },
            {
                "label": "E.",
                "text": "Cyclosporine"
            }
        ],
        "correct_answer": "Rituximab",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate next step in managing this patient with membranous nephropathy (MN) is treating with rituximab.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Anti-phospholipase A2 receptor (PLA2R) antibodies are highly specific for MN. Per the 2021 KDIGO guidelines on MN, the presence of anti-PLAR2 antibodies is sufficient to diagnose MN, and kidney biopsy is not required. Although biopsy may still be considered for the additional prognostic information it provides, this patient is at increased risk for biopsy-related complications due to his mechanical mitral valve and requirement for uninterrupted anticoagulation. It would thus be appropriate to initiate treatment without histologic confirmation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Accepted immunosuppressive regimens for treating MN include rituximab, cyclophosphamide or chlorambucil plus glucocorticoids, and calcineurin inhibitors. As this patient has a history of bladder cancer, positive anti-PLA2R antibodies, and no life-threatening disease complications, rituximab would be an acceptable choice for induction therapy. Cyclophosphamide may also be acceptable, depending on the status of the patient’s bladder cancer, with one recent trial showing better outcomes with cyclophosphamide and corticosteroids compared with rituximab and tacrolimus. However, monotherapy with a corticosteroid would not be an effective induction regimen. Treatment with rituximab confers a longer duration of remission and lower rates of relapse than treatment with calcineurin inhibitors, which are usually reserved for second-line or rescue therapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">General supportive measures are appropriate in all patients with MN. These include BP control, sodium restriction, control of edema with diuretics, reduction of albuminuria with renin-angiotensin system inhibitors, management of hyperlipidemia with statins, and in select cases, anticoagulation to prevent venous thromboembolism. As up to 40% of patients with MN will have spontaneous remission, those who have neither severe nephrotic syndrome nor high-risk features for disease progression at diagnosis can be managed expectantly with supportive measures alone for 3–6 months, while the need for initiating immunosuppression is regularly monitored. In this high-risk patient who has severe hypoalbuminemia, reduced kidney function, heavy albuminuria (estimated &gt;8 g/d), and a high anti-PLA2R titer, delaying immunosuppressive treatment would not be advisable. The addition of lisinopril would not be expected to be beneficial, as this patient is already prescribed losartan, although the dose of losartan should be maximized.</p>\n</div>",
        "references": [
            "Rovin BH, Adler SG, Barratt J, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.Kidney Int100(4S): S1–S276, 2021",
            "Behnert A, Schiffer M, Müller-Deile J, et al. Antiphospholipase A₂ receptor autoantibodies: A comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy.J Immunol Res2014: 143274, 2014",
            "Du Y, Li J, He F, et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: A meta-analysis.PLoS One9(8): e104936, 2014",
            "Fervenza FC, Appel GB, Barbour SJ, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy.N Engl J Med381(1): 36–46, 2019",
            "Couser WG. Primary membranous nephropathy.Clin J Am Soc Nephrol12(6): 983–997, 2017",
            "Fernandez-Juarez G, Rojas-Rivera J, van de Logt A, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.Kidney Int99(4): 986–998, 2021"
        ]
    },
    "26": {
        "question": "<div class=\"qtext\"><p>A 17-year-old woman presents to nephrology clinic for evaluation of hypertension. She has no known past medical history. She reports that her father and maternal grandmother were diagnosed with hypertension before the age of 25, and her father has taken potassium supplements for most of his life. The patient takes no prescribed or over-the-counter medications and does not use cigarettes, alcohol, or drugs.</p>\n<p>Her physical examination is notable for an automated office BP of 185/100 mm Hg but is otherwise unremarkable. </p>\n<p>A chemistry panel reveals normal kidney function, hypokalemia, and metabolic alkalosis. Vascular imaging of the renal arteries does not reveal any stenoses, and a transthoracic echocardiogram reveals moderate left ventricular hypertrophy.  </p>\n<p>Subsequent laboratory evaluation reveals suppressed plasma renin activity and aldosterone levels, normal cortisol and 11-deoxycortisone levels, and a normal 24-hour urine free cortisol-to-cortisone ratio. </p>\n<p><strong>Which of the following is MOST likely to reveal the etiology of this patient’s hypertension?</strong> </p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Genetic testing for mutations in the epithelial sodium channel"
            },
            {
                "label": "B.",
                "text": "Genetic testing for chimeric fusion between the promoter for the gene\nencoding 11β-hydroxylase and the gene encoding aldosterone synthase"
            },
            {
                "label": "C.",
                "text": "Genetic testing for mutations in 11β-hydroxysteroid dehydrogenase type 2"
            },
            {
                "label": "D.",
                "text": "Measurement of serum androgen and estrogen levels"
            },
            {
                "label": "E.",
                "text": "Measurement of 24-hour urinary aldosterone and sodium levels after 3\ndays of a high sodium diet"
            }
        ],
        "correct_answer": "Genetic testing for mutations in the epithelial sodium channel",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with hypertension, hypokalemia, metabolic alkalosis, and a negative evaluation for mineralocorticoid excess syndromes likely has Liddle syndrome (LS) and should be tested for gain-of-function mutations in the <em>SCNN1A, SCNN1B, </em>or <em>SCCN1G </em>genes.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">LS is an autosomal dominant condition in which the epithelial sodium channel (ENaC) is constitutively active, resulting in hypertension, hypokalemia, and metabolic alkalosis. LS is caused by gain-of-function pathogenic variants in <em>SCNN1A, SCNN1B, </em>or <em>SCCN1G, </em>which result in the α, β, or γ subunits of ENaC, respectively, being unable to interact with Nedd4, which normally leads to removal of ENaC from the luminal membrane.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Glucocorticoid-remediable aldosteronism (GRA) is an autosomal dominant condition caused by the chimeric fusion between the promoter region of the gene encoding 11β-hydroxylase, which responds to adrenocorticotropic hormone (ACTH), and the gene encoding aldosterone synthase. The net effect of this defect is ACTH-dependent activation of aldosterone synthase and hyperaldosteronism, although patients with GRA often have normal potassium levels. This patient’s suppressed aldosterone levels make GRA less likely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The syndrome of apparent mineralocorticoid excess is a rare form of juvenile hypertension that exhibits an autosomal recessive inheritance pattern and is caused by a deficiency of 11β-hydroxysteroid dehydrogenase enzyme type 2, which normally detoxifies cortisol to cortisone. The enzyme may also be inhibited by glycyrrhetinic acid, present in black licorice and chewing tobacco. If this enzyme is deficient or inhibited, then cortisol will exert a mineralocorticoid effect on the distal tubule. The family history and this patient’s normal 24-hour urine free cortisol-to-cortisone ratio makes this diagnosis less likely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Congenital adrenal hyperplasia (CAH) refers to one of several disorders characterized by genetic defects in the cortisol biosynthesis pathway. Certain subtypes of CAH may result in elevated levels of mineralocorticoids and abnormal levels of sex hormones.  This patient’s normal physical examination along with normal cortisol and 11-deoxycortisone levels make CAH less likely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Obtaining a 24-hour urine collection for aldosterone and sodium while receiving a high sodium diet is a method to confirm primary aldosteronism, although the patient’s low aldosterone level makes this diagnosis much less likely.</p>\n</div>",
        "references": [
            "Cui Y, Tong A, Jiang J, et al. Liddle syndrome: Clinical and genetic profiles.J Clin Hypertens (Greenwich)19(5): 524–529, 2017",
            "Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension.Nature355(6357): 262–265, 1992",
            "Dave-Sharma S, Wilson RC, Harbison MD, et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess.J Clin Endocrinol Metab83(7): 2244–2254, 1998",
            "White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.Endocr Rev21(3): 245–291, 2000; Erratum in:Endocr Rev;21(5): 550, 2000",
            "Young WF. Primary aldosteronism: Renaissance of a syndrome.Clin Endocrinol (Oxf)66(5): 607–618, 2007"
        ]
    },
    "27": {
        "question": "<div class=\"qtext\"><p>A 65-year-old woman with ESRD due to IgA nephropathy, treated for the last 2 years with CCPD, presents for her monthly outpatient dialysis clinic visit. Her PD prescription is four exchanges over 9 hours, with 1.5-L bags of 2.5% dextrose. She feels well but has developed lower extremity edema. Her 24-hour urine output had been 600 mL when she started PD, but is now 75 mL. Her dry weight is 60 kg.</p>\n<p>On examination, her BP is 145/85 mm Hg, and her weight is 60.9 kg. She has a normal cardiopulmonary examination and 1+ lower extremity edema bilaterally.</p>\n<p>Her total weekly Kt/V<sub>urea</sub> is 1.6, with a renal Kt/V of 0.1 (KDOQI target Kt/V<sub>urea</sub> ≥1.7). A peritoneal equilibration test (PET) shows a dialysate-to-plasma creatinine ratio of 0.7.</p>\n<p><strong>Which ONE of the following changes to the PD regimen would confer the HIGHEST risk of future ultrafiltration insufficiency?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Adding an icodextrin daytime dwell"
            },
            {
                "label": "B.",
                "text": "Increasing fill volumes to 2 L"
            },
            {
                "label": "C.",
                "text": "Changing modality to CAPD with 2.5% dextrose dialysate"
            },
            {
                "label": "D.",
                "text": "Adding a 4.25% dextrose daytime dwell"
            },
            {
                "label": "E.",
                "text": "Changing to all 1.5% dextrose dialysate"
            }
        ],
        "correct_answer": "Adding a 4.25% dextrose daytime dwell",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The risk of acquired ultrafiltration (UF) insufficiency would be highest with the addition of a 4.25% daytime dwell.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">UF insufficiency (formerly called “UF failure”) is defined as a net UF of &lt;400 mL after a 4-hour dwell with 4.25% dextrose dialysate. This test is known as the “modified PET” and provides more accurate data on ultrafiltration adequacy than the standard PET (peritoneal equilibration test), which uses 2.5% dextrose dialysate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">PD is associated with membrane function changes that eventually lead to UF insufficiency, with prolonged exposure to higher glucose solutions conferring greater risk. In a prospective cohort study, 177 anuric patients receiving PD in the European Automated Peritoneal Dialysis Outcome Study (EAPOS) were assessed for membrane function (solute transport and UF capacity) at 1 and 2 years, with the full cohort demonstrating increased solute transport and decreased UF at the measured time points. Patients who used dialysate with higher concentrations of glucose experienced greater dysfunction, and patients who used icodextrin had the least amount of change in membrane transport characteristics. The mechanism for acquired membrane dysfunction is believed to be due to the development of interstitial fibrosis within the peritoneal membrane caused by mesothelial-to-mesenchymal and endothelial-to-mesenchymal transition and the exposure to locally produced inflammatory, angiogenic, and fibrotic molecules. Higher concentrations of glucose contribute to the fibrotic process by inducing metabolic changes within the peritoneal cells that result in this cellular transformation. Glucose degradation products are produced during the heat sterilization process and form adducts with the peritoneal endothelium, causing further dysfunction. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Of the options listed, the prescription change that would lead to the highest peritoneal membrane glucose exposure is adding a daytime dwell of 4.25% dextrose. Icodextrin, a high-molecular-weight glucose polymer, would allow for increased UF with the least exposure to glucose. None of the other options listed would increase the exposure to glucose and its subsequent membrane toxicity and significantly increase the risk of membrane failure.</p>\n</div>",
        "references": [
            "Boudville N. PGB: Volume status and fluid overload in peritoneal dialysis. In:Handbook of Dialysis,5th ed., edited by Daugirdas, J, Blake P, Ing T.Wolters, Philadelphia, Kluwer, 2015, pp 483–489.",
            "Davies SJ, Brown EA, Frandsen NE, et al. Longitudinal membrane function in functionally anuric patients treated with APD: Data from EAPOS on the effects of glucose and icodextrin prescription.Kidney Int67:1609–1615, 2005",
            "Zhou Q, Bajo MA, Del Peso G, et al. Preventing peritoneal membrane fibrosis in peritoneal dialysis patients.Kidney Int90:515–524, 2016",
            "Morelle J, Stachowska-Pietka J, Öberg C, et al. ISPD recommendations for the evaluation of peritoneal membrane dysfunction in adults: Classification, measurement, interpretation and rationale for intervention.Perit Dial Int41(4): 352–372, 2021",
            "Krediet RT. Acquired decline in ultrafiltration in peritoneal dialysis: The role of glucose.J Am Soc Nephrol32(10): 2408–2415, 2021"
        ]
    },
    "28": {
        "question": "<div class=\"qtext\"><p>A 61-year-old man is evaluated in the nephrology clinic for CKD stage G4/A3 and hyperkalemia. He has a past medical history of type 1 diabetes complicated by episodes of diabetic ketoacidosis (DKA), hypertension, heart failure with moderately reduced ejection fraction, peripheral artery disease, and benign prostatic hypertrophy. Six months ago, he had an ST-elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention. He has no cardiopulmonary, gastrointestinal, or genitourinary symptoms. He has a history of hyperkalemia with a maximal potassium level of 6.2 mEq/L while taking an unknown dose of losartan, which resolved when losartan was discontinued. He has previously undergone dietary counseling about restricting potassium intake and reports adherence to a low-potassium diet.</p>\n<p>His current medications include furosemide, atorvastatin, ticagrelor, carvedilol, aspirin, lisinopril, and insulin.</p>\n<p>On examination, BP is 124/78 mm Hg, heart rate is 80/min, and oxygen saturation is 98% while breathing room air. His cardiac and pulmonary examinations are unremarkable. There is no jugular venous distention, hepatojugular reflux, or peripheral edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                139 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.0 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                106 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                43 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.6 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                eGFR\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                27 mL/min/1.73 m<sup>2</sup>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≥60\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urine protein-to-creatinine ratio is 1.5 mg/mg (reference range, &lt;0.2). The urine sediment is unremarkable.</p>\n<p>The EKG shows no features of hyperkalemia. A post-void residual bladder volume by office ultrasound is &lt;50 mL.</p>\n<p><strong>Which ONE of the following is the next best step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe sodium zirconium cyclosilicate"
            },
            {
                "label": "B.",
                "text": "Discontinue lisinopril"
            },
            {
                "label": "C.",
                "text": "Prescribe sodium bicarbonate"
            },
            {
                "label": "D.",
                "text": "Prescribe canagliflozin"
            },
            {
                "label": "E.",
                "text": "Increase furosemide"
            }
        ],
        "correct_answer": "Prescribe sodium zirconium cyclosilicate",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with hyperkalemia while receiving a blocker of the renin-angiotensin-aldosterone system (RAAS) should be treated with a potassium exchange resin to permit ongoing use of a RAAS blocker.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The incidence and prevalence of hyperkalemia increases with CKD. Accommodation occurs, but mortality significantly increases when the serum potassium level exceeds 5.5 mEq/L.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sodium zirconium cyclosilicate (SCZ) is an oral potassium binder that exchanges potassium ions for sodium and hydrogen in the gut. SCZ starts working in the small intestine and has been shown to reduce serum potassium levels within 4–6 hours of administration. It has also been shown to reduce and maintain normal potassium concentrations in patients with CKD receiving RAAS inhibitors for up to 1 year. These drugs are not indicated for the treatment of acute, life-threatening hyperkalemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although stopping lisinopril will likely ameliorate this patient’s hyperkalemia, there are strong indications to continue this patient’s RAAS blocker, including diabetic nephropathy, proteinuria, recent STEMI, and heart failure with reduced ejection fraction. Ongoing treatment with lisinopril (or other RAAS blocker) has been shown to improve kidney and overall survival in large-scale clinical trials. Therefore, there are compelling indications to continue lisinopril if possible, so stopping lisinopril would not the best option. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sodium-glucose cotransporter-2 inhibitors (SGLT2i) such as canagliflozin have been approved for type 2 diabetes but not type 1 diabetes. A meta-analysis of six major clinical trials of SGLT2i showed a reduced risk of hyperkalemia in patients treated with these agents (hazard ratio, 0.84; 95% confidence interval, 0.76–0.93). SGLT2i decrease serum glucose, leading to decreased insulin secretion, increased glucagon, a shift in metabolism that favors lipid oxidation and lipolysis, and increased ketoacid generation. This cascade of events increases the risk of DKA. This patient with type 1 diabetes and a prior history of DKA should not be prescribed an SGLT2i.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In patients with CKD and metabolic acidosis, administration of sodium bicarbonate is indicated to address the metabolic acidosis and is also associated with a dose-dependent reduction in serum potassium concentration by approximately 0.04 mEq/L per 0.1 mEq/kg/day of sodium bicarbonate. This patient would therefore require approximately 70 mEq of sodium bicarbonate to reduce potassium levels by 0.4 mEq. Furthermore, this patient’s bicarbonate level is already within normal limits, and additional bicarbonate could induce metabolic alkalosis. The addition of sodium bicarbonate is not the best option.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Increasing furosemide in a euvolemic patient could cause hypovolemia, hypotension, and pre-renal AKI and is not the best option in this case.</p>\n</div>",
        "references": [
            "Gasparini A, Evans M, Barany P, et al. Plasma potassium ranges associated with mortality across stages of chronic kidney disease: The Stockholm CREAtinine Measurements (SCREAM) project,Nephrol Dial Transplant34(9): 1534–1541, 2019",
            "Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: A meta-analysis of individual participant data from randomized, controlled trials.Circulation145(19): 1460–1470, 2022",
            "Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: A 12-month phase 3 study.Clin J Am Soc Nephrol14(6): 798–809, 2019",
            "Palmer BF, Clegg DJ. Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy. Clin J Am Soc Nephrol16(8): 1284–1291, 2021",
            "Abramowitz MK, Melamed ML, Bauer C, et al. Effects of oral sodium bicarbonate in patients with CKD.Clin J Am Soc Nephrol8(5): 714–720, 2013"
        ]
    },
    "29": {
        "question": "<div class=\"qtext\"><p>A 26-year-old woman is referred to the nephrology clinic by her gynecologist for evaluation of hypokalemia and hypomagnesemia. She recently delivered a healthy baby after a pregnancy complicated by episodes of hypokalemia and hypomagnesemia that required hospital admission for IV potassium and magnesium therapy. Her only medications are magnesium oxide and potassium chloride. </p>\n<p>She denies any recent or prior history of diuretic use and has no history of psychiatric illness. She reports a good appetite and varied diet, a history of salt craving, and chronic fatigue and muscle weakness that have limited her physical activity throughout her life. Family history is notable for 2 healthy siblings and one sibling who died as an infant of unknown causes. Her review of systems is negative other than recent loose stools that began when she was prescribed oral magnesium, accompanied by lightheadedness.</p>\n<p>On examination, BP is 112/72 mm Hg and heart rate is 82/min (sitting) and BP is 84/54 mm Hg and heart rate is 116/min (standing). The remainder of the examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                137 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.7 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5‒5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98‒106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                26 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23‒28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8‒20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5‒1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                87 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70‒99, fasting\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6‒10.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.2 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                47 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                36 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                47 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                19 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Calcium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n</tbody>\n</table><br/><strong>Which ONE of the following is the MOST appropriate next step in management of hypomagnesemia?</strong><br/></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase dose of magnesium oxide"
            },
            {
                "label": "B.",
                "text": "Refer to dietician"
            },
            {
                "label": "C.",
                "text": "Change formulation to magnesium lactate"
            },
            {
                "label": "D.",
                "text": "Prescribe psyllium"
            },
            {
                "label": "E.",
                "text": "Prescribe amiloride"
            }
        ],
        "correct_answer": "Change formulation to magnesium lactate",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate next step in management for this patient with Gitelman syndrome and hypomagnesemia is to change her PO supplementation from magnesium oxide to magnesium lactate. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient most likely has Gitelman syndrome, an autosomal recessive disorder characterized by a loss-of-function mutation in the <em>SLC12A3 </em>gene, leading to dysfunctional transport through the thiazide-sensitive Na-Cl cotransporter (NCC). Patients with Gitelman syndrome frequently have hypomagnesemia, hypokalemia, and hypovolemia due to urinary loss of magnesium, potassium, and sodium, respectively. Compensatory activation of the renin-angiotensin-aldosterone system causes metabolic alkalosis and worsens hypokalemia. This patient’s high fractional excretion of magnesium (12.9%), hypocalciuria (urine calcium-to-creatinine ratio of 0.04 mg/mg &lt;0.14 cut-off threshold), hypokalemia, metabolic alkalosis, and orthostatic vital signs all suggest a diagnosis of Gitelman syndrome. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although this disorder is associated with hypocalciuria, hypocalcemia may also be seen due to hypomagnesemia-induced reduced PTH secretion or PTH resistance. Symptoms ranging from mild muscle fatigue to tetany, seizures, and arrhythmias may be observed. Late presentation is common, with diuretics and pregnancy (hyperemesis-related, with physiologic renin and angiotensin secretion) unmasking a previously indolent case.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The mechanism of hypomagnesemia associated with Gitelman syndrome is incompletely understood. Studies have shown decreased NCC activity causing decreased expression of transient receptor potential melastatin-6 (TRPM-6) expression on the apical side of distal nephron cells, as well as apoptosis of these cells.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Management is supportive, with lifelong PO magnesium and potassium supplementation. Magnesium oxide supplementation may be poorly tolerated due to diarrhea, which may worsen hypovolemia-mediated hypotension. Studies have shown that slow-release magnesium lactate preparations are better tolerated than fast-release magnesium oxide supplementation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Potassium-sparing diuretics, notably the epithelial sodium channel blockers amiloride and triamterene, are useful in hypomagnesemia caused by renal wasting. By blocking sodium entry from the tubular lumen, these agents increase the positive charge in the urine, stimulating magnesium entry through TRPM-6. In this patient with lightheadedness and positive orthostatic vital signs, a potassium-sparing diuretic would not be the next best step in management. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Referral to a dietician to improve potassium, magnesium, and sodium intake may be a useful adjunctive strategy but would not address the poor tolerability of her current magnesium supplementation. The high fractional excretion of magnesium argues against gastrointestinal magnesium losses, so stool bulking agents such as psyllium are unlikely to treat her hypomagnesemia.</p>\n</div>",
        "references": [
            "Blanchard A, Bockenhauer D, Bolignano D, et al: Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney Int91(1): 24–33, 2017",
            "de Baaij JHF, Hoenderop JGJ, Bindels RJM: Regulation of magnesium balance: lessons learned from human genetic disease.Clin Kidney J5(Suppl 1): i15–i24, 2012",
            "Nijenhuis T, Vallon V, van der Kemp AW, et al: Enhanced passive Ca2+reabsorption and reduced Mg2+channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia.J Clin Invest115: 1651–1658, 2005",
            "Franken GAC, Adella A, Bindels RJM, de Baaij JHF: Mechanisms coupling sodium and magnesium reabsorption in the distal convoluted tubule of the kidney.ActaPhysiol (Oxf)231(2): e13528, 2021",
            "Robinson CM, Karet Frankl FE: Magnesium lactate in the treatment of Gitelman syndrome: patient-reported outcomes.Nephrol Dial Transplant32(3): 508–512, 2017"
        ]
    },
    "30": {
        "question": "<div class=\"qtext\"><p>A 64-year-old man is evaluated in the HD center for hypotension prior to treatment initiation. His past medical history includes hypertension, diabetes, and ESRD, for which he has been treated with HD via a tunneled dialysis catheter for 7 months. A radiocephalic arteriovenous fistula (AVF) was placed 3 weeks ago. His only complaint is 1 day of weakness and fatigue. Review of his treatment record for the last 3 weeks shows that his typical BP during HD is 140–150/70–80 mm Hg. His estimated dry weight is 81.5 kg. His medications include amlodipine, glipizide, lisinopril, sevelamer, and metoprolol. He reports taking all medications prior to HD treatment.</p>\n<p>On examination, BP is 84/52 mm Hg, heart rate is 112/min, temperature is 37.6°C, and weight is 84 kg. He appears tired. His heart is tachycardic but regular, his lungs are clear, and he has 1+ edema of the ankles and feet bilaterally. He has a right internal jugular tunneled dialysis catheter without exudate or tenderness along the tunnel. The site of his maturing AVF is healing well. </p>\n<p><strong>Which ONE of the following is the BEST next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increase estimated dry weight"
            },
            {
                "label": "B.",
                "text": "Obtain blood cultures"
            },
            {
                "label": "C.",
                "text": "Discontinue amlodipine"
            },
            {
                "label": "D.",
                "text": "Obtain an outpatient echocardiogram"
            },
            {
                "label": "E.",
                "text": "Refer for fistula ligation"
            }
        ],
        "correct_answer": "Obtain blood cultures",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Blood cultures should be obtained in this patient with a tunneled HD catheter and new-onset hypotension and tachycardia to rule out a dialysis catheter-related blood stream infection (CRBSI). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A high index suspicion for CRBSI must be maintained in patients with central venous catheters (CVCs), as studies have reported CRBSI by 6 months in &gt;50% of patients who initiate HD with a CVC. Absence of fever does not rule out a bloodstream infection, and lack of fever or rigors has been reported in 20–50% of patients, depending on the series. Patients without fever often will present with hypotension and/or fatigue. Other signs and symptoms include rigors, confusion, tachycardia, nausea, malaise, and redness or drainage from the catheter exit site. Promptly obtaining blood cultures and initiating antibiotic therapy, including empiric coverage for both gram-positive and gram-negative organisms, are essential in the management of a suspected CRBSI. Catheter removal with “line holiday” and echocardiography to rule out endocarditis may be indicated depending on the microbiology of the organism identified and the patient’s vascular access history. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Increasing the patient’s target weight would not be the best next step in management, as there is no evidence that hypovolemia is the cause of the new-onset hypotension. Discontinuing amlodipine should be considered, but this choice alone would not be sufficient to rule out CRBSI as the cause of the hypotension. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A transthoracic echocardiogram should be considered to evaluate for valvular disease and to assess ejection fraction in patients with progressive intradialytic hypotension but would not be the best initial step in evaluation for acute-onset hypotension. Although a new AVF can contribute to hypotension due to arteriovenous shunting of blood and high output heart failure, it is unlikely that this patient’s 3-week-old, immature radiocephalic fistula is the cause of his sudden-onset hypotension. Thus, ligation would not be an appropriate next step. Furthermore, it would lengthen the time that this patient is dependent on a CVC for dialysis access.</p>\n</div>",
        "references": [
            "Farrington CA, Allon M. Management of the hemodialysis patient with catheter-related bloodstream infection.Clin J Am Soc Nephrol14(4): 611–613, 2019",
            "Al-Solaiman Y, Estrada E, Allon M. The spectrum of infections in catheter-dependent hemodialysis patients.Clin J Am Soc Nephrol6(9): 2247–2252, 2011",
            "Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 update.Am J Kidney Dis75(4 suppl 2): S1–S164, 2020"
        ]
    },
    "31": {
        "question": "<div class=\"qtext\"><p>A 45-year-old man is evaluated in the ICU for AKI and septic shock. His symptoms of abdominal pain, nausea, vomiting, and poor oral intake started 3 days prior to admission. His past medical history is notable for obesity, hypertension, and prediabetes. His medications on admission were irbesartan and a multivitamin.</p>\n<p>His vital signs on admission were a BP of 85/45 mm Hg, heart rate of 110/min, and temperature of 38.9°C. His body mass index was 40 kg/m². On examination, he was somnolent, and his abdomen was distended and tender to palpation.</p>\n<p>Broad-spectrum antibiotics and IV pressor support were initiated. His course was complicated by worsening AKI and anuria, and CRRT was started for severe AKI and metabolic acidosis. After 72 hours in the ICU, the patient is now afebrile, and pressor support is discontinued. His urine output has improved to 850 mL over the last 24 hours.   </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Values (Admission)</strong><strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Values (48 Hours on CRRT)</strong><strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong><strong> </strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Serum \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Potassium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.0 mEq/L \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Total CO<sub>2</sub> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10 mEq/L \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                21 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   BUN \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                   Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.1 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine neutrophil gelatinase-associated lipocalin (NGAL)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                350 ng/mL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                280 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;50 \n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the BEST marker of renal recovery in this patient?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increased urine output"
            },
            {
                "label": "B.",
                "text": "Decreased\ncreatinine"
            },
            {
                "label": "C.",
                "text": "Decreased\nBUN"
            },
            {
                "label": "D.",
                "text": "Decreased\nNGAL"
            },
            {
                "label": "E.",
                "text": "Improved clinical status"
            }
        ],
        "correct_answer": "Increased urine output",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urine output, timed creatinine clearance (CrCl), and interdialytic creatinine trends remain the best markers of renal recovery in patients with AKI requiring dialysis (AKI-D). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Recovery of kidney function after a severe episode of AKI requiring renal replacement therapy (RRT) remains vital, as it impacts the patient’s long-term clinical and kidney prognosis. Despite the impact of AKI-D on mortality, there are no evidence-based clinical management guidelines available to assess for kidney function recovery. Recognizing kidney recovery in patients receiving RRT remains challenging. Recent studies in patients with AKI-D have used urine output and creatinine clearance as markers of renal recovery. In the Artificial Kidney Initiation in Kidney Injury (AKIKI) and AKIKI-2 trials, the investigators used urine output as marker of renal recovery. In this trial, discontinuation of RRT was recommended when spontaneous urine output was &gt;1000 mL/24 hours or &gt;2000 mL/24 hours with diuretics. In the Early versus Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury (ELAIN) trial, renal recovery was defined by urine output and creatinine clearance. Their cutoffs were spontaneous urine output &gt;400 mL/24 hours, &gt;2100 mL/24 hours with diuretics, and CrCl &gt;20 mL/min. The Veterans’ Affairs acute tubular necrosis (VA/ATN) trial network defined renal recovery based on timed urine creatinine clearance (6 hours) when urine output improved to 30 mL/hour or when there was a spontaneous improvement in serum creatinine. In this trial, RRT was discontinued when CrCl was more than 20 mL/min. The KDIGO AKI guidelines recommend measuring CrCl when possible, because this remains one of the best clinical markers of kidney function. Even though these are useful markers, sensitivity and specificity are limited. Despite being used as markers in clinical trials, cutoffs are not well established and vary from one study to another.   </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Improvement in serum creatinine and BUN are not good markers of kidney recovery once a patient is treated with RRT, as these laboratory values will vary widely depending on the dose of and the type of dialysis the patient is receiving. In CRRT, dose delivery of 25–35 mL/kg/min will stabilize serum markers after 48 hours. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">NGAL has been used as a marker to predict AKI. The role of this marker, especially in patients with sepsis, has been questioned, because levels can be markedly elevated in response to bacterial infection. Even though there are some studies suggesting the role of urinary NGAL and other novel urinary markers in predicting renal recovery, larger studies are needed to validate these findings.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Overall clinical improvement is important but is not a good marker or predictor of renal recovery. The range of kidney recovery can vary widely from complete recovery to ESRD, irrespective of improvement in or resolution of primary illness. Depending on the degree of CKD prior to an episode of AKI-D, 70–90% of patients will recover kidney function and 10–30% will require dialysis at the time of discharge. Patients who are discharged from the hospital requiring dialysis or with partial recovery can show kidney function improvement up to 1 year later.</p>\n</div>",
        "references": [
            "Cerdá J, Liu KD, Cruz DN, et al. Promoting kidney function recovery in patients with AKI requiring RRT.Clin J Am Soc Nephrol10(10): 1859–1867, 2015",
            "Schiffl H, Lang SM. Current approach to successful liberation from renal replacement therapy in critically ill patients with severe acute kidney injury: The quest for biomarkers continues [published correction appears inMol Diagn Ther25(4): 527, 2021].Mol Diagn Ther25(1): 1–8, 2021",
            "Schiffl H. Anticipation of recovery of native renal function and liberation from renal replacement therapy in critically ill patients with severe acute kidney injury.Ren Replace Ther8(7): 2022",
            "Gaudry S, Hajage D, Schortgen F, et al. Initiation strategies for renal-replacement therapy in the intensive care unit.N Engl J Med375(2): 122–133, 2016",
            "Gaudry S, Hajage D, Martin-Lefevre L, et al. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): A multicenter, open-label, randomized, controlled trial.Lancet397(10281): 1293–1300, 2021",
            "Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: The ELAIN randomized clinical trial.JAMA315(20): 2190–2199, 2016",
            "VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, et al. Intensity of renal support in critically ill patients with acute kidney injury [published correction appears inN Engl J Med361(24): 2391, 2009].N Engl J Med359(1): 7–20, 2008",
            "Acute Kidney Injury Work Group. KDIGO clinical practice for acute kidney injury.Kidney Int2(suppl): 1–138, 2012",
            "Srisawat N, Wen X, Lee M, et al. Urinary biomarkers and renal recovery in critically ill patients with renal support.Clin J Am Soc Nephrol6(8): 1815–1823, 2011",
            "Gaião SM, Paiva JAOC. Biomarkers of renal recovery after acute kidney injury.Rev Bras Ter Intensiva29(3): 373–381, 2017"
        ]
    },
    "32": {
        "question": "<div class=\"qtext\"><p>A 22-year-old man is taken to the emergency department by his friend after accidental ingestion of an unknown fluid earlier that day. He complains of abdominal pain but has not experienced any nausea or vomiting. He has no past medical history and takes no medications.</p>\n<p>On examination, BP is 110/77 mm Hg, heart rate is 112/min, respiratory rate is 19/min, and oxygen saturation is 98% while breathing room air. He appears distressed and is alert to person and place but is unsure of the date. Physical examination reveals mild tenderness to palpation of the abdomen but is otherwise normal.</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                142 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                106 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                81 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99, fasting</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Osmolality\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                322 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                275–295\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Shortly after arrival, the patient provides a urine sample, which shows blue-green fluorescence under a Wood’s lamp. </p>\n<p><strong>Which ONE of the following is the most appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Gastric lavage"
            },
            {
                "label": "B.",
                "text": "Activated charcoal"
            },
            {
                "label": "C.",
                "text": "Fomepizole"
            },
            {
                "label": "D.",
                "text": "Hemodialysis"
            },
            {
                "label": "E.",
                "text": "Ethanol IV"
            }
        ],
        "correct_answer": "Fomepizole",
        "abim_content_category": "Acid base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most appropriate next step in this patient with suspected ethylene glycol toxicity is the prompt administration of fomepizole.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has an elevated anion gap, an elevated osmolal gap, and fluorescent urine under a Wood’s lamp, all of which strongly suggest ethylene glycol ingestion. Other evidence of ethylene glycol ingestion would be AKI and oxalate crystals in the urine. Antifreeze ingestion is a common cause of ethylene glycol toxicity. Sodium fluorescein is added to some commercial antifreeze preparations to aid in detecting automobile cooling system leaks and can produce the urinary fluorescence described in this patient. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has an anion gap metabolic acidosis with a calculated anion gap of 22. The osmolality can be calculated using the following equation:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Calculated serum osmolality = 2 [Na<sup>+</sup>] + [BUN]/2.8 + [Glucose]/18</p>\n<p>The calculated serum osmolality for this patient is 292 mOsm/kg H<sub>2</sub>O, with a measured serum osmolality of 322 mOsm/kg H<sub>2</sub>O, leading to an osmolal gap of 30 mOsm/kg H<sub>2</sub>O. A normal osmolal gap is &lt;10 mOsm/kg H<sub>2</sub>O. Ingestion of ethylene glycol, methanol, and propylene glycol causes elevated osmolal gap due to their accumulation in the serum. As these compounds are metabolized to organic acids, the anion gap will rise. Isopropyl alcohol is associated with an elevated osmolal gap but a normal anion gap, as its metabolite is neutral acetone. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In normal physiologic states, ingested ethanol is metabolized to acetaldehyde, a reaction catalyzed by the enzyme alcohol dehydrogenase. Aldehyde dehydrogenase then converts acetaldehyde into acetic acid. Alcohol dehydrogenase also plays a role in metabolizing the alcohols methanol and ethylene glycol into formaldehyde and glycoaldehyde, respectively. Glycoaldehyde is further oxidized to its final end products, which include the toxins glycolate and oxalate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Fomepizole is an alcohol dehydrogenase inhibitor used to attenuate the metabolism of toxic alcohols. It has a 500–1000 times greater affinity for alcohol dehydrogenase than ethanol and helps prevent the metabolism of ethylene glycol or methanol into their toxic byproducts.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">HD is effective in removing ethylene glycol and its toxic metabolites and is recommended in the setting of severe metabolic acidosis (pH &lt;7.25), AKI, ethylene glycol level &gt;50 mg/dL, or glycolate level &gt;10 mg/dL. HD is generally continued until the ethylene glycol level is &lt;20 mg/dL. Even in patients who require HD, fomepizole should be given first to prevent further damage while preparing for dialysis initiation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Gastric lavage and activated charcoal are unlikely to be effective unless given in the first 30–60 minutes after ingestion. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">IV ethanol works by acting as a competitive inhibitor of alcohol dehydrogenase and can be used in low resource settings to prevent ethylene glycol metabolism if fomepizole is not available. </p>\n</div>",
        "references": [
            "Purssell RA, Oudek M, Brubacher J, et al. Derivation and validation of a formula to calculate the contribution of ethanol to the osmolal gap.Ann Emerg Med38(6): 653–659, 2001",
            "Kraut JA, Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis, and management.Clin J Am Soc Nephrol3(1): 208–225, 2008",
            "McStay CM, Gordon PE. Images in clinical medicine. Urine fluorescence in ethylene glycol poisoning.N Engl J Med356(6): 611, 2007"
        ]
    },
    "33": {
        "question": "<div class=\"qtext\">A 33-year-old woman presents to the nephrology clinic for hyponatremia noted on routine laboratory testing. She has a past medical history of bipolar disorder and irregular menstrual cycles. Her only medications are lithium and acetaminophen as needed. She denies the use of any nutritional supplements or herbal products. She says that she follows a strict plant-based diet to stay healthy. She reports no diarrhea, nausea, or dizziness.<p></p>\n<p>BP is 102/66 mm Hg and heart rate is 64/min while supine, and 98/58 mm Hg and 70/min, respectively, when measured after 3 minutes of standing. Her body mass index (BMI) is 17 kg/m<sup>2</sup>. Physical examination is normal. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference </strong><strong>Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                126 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                26 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Osmolality\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                261 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                275–295\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine, random</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                     Osmolality  \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                92 mOsm/kg H<sub>2</sub>O\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies with intake\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urine volume is 2.8 L/day.</p>\n<p><strong>Which ONE of the following is the MOST likely cause of this patient’s hyponatremia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Lithium use"
            },
            {
                "label": "B.",
                "text": "Low solute intake"
            },
            {
                "label": "C.",
                "text": "Psychogenic polydipsia"
            },
            {
                "label": "D.",
                "text": "Syndrome of inappropriate diuretic hormone secretion (SIADH)"
            },
            {
                "label": "E.",
                "text": "Hypovolemia"
            }
        ],
        "correct_answer": "Low solute intake",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p style=\"margin-bottom: 15px;\">The most likely explanation of this patient’s hyponatremia is low solute intake. Evidence for this diagnosis includes an appropriately dilute urine (as noted by the low urine osmolality) without polyuria. </p>\n<p style=\"margin-bottom: 15px;\">This patient’s low urine osmolality indicates an appropriate suppression of anti-diuretic hormone (ADH). She likely has a solute intake that is so low that water excretion cannot be met even with maximal urine dilution. This physiology is frequently referred to as “tea and toast” hyponatremia, in which low solute intake and correspondingly low solute and water excretion are the primary driving factors for hyponatremia. “Beer potomania” is similar and refers to individuals who consume large quantities of beer with almost no other food. They will also have a maximally dilute urine but insufficient solute for adequate free water excretion, resulting in hyponatremia.</p>\n<p style=\"margin-bottom: 15px;\">A useful way to determine whether someone has low solute intake is to determine their solute excretion, which would be equivalent at steady state. Calculating daily solute excretion can be done using the following equation: </p>\n<p style=\"margin-bottom: 15px;\">Daily solute excretion = urine volume × (2 × (urine [Na<sup>+</sup>] mEq/L + urine [K<sup>+</sup>] mEq/L) + (urine urea nitrogen mg/dL ÷ 2.8).</p>\n<p style=\"margin-bottom: 15px;\">However, an easier way to approximate the daily solute excretion is to multiply the urine volume by the urine osmolality. In this case, the daily solute excretion is only 92 mOsm/kg H<sub>2</sub>O × 2.8 L/day = 258 mOsm/day, whereas typical solute intake is roughly 600–900 mOsm/day.</p>\n<p style=\"margin-bottom: 15px;\">Long-term lithium use can cause nephrogenic diabetes insipidus, which would result in normal or high serum sodium and not hyponatremia with dilute urine.</p>\n<p style=\"margin-bottom: 15px;\">Although psychogenic polydipsia could result in hyponatremia with maximally dilute urine, the 24-hour urinary volume would be expected to be higher in a patient with psychogenic polydipsia and adequate solute intake. Additionally, urinary free water clearance is usually adequate to excrete the daily water load, so hyponatremia would be unusual. This patient’s normal urine volume and moderate hyponatremia would not be consistent with psychogenic polydipsia.</p>\n<p style=\"margin-bottom: 15px;\">SIADH is a common cause of hyponatremia that presents with inappropriately concentrated urine. This patient’s low urine osmolality suggests appropriate suppression of ADH.</p>\n<p style=\"margin-bottom: 15px;\">Hyponatremic hypovolemia can be seen when ADH release is triggered by a &gt;10% decrease in mean arterial pressure; in these patients, the suppressive stimulus of hypo-osmolality is overridden by hypotension. Although these patients would be expected to have a low urinary sodium concentration, their urine osmolality would be elevated because of the effects of ADH. Additionally, this patient has no evidence of hypovolemia on physical examination.</p>\n</div>",
        "references": [
            "Thaler SM, Teitelbaum I, Berl T. \"Beer potomania\" in non-beer drinkers: Effect of low dietary solute intake.Am J Kidney Dis31(6): 1028–1031, 1998",
            "Srisung W, Mankongpaisarnrung C, Anaele C, et al. A rare case of low-solute hyponatremia in a nonalcoholic person.Case Rep Nephrol Dial5(1): 49–53, 2014",
            "Sanghvi SR, Kellerman PS, Nanovic L. Beer potomania: An unusual cause of hyponatremia at high risk of complications from rapid correction.Am J Kidney Dis50(4): 673–680, 20070.",
            "Rangan GK, Dorani N, Zhang MM, et al. Clinical characteristics and outcomes of hyponatraemia associated with oral water intake in adults: A systematic review.BMJ Open11(12): e046539, 2021",
            "Seay NW, Lehrich RW, Greenberg A. Diagnosis and management of disorders of body tonicity-hyponatremia and hypernatremia: Core curriculum 2020.Am J Kidney Dis75(2): 272–286, 2020"
        ]
    },
    "34": {
        "question": "<div class=\"qtext\"><p>A 57-year-old man with CKD stage 3b, hypertension, type 2 diabetes mellitus, gastroesophageal reflux disease, and osteoarthritis is admitted for elective right knee arthroplasty. He feels well aside from several days of constipation and mild, chronic right knee pain. Home medications include lisinopril, dapagliflozin, insulin glargine and lispro, and famotidine. </p>\n<p>Vital signs on admission include the following: BP is 129/79 mm Hg, heart rate is 78/min, respiratory rate is 16 /min, and oxygen saturation is 99% while breathing room air. Physical examination reveals mild tenderness and swelling of the right knee but is otherwise normal.</p>\n<p>The patient undergoes an uncomplicated surgical procedure, with a minimum BP of 92/68 mm Hg and adequate urine output reported. Postoperative laboratory data reveal a serum potassium level of 6.1 mEq/L (reference range, 3.5–5.0), and he is treated with insulin, dextrose, and two doses of sodium polystyrene sulfonate. Other hospital medications include perioperative cefazolin, insulin, famotidine, oxycodone, and heparin for venous thromboembolism prophylaxis.</p>\n<p>On hospital day 3, he develops severe lower abdominal pain and is noted to have decreased bowel sounds and a BP of 95/40 mm Hg. Laboratory data are notable for a decrease in hemoglobin from 9.2 to 7.5 g/dL (reference range, 14–18). Serum lactate is normal. An abdominal x-ray reveals free air under the diaphragm.</p>\n<p><strong>Which ONE of the following is the MOST LIKELY diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Mesenteric ischemia"
            },
            {
                "label": "B.",
                "text": "Clostridium difficilecolitis"
            },
            {
                "label": "C.",
                "text": "Perforated duodenal ulcer"
            },
            {
                "label": "D.",
                "text": "Perforated colon"
            },
            {
                "label": "E.",
                "text": "Inflammatory bowel disease"
            }
        ],
        "correct_answer": "Perforated colon",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely diagnosis is colonic perforation due to sodium polystyrene sulfonate (SPS) use. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">SPS is a cation exchange resin designed to exchange sodium for potassium in the colon and administered orally or by enema. SPS has proven superior to placebo in reducing serum potassium levels over days to weeks; however, its utility is limited by drug interactions and safety concerns, including significant adverse gastrointestinal (GI) effects. Numerous case reports of GI bleeding, ischemic colonic necrosis, and colonic perforation have been published, prompting the US Food and Drug Administration in 2009 to issue a black box warning for the risk of serious GI adverse events with SPS use and caution against use with sorbitol, given concomitantly as a cathartic agent. The incidence of colonic perforation with SPS use has been estimated at 0.14%–1.8%, and a large retrospective cohort study showed a 1.9-fold higher risk of hospitalization for GI complications with SPS use compared with non-use. Despite this and despite the development of faster-acting relatively safer potassium binders, SPS is still often used for reasons of cost, availability, and prescriber habit. Studies examining the efficacy of SPS versus new agents such as patiromer or sodium zirconium cyclosilicate are limited. SPS is contraindicated in patients with obstructive bowel disease, hypersensitivity to SPS resins, or hypokalemia and should be used with caution in patients with reduced gut motility or constipation or patients who cannot tolerate even a small increase in sodium load. Note that none of the oral potassium exchange resins or binders are approved for acute, life-threatening hyperkalemia. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mesenteric ischemia can lead to bowel perforation but would be less likely given this patient’s lack of other risk factors (older age, smoking, heart disease, coagulopathy) and a normal serum lactate. Additionally, although SPS can cause ischemic necrosis, with a hazard ratio of 4.95 compared to non-use of SPS, the finding of free air under the diaphragm is more consistent with a colonic perforation. Fulminant <em>Clostridium difficile</em> infection due to antibiotic use typically requires prolonged antibiotic exposure rather than a single peri-operative dose, and cefazolin is less commonly associated with <em>C. difficile </em>infection than other antibiotics. Although this patient has been taking NSAIDs and is hospitalized, his ongoing use of an H2-receptor blocker (famotidine) makes a perforated peptic ulcer less likely. Similarly, new-onset inflammatory bowel disease is less likely given the acuity and severity of his presentation.  </p>\n</div>",
        "references": [
            "Lepage L, Dufour AC, Doiron J, et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD.Clin J Am Soc Nephrol10(12): 2136–2142, 2015",
            "US Food and Drug Administration. Kayexelate: Sodium polystyrene sulfonate, USP, cation-exchange resin.https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/011287s022lbl.pdf. Accessed April 16, 2023",
            "Watson M, Baker TP, Nguyen A, et al. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: A retrospective cohort study.Am J Kidney Dis60: 409–416, 2012",
            "Chou YH, Wang HY, Hsieh MS. Colonic necrosis in a young patient receiving oral kayexalate in sorbitol: Case report and literature review.Kaohsiung J Med Sci27(4): 155–58, 2011",
            "Noel JA, Bota SE, Petrcich W, et al. Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. JAMA Intern Med 179(8): 1025–1033, 2019"
        ]
    },
    "35": {
        "question": "<div class=\"qtext\"><p>A 52-year-old woman with a history of CKD stage G3b/A2 attributed to hypertension and type 2 diabetes presents to the nephrology clinic for management of hypertension and persistent lower extremity edema. Home BP readings with a validated BP monitor have ranged from 138/70 to 145/90 mm Hg. Her current antihypertensive regimen includes losartan 100 mg daily and furosemide 60 mg twice daily. She has not had any recent dietary changes. She states that she has been adherent to these medications to the best of her ability, but notes that her urinary frequency makes it difficult for her to perform her job as an assembly line worker for a large automotive company.</p>\n<p>Serum creatinine level has been stable at her baseline of 1.6 mg/dL (reference range, 0.5–1.1). A spot urine albumin-to-creatinine ratio is &lt;30 mg/g (reference range, &lt;30). </p>\n<p>A 24-hour urine collection shows the following data:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Volume\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2100 mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                240 mEq \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                65 mEq\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the next best step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Restrict dietary sodium intake"
            },
            {
                "label": "B.",
                "text": "Increase furosemide to 80 mg twice daily"
            },
            {
                "label": "C.",
                "text": "Increase furosemide to 60 mg three times daily"
            },
            {
                "label": "D.",
                "text": "Prescribe chlorthalidone"
            },
            {
                "label": "E.",
                "text": "Change furosemide to 120 mg once daily at shift completion"
            }
        ],
        "correct_answer": "Restrict dietary sodium intake",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Dietary sodium restriction would be the best next step to treat this patient’s hypertension and hypervolemia (edema). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Excessive dietary sodium intake has long been linked to hypertension, giving rise to the concept of sodium-sensitive hypertension. In the absence of significant external factors, a steady state in sodium balance allows for the estimation of total dietary sodium intake using a 24-hour urinary sodium excretion. This is true even in patients who take diuretics, as long as they are receiving a stable dose of medication. A 24-hour collection is preferred to a spot urine sodium management, which can be affected by fluctuations in sodium excretion over the course of the day. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A patient in steady state, who consumed 2 g of sodium daily, would excrete approximately 88 mEq of sodium daily. This value is calculated by dividing the total amount of sodium in milligrams by the molecular weight of sodium, 23 mg/mmol (or mg/mEq). Similarly, a 24-hour urine sodium measurement can be used to calculate the dietary intake.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient, 240 mEq/day × 23 mg/mEq = 5,520 mg/day sodium consumed, which is substantially higher than the recommended amount of 2 g/day and is likely contributing to her edema and hypertension. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The first step in decreasing sodium intake is counseling. The use of formal diet diaries, many of which allow for cross referencing databases via electronic record-keeping, have been used to better estimate daily sodium intake.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urine volumes have been significant in this patient, who states that her lifestyle is being impacted by her current diuretic dose. Her current dose appears to have reached the threshold needed to increase urine output. Increasing the frequency of diuretic dosing and/or adding a distal diuretic such as chlorthalidone would likely exacerbate urinary frequency and further impact her lifestyle. These therapeutic changes may be needed in the future should dietary restriction alone be insufficient, but dietary sodium restriction should be attempted first. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Once-daily dosing of furosemide may result in increased sodium reabsorption after the plasma concentration of drug decreases below the desired threshold and is not recommended except in rare circumstances in which dietary sodium content is extremely low. Note that torsemide has a longer half-life than furosemide and may be given once daily.</p>\n</div>",
        "references": [
            "Testani JM, Hanberg JS, Cheng S, et al. Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure.Circ Heart Fail9(1): e002370, 2016",
            "Xu J, Wang M, Chen Y, et al. Estimation of salt intake by 24-hour urinary sodium excretion: A cross-sectional study in Yantai, China.BMC Public Health14: 136, 2014",
            "Kang SS, Kang EH, Kim SO, et al. Use of mean spot urine sodium concentrations to estimate daily sodium intake in patients with chronic kidney disease.Nutrition28(3): 256–261, 2012"
        ]
    },
    "36": {
        "question": "<div class=\"qtext\"><p>A 62-year-old woman with a history of type 2 diabetes and hyperlipidemia presents to the emergency department with a 2-day history of hematuria and lower extremity swelling. Four weeks ago, she was prescribed a 5-day course of cephalexin for an area of cellulitis on her right lower leg that had developed over the preceding week.</p>\n<p>She has a BP of 152/90 mm Hg, a heart rate of 88/min, and a temperature of 37.1°C. There is no conjunctival erythema, skin rash, or murmur on cardiac auscultation. Her lungs are clear to auscultation bilaterally, and there is 2+ pretibial edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                139 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.1 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                19 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.9 mg/dL (0.9, 1 month ago)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  C3\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                40 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100–233\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  C4\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                38 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–48\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  ANA\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≤1:40\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≤1:40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  ANCA\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Anti-GBM antibodies\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Antistreptolysin O titer\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                350 Todd units\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;200\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Anti-DNase B antibodies\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Positive\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Protein-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.9 mg/mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.2\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urine sediment shows 20–30 RBCs/HPF, 20% of which are acanthocytes, and rare RBC casts.</p>\n<p>A kidney biopsy is performed.</p>\n<p><strong>Which ONE of the following is MOST likely to be seen on light microscopy?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Mesangial hypercellularity and increased mesangial matrix"
            },
            {
                "label": "B.",
                "text": "Diffuse necrotizing crescents"
            },
            {
                "label": "C.",
                "text": "Tubulitis with eosinophilic predominance"
            },
            {
                "label": "D.",
                "text": "Endocapillary hypercellularity with neutrophilic predominance"
            },
            {
                "label": "E.",
                "text": "Necrosis and sloughing of tubular cells"
            }
        ],
        "correct_answer": "Endocapillary hypercellularity with neutrophilic predominance",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with presumed post-streptococcal glomerulonephritis (GN) will most likely demonstrate endocapillary hypercellularity with a neutrophilic predominance on biopsy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely diagnosis of this patient’s AKI is post-streptococcal GN (PSGN). The patient’s history and laboratory testing support a streptococcal skin infection roughly 4 weeks prior to presentation. PSGN is caused by preceding bacterial infections (usually within the prior 8 weeks) with certain strains of group A β-hemolytic streptococci that express nephritogenic antigens. In children, pharyngitis is the most common site of infection, whereas in adults, skin infections are more common. C3 is typically low, and evidence of a recent streptococcal infection can be demonstrated by positive anti-streptolysin O titers (95% of post-pharyngitis cases, 80% of post-skin infection cases) and positive anti-DNase B antibodies. The disease is much more common in children but does occur in adults, mostly commonly in patients 60 years of age or older. One study identified diabetes and malignancies as the most common comorbidities in elderly patients diagnosed with PSGN. Kidney biopsy shows endocapillary hypercellularity, C3 and/or IgG staining, and subepithelial electron-dense deposits classically described as “humps.”</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mesangial hypercellularity and increased mesangial matrix are characteristic of IgA nephropathy. The low C3 value and evidence of a recent streptococcal infection make IgA nephropathy less likely than PSGN. Although infection with <em>Staphylococcus </em>species may produce a pattern of injury similar to IgA nephropathy, this condition frequently coexists with the infection (peri-infectious) in comparison to PSGN, which is typically post-infectious.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Necrotizing, crescentic GN would be typical for ANCA-associated vasculitis (AAV). The patient’s low C3 level along with negative ANCA serologies make a diagnosis of AAV less likely than PSGN.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Exposure to antibiotics can lead to acute interstitial nephritis (AIN), which appears as tubulitis, often with eosinophils. However, the time course of exposure to antibiotics and the development of AKI do not correlate with AIN, and AIN is not likely to present as a nephritic syndrome.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Finally, acute tubular necrosis, which appears as necrotic and sloughed tubular cells on biopsy, is not likely to present with hematuria or nephritic syndrome. </p>\n</div>",
        "references": [
            "Sethi S, Vriese AS, Fervenza FC Acute glomerulonephritis.Lancet399: 1646–1663, 2022",
            "Satoskar AA, Parikh SV, Nadasdy T. Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis.Nat Rev Nephrol16(1): 32–50, 2020"
        ]
    },
    "37": {
        "question": "<div class=\"qtext\"><p>A 65-year-old man with CKD stage 4 is seen in the nephrology clinic for routine follow-up. His past medical history includes hypertension and coronary artery disease treated with percutaneous transluminal coronary angioplasty and stenting over 10 years ago. His medications include losartan, aspirin, metoprolol, furosemide, and simvastatin. </p>\n<p>His BP is 128/70 mm Hg, and his physical examination is unremarkable.</p><p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range </strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.1 mEq/L \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                17 mEq/L (20 mEq/L, 3 months ago)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.7 mg/dL (baseline)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                eGFR\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25 mL/min/1.73 m<sup>2</sup>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≥60\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.2 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.7 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5 \n            </td>\n</tr>\n</tbody>\n</table><p>Urine albumin-to-creatinine ratio is &lt;30 mg/g (reference range, &lt;30).</p>\n<p><strong></strong></p>\n<p><b>Which ONE of\n        the following is the BEST next step in management of this patient’s electrolyte\n        abnormalities?</b> </p>\n<p></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Sodium bicarbonate PO"
            },
            {
                "label": "B.",
                "text": "Decreased intake of fruits and vegetables"
            },
            {
                "label": "C.",
                "text": "Monitor serum electrolytes every 3 months"
            },
            {
                "label": "D.",
                "text": "Reduce animal protein intake to <0.5 g/kg/day"
            },
            {
                "label": "E.",
                "text": "Potassium citrate PO"
            }
        ],
        "correct_answer": "Sodium bicarbonate PO",
        "abim_content_category": "Acid-Base and Potassium Disorders;",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with advanced CKD and worsening metabolic acidosis should be prescribed sodium bicarbonate PO.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Chronic metabolic acidosis is a common complication of advanced CKD and has been associated with increased mortality, muscle wasting, bone disease, and CKD progression. KDIGO guidelines recommend bicarbonate supplementation in patients with a serum total CO<sub>2</sub> &lt;22 mEq/L. Supplementation can be done in the form of sodium bicarbonate or sodium citrate, with dosing of 0.5–1 mEq/kg/day. Although studies have shown that the addition of base-containing foods such as fruits and vegetables can ameliorate metabolic acidosis in patients with CKD, KDIGO guidelines advise caution in using this approach in patients with hyperkalemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Decreased intake of fruits and vegetables would decrease the dietary alkali load and is not recommended, as it would likely worsen metabolic acidosis.  </p>\n<p> Because the treatment of metabolic acidosis has been shown to slow the rate of progression of CKD, simply monitoring electrolytes in the presence of worsening acidosis would not be an appropriate management strategy. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A reduction of animal protein intake may be helpful in reducing the dietary acid load but would likely be insufficient to correct the serum bicarbonate level. Additionally, decreased protein intake by itself would risk nutritional deficiency, although substitution with vegetable sources of protein may be recommended.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Potassium citrate is a form of alkali that is often used to treat renal tubular acidoses. However, the use of potassium citrate to correct acidosis in patients with CKD is not recommended due to the potential risk of hyperkalemia in patients with diminished ability to renally excrete potassium. </p>\n</div>",
        "references": [
            "Goraya N, Wesson DE. Management of the metabolic acidosis of chronic kidney disease.Adv Chronic Kidney Disease24(5): 298–304, 2017",
            "Goraya N, Simoni J, Jo CH, et al. A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate.Clin J Am Soc Nephrol8(3): 371–381, 2013",
            "KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease. KI. January 2013. Volume 1 (3).."
        ]
    },
    "38": {
        "question": "<div class=\"qtext\"><p>A 50-year-old woman with ESRD treated with PD for the last 2 months presents to the home dialysis clinic for evaluation of new-onset difficulty with instilling and draining her dialysate. Her past medical history includes type 2 diabetes, hypertension, and peripheral vascular disease.</p>\n<p>She reports that her instill and drain times are &gt;30 minutes but has not noticed changes in the effluent color or clarity. She does not have pain at the PD catheter site, any sensations of pulling, or abdominal pain, but reports abdominal fullness. She has not had any prior episodes of peritonitis. </p>\n<p><strong>Which ONE of the following is the next BEST step in management?</strong> </p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Evaluate for encapsulating peritoneal sclerosis"
            },
            {
                "label": "B.",
                "text": "Evaluate for omental wrapping of the PD catheter"
            },
            {
                "label": "C.",
                "text": "Transition to HD"
            },
            {
                "label": "D.",
                "text": "Retrain on PD technique"
            },
            {
                "label": "E.",
                "text": "Evaluate for constipation"
            }
        ],
        "correct_answer": "Evaluate for constipation",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in this patient with probable PD catheter malfunction is to evaluate for constipation and institute a bowel regimen if necessary.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The combination of difficulty instilling dialysate and a prolonged drain period is consistent with catheter malfunction. Constipation is the most common cause of catheter malfunction, often stemming from the migration of the PD catheter tip from the pelvis to the abdomen. Bowel peristalsis can assist in moving the catheter tip back to the pelvis, but during constipation, this benefit is attenuated. Enemas and laxatives can help migrate the catheter back to the correct position to facilitate instillation and drainage. Conservative management with a bowel regimen should be pursued prior to imaging studies to evaluate the peritoneum, omentum, or catheter tip.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Encapsulating peritoneal sclerosis is a devastating complication of long-term PD and can manifest as abdominal pain, difficulty draining dialysate, and nausea. However, this complication would not develop in a patient who has only performed PD for 2 months. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has not had previous peritonitis, which would be a risk factor for scarring of the PD membrane and resultant membrane failure and which can present as difficulty with ultrafiltration and/or clearance. A transition to HD would not be appropriate before more conservative management is undertaken.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Retraining on PD technique would not be necessary until constipation is ruled out.</p>\n</div>",
        "references": [
            "Kosmadakis G, Albaret J, De Costa Correia E, et al. Constipation in peritoneal dialysis patients.Perit Dial Int39(5): 399–404, 2019",
            "Diaz-Buxo JA. Management of peritoneal catheter malfunction.Perit Dial Int18(3): 256–259, 1998"
        ]
    },
    "39": {
        "question": "<div class=\"qtext\"><p>A 30-year-old woman with no past medical history presents to the emergency department 1 day after an acetaminophen overdose. She is unable to give any history. </p>\n<p>Her BP is 115/70 mm Hg, heart rate is 95/min, and temperature is 37.5°C. On examination, she is confused, with slurred speech and a tender abdomen. Her pulse is regular. She does not have any peripheral edema. Capillary refill time is &lt;3 seconds. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                13.3 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                137 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.5 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                102 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                17 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                50 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alanine aminotransferase (ALT)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1236 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Aspartate aminotransaminase (AST)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1158 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total bilirubin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.3–1.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Ammonia\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                203 µg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                40–70\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Prothrombin time (PT)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                22 s\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                11–13\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Activated partial thromboplastin time (aPTT)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                43 s\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25–35\n            </td>\n</tr>\n</tbody>\n</table>\n<p>The patient is admitted to the ICU for closer monitoring. Over the ensuing 12 hours, her urine output is 150 mL. Her urine sediment reveals numerous muddy brown casts.</p>\n<p>Her repeat potassium level is 6.0 mEq/L, total CO<sub>2 </sub>is 12 mEq/L, and creatinine level is 3.0 mg/dL. Her vital signs remain unchanged, but she is increasingly somnolent.</p>\n<p><strong>Which ONE of the following is the most appropriate next step in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hemodialysis"
            },
            {
                "label": "B.",
                "text": "Continuous venovenous hemofiltration (CVVH)"
            },
            {
                "label": "C.",
                "text": "Mannitol"
            },
            {
                "label": "D.",
                "text": "Isotonic sodium bicarbonate"
            },
            {
                "label": "E.",
                "text": "Isotonic saline"
            }
        ],
        "correct_answer": "Continuous venovenous hemofiltration (CVVH)",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with acetaminophen-induced acute liver failure (ALF) and severe AKI, the most appropriate next step in therapy is to prescribe CRRT, such as CVVH. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Up to 50% of patients with ALF will experience AKI. Acetaminophen overdose remains the most common cause of ALF in the United States and may cause acute tubular injury via the production of toxic metabolites by the injured liver. Additional causes of kidney injury in ALF include sepsis and ALF-associated hypotension and circulatory dysfunction. AKI confers a poorer prognosis in patients with acetaminophen-induced ALF and more generally in patients with fulminant liver failure. In addition to oliguric AKI, this patient has evidence of worsening hepatic encephalopathy in the setting of hyperammonemia. Severe hepatic encephalopathy (grades III and IV) is associated with a higher risk of cerebral edema. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">CRRT will best address this patient’s hyperkalemia, hyperammonemia, and metabolic acidosis while minimizing the risk of volume overload. This patient’s BP is adequate for HD, but CRRT is the preferred modality in patients with ALF. Compared with HD, CRRT reduces the risk of cerebral edema by reducing ammonia levels slowly and limiting changes in intracranial pressure that occur during intermittent HD. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although administration of mannitol may help to reduce elevated intracranial pressures, it would not help to improve the metabolic abnormalities observed, and in the setting of oliguria, could contribute to volume overload. This patient has an anion gap metabolic acidosis attributable to lactic acid accumulation and AKI, but starting a sodium bicarbonate infusion may contribute to volume overload without addressing the patient’s risk of cerebral edema. The patient does not have evidence of volume depletion by vital signs or examination, so administration of isotonic saline is not necessary. Furthermore, administration of saline could worsen metabolic acidosis by dilution of serum bicarbonate.</p>\n</div>",
        "references": [
            "Leventhal TM, Liu KD. What a nephrologist needs to know about acute liver failure. Adv Chronic Kidney Dis 22(5): 376–381, 2015",
            "Gu J, Cui H, Behr M, et al. In vivo mechanisms of tissue-selective drug toxicity: Effects of liver-specific knockout of the NADPH-cytochrome P450 reductase gene on acetaminophen toxicity in kidney, lung, and nasal mucosa. Mol Pharmacol 67(3): 623–630, 2005",
            "Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 21(3): 328–338, 1993",
            "O’Grady JG, Alexander GJ, Hayllar KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97(2): 439–445, 1989"
        ]
    },
    "40": {
        "question": "<div class=\"qtext\"><p>A 65-year-old man with amyloid light chain (AL) amyloidosis presents to his nephrologist with 1 month of progressive leg edema, weight gain, fatigue, and muscle weakness. He receives daratumumab, cyclophosphamide, bortezomib, and dexamethasone for AL amyloidosis with partial response. He denies diarrhea or vomiting. He adheres to a low-sodium, fluid-restricted diet. At a recent visit to his oncologist, his furosemide dose was increased and metolazone was added, but his weight continues to increase. His current medications include losartan 100 mg daily, furosemide 120 mg twice daily, and metolazone 5 mg daily. He takes no over-the-counter medications.</p>\n<p>On examination, BP is 153/80 mm Hg, and heart rate is 72/min. His lungs are clear, his abdomen is distended with a positive fluid wave, and he has 3+ pitting leg edema to his thighs bilaterally. The remainder of the examination is unremarkable.</p>\n<p>Laboratory results are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Current</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>\n                Serum\n            </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                144 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                110 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                31 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.5 mg/dL, baseline\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.2 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>\n                Urine, random</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                850 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                720 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1+\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n</tbody>\n</table>\n<p>The patient receives IV potassium and magnesium, and his symptoms of weakness improve.</p>\n<p><strong>Which ONE of the following is the next best step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe amiloride"
            },
            {
                "label": "B.",
                "text": "Increase furosemide and metolazone doses"
            },
            {
                "label": "C.",
                "text": "Measure urine potassium and magnesium levels"
            },
            {
                "label": "D.",
                "text": "Prescribe furosemide with albumin IV"
            },
            {
                "label": "E.",
                "text": "Prescribe spironolactone"
            }
        ],
        "correct_answer": "Prescribe amiloride",
        "abim_content_category": "Sodium and Water Abnormalities",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with nephrotic syndrome due to AL amyloidosis and diuretic resistance, blockade of the epithelial sodium channel (ENaC) with amiloride is the next best step in management.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient presents with hypoalbuminemia, nephrotic-range proteinuria, hypertension, and fluid overload consistent with nephrotic syndrome. Nephrotic syndrome is a common complication of AL amyloidosis, even in patients who achieve remission. Renal glycosuria in the absence of hyperglycemia is also common in patients with AL amyloidosis due to proximal tubule dysfunction caused by amyloid deposition. This patient’s calculated urine protein-to-creatinine ratio is 8.5 mg/mg (reference range, &lt;0.2 mg/mg), most of which is albuminuria, which is a finding consistent with amyloidosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Causes for diuretic resistance include nonadherence to fluid and salt restriction, poor absorption of diuretics due to intestinal edema, reduced tubular uptake due to advanced CKD, nephron adaptation by upregulating sodium transporters, renin-angiotensin-aldosterone (RAA) system activation, use of NSAIDs, and reduced intravascular volume. The etiology of diuretic resistance in nephrotic syndrome is likely multifactorial: (1) direct activation of ENaC by elevated levels of urinary plasmin (“overfill”) and (2) decreased intravascular volume from reduced oncotic pressure and capillary permeability, leading to RAA activation (“underfill”). Thus, the addition of an ENaC inhibitor is the next logical choice for this patient. Data in animals suggest that mineralocorticoid receptor antagonists (MRAs) may not be as efficacious in this situation, given that ENaC is independently activated and may bypass the MRA pathway. Amiloride also increases potassium and magnesium reabsorption in the cortical collecting duct, which can be useful in patients with hypokalemia and hypomagnesemia such as this one.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s electrolyte disorders are almost certainly consequent to high-dose loop and thiazide diuretic treatment. Measuring urine potassium and magnesium would confirm urinary wasting of these cations but would not help manage urinary losses or address worsening hypervolemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Increasing the dose of the loop and thiazide diuretics may help with volume management but would likely worsen hypokalemia and hypomagnesemia. Additionally, this patient has evidence of significant diuretic resistance, given the high dose of furosemide already prescribed, so additional therapeutic mechanisms to effect improved volume management will likely be required.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There is a paucity of data to suggest that diuretics combined with albumin IV is useful in adult patients with nephrotic syndrome, but it may be considered if edema remains refractory to oral management. This measure would require hospitalization and would not be the next best step in management for this patient who otherwise has no indications for hospital admission.</p>\n</div>",
        "references": [
            "Hoorn EJ, Ellison DH. Diuretic resistance.Am J Kidney Dis69(1): 136–142, 2017",
            "Gupta S, Pepper RJ, Ashman N, et al. Nephrotic syndrome: Oedema formation and its treatment with diuretics.Front Physiol15(9): 1868, 2019",
            "Bohnert BN, Essigke D, Janessa A, et al. Experimental nephrotic syndrome leads to proteolytic activation of the epithelial Na+ channel in the mouse kidney. Am J Physiol Renal Physio. 321(4): F480–F493, 2021",
            "Hinrichs GR, Mortensen LA, Jensen BL, et al. Amiloride resolves resistant edema and hypertension in a patient with nephrotic syndrome: A case report. Physiol Rep. 6(12): e13743, 2018",
            "Naljayan M, Kumar S, Steinman T, et al. Hypomagnesemia and hypokalemia: A successful oral therapeutic approach after 16 years of potassium and magnesium intravenous replacement therapy.Clin Kidney J7(2): 214–216, 2014",
            "Ho JJ, Adnan AS, Kueh YC, et al. Human albumin infusion for treating oedema in people with nephrotic syndrome.Cochrane Database Syst Rev7(7): CD009692, 2019"
        ]
    },
    "41": {
        "question": "<div class=\"qtext\"><p>A 73-year-old man with CKD stage G3b presents to the nephrology clinic with complaints of foamy urine, fatigue, back pain, and a 7-kg weight loss over the last year. He reports no chest pain, shortness of breath, melena, or hematochezia. His past medical history includes hypertension and type 2 diabetes. His prescribed medications include insulin and lisinopril; for the past 2 months, he has also been taking daily ibuprofen.</p>\n<p>On examination, BP is 120/70 mm Hg and heart rate is 86/min. He has a pale complexion, clear lungs, and no lower extremity edema. The remainder of the examination is unremarkable.</p>\n<p>Laboratory results are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Current</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.4 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelet count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                175,000/μL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>\n                Serum\n            </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                138 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                110 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.8 mg/dL (baseline)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                90 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99, fasting\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.3 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.6 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Protein, total\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.8 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.5–9.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin A1<sub>C</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.2%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.0–5.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>\n                Urine\n            </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                200 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Varies\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the next best step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Erythropoietin"
            },
            {
                "label": "B.",
                "text": "Blood transfusion"
            },
            {
                "label": "C.",
                "text": "Kidney biopsy"
            },
            {
                "label": "D.",
                "text": "Anti-phospholipase A2 receptor antibody serology"
            },
            {
                "label": "E.",
                "text": "Bone marrow biopsy"
            }
        ],
        "correct_answer": "Bone marrow biopsy",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with anemia, elevated protein gap, and significant non-albumin proteinuria, the next best step in management is a bone marrow biopsy to evaluate for multiple myeloma. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Clues that this patient has a plasma cell dyscrasia include anemia, relative hypercalcemia corrected for hypoalbuminemia, an elevated serum protein “gamma” gap ([serum protein – serum albumin] &gt; 3.5‒4.0 g/dL), and an elevated urine protein-to-creatinine ratio (2 mg/mg; reference range, &lt;0.2) without significant albuminuria. Given this patient’s weight loss and back pain, he should be urgently evaluated by hematology for bone marrow biopsy and skeletal survey to assess for multiple myeloma. Although patients with moderate to severe CKD frequently develop anemia, in patients with eGFR &gt;30 mL/min per 1.73 m<sup>2</sup> (or &gt;45 mL/min per 1.73 m<sup>2</sup> in patients with diabetes), an alternate etiology should be considered. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">As this patient exhibits all four “CRAB” symptoms (hypercalcemia, renal dysfunction, anemia, and bone pain), bone marrow biopsy takes precedence over kidney biopsy. If the bone marrow biopsy is inconclusive, kidney biopsy could then be considered to evaluate for monoclonal gammopathy of renal significance (MGRS).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Additional laboratory data that may help diagnose plasma cell dyscrasia include protein electrophoresis and immunofixation of serum and urine and serum free light chain analysis. This additional evaluation should not delay a bone marrow biopsy. Anti-phospholipase A2 receptor antibody testing may be considered if hematology evaluation is negative, but membranous nephropathy (MN) typically presents as nephrotic syndrome with nephrotic-range albuminuria. This patient’s normal urine albumin excretion makes MN less likely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Blood transfusion may be considered for symptomatic anemia, but this patient’s hemoglobin is above the usual threshold for transfusion (&gt;7–8 g/dL), especially in the absence of severe symptoms, progressively and rapidly worsening anemia, or acute coronary ischemia.</p>\n<p>Erythropoietin and other erythropoiesis-stimulating agents (ESAs) are prescribed for patients with anemia due to CKD, but given the preponderance of evidence that this patient has an underlying plasma cell dyscrasia, ESA administration would not be the next best step in management.</p>\n</div>",
        "references": [
            "Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease.BMC Nephrol18(1): 345, 2017",
            "Leung N, Bridoux F, Nasr SH. Monoclonal gammopathy of renal significance.N Engl J Med384(20): 1931–1941, 2021",
            "Carson JL, Stanworth SJ, Dennis JA, et al. Transfusion thresholds for guiding red blood cell transfusion.Cochrane Database Syst Rev12(12): CD002042, 2021",
            "Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.Nat Rev Nephrol15(1); 45–59, 2019",
            "Dupuis MM, Paul B, Loitsch G, et al. Gamma gap: A point-of-care test that correlates with disease burden and treatment response in multiple myeloma.JCO Oncol Practice16(8): e751–e757, 2020",
            "Sidiqi MH, Aljama M, Kumar SK, et al. The role of bone marrow biopsy in patients with plasma cell disorders: Should all patients with a monoclonal protein be biopsied?Blood Cancer J10(5): 52, 2020"
        ]
    },
    "42": {
        "question": "<div class=\"qtext\"><p>An 18-year-old man with no past medical history was referred to the nephrology clinic after his physician found 4+ protein on a dipstick urinalysis. There is no history of edema, gross hematuria, decreased urine output, headaches, or elevated BP. He has not had any recent illnesses. He reports no arthralgias, fevers, night sweats, or weight changes. His only medication is a multivitamin. His parents report that he has a paternal cousin who required a kidney transplant, but they do not know the cause of his kidney disease. His father has type 2 diabetes.</p>\n<p>On examination, BP is 100/68 mm Hg. The remainder of his examination is normal. He does not have peripheral or periorbital edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.0 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.5 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total cholesterol\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                270 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Desirable &lt;200\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Triglycerides\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                179\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Normal &lt;150\n            </td>\n</tr>\n</tbody>\n</table>\n<p>A urinalysis shows 0 RBC/HPF and 0–5 WBC/HPF. A urine protein-to-creatinine ratio is 5.3 mg/mg (reference range, &lt;0.2)</p>\n<p>A kidney biopsy is performed (see images below), and genetic testing is ordered.</p>\n<figure><br/></figure>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/ksapv9m1b2q3a.png\" width=\"50%\"/>\n<p></p>\n<figure></figure><i>Transmission electron microscopy (TEM). Image courtesy of Surya Seshan MD, Weill Cornell Medicine</i></figure>\n<figure><i><br/></i>\n<figure><img class=\"img-responsive atto_image_button_text-bottom\" height=\"auto\" src=\"https://education.asn-online.org/file.php/1/ksapv9m1b2q3b.png\" width=\"50%\"/>\n<figcaption><em>\n<p>Periodic Acid Schiff (PAS) stain, 60× magnification. Image courtesy of Surya Seshan MD, Weill Cornell Medicine</p>\n<p><i></i></p>\n</em></figcaption>\n</figure>\n<p><strong>Which ONE of the following gene products is MOST likely abnormal in this patient?</strong></p>\n</figure></div>",
        "choices": [
            {
                "label": "A.",
                "text": "α-Galactosidase"
            },
            {
                "label": "B.",
                "text": "Podocin"
            },
            {
                "label": "C.",
                "text": "Type IV collagen, α5 chain"
            },
            {
                "label": "D.",
                "text": "Fibrocystin"
            },
            {
                "label": "E.",
                "text": "Uromodulin"
            }
        ],
        "correct_answer": "Podocin",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this young adult patient with a family history of ESRD and evidence of focal segmental glomerulosclerosis (FSGS) on biopsy, the most likely genetic cause is a mutation in the <em>NPHS2 </em>gene that encodes podocin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">FSGS is a histologic lesion commonly found in inherited nephrotic syndromes in children and young adults. FSGS is commonly classified as primary, secondary, or genetic. The prevalence of monogenic FSGS is estimated to be approximately 30%–50% in patients with familial disease (as in this case vignette) and 5%–30% in sporadic FSGS. Histologic evidence of FSGS by itself does not establish the diagnosis but should trigger further evaluation to determine the etiology, which confers implications for treatment and prognosis. Mutations in the <em>NPHS2</em> gene result in defective podocin and are inherited in an autosomal recessive pattern. Although most patients with mutations in <em>NPHS2</em> present in early childhood, there have been reports of patients with milder disease who present in adolescence or young adulthood.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mutations in the gene for α-galactosidase cause Fabry disease, a lysosomal storage disorder. Patients with Fabry disease typically display a variety of systemic manifestations, including neuropathy, skin telangiectasias, and corneal opacities. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mutations in the gene encoding the α5 chain of type IV collagen are one cause of hereditary nephritis (Alport syndrome). These patients often present with hearing loss and anterior lenticonus, and EM findings include a lamellated appearance of the GBM.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Fibrocystin gene mutations cause autosomal recessive polycystic kidney disease, a disorder that would typically present in a young adult patient with symptoms and signs related to hepatic fibrosis and progressive CKD; nephrotic syndrome would be atypical.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Uromodulin gene mutations are one of the causes of autosomal dominant tubulointerstitial kidney disease. These patients do not exhibit nephrotic syndrome, as the lesions spare the glomerulus. They present with bland urine sediment and subnephrotic proteinuria.</p>\n</div>",
        "references": [
            "De Vriese AS, Sethi S, Nath KA, et al. Differentiating primary, genetic, and secondary FSGS in adults: A clinicopathologic approach.J Am Soc Nephrol29(3): 759–774, 2018",
            "Santín S, Bullich G, Tazón-Vega B, et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome.Clin J Am Soc Nephrol6(5): 1139–1148, 2011",
            "Lovric S, Fang H, Vega-Warner V, et al. Rapid detection of monogenic causes of childhood-onset steroid-resistant nephrotic syndrome.Clin J Am Soc Nephrol9(6): 1109–1116, 2014",
            "Bouchireb K, Boyer O, Gribouval O, et al. NPHS2 mutations in steroid-resistant nephrotic syndrome: A mutation update and the associated phenotypic spectrum. Hum Mutat 35(2): 178–186, 2014",
            "Franceschini N, North KE, Kopp JB, et al. NPHS2 gene, nephrotic syndrome and focal segmental glomerulosclerosis: A HuGE review.Genet Med8(2): 63–75, 2006",
            "Büscher AK, Kranz B, Büscher R, et al. Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 5(11): 2075–2084, 2010"
        ]
    },
    "43": {
        "question": "<div class=\"qtext\"><p>A 63-year-old man presents to the nephrology clinic for a scheduled dialysis modality discussion. He has a history of CKD stage G5 due to diabetic nephropathy, type 2 diabetes for more than 20 years, hypertension, and diverticulosis. He also has a surgical history of an open repair of infrarenal abdominal aortic aneurysm with a graft and a remote history of appendectomy. His eGFR declined after a hospitalization 6 months ago that was complicated by AKI that did not require dialysis. He is prescribed losartan, amlodipine, and chlorthalidone with adequate BP control. Other medications include atorvastatin, calcitriol, dapagliflozin, sodium bicarbonate, and nightly gabapentin. He has no complaints. He is here today with his wife. He continues to work and lead an active life but notes fatigue and poor appetite. </p>\n<p>On examination, BP is 132/69 mm Hg, and body mass index (BMI) is 36 kg/m<sup>2</sup>. He appears comfortable. Abdominal examination reveals well-healed abdominal scars. He has a nontender, reducible umbilical hernia. There is trace edema around the ankles. He has no asterixis. The examination is otherwise unremarkable. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                138 mEq/L \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.9 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                22 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                49 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.7 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                eGFR\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                13 mL/min/1.73 m<sup>2</sup>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≥60\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                PTH, intact\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                215 pg/mL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–65 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.9 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5 \n            </td>\n</tr>\n</tbody>\n</table>\n<p>After revisiting your previous discussion on dialysis modality options, he indicates that he prefers PD. He has already been referred for transplant evaluation. </p>\n<p><strong>Which ONE of the following is the MOST appropriate next step?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Refer for surgical PD catheter placement"
            },
            {
                "label": "B.",
                "text": "Refer for percutaneous PD catheter placement"
            },
            {
                "label": "C.",
                "text": "Refer for HD catheter placement"
            },
            {
                "label": "D.",
                "text": "Refer for HD arteriovenous access placement"
            },
            {
                "label": "E.",
                "text": "Reevaluate symptoms, volume status, and laboratory data in 6 months"
            }
        ],
        "correct_answer": "Refer for surgical PD catheter placement",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with advanced CKD and prior abdominal surgeries, who prefers PD as a dialysis modality, referral should be made for surgical PD catheter placement.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Shared decision making is important in advanced CKD. Home modalities such as PD should be offered whenever possible. Patients should have sufficient time to review and discuss treatment modalities. Late nephrology referral and poor preparation for dialysis initiation are associated with higher rates of central venous catheter insertions and poorer survival. PD is associated with higher patient satisfaction (health-related quality of life) and improved survival in the first 2 years compared with in-center HD with a dialysis catheter. PD catheters may be placed surgically or percutaneously, the latter with ultrasound or fluoroscopic guidance. The catheter is preferably placed at least 2 weeks before initiation whenever possible to avoid mechanical complications such as leakage. To make the appropriate referral, potential barriers to successful PD and barriers to catheter insertion and function such as adhesions and hernias must first be assessed. In those with barriers to safely perform PD such as impaired manual dexterity, vision, or cognition, the availability of appropriate caregiver assistance must first be ascertained.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There are very few absolute contraindications to PD. These primarily include lack of a suitable peritoneal cavity due to scarring and adhesions, a nonfunctional peritoneal membrane such as in the case of known peritoneal membrane ultrafiltration failure, or if catheter access is not possible. Active intra-abdominal, skin, or abdominal wall infection are clear contraindications. However, asymptomatic diverticulosis or a history of resolved diverticulitis is not a contraindication to PD. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">History of complex abdominal surgery is a risk factor for peritoneal scarring and adhesions but is not a contraindication for PD catheter insertion. Patients with complex abdominal surgery benefit from surgical referral due to the high risk of catheter malfunction associated with adhesions. Patients must be examined for the presence of abdominal scars and hernias at the time of modality discussion and referral. The presence of abdominal hernias is not a contraindication. However, if a hernia is present, it must be repaired at the time of surgical PD catheter insertion. Repair with a mesh at the time of catheter insertion is associated with decreased recurrence. Surgical (laparoscopic or open) catheter placement allows visualization of the peritoneal cavity to assess the extent of adhesions and perform lysis of adhesions if necessary. Although many patients can have PD catheters placed 2 weeks before planned PD initiation, in a patient who may require advanced imaging or has other surgical concerns, earlier evaluation by a surgeon can help ensure anatomic problems are discussed and addressed before initiation is imminent. The presence of vascular grafts has not been shown to be associated with higher incidence of peritonitis or graft infection. PD may theoretically be a more optimal modality in such patients due to the lower risk of bacteremia compared with HD. However, KDOQI guidelines recommend at least 4 months wait time between endovascular graft placement and PD to allow epithelialization of the graft. Other perceived barriers to PD, such as symptomatic cholelithiasis, morbid obesity, ADPKD, or the presence of an ostomy have potential solutions such as cholecystectomy at the time of insertion and modified catheter and insertion site selection for the rest.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with at least two previous significant abdominal surgeries and an umbilical hernia, surgical placement would be preferred to percutaneous placement, as it would decrease the likelihood of catheter placement failure.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">As previously mentioned, this patient does not have absolute contraindications to PD catheter placement, so HD catheter or arteriovenous access placement would not be appropriate at this time unless he were subsequently found to be ineligible to perform PD, which he prefers.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with fatigue, anorexia, and developing edema, it would be inappropriate to wait 6 months for reevaluation without active dialysis planning. </p>\n</div>",
        "references": [
            "Al-Natour M, Thompson D. Peritoneal dialysis.Semin Intervent Radiol33(1): 3–5, 2016",
            "Chan CT, Blankestijn PJ, Dember LM, et al. Dialysis initiation, modality choice, access, and prescription: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney Int96(1): 37–47, 2019",
            "Crabtree JH, Shrestha BM, Chow KM, et al. Creating and maintaining optimal peritoneal dialysis access in the adult patient: 2019 update.”Perit Dial Int39(5): 414–436, 2019",
            "Chuasuwan A, Pooripussarakul S, Thakkinstian A, et al. Comparisons of quality of life between patients underwent peritoneal dialysis and hemodialysis: A systematic review and meta-analysis.Health Qual Life Outcomes18(1): 191, 2020",
            "Teitelbaum I. Peritoneal dialysis.N Engl J Med.385(19): 1786–1795, 2021"
        ]
    },
    "44": {
        "question": "<div class=\"qtext\"><p>A 35-year-old woman presents to the hospital with 2 days of worsening nausea, vomiting, and abdominal pain. Her past medical history is significant for type 1 diabetes and hypothyroidism. She reports running out of her home insulin several days ago, and a review of systems is positive for polyuria and increased thirst.</p>\n<p>On arrival, BP is 94/52 mm Hg, heart rate is 134/min, and respiratory rate is 24/min. On physical examination, she appears somewhat lethargic, with dry mucus membranes and a 2/6 systolic murmur best heard over the left upper sternal border. The rest of her physical examination is unremarkable.   </p>\n<p>Based on her initial laboratory results, she is initiated on an IV insulin drip and potassium-containing IV fluids for management of diabetic ketoacidosis (DKA). Several hours later, she reports improving nausea and abdominal pain, and she is able to eat crackers.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Initial</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Five Hours Later</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                132 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                138\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                106\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                22\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.4 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.1\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                384 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                235\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99, fasting</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.6 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.3\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  β-Hydroxybutyrate\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.2 mmol/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.4\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.5 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Lactate\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.0 mmol/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7-2.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Venous Blood Gas</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  pH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.22\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.30\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7.32–7.41\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  pCO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                32 mm Hg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                42\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                42–53 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  pO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                42 mm Hg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                44\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                35–42 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urinalysis</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  pH\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.0\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.5\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.5–8.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Specific gravity\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.023\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.012\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.005–1.025\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4+\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2+\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Ketones\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Small\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Large\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2+\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1+\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n</tbody>\n</table>\n \n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Continue insulin IV until urinary ketones are decreasing"
            },
            {
                "label": "B.",
                "text": "Continue insulin IV until urinary ketones are undetectable"
            },
            {
                "label": "C.",
                "text": "Transition insulin from IV to subcutaneous dosing"
            },
            {
                "label": "D.",
                "text": "Continue insulin IV and transition to dextrose-containing IV fluids"
            },
            {
                "label": "E.",
                "text": "Discontinue insulin IV until serum glucose level rises to 250 mg/dL"
            }
        ],
        "correct_answer": "Transition insulin from IV to subcutaneous dosing",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step is to transition the patient from IV insulin to subcutaneous insulin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Expert opinion recommends transitioning to subcutaneous insulin once DKA has resolved. Resolution of DKA is evidenced by normalization of both the anion gap (AG) and levels of serum ketoacids, specifically β-hydroxybutyrate (BHB). In this patient, the AG has normalized from 20 to 10, and BHB is now normal at 0.4 mmol/L, indicating that a switch to subcutaneous insulin is appropriate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Urinary ketones are not a reliable indicator of resolution of DKA, especially during treatment. Unlike direct measurements of serum BHB, urinary measurements of ketones are based on the use of a nitroprusside reaction that provides a semiquantitative measure of the ketoacid acetoacetate and does not register the presence of BHB. As ketoacidosis resolves with treatment, BHB is oxidized to acetoacetate and nitroprusside testing of ketones (in urine or serum) may give the misleading impression that ketosis is not improving or even worsening, as seen in this patient, in whom urinary ketones are increasing, whereas other measures of DKA are improving. Thus, treatment decisions should not be made based on urine ketone values.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">As this patient’s DKA has resolved, it is inappropriate to continue IV insulin therapy with or without the addition of dextrose-containing fluids. Dextrose-containing fluids may be added once serum glucose decreases below 200 mg/dL and thus are not needed here, particularly in the setting of planned transition of insulin therapy from IV to subcutaneous. Insulin should never be completely discontinued in patients with type 1 diabetes, as they are unable to generate endogenous insulin. </p>\n</div>",
        "references": [
            "Dhatariya K. Blood ketones: Measurement, interpretation, limitations, and utility in the management of diabetic ketoacidosis.Rev Diabet Stud13(4): 217–225, 2016",
            "Wallace TM, Matthews DR. Recent advances in the monitoring and management of diabetic ketoacidosis.QJM97(12):773–780, 2004",
            "Stephens JM, Sulway MJ, Watkins PJ. Relationship of blood acetoacetate and 3-hydroxybutyrate in diabetes.Diabetes20(7): 485–489, 1971"
        ]
    },
    "45": {
        "question": "<div class=\"qtext\"><p>A 50-year-old woman presented to the emergency room 10 days ago for evaluation of a swollen and painful left prosthetic knee joint. She underwent a CT scan of her knee with IV contrast and a synovial fluid aspiration and was prescribed empiric gentamycin and ciprofloxacin until cultures resulted. After 2 days, cultures grew gram-negative bacilli, and gentamycin was discontinued. She remained on ciprofloxacin. Her past medical history includes multiple myeloma with bony lesions, for which she is prescribed bortezomib and pamidronate. Her last dose of both was 1 day before admission.</p>\n<p>Serum creatinine level on admission was 0.8 mg/dL (reference range, 0.5–1.1), which increased to 1.2 mg/dL on day 7 and to 3.1 mg/dL on day 10. Urine output decreased to &lt;100 mL/24 h. Her urinalysis was notable for WBC count &gt;30/HPF. A kidney biopsy showed an interstitial infiltrate consisting of mononuclear cells, eosinophils, and interstitial edema. The glomerulus and vessels had no pathologic changes. </p>\n<p><strong>Which ONE of the following is the most likely cause of AKI?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Gentamycin"
            },
            {
                "label": "B.",
                "text": "CT contrast"
            },
            {
                "label": "C.",
                "text": "Bortezomib"
            },
            {
                "label": "D.",
                "text": "Ciprofloxacin"
            },
            {
                "label": "E.",
                "text": "Pamidronate"
            }
        ],
        "correct_answer": "Ciprofloxacin",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of this patient’s acute interstitial nephritis (AIN) and AKI is ciprofloxacin. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although several drugs have been associated with AIN, antibiotics, NSAIDs, and proton-pump inhibitors account for most of the cases reported. Among the antibiotics, β-lactam antibiotics, sulfa-containing drugs, fluoroquinolones, and rifampin are commonly associated with AIN. The onset of drug-induced AIN typically varies from 5–7 days to several weeks after exposure to the drug. The pathogenesis is thought to be via a T-cell-mediated immune responses. Patients may present with rash, fever, eosinophilia, and RBCs and WBCs in the urine, but more often, patients are asymptomatic, and AIN is suspected based on routine monitoring of creatinine. A kidney biopsy is often required to establish the diagnosis of drug-induced AIN. Discontinuing the offending drug is crucial. Based on retrospective observational studies, glucocorticoid therapy also has been suggested to improve kidney outcomes in some patients with AIN, although placebo-controlled trial evidence is lacking.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Aminoglycosides such as gentamycin, tobramycin, and amikacin are associated with AKI. Risk factors include concurrent toxins, decreased baseline kidney function, and prolonged exposure. Aminoglycosides accumulate in proximal tubular cells and impair lysosomal and mitochondrial function, leading to cell apoptosis. Patients usually develop nonoliguric AKI after 5–7 days of treatment with gentamycin. In this patient with a short exposure to gentamycin and anuria, gentamycin would not be the most likely etiology of AKI. Additionally, although kidney biopsy findings in gentamycin toxicity may include interstitial inflammation, the hallmark is acute tubular necrosis (ATN). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In patients suspected to have contrast-associated AKI (CA-AKI), a rise in creatinine level is expected within 24–48 hours of exposure to iodinated contrast. It is uncommon to see CA-AKI in patients with normal baseline kidney function. Urinalysis may show muddy brown tubular casts, and biopsy may show focal ATN. The timeline between exposure and AKI and the biopsy findings do not favor a diagnosis of CA-AKI in this patient.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Bortezomib is a proteasome inhibitor used in the treatment of multiple myeloma. Cases of thrombotic microangiopathy (TMA) have been associated with proteasome inhibitors. Patients may present with microangiopathic hemolytic anemia and thrombocytopenia, and urinalysis may show hematuria and proteinuria. The kidney biopsy usually demonstrates thickening of capillary walls and microthrombi. This patient does not have clinical features or biopsy findings suggesting TMA.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Biphosphonates are used to treat the hypercalcemia of malignancy and osteolytic bone metastasis. The dosage must be adjusted in patients with decreased kidney function. Pamidronate may present with proteinuria and is most commonly associated with focal segmental glomerular sclerosis lesions on biopsy. The temporal association of antibiotic exposure and AIN on kidney biopsy suggests that ciprofloxacin rather than pamidronate is the offending agent.</p>\n</div>",
        "references": [
            "Perazella MA, Rosner MH. Drug-induced acute kidney injury.Clin J Am Soc Nephrol17(8): 1220–1233, 2022",
            "Barreto EF, Rule AD. Management of drug-associated acute interstitial nephritis.Kidney3601(1): 62–64, 2020"
        ]
    },
    "46": {
        "question": "<div class=\"qtext\"><p>A 58-year-old woman with CKD stage 4, type 2 diabetes, and hypertension presents to the nephrology clinic for a follow-up visit to discuss her BP. She has required titration of her antihypertensive regimen in recent months, and at her last visit, carvedilol was added. She notes that her home BPs have been 135–155/75–85 mm Hg. Overall, she feels well and has no complaints.</p>\n<p>Her current medications include carvedilol 12.5 mg twice daily, furosemide 60 mg twice daily, lisinopril 40 mg daily, atorvastatin, empagliflozin, and insulin.</p>\n<p>On examination, BP is 140/78 mm Hg, and heart rate is 62/min. Her weight is 75 kg. She has a normal cardiopulmonary examination and no pedal edema.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Blood</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">137 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136–145 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">5.0 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Chloride </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">102 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">98–106 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">24 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28  </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  eGFR</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">27 mL/min/1.73 m<sup>2</sup></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">≥60 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Hemoglobin A1<sub>c</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">6.6%</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.0–5.6</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Urine, random</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Protein</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">78 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">52 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the next best step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe chlorthalidone"
            },
            {
                "label": "B.",
                "text": "Increase furosemide dose"
            },
            {
                "label": "C.",
                "text": "Increase carvedilol dose"
            },
            {
                "label": "D.",
                "text": "Prescribe spironolactone"
            },
            {
                "label": "E.",
                "text": "Continue current regimen"
            }
        ],
        "correct_answer": "Prescribe chlorthalidone",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in this patient with CKD stage 4 and uncontrolled hypertension is to prescribe chlorthalidone.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Thiazide diuretics are well recognized as effective antihypertensives, constituting first- or second-line therapy in many patients. However, there has been concern about the potency and efficacy of thiazide diuretics when eGFR falls below 30 mL/min/1.73 m<sup>2</sup>, and their use in patients with advanced CKD has been limited. Much of this hesitancy is based on small, older studies, but more recent data clearly demonstrate the efficacy of thiazide diuretics in CKD. In a 2021 randomized controlled trial, chlorthalidone was shown to improve systolic BP by 10.5 mm Hg in patients with advanced CKD when added to their existing regimen compared with placebo. Approximately 60% of patients in that trial were also receiving loop diuretics. Additionally, in the 12-week study, patients randomized to chlorthalidone had a reduction in albuminuria compared with placebo. In this patient with suboptimal BP control and ongoing proteinuria, adding chlorthalidone would be the next best step. Notably, chlorthalidone is more potent than hydrochlorothiazide and has a longer half-life, making it a preferred thiazide diuretic in advanced CKD.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Furosemide is a threshold drug, meaning that once a threshold dose of the drug is shown to be efficacious, additional increases will not confer much additional benefit. Thus, for this euvolemic patient, increasing the furosemide dose would not be the next best step in management. Additionally, chlorthalidone offers more potential benefit for decreasing proteinuria.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient is unlikely to tolerate an increase in carvedilol dose due to her already low heart rate. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Spironolactone is effective in resistant hypertension but likely to cause hyperkalemia in this patient with advanced CKD and a borderline elevated potassium level. If BP remains above goal after the addition of chlorthalidone, spironolactone would a reasonable next step.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Given this patient’s elevated BP above the target range of 120–130/80–90 mm Hg, continuing the same medical regimen would not be appropriate.</p>\n</div>",
        "references": [
            "Agarwal R, Sinha A, Cramer A, et al. Chlorthalidone for hypertension in advanced chronic kidney disease.N Engl J Med385(27): 2507–2519, 2021",
            "Sinha A, Agarwal R. Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD.Clin J Am Soc Nephrol14(5): 757–764, 2019",
            "Peterzan M, Hardy R, Chaturvedi N, et al. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium and urate.Hypertension59(6): 1104–1109, 2012"
        ]
    },
    "47": {
        "question": "<div class=\"qtext\"><p>A 41-year-old man presents to nephrology clinic for evaluation of CKD, which was found by his primary care physician on blood draws 3 months apart. He has no significant medical history. He is physically active and works as a personal trainer. His father, who is being evaluated for a kidney transplant, has ESRD attributed to diabetic nephropathy. He takes no prescription or over-the-counter medications but does use protein and creatine supplements daily.</p>\n<p>Physical examination reveals a well-appearing man. BP is 122/68 mm Hg, and heart rate is 62/min. His body mass index is 26 kg/m<sup>2</sup>, and he is muscular with numerous skin tattoos. </p>\n<p>His creatinine level is 1.6 mg/dL (reference range, 0.7–1.3 ). Using the CKD-Epidemiology Collaboration (CKD-EPI) creatinine formula, he has an eGFR of 55 mL/min/1.73 m<sup>2</sup>.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in evaluation or management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Creatinine clearance (24-hour urine)"
            },
            {
                "label": "B.",
                "text": "Iothalamate clearance"
            },
            {
                "label": "C.",
                "text": "Kidney ultrasound"
            },
            {
                "label": "D.",
                "text": "Lisinopril"
            },
            {
                "label": "E.",
                "text": "Hepatitis C serology"
            }
        ],
        "correct_answer": "Creatinine clearance (24-hour urine)",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with a low eGFR who has high muscle mass and takes creatine supplements, the next best step in evaluation is to collect a 24-hour urine for creatinine clearance. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">GFR is estimated from clearance measurements or serum levels of filtration markers. Most commonly, GFR is estimated using serum levels of the endogenous filtration markers creatinine or cystatin. Blood levels of creatinine and cystatin are dependent on GFR and non-GFR determinants. Creatinine is the most commonly used endogenous marker, and eGFR<sub>cr </sub>is the recommended initial assessment in adults due to its wide availability and low cost. However, the accuracy of eGFR<sub>cr</sub> may be limited in certain settings, including extremes of muscle mass, severe illness, and during protein and creatine supplementation. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Measurement of urinary or plasma clearance of an exogenous filtration marker is the most accurate method to determine GFR. Although the clearance of the exogenous filtration markers inulin or iothalamate is considered the gold standard for GFR measurement, these tests are more cumbersome to obtain and may not be necessary to estimate kidney function, especially in this patient in whom there is an alternate explanation for inaccurate eGFR.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Estimation of GFR from the endogenous filtration marker cystatin C seems to be influenced by different non-GFR determinants than creatinine. Cystatin C clearance may be affected by obesity, thyroid disease, and diabetes. Although estimation of GFR with cystatin C may be used to confirm creatinine-based eGFR in patients with high muscle mass and in those taking creatine supplements, eGFR<sub>cr-cys</sub> seems to be more accurate than either eGFR<sub>cr </sub>or eGFR<sub>cys.</sub></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A kidney ultrasound or hepatitis serology may be a useful next step if CKD is confirmed by 24-hour creatinine clearance but would be premature if his kidney function is normal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Lisinopril may be beneficial if this patient has evidence of proteinuria or hypertension. As his BP is normal and there are no urine protein excretion data, lisinopril prescription would not be the next best step in management.</p>\n</div>",
        "references": [
            "Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race.N Engl J Med385: 1737–1749, 2021",
            "Williamson L, New D. How the use of creatine supplements can elevate serum creatinine in the absence of underlying kidney pathology. BMJ Case Rep. 2014: bcr20144204754, 2014",
            "Willis J, Jones R, Nwokolo N, et al. Protein and creatine supplements and misdiagnosis of kidney disease.BMJ340: b5027, 2010"
        ]
    },
    "48": {
        "question": "<div class=\"qtext\"><p>A 57-year-old man with ESRD treated with HD presents to the emergency department with a painful and enlarged arteriovenous (AV) fistula immediately following his HD treatment. His AV fistula has been progressively enlarging over the past few weeks, and he required 7–10 minutes of manual compression to achieve hemostasis of his cannulation sites following his last few dialysis treatments. Dialysis staff have routinely used 16-gauge needles and the rope-ladder technique for his cannulation. He is prescribed apixaban for a history of atrial fibrillation.</p>\n<p>On examination, his BP is 155/87 mm Hg, heart rate 97/min, and respiratory rate 20/min, with an oxygen saturation of 94% while breathing room air. He appears uncomfortable. The arterial anastomosis of the left arm AV fistula is expanded and pulsatile. His skin appears to be blanched and tight with several needle puncture sites noted.</p>\n<p><strong>Which ONE of the following is the next best step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Ultrasound-guided manual compression"
            },
            {
                "label": "B.",
                "text": "Duplex Doppler ultrasound of expanded area"
            },
            {
                "label": "C.",
                "text": "Avoid cannulation of expanded area"
            },
            {
                "label": "D.",
                "text": "Prescribe andexanet"
            },
            {
                "label": "E.",
                "text": "Urgent surgical referral"
            }
        ],
        "correct_answer": "Urgent surgical referral",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient, with signs of a rapidly expanding pseudoaneurysm of his AV fistula, should be evaluated by vascular surgery for urgent repair.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A pseudoaneurysm is the result of a blood leak outside of a vessel but contained by surrounding structures, causing development of a fibrotic sac that communicates with the native vessel. Depending on the definition used, the incidence of symptomatic AV access pseudoaneurysms has been reported to be 5–60%. Pseudoaneurysms occur more commonly in synthetic AV grafts compared to fistulas due to repeated localized puncture of the synthetic membrane.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A rapidly enlarging AV fistula with thin or shiny depigmented skin, ulcerations or scabbing, and prolonged bleeding from puncture sites is concerning for an expanding pseudoaneurysm/aneurysm that requires immediate surgical attention. KDOQI guidelines state that surgical repair is preferred for definitive management in patients with symptomatic, large, or rapidly expanding AV access aneurysm/pseudoaneurysm.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Ultrasound with manual compression is a non-invasive method to cause thrombosis and prevent further rupturing in early, stable cases of AVF enlargement. In a small case series, this technique caused thrombosis after 30–45 minutes of compression while still preserving the AV access. In this patient with signs of impending rupture, manual compression would not be indicated. Duplex Doppler ultrasound of the aneurysmal area might help confirm the diagnosis but would not allow for prompt treatment.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In patients with stable aneurysmal areas, without concerning findings as described above, rotating cannulation sites and avoiding aneurysmal areas is recommended. In this patient, observation without definitive treatment would risk a life-threatening bleed.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Andexanet, a recombinant modified Factor Xa approved for the reversal of anticoagulation with apixaban and rivaroxaban, might be useful as adjunctive therapy pre-operatively, but would not treat the etiology of his bleed.</p>\n</div>",
        "references": [
            "Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 update.Am J Kidney Dis 75(4 Suppl 2), S1–S164, 2020",
            "Mudoni A, Cornacchiari M, Gallieni M, et al. Aneurysms and pseudoaneurysms in dialysis access.Clin Kidney J8(4): 363–367, 2015",
            "Rahil MA. Successful treatment of a venous pseudoaneurysm in a brachiobasilic fistula using ultrasound-guided manual compression: Two case reports.J Ultrasound22(3): 345–347, 2019",
            "Florescu MC, Plumb TJ. Approach to a patient with pseudoaneurysm. In:Interventional Nephrology: Principles and Practice.New York: Springer Science+Business Media; 2014:143–115"
        ]
    },
    "49": {
        "question": "<div class=\"qtext\"><p>A 63-year-old woman with a history of ESRD due to IgA nephropathy who is 5 years status post deceased donor kidney transplant presents to the kidney transplant clinic with 3 days of decreased oral intake and diarrhea. She describes the diarrhea as watery, non-bloody, and occurring 4-6 times per day. She lives with her grandson, who attends daycare. Past medical history includes post-transplant diabetes and hypertension. Her medications include tacrolimus, mycophenolate mofetil, prednisone, losartan, metoprolol, empagliflozin, and metformin.</p>\n<p>On examination, her BP is 117/60 mm Hg, heart rate is 83/min, and temperature is 37.5°C. Her cardiopulmonary examinations are normal. Her abdomen has mild epigastric tenderness but is soft, and her allograft is nontender. She has no edema of her lower extremities. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"><strong> </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Results</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Hemoglobin</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">13.2 g/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">12–16</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Platelet count</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">250,000/µL </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">150,000–450,000 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Serum</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136–145 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">6.2 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">17 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28  </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  BUN</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">39 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.0 mg/dL (0.9 mg/dL 1 month ago)</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Urine</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;20 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Chloride</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;20 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Albumin-to-creatinine ratio</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">200 mg/g</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;30</td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis is negative for blood, albumin, and leukocytes. A stool viral panel is positive for norovirus.</p>\n<p><strong>Which ONE of the following is the most likely cause of this patient’s AKI and electrolyte abnormalitie</strong><strong>s?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Thrombotic microangiopathy"
            },
            {
                "label": "B.",
                "text": "Transplant glomerulopathy"
            },
            {
                "label": "C.",
                "text": "Tacrolimus toxicity"
            },
            {
                "label": "D.",
                "text": "Recurrent IgA nephropathy"
            },
            {
                "label": "E.",
                "text": "Acute interstitial nephritis"
            }
        ],
        "correct_answer": "Tacrolimus toxicity",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of this patient’s AKI and electrolyte abnormalities is tacrolimus toxicity. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Calcineurin (CNI) nephrotoxicity may occur at any time in the post-transplant period, particularly in patients who are volume-depleted, receive high-dose CNIs, or have an allograft from an older donor. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">AKI in the setting of CNI toxicity manifests as supratherapeutic trough levels of CNI and results in the acute vasoconstriction of afferent arterioles. The mechanism is likely impaired endothelial cell function in the setting of decreased production of the vasodilatory molecules prostaglandin E<sub>2</sub> and nitric oxide and afferent arteriolar vasoconstriction attributable to increased generation of thromboxane and endothelin. The result is a reduction in renal blood flow, a change that is reversible once CNI levels return to normal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">CNI exposure is dependent on mechanisms that inhibit or induce the cytochrome P450 isozyme CYP3A4, which metabolizes tacrolimus and cyclosporin. Infectious diarrhea can cause dysfunction of intestinal CYP3A4 activity, leading to decreased CNI metabolism and impairment of P-glycoprotein, which pumps CNIs into the gut lumen. These derangements result in increased CNI absorption and elevated CNI levels. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A hyperkalemic, hyperchloremic metabolic acidosis commonly occurs in the setting of CNI toxicity, but the mechanism is not fully understood. The generation of hyperkalemia may be a result of impaired response to aldosterone in principal cells of the cortical collecting duct. In this patient, hyperkalemia may also be due to decreased renal blood flow and losartan use. Because of this impaired aldosterone action, CNIs may also cause a type 4 renal tubular acidosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Thrombotic microangiopathy (TMA) may occur in the setting of CNI use and typically results in hypertension, hemolytic anemia, thrombocytopenia, and AKI. This patient has normal BP and hematologic parameters inconsistent with TMA, making this diagnosis unlikely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Transplant glomerulopathy manifests as a slowly progressive decline in allograft function and is associated with hypertension and proteinuria. This patient, who had a normal creatinine 1 month ago, is unlikely to have transplant glomerulopathy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Recurrent IgA nephropathy may cause AKI, although most patients with recurrent disease will present with microscopic hematuria and/or albuminuria only. This patient’s urinalysis is bland and does not suggest IgA nephropathy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute interstitial nephritis (AIN) is less likely without a recent infection or exposure to a new medication. Classically, AIN presents with fever, rash, and eosinophilia, but these findings are unreliable, and kidney biopsy is required for diagnosis. The bland urine, severe hyperkalemia, and non-anion gap metabolic acidosis are more characteristic of CNI toxicity than AIN.</p>\n</div>",
        "references": [
            "Farouk SS, Rein JL. The many faces of calcineurin inhibitor toxicity: What the FK?Adv Chronic Kidney Dis27(1): 55–66, 2020",
            "Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles.J Clin Invest91(5): 2144–2149, 1993",
            "Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: A review and perspective of the evidence.Am J Nephrol37(6): 602–612, 2013",
            "Ponticelli C, Banfi G.  Thrombotic microangiopathy after kidney transplantation.Transplant Int19(10): 789–794, 2006",
            "Cosio FG, Gloor JM, Sethi S, et al. Transplant glomerulopathy.Am J Transplant8(3): 492–496, 2008"
        ]
    },
    "50": {
        "question": "<div class=\"qtext\"><p>A 56-year-old man with CKD stage G4/A1 and hypertension presents to the nephrology clinic for follow-up. His history is significant for stage 3 colon cancer diagnosed 18 months ago, which was successfully treated with laparoscopic surgical resection and lysis of extensive adhesions followed by adjuvant chemotherapy. His most recent imaging showed no evidence of malignancy. His only other history includes an appendectomy for a perforated appendix at age 22 years and a hospitalization 5 years ago for a partial small bowel obstruction, which resolved with nasogastric tube suction and bowel rest. The patient feels well and reports normal urine output and strong urine stream. He reports that he leads an active life, and if dialysis is required, he would prefer a home-based therapy. He has been evaluated by the kidney transplant team, and his partner is a compatible kidney donor. </p>\n<p>His BP is 127/73 mm Hg. His cardiopulmonary examination is normal. His abdomen has well-healed surgical scars and a reducible, non-tender umbilical hernia. He has no asterixis.</p>\n<p>One year ago, his eGFR was 22 mL/min/1.73 m<sup>2</sup> (reference range, ≥60). Six months ago, it was 19 mL/min/1.73 m<sup>2</sup>, and 1 week ago, it was 17 mL/min/1.73 m<sup>2</sup>.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Refer for tunneled HD catheter placement"
            },
            {
                "label": "B.",
                "text": "Refer for arteriovenous HD access placement"
            },
            {
                "label": "C.",
                "text": "Refer for PD catheter placement"
            },
            {
                "label": "D.",
                "text": "Continued observation"
            },
            {
                "label": "E.",
                "text": "Refer for palliative care"
            }
        ],
        "correct_answer": "Refer for arteriovenous HD access placement",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with advanced CKD and evidence of progressive decline in kidney function should be referred for arteriovenous access creation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has had a progressive decline in his eGFR but thus far has no indications for immediate initiation of dialysis. Preparation for renal replacement therapy is warranted at this time. For most patients, education about dialysis modalities (including transplant) and preparation for renal replacement therapy is warranted. However, in this patient, transplant and PD are contraindicated at this time because of his recent malignancy with extensive abdominal adhesions, and he should be referred for arteriovenous HD access creation. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">KDOQI guidelines “considers it reasonable” to refer patients for dialysis access assessment and creation for patients with progressive decline in kidney function once the eGFR is 15–20 mL/min per 1.73 m<sup>2</sup>. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although KDOQI “considers it reasonable” to place a PD catheter 2 weeks prior to PD initiation, patients who may require surgical intervention (such as a patient with an umbilical hernia), should be referred earlier to a surgeon to establish care and plan for hernia repair at the time of PD catheter insertion. Additionally, this patient has had multiple abdominal surgeries with abdominal adhesions, as well as a small bowel obstruction, which constitute relative or absolute contraindications to PD catheter placement and may impair the effectiveness of PD. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Placement of a central venous catheter is considered “reasonable” by KDOQI guidelines in patients who are anticipated to receive a kidney transplant within 90 days of initiating HD. The history of colon cancer, although successfully treated, limits this patient’s ability to receive a kidney transplant at this time, even with an available living donor. Current recommendations for patients with intermediate to higher risk disease (stage II or higher colon cancer) suggest waiting 3–5 years before undergoing kidney transplantation. Given his rate of progressive kidney function decline, it is likely that the patient would need renal replacement therapy for &gt;90 days before receiving a kidney transplant. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Due to the rate of decline of his kidney function, continued observation risks timely dialysis access placement and increases the odds that the patient will require initiation through a central venous catheter. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Reexamining goals of care is often preferred by patients and providers to preserve quality of life in cases of progressive kidney disease in the setting of incurable malignancy. In this patient, who has been successfully treated for colon cancer and is willing and able to undergo renal replacement therapy, referral for palliative care would be premature before a trial of dialysis.</p>\n</div>",
        "references": [
            "Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 update.Am J Kidney Dis75(4 Suppl 2): S1–S164, 2020",
            "Al-Adra DP, Hammel L, Roberts J, et al. Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement.Am J Transplant21(2): 460–474, 2021",
            "Eroglu E, Heimbürger O, Lindholm B. Peritoneal dialysis patient selection from a comorbidity perspective.Semin Dial35(1): 25–39, 2022"
        ]
    },
    "51": {
        "question": "<div class=\"qtext\"><p>A 63-year-old woman with obesity, type 2 diabetes, and hypertension is evaluated in the nephrology clinic 2 days after discharge from the hospital. Five days ago, she was admitted to the hospital with an expanding, ulcerated right shin wound with purulent discharge. Wound cultures grew <em>Pseudomonas aeruginosa</em>, and she was prescribed a 2-week course of piperacillin/tazobactam IV, which she has continued upon discharge. Other medications include metformin, hydrochlorothiazide, and lisinopril.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 25%;\"><strong> </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Admission</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Current</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Serum</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">138 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">140</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.8 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2.6 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Chloride</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">104 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">99</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">98–106</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">26 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">33</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  BUN</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">16 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">12</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.1 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.8 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Albumin</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.3 g/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.1</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.5</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Arterial blood gas </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>  </strong>pH</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">7.42</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">7.52</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">7.38–7.44</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  pCO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">40 mm Hg</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">46</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">38–42</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  pO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">98 mm Hg</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">98</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">75–100 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>Urine, random</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">20 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">40</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">40 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">74 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Chloride</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">66 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">52 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Varies</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management? </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Change piperacillin/tazobactam to ciprofloxacin"
            },
            {
                "label": "B.",
                "text": "Discontinue metformin"
            },
            {
                "label": "C.",
                "text": "Prescribe spironolactone"
            },
            {
                "label": "D.",
                "text": "Discontinue hydrochlorothiazide"
            },
            {
                "label": "E.",
                "text": "Prescribe potassium citrate"
            }
        ],
        "correct_answer": "Change piperacillin/tazobactam to ciprofloxacin",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has metabolic alkalosis and hypokalemia due to urinary excretion of the non-reabsorbable anion piperacillin. The drug should be changed to an alternate agent with anti-pseudomonal activity, such as ciprofloxacin.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Piperacillin is a non-reabsorbable anion, meaning that it enters the urine space but cannot be reabsorbed in the nephron. In the collecting duct, this causes a negative transtubular potential gradient, favoring the secretion of potassium and hydrogen into the lumen, where they are excreted, causing hypokalemia and metabolic alkalosis. Additionally, the conjugate cation for both piperacillin and tazobactam is sodium. The increased sodium delivery to the collecting duct further favors potassium excretion, especially in a patient who is prescribed hydrochlorothiazide. Although the urine anion gap has poor sensitivity and specificity for estimating urine ammonium excretion, it is useful in this case by suggesting the presence of a new, non-reabsorbable anion. Urine anion gap is calculated as urine sodium + potassium – chloride, which was initially (20 + 40) – 66 = -6 mEq/L, but subsequently increased to (40 + 74) – 52 = 62 mEq/L, suggesting the presence of the unmeasured urinary anion.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The hypokalemia leads to increased ammoniagenesis, further increasing hydrogen excretion and worsening the metabolic alkalosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Metformin is associated with a high anion gap metabolic acidosis from type B lactic acidosis and does not cause metabolic alkalosis or hypokalemia. Discontinuing this drug will not improve her hypokalemic metabolic alkalosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although spironolactone could be used for refractory hypokalemia and metabolic alkalosis due to hyperaldosteronism, it would not treat the underlying etiology of potassium and hydrogen wasting and may cause hypotension.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hydrochlorothiazide may cause hypokalemia and metabolic alkalosis through various mechanisms, including increased distal sodium delivery. However, this patient has taken hydrochlorothiazide chronically without problems, so this drug is an unlikely explanation for the acute changes in serum potassium and bicarbonate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The addition of potassium citrate may improve hypokalemia, but it would be an additional alkali load, potentially exacerbating metabolic alkalosis. Oral potassium chloride would be the preferable form of potassium replacement and would provide chloride for proximal tubular sodium reabsorption and for exchange with bicarbonate distally, resulting in urinary bicarbonate excretion.</p>\n</div>",
        "references": [
            "Brunner FP, Frick PG. Hypokalaemia, metabolic alkalosis, and hypernatraemia due to \"massive\" sodium penicillin therapy.Br Med J4(5630): 550–552, 1968",
            "Leegwater E, Westgeest A, Schippers E, et al. Hypokalaemia in patients treated with intravenous flucloxacillin: Incidence and risk factors.Br J Clin Pharmacol88: 2938–2945, 2022",
            "van der Heijden CD, Duizer ML, Fleuren HW, et al. Intravenous flucloxacillin treatment is associated with a high incidence of hypokalaemia.Br J Clin Pharmacol85(12): 2886–2890, 2019",
            "Hoorn EJ, Zietse R. Severe hypokalaemia caused by flucloxacillin.J Antimicrob Chemother61(6): 1396–1398, 2008",
            "Lipner HI, Ruzany F, Dasgupta M, et al. The behavior of carbenicillin as a nonreabsorbable anion.J Lab Clin Med86(2): 183–194, 1975"
        ]
    },
    "52": {
        "question": "<div class=\"qtext\"><p>A 62-year-old-man presents to nephrology clinic for follow-up 2 weeks after deceased donor kidney transplant. His past medical history is significant for long-standing type 2 diabetes, gastroparesis, hypertension, and benign prostatic hyperplasia. Since his transplant, he has been treated in the emergency department twice for hyperkalemia discovered on routine blood draws. He reports intermittent constipation since his transplant.</p>\n<p>His BP is 150/85 mm Hg, and heart rate is 72/min. His examination is remarkable for trace bilateral pitting ankle edema and a well-healing surgical incision in the right lower quadrant over his transplant.</p>\n<p>His medications are tacrolimus, mycophenolate mofetil, trimethoprim-sulfamethoxazole, valgancyclovir, amlodipine, and metoclopramide.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                138 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.9 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                111 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.5 mg/dL (1.4 on hospital discharge)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Tacrolimus trough, whole blood</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.0 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–15, 0-3 months after transplantation\n            </td>\n</tr>\n</tbody>\n</table>\n<p>US of the allograft shows a 9.8-cm kidney with normal resistive indices and no signs of hydronephrosis. The bladder is collapsed after voiding, and there is mild prostate enlargement.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management of this patient’s hyperkalemia?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe sodium zirconium cyclosilicate"
            },
            {
                "label": "B.",
                "text": "Discontinue trimethoprim-sulfamethoxazole"
            },
            {
                "label": "C.",
                "text": "Reduce tacrolimus dose"
            },
            {
                "label": "D.",
                "text": "Prescribe chlorthalidone"
            },
            {
                "label": "E.",
                "text": "Prescribe tamsulosin"
            }
        ],
        "correct_answer": "Prescribe chlorthalidone",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with hypertension and ongoing hyperkalemia, chlorthalidone should be prescribed. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Hyperkalemia is a common occurrence in the kidney transplant recipient, particularly in the early period after transplantation. The etiology is often multifactorial, and calcineurin inhibitor (CNI) therapy typically plays a central role via multiple potential mechanisms. Tacrolimus and cyclosporine have been shown to inhibit mineralocorticoid receptor activity, ultimately leading to aldosterone resistance and clinical features of a type 4 renal tubular acidosis. Furthermore, tacrolimus activates the thiazide-sensitive sodium chloride co-transporter in the distal convoluted tubule, leading to hyperkalemia by decreasing distal sodium delivery. Chlorthalidone inhibits this sodium chloride co-transporter and results in greater urinary excretion of potassium. Adding a thiazide diuretic will also help to manage this patient’s hypertension. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although adding an intestinal potassium binding resin like sodium zirconium cyclosilicate may be effective in treating hyperkalemia, it is a less optimal long-term solution for this patient due to his history of gastrointestinal motility problems (gastroparesis and post-operative constipation).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Stopping trimethoprim-sulfamethoxazole and reducing the dose of tacrolimus could also be effective in reducing the patient’s serum potassium levels, but the risks of opportunistic infection and rejection in this early period after kidney transplant make these choices inferior to a trial of chlorthalidone. The patient’s tacrolimus trough level is at goal.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The US does not show signs of urinary outlet tract obstruction related to benign prostatic hyperplasia, so initiation of tamsulosin is unlikely to be of benefit in this case. </p>\n</div>",
        "references": [
            "Heering PJ, Kurschat C, Vo DT, et al. Aldosterone resistance in kidney transplantation is part in part induced by a down-regulation of mineralocorticoid receptor expression.Clin Transplant18(24): 186–192, 2004",
            "Hoorn EJ, Walsh SB, McCormick JA, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension.Nat Med17(10): 1304–1309, 2011",
            "Moes AD, Hesselink DA, van den Meiracker AH, et al. Chlorthalidone versus amlodipine for hypertension in kidney transplant recipients treated with tacrolimus: A randomized crossover trial. Am J Kidney Dis 69(6): 796–804, 2017"
        ]
    },
    "53": {
        "question": "<div class=\"qtext\"><p>A 57-year-old man with a history of heart failure with preserved ejection fraction and CKD stage 3a was admitted to the hospital 2 days ago for the management of acute decompensated heart failure. A chest x-ray demonstrated diffuse bilateral opacities consistent with pulmonary edema. He was prescribed furosemide 40 mg IV twice daily, which is twice his usual home oral dose. After 48 hours of therapy, his creatinine level rose from his baseline of 1.4 to 1.8 mg/dL (reference range, 0.7–1.3). His cumulative fluid balance is now -2.2 L, and his shortness of breath has resolved. His serum potassium level is 3.4 mEq/L (reference range, 3.5–5.0).</p>\n<p></p>\n<p>On examination, the patient has an oxygen saturation of 97% while breathing room air. He appears comfortable and can speak in full sentences. His lungs are clear bilaterally, and there is trace pedal edema. </p>\n<p>A point-of-care US (POCUS) is performed on his lungs and inferior vena cava (IVC; see images below).</p>\n<p><em>Play videos and click lower right hand corner buttons to expand viewing panes.</em></p>\n<p>\n</p>\n<p> <span class=\"fr-video fr-deletable fr-fvc fr-dvi fr-draggable\" contenteditable=\"false\"></span></p><div class=\"mediaplugin mediaplugin_videojs d-block\"><div style=\"max-width:400px;\"><div aria-label=\"Video Player\" class=\"video-js vjs-paused vjs-fluid id_videojs_68a28ac928cb3_1-dimensions vjs-controls-enabled vjs-workinghover vjs-v8 vjs-user-active\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28ac928cb3_1\" lang=\"en-gb\" role=\"region\" tabindex=\"-1\" title=\"Koratala\" translate=\"no\"><video class=\"vjs-tech\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28ac928cb3_1_html5_api\" role=\"application\" tabindex=\"-1\" title=\"Koratala\"><source src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b2q17a_Koratala-Q1_Video_1.mp4\" type=\"video/mp4\"/>\n            https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b2q17a_Koratala-Q1_Video_1.mp4\n        </video><div aria-disabled=\"false\" class=\"vjs-poster vjs-hidden\"></div><div class=\"vjs-title-bar vjs-hidden\"><div class=\"vjs-title-bar-title\" id=\"vjs-title-bar-title-27\"></div><div class=\"vjs-title-bar-description\" id=\"vjs-title-bar-description-28\"></div></div><div aria-atomic=\"true\" aria-live=\"off\" class=\"vjs-text-track-display\" translate=\"yes\"><div style=\"position: absolute; inset: 0px; margin: 1.5%;\"></div></div><div class=\"vjs-loading-spinner\" dir=\"ltr\"><span class=\"vjs-control-text\">Video Player is loading.</span></div><button aria-disabled=\"false\" class=\"vjs-big-play-button\" title=\"Play Video\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play Video</span></button><div class=\"vjs-control-bar\" dir=\"ltr\"><button aria-disabled=\"false\" class=\"vjs-play-control vjs-control vjs-button\" title=\"Play\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play</span></button><button aria-disabled=\"false\" class=\"vjs-skip-backward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Backward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Backward</span></button><button aria-disabled=\"false\" class=\"vjs-skip-forward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Forward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Forward</span></button><div class=\"vjs-volume-panel vjs-control vjs-volume-panel-horizontal\"><button aria-disabled=\"false\" class=\"vjs-mute-control vjs-control vjs-button vjs-vol-3\" title=\"Mute\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Mute</span></button><div class=\"vjs-volume-control vjs-control vjs-volume-horizontal\"><div aria-label=\"Volume Level\" aria-live=\"polite\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"100\" aria-valuetext=\"100%\" class=\"vjs-volume-bar vjs-slider-bar vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-volume-tooltip\"></div></div><div class=\"vjs-volume-level\"><span class=\"vjs-control-text\"></span></div></div></div></div><div class=\"vjs-current-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Current Time </span><span class=\"vjs-current-time-display\" role=\"presentation\">0:00</span></div><div aria-hidden=\"true\" class=\"vjs-time-control vjs-time-divider\"><div><span>/</span></div></div><div class=\"vjs-duration vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Duration </span><span class=\"vjs-duration-display\" role=\"presentation\">0:08</span></div><div class=\"vjs-progress-control vjs-control\"><div aria-label=\"Progress Bar\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"0.00\" aria-valuetext=\"0:00 of 0:08\" class=\"vjs-progress-holder vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-load-progress\" style=\"width: 31.87%;\"><span class=\"vjs-control-text\"><span>Loaded</span>: <span class=\"vjs-control-text-loaded-percentage\">31.87%</span></span><div data-end=\"2.556\" data-start=\"0\" style=\"left: 0%; width: 100%;\"></div></div><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\"></div></div><div aria-hidden=\"true\" class=\"vjs-play-progress vjs-slider-bar\" style=\"width: 0%;\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\" style=\"right: 0px;\">0:00</div></div></div></div><div class=\"vjs-live-control vjs-control vjs-hidden\"><div aria-live=\"off\" class=\"vjs-live-display\"><span class=\"vjs-control-text\">Stream Type </span>LIVE</div></div><button aria-disabled=\"false\" class=\"vjs-seek-to-live-control vjs-control\" title=\"Seek to live, currently behind live\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Seek to live, currently behind live</span><span aria-hidden=\"true\" class=\"vjs-seek-to-live-text\">LIVE</span></button><div class=\"vjs-remaining-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Remaining Time </span><span aria-hidden=\"true\">-</span><span class=\"vjs-remaining-time-display\" role=\"presentation\">0:08</span></div><div class=\"vjs-custom-control-spacer vjs-spacer\"> </div><div class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-control vjs-button\"><div class=\"vjs-playback-rate-value\" id=\"vjs-playback-rate-value-label-id_videojs_68a28ac928cb3_1_component_285\">1x</div><button aria-describedby=\"vjs-playback-rate-value-label-id_videojs_68a28ac928cb3_1_component_285\" aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Playback Rate\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Playback Rate</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\" role=\"menu\"><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">2x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.25x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1x</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li></ul></div></div><div class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Chapters\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Chapters</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li class=\"vjs-menu-title\" tabindex=\"-1\">Chapters</li></ul></div></div><div class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Descriptions\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Descriptions</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">descriptions off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Subtitles\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Subtitles</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-disabled=\"false\" class=\"vjs-menu-item vjs-texttrack-settings\" role=\"menuitem\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles settings</span><span aria-live=\"polite\" class=\"vjs-control-text\">, opens subtitles settings dialog</span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Audio Track\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Audio Track</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"></ul></div></div><button aria-disabled=\"false\" class=\"vjs-picture-in-picture-control vjs-control vjs-button\" title=\"Picture-in-Picture\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Picture-in-Picture</span></button><button aria-disabled=\"false\" class=\"vjs-fullscreen-control vjs-control vjs-button\" title=\"Fullscreen\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Fullscreen</span></button></div><div aria-describedby=\"id_videojs_68a28ac928cb3_1_component_589_description\" aria-hidden=\"true\" aria-label=\"Modal Window\" aria-live=\"polite\" class=\"vjs-error-display vjs-modal-dialog vjs-hidden\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28ac928cb3_1_component_589_description\">This is a modal window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"></div></div><div aria-describedby=\"id_videojs_68a28ac928cb3_1_component_595_description\" aria-hidden=\"true\" aria-label=\"Caption Settings Dialog\" aria-live=\"polite\" class=\"vjs-modal-dialog vjs-hidden vjs-text-track-settings\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28ac928cb3_1_component_595_description\">Beginning of dialog window. Escape will cancel and close the window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"><div class=\"vjs-track-settings-colors\"><fieldset class=\"vjs-fg vjs-track-setting\"><legend id=\"captions-text-legend-id_videojs_68a28ac928cb3_1_component_595\">Text</legend><span class=\"vjs-text-color\"><label class=\"vjs-label\" for=\"vjs_select_622\" id=\"captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595\">Color</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595\" id=\"vjs_select_622\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-White\" id=\"captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-Black\" id=\"captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-Red\" id=\"captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-Green\" id=\"captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-Blue\" id=\"captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-Yellow\" id=\"captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-Magenta\" id=\"captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-Cyan\" id=\"captions-foreground-color-id_videojs_68a28ac928cb3_1_component_595-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-text-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_627\" id=\"captions-foreground-opacity-id_videojs_68a28ac928cb3_1_component_595\">Opacity</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-opacity-id_videojs_68a28ac928cb3_1_component_595\" id=\"vjs_select_627\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-opacity-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-opacity-id_videojs_68a28ac928cb3_1_component_595-Opaque\" id=\"captions-foreground-opacity-id_videojs_68a28ac928cb3_1_component_595-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-opacity-id_videojs_68a28ac928cb3_1_component_595 captions-foreground-opacity-id_videojs_68a28ac928cb3_1_component_595-SemiTransparent\" id=\"captions-foreground-opacity-id_videojs_68a28ac928cb3_1_component_595-SemiTransparent\" value=\"0.5\">Semi-Transparent</option></select></span></fieldset><fieldset class=\"vjs-bg vjs-track-setting\"><legend id=\"captions-background-id_videojs_68a28ac928cb3_1_component_595\">Text Background</legend><span class=\"vjs-bg-color\"><label class=\"vjs-label\" for=\"vjs_select_637\" id=\"captions-background-color-id_videojs_68a28ac928cb3_1_component_595\">Color</label><select aria-labelledby=\"captions-background-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595\" id=\"vjs_select_637\"><option aria-labelledby=\"captions-background-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595-Black\" id=\"captions-background-color-id_videojs_68a28ac928cb3_1_component_595-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595-White\" id=\"captions-background-color-id_videojs_68a28ac928cb3_1_component_595-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595-Red\" id=\"captions-background-color-id_videojs_68a28ac928cb3_1_component_595-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595-Green\" id=\"captions-background-color-id_videojs_68a28ac928cb3_1_component_595-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595-Blue\" id=\"captions-background-color-id_videojs_68a28ac928cb3_1_component_595-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595-Yellow\" id=\"captions-background-color-id_videojs_68a28ac928cb3_1_component_595-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595-Magenta\" id=\"captions-background-color-id_videojs_68a28ac928cb3_1_component_595-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595 captions-background-color-id_videojs_68a28ac928cb3_1_component_595-Cyan\" id=\"captions-background-color-id_videojs_68a28ac928cb3_1_component_595-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-bg-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_642\" id=\"captions-background-opacity-id_videojs_68a28ac928cb3_1_component_595\">Opacity</label><select aria-labelledby=\"captions-background-id_videojs_68a28ac928cb3_1_component_595 captions-background-opacity-id_videojs_68a28ac928cb3_1_component_595\" id=\"vjs_select_642\"><option aria-labelledby=\"captions-background-id_videojs_68a28ac928cb3_1_component_595 captions-background-opacity-id_videojs_68a28ac928cb3_1_component_595 captions-background-opacity-id_videojs_68a28ac928cb3_1_component_595-Opaque\" id=\"captions-background-opacity-id_videojs_68a28ac928cb3_1_component_595-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928cb3_1_component_595 captions-background-opacity-id_videojs_68a28ac928cb3_1_component_595 captions-background-opacity-id_videojs_68a28ac928cb3_1_component_595-SemiTransparent\" id=\"captions-background-opacity-id_videojs_68a28ac928cb3_1_component_595-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928cb3_1_component_595 captions-background-opacity-id_videojs_68a28ac928cb3_1_component_595 captions-background-opacity-id_videojs_68a28ac928cb3_1_component_595-Transparent\" id=\"captions-background-opacity-id_videojs_68a28ac928cb3_1_component_595-Transparent\" value=\"0\">Transparent</option></select></span></fieldset><fieldset class=\"vjs-window vjs-track-setting\"><legend id=\"captions-window-id_videojs_68a28ac928cb3_1_component_595\">Caption Area Background</legend><span class=\"vjs-window-color\"><label class=\"vjs-label\" for=\"vjs_select_652\" id=\"captions-window-color-id_videojs_68a28ac928cb3_1_component_595\">Color</label><select aria-labelledby=\"captions-window-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595\" id=\"vjs_select_652\"><option aria-labelledby=\"captions-window-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595-Black\" id=\"captions-window-color-id_videojs_68a28ac928cb3_1_component_595-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595-White\" id=\"captions-window-color-id_videojs_68a28ac928cb3_1_component_595-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595-Red\" id=\"captions-window-color-id_videojs_68a28ac928cb3_1_component_595-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595-Green\" id=\"captions-window-color-id_videojs_68a28ac928cb3_1_component_595-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595-Blue\" id=\"captions-window-color-id_videojs_68a28ac928cb3_1_component_595-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595-Yellow\" id=\"captions-window-color-id_videojs_68a28ac928cb3_1_component_595-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595-Magenta\" id=\"captions-window-color-id_videojs_68a28ac928cb3_1_component_595-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595 captions-window-color-id_videojs_68a28ac928cb3_1_component_595-Cyan\" id=\"captions-window-color-id_videojs_68a28ac928cb3_1_component_595-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-window-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_657\" id=\"captions-window-opacity-id_videojs_68a28ac928cb3_1_component_595\">Opacity</label><select aria-labelledby=\"captions-window-id_videojs_68a28ac928cb3_1_component_595 captions-window-opacity-id_videojs_68a28ac928cb3_1_component_595\" id=\"vjs_select_657\"><option aria-labelledby=\"captions-window-id_videojs_68a28ac928cb3_1_component_595 captions-window-opacity-id_videojs_68a28ac928cb3_1_component_595 captions-window-opacity-id_videojs_68a28ac928cb3_1_component_595-Transparent\" id=\"captions-window-opacity-id_videojs_68a28ac928cb3_1_component_595-Transparent\" value=\"0\">Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928cb3_1_component_595 captions-window-opacity-id_videojs_68a28ac928cb3_1_component_595 captions-window-opacity-id_videojs_68a28ac928cb3_1_component_595-SemiTransparent\" id=\"captions-window-opacity-id_videojs_68a28ac928cb3_1_component_595-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928cb3_1_component_595 captions-window-opacity-id_videojs_68a28ac928cb3_1_component_595 captions-window-opacity-id_videojs_68a28ac928cb3_1_component_595-Opaque\" id=\"captions-window-opacity-id_videojs_68a28ac928cb3_1_component_595-Opaque\" value=\"1\">Opaque</option></select></span></fieldset></div><div class=\"vjs-track-settings-font\"><fieldset class=\"vjs-font-percent vjs-track-setting\"><legend id=\"captions-font-size-id_videojs_68a28ac928cb3_1_component_595\">Font Size</legend><select aria-labelledby=\"captions-font-size-id_videojs_68a28ac928cb3_1_component_595\" id=\"vjs_select_672\"><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-673-50\" id=\"vjs-track-option-673-50\" value=\"0.50\">50%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-674-75\" id=\"vjs-track-option-674-75\" value=\"0.75\">75%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-675-100\" id=\"vjs-track-option-675-100\" value=\"1.00\">100%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-676-125\" id=\"vjs-track-option-676-125\" value=\"1.25\">125%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-677-150\" id=\"vjs-track-option-677-150\" value=\"1.50\">150%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-678-175\" id=\"vjs-track-option-678-175\" value=\"1.75\">175%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-679-200\" id=\"vjs-track-option-679-200\" value=\"2.00\">200%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-680-300\" id=\"vjs-track-option-680-300\" value=\"3.00\">300%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-681-400\" id=\"vjs-track-option-681-400\" value=\"4.00\">400%</option></select></fieldset><fieldset class=\"vjs-edge-style vjs-track-setting\"><legend id=\"captions-edge-style-id_videojs_68a28ac928cb3_1_component_595\">Text Edge Style</legend><select aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928cb3_1_component_595\" id=\"vjs_select_691\"><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-692-None\" id=\"vjs-track-option-692-None\" value=\"none\">None</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-693-Raised\" id=\"vjs-track-option-693-Raised\" value=\"raised\">Raised</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-694-Depressed\" id=\"vjs-track-option-694-Depressed\" value=\"depressed\">Depressed</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-695-Uniform\" id=\"vjs-track-option-695-Uniform\" value=\"uniform\">Uniform</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-696-Dropshadow\" id=\"vjs-track-option-696-Dropshadow\" value=\"dropshadow\">Drop shadow</option></select></fieldset><fieldset class=\"vjs-font-family vjs-track-setting\"><legend id=\"captions-font-family-id_videojs_68a28ac928cb3_1_component_595\">Font Family</legend><select aria-labelledby=\"captions-font-family-id_videojs_68a28ac928cb3_1_component_595\" id=\"vjs_select_706\"><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-707-ProportionalSansSerif\" id=\"vjs-track-option-707-ProportionalSansSerif\" value=\"proportionalSansSerif\">Proportional Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-708-MonospaceSansSerif\" id=\"vjs-track-option-708-MonospaceSansSerif\" value=\"monospaceSansSerif\">Monospace Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-709-ProportionalSerif\" id=\"vjs-track-option-709-ProportionalSerif\" value=\"proportionalSerif\">Proportional Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-710-MonospaceSerif\" id=\"vjs-track-option-710-MonospaceSerif\" value=\"monospaceSerif\">Monospace Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-711-Casual\" id=\"vjs-track-option-711-Casual\" value=\"casual\">Casual</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-712-Script\" id=\"vjs-track-option-712-Script\" value=\"script\">Script</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928cb3_1_component_595 vjs-track-option-713-SmallCaps\" id=\"vjs-track-option-713-SmallCaps\" value=\"small-caps\">Small Caps</option></select></fieldset></div><div class=\"vjs-track-settings-controls\"><button aria-disabled=\"false\" class=\"vjs-default-button\" title=\"restore all settings to the default values\" type=\"button\">Reset</button><button aria-disabled=\"false\" class=\"vjs-done-button\" title=\"restore all settings to the default values\" type=\"button\">Done</button></div></div><button aria-disabled=\"false\" class=\"vjs-close-button vjs-control vjs-button\" title=\"Close Modal Dialog\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Close Modal Dialog</span></button><p class=\"vjs-control-text\">End of dialog window.</p></div></div></div></div><em> </em><p></p>\n<p> <span class=\"fr-video fr-deletable fr-fvc fr-dvi fr-draggable\" contenteditable=\"false\"></span></p><div class=\"mediaplugin mediaplugin_videojs d-block\"><div style=\"max-width:400px;\"><div aria-label=\"Video Player\" class=\"video-js vjs-paused vjs-fluid id_videojs_68a28ac928d71_2-dimensions vjs-controls-enabled vjs-workinghover vjs-v8 vjs-user-active\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28ac928d71_2\" lang=\"en-gb\" role=\"region\" tabindex=\"-1\" title=\"Koratala\" translate=\"no\"><video class=\"vjs-tech\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28ac928d71_2_html5_api\" role=\"application\" tabindex=\"-1\" title=\"Koratala\"><source src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b2q17b_Koratala-Q1_Video_2.mp4\" type=\"video/mp4\"/>\n            https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b2q17b_Koratala-Q1_Video_2.mp4\n        </video><div aria-disabled=\"false\" class=\"vjs-poster vjs-hidden\"></div><div class=\"vjs-title-bar vjs-hidden\"><div class=\"vjs-title-bar-title\" id=\"vjs-title-bar-title-778\"></div><div class=\"vjs-title-bar-description\" id=\"vjs-title-bar-description-779\"></div></div><div aria-atomic=\"true\" aria-live=\"off\" class=\"vjs-text-track-display\" translate=\"yes\"><div style=\"position: absolute; inset: 0px; margin: 1.5%;\"></div></div><div class=\"vjs-loading-spinner\" dir=\"ltr\"><span class=\"vjs-control-text\">Video Player is loading.</span></div><button aria-disabled=\"false\" class=\"vjs-big-play-button\" title=\"Play Video\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play Video</span></button><div class=\"vjs-control-bar\" dir=\"ltr\"><button aria-disabled=\"false\" class=\"vjs-play-control vjs-control vjs-button\" title=\"Play\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play</span></button><button aria-disabled=\"false\" class=\"vjs-skip-backward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Backward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Backward</span></button><button aria-disabled=\"false\" class=\"vjs-skip-forward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Forward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Forward</span></button><div class=\"vjs-volume-panel vjs-control vjs-volume-panel-horizontal\"><button aria-disabled=\"false\" class=\"vjs-mute-control vjs-control vjs-button vjs-vol-3\" title=\"Mute\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Mute</span></button><div class=\"vjs-volume-control vjs-control vjs-volume-horizontal\"><div aria-label=\"Volume Level\" aria-live=\"polite\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"100\" aria-valuetext=\"100%\" class=\"vjs-volume-bar vjs-slider-bar vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-volume-tooltip\"></div></div><div class=\"vjs-volume-level\"><span class=\"vjs-control-text\"></span></div></div></div></div><div class=\"vjs-current-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Current Time </span><span class=\"vjs-current-time-display\" role=\"presentation\">0:00</span></div><div aria-hidden=\"true\" class=\"vjs-time-control vjs-time-divider\"><div><span>/</span></div></div><div class=\"vjs-duration vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Duration </span><span class=\"vjs-duration-display\" role=\"presentation\">0:08</span></div><div class=\"vjs-progress-control vjs-control\"><div aria-label=\"Progress Bar\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"0.00\" aria-valuetext=\"0:00 of 0:08\" class=\"vjs-progress-holder vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-load-progress\" style=\"width: 4.36%;\"><span class=\"vjs-control-text\"><span>Loaded</span>: <span class=\"vjs-control-text-loaded-percentage\">4.36%</span></span><div data-end=\"0.35\" data-start=\"0\" style=\"left: 0%; width: 100%;\"></div></div><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\"></div></div><div aria-hidden=\"true\" class=\"vjs-play-progress vjs-slider-bar\" style=\"width: 0%;\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\" style=\"right: 0px;\">0:00</div></div></div></div><div class=\"vjs-live-control vjs-control vjs-hidden\"><div aria-live=\"off\" class=\"vjs-live-display\"><span class=\"vjs-control-text\">Stream Type </span>LIVE</div></div><button aria-disabled=\"false\" class=\"vjs-seek-to-live-control vjs-control\" title=\"Seek to live, currently behind live\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Seek to live, currently behind live</span><span aria-hidden=\"true\" class=\"vjs-seek-to-live-text\">LIVE</span></button><div class=\"vjs-remaining-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Remaining Time </span><span aria-hidden=\"true\">-</span><span class=\"vjs-remaining-time-display\" role=\"presentation\">0:08</span></div><div class=\"vjs-custom-control-spacer vjs-spacer\"> </div><div class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-control vjs-button\"><div class=\"vjs-playback-rate-value\" id=\"vjs-playback-rate-value-label-id_videojs_68a28ac928d71_2_component_1023\">1x</div><button aria-describedby=\"vjs-playback-rate-value-label-id_videojs_68a28ac928d71_2_component_1023\" aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Playback Rate\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Playback Rate</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\" role=\"menu\"><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">2x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.25x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1x</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li></ul></div></div><div class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Chapters\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Chapters</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li class=\"vjs-menu-title\" tabindex=\"-1\">Chapters</li></ul></div></div><div class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Descriptions\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Descriptions</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">descriptions off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Subtitles\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Subtitles</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-disabled=\"false\" class=\"vjs-menu-item vjs-texttrack-settings\" role=\"menuitem\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles settings</span><span aria-live=\"polite\" class=\"vjs-control-text\">, opens subtitles settings dialog</span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Audio Track\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Audio Track</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"></ul></div></div><button aria-disabled=\"false\" class=\"vjs-picture-in-picture-control vjs-control vjs-button\" title=\"Picture-in-Picture\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Picture-in-Picture</span></button><button aria-disabled=\"false\" class=\"vjs-fullscreen-control vjs-control vjs-button\" title=\"Fullscreen\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Fullscreen</span></button></div><div aria-describedby=\"id_videojs_68a28ac928d71_2_component_1324_description\" aria-hidden=\"true\" aria-label=\"Modal Window\" aria-live=\"polite\" class=\"vjs-error-display vjs-modal-dialog vjs-hidden\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28ac928d71_2_component_1324_description\">This is a modal window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"></div></div><div aria-describedby=\"id_videojs_68a28ac928d71_2_component_1330_description\" aria-hidden=\"true\" aria-label=\"Caption Settings Dialog\" aria-live=\"polite\" class=\"vjs-modal-dialog vjs-hidden vjs-text-track-settings\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28ac928d71_2_component_1330_description\">Beginning of dialog window. Escape will cancel and close the window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"><div class=\"vjs-track-settings-colors\"><fieldset class=\"vjs-fg vjs-track-setting\"><legend id=\"captions-text-legend-id_videojs_68a28ac928d71_2_component_1330\">Text</legend><span class=\"vjs-text-color\"><label class=\"vjs-label\" for=\"vjs_select_1357\" id=\"captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330\">Color</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330\" id=\"vjs_select_1357\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-White\" id=\"captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-Black\" id=\"captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-Red\" id=\"captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-Green\" id=\"captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-Blue\" id=\"captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-Yellow\" id=\"captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-Magenta\" id=\"captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-Cyan\" id=\"captions-foreground-color-id_videojs_68a28ac928d71_2_component_1330-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-text-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_1362\" id=\"captions-foreground-opacity-id_videojs_68a28ac928d71_2_component_1330\">Opacity</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-opacity-id_videojs_68a28ac928d71_2_component_1330\" id=\"vjs_select_1362\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-opacity-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-opacity-id_videojs_68a28ac928d71_2_component_1330-Opaque\" id=\"captions-foreground-opacity-id_videojs_68a28ac928d71_2_component_1330-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-opacity-id_videojs_68a28ac928d71_2_component_1330 captions-foreground-opacity-id_videojs_68a28ac928d71_2_component_1330-SemiTransparent\" id=\"captions-foreground-opacity-id_videojs_68a28ac928d71_2_component_1330-SemiTransparent\" value=\"0.5\">Semi-Transparent</option></select></span></fieldset><fieldset class=\"vjs-bg vjs-track-setting\"><legend id=\"captions-background-id_videojs_68a28ac928d71_2_component_1330\">Text Background</legend><span class=\"vjs-bg-color\"><label class=\"vjs-label\" for=\"vjs_select_1372\" id=\"captions-background-color-id_videojs_68a28ac928d71_2_component_1330\">Color</label><select aria-labelledby=\"captions-background-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330\" id=\"vjs_select_1372\"><option aria-labelledby=\"captions-background-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330-Black\" id=\"captions-background-color-id_videojs_68a28ac928d71_2_component_1330-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330-White\" id=\"captions-background-color-id_videojs_68a28ac928d71_2_component_1330-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330-Red\" id=\"captions-background-color-id_videojs_68a28ac928d71_2_component_1330-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330-Green\" id=\"captions-background-color-id_videojs_68a28ac928d71_2_component_1330-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330-Blue\" id=\"captions-background-color-id_videojs_68a28ac928d71_2_component_1330-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330-Yellow\" id=\"captions-background-color-id_videojs_68a28ac928d71_2_component_1330-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330-Magenta\" id=\"captions-background-color-id_videojs_68a28ac928d71_2_component_1330-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330 captions-background-color-id_videojs_68a28ac928d71_2_component_1330-Cyan\" id=\"captions-background-color-id_videojs_68a28ac928d71_2_component_1330-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-bg-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_1377\" id=\"captions-background-opacity-id_videojs_68a28ac928d71_2_component_1330\">Opacity</label><select aria-labelledby=\"captions-background-id_videojs_68a28ac928d71_2_component_1330 captions-background-opacity-id_videojs_68a28ac928d71_2_component_1330\" id=\"vjs_select_1377\"><option aria-labelledby=\"captions-background-id_videojs_68a28ac928d71_2_component_1330 captions-background-opacity-id_videojs_68a28ac928d71_2_component_1330 captions-background-opacity-id_videojs_68a28ac928d71_2_component_1330-Opaque\" id=\"captions-background-opacity-id_videojs_68a28ac928d71_2_component_1330-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928d71_2_component_1330 captions-background-opacity-id_videojs_68a28ac928d71_2_component_1330 captions-background-opacity-id_videojs_68a28ac928d71_2_component_1330-SemiTransparent\" id=\"captions-background-opacity-id_videojs_68a28ac928d71_2_component_1330-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928d71_2_component_1330 captions-background-opacity-id_videojs_68a28ac928d71_2_component_1330 captions-background-opacity-id_videojs_68a28ac928d71_2_component_1330-Transparent\" id=\"captions-background-opacity-id_videojs_68a28ac928d71_2_component_1330-Transparent\" value=\"0\">Transparent</option></select></span></fieldset><fieldset class=\"vjs-window vjs-track-setting\"><legend id=\"captions-window-id_videojs_68a28ac928d71_2_component_1330\">Caption Area Background</legend><span class=\"vjs-window-color\"><label class=\"vjs-label\" for=\"vjs_select_1387\" id=\"captions-window-color-id_videojs_68a28ac928d71_2_component_1330\">Color</label><select aria-labelledby=\"captions-window-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330\" id=\"vjs_select_1387\"><option aria-labelledby=\"captions-window-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330-Black\" id=\"captions-window-color-id_videojs_68a28ac928d71_2_component_1330-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330-White\" id=\"captions-window-color-id_videojs_68a28ac928d71_2_component_1330-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330-Red\" id=\"captions-window-color-id_videojs_68a28ac928d71_2_component_1330-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330-Green\" id=\"captions-window-color-id_videojs_68a28ac928d71_2_component_1330-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330-Blue\" id=\"captions-window-color-id_videojs_68a28ac928d71_2_component_1330-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330-Yellow\" id=\"captions-window-color-id_videojs_68a28ac928d71_2_component_1330-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330-Magenta\" id=\"captions-window-color-id_videojs_68a28ac928d71_2_component_1330-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330 captions-window-color-id_videojs_68a28ac928d71_2_component_1330-Cyan\" id=\"captions-window-color-id_videojs_68a28ac928d71_2_component_1330-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-window-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_1392\" id=\"captions-window-opacity-id_videojs_68a28ac928d71_2_component_1330\">Opacity</label><select aria-labelledby=\"captions-window-id_videojs_68a28ac928d71_2_component_1330 captions-window-opacity-id_videojs_68a28ac928d71_2_component_1330\" id=\"vjs_select_1392\"><option aria-labelledby=\"captions-window-id_videojs_68a28ac928d71_2_component_1330 captions-window-opacity-id_videojs_68a28ac928d71_2_component_1330 captions-window-opacity-id_videojs_68a28ac928d71_2_component_1330-Transparent\" id=\"captions-window-opacity-id_videojs_68a28ac928d71_2_component_1330-Transparent\" value=\"0\">Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928d71_2_component_1330 captions-window-opacity-id_videojs_68a28ac928d71_2_component_1330 captions-window-opacity-id_videojs_68a28ac928d71_2_component_1330-SemiTransparent\" id=\"captions-window-opacity-id_videojs_68a28ac928d71_2_component_1330-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928d71_2_component_1330 captions-window-opacity-id_videojs_68a28ac928d71_2_component_1330 captions-window-opacity-id_videojs_68a28ac928d71_2_component_1330-Opaque\" id=\"captions-window-opacity-id_videojs_68a28ac928d71_2_component_1330-Opaque\" value=\"1\">Opaque</option></select></span></fieldset></div><div class=\"vjs-track-settings-font\"><fieldset class=\"vjs-font-percent vjs-track-setting\"><legend id=\"captions-font-size-id_videojs_68a28ac928d71_2_component_1330\">Font Size</legend><select aria-labelledby=\"captions-font-size-id_videojs_68a28ac928d71_2_component_1330\" id=\"vjs_select_1407\"><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1408-50\" id=\"vjs-track-option-1408-50\" value=\"0.50\">50%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1409-75\" id=\"vjs-track-option-1409-75\" value=\"0.75\">75%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1410-100\" id=\"vjs-track-option-1410-100\" value=\"1.00\">100%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1411-125\" id=\"vjs-track-option-1411-125\" value=\"1.25\">125%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1412-150\" id=\"vjs-track-option-1412-150\" value=\"1.50\">150%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1413-175\" id=\"vjs-track-option-1413-175\" value=\"1.75\">175%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1414-200\" id=\"vjs-track-option-1414-200\" value=\"2.00\">200%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1415-300\" id=\"vjs-track-option-1415-300\" value=\"3.00\">300%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1416-400\" id=\"vjs-track-option-1416-400\" value=\"4.00\">400%</option></select></fieldset><fieldset class=\"vjs-edge-style vjs-track-setting\"><legend id=\"captions-edge-style-id_videojs_68a28ac928d71_2_component_1330\">Text Edge Style</legend><select aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928d71_2_component_1330\" id=\"vjs_select_1426\"><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1427-None\" id=\"vjs-track-option-1427-None\" value=\"none\">None</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1428-Raised\" id=\"vjs-track-option-1428-Raised\" value=\"raised\">Raised</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1429-Depressed\" id=\"vjs-track-option-1429-Depressed\" value=\"depressed\">Depressed</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1430-Uniform\" id=\"vjs-track-option-1430-Uniform\" value=\"uniform\">Uniform</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1431-Dropshadow\" id=\"vjs-track-option-1431-Dropshadow\" value=\"dropshadow\">Drop shadow</option></select></fieldset><fieldset class=\"vjs-font-family vjs-track-setting\"><legend id=\"captions-font-family-id_videojs_68a28ac928d71_2_component_1330\">Font Family</legend><select aria-labelledby=\"captions-font-family-id_videojs_68a28ac928d71_2_component_1330\" id=\"vjs_select_1441\"><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1442-ProportionalSansSerif\" id=\"vjs-track-option-1442-ProportionalSansSerif\" value=\"proportionalSansSerif\">Proportional Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1443-MonospaceSansSerif\" id=\"vjs-track-option-1443-MonospaceSansSerif\" value=\"monospaceSansSerif\">Monospace Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1444-ProportionalSerif\" id=\"vjs-track-option-1444-ProportionalSerif\" value=\"proportionalSerif\">Proportional Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1445-MonospaceSerif\" id=\"vjs-track-option-1445-MonospaceSerif\" value=\"monospaceSerif\">Monospace Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1446-Casual\" id=\"vjs-track-option-1446-Casual\" value=\"casual\">Casual</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1447-Script\" id=\"vjs-track-option-1447-Script\" value=\"script\">Script</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928d71_2_component_1330 vjs-track-option-1448-SmallCaps\" id=\"vjs-track-option-1448-SmallCaps\" value=\"small-caps\">Small Caps</option></select></fieldset></div><div class=\"vjs-track-settings-controls\"><button aria-disabled=\"false\" class=\"vjs-default-button\" title=\"restore all settings to the default values\" type=\"button\">Reset</button><button aria-disabled=\"false\" class=\"vjs-done-button\" title=\"restore all settings to the default values\" type=\"button\">Done</button></div></div><button aria-disabled=\"false\" class=\"vjs-close-button vjs-control vjs-button\" title=\"Close Modal Dialog\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Close Modal Dialog</span></button><p class=\"vjs-control-text\">End of dialog window.</p></div></div></div></div><em> </em><p></p>\n<p><em>Images courtesy of Abhilash Koratala, MD, FASN, Medical College of Wisconsin</em></p>\n<p><strong>In addition to supplementing potassium, which ONE of the following is the MOST APPROPRIATE next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Discontinue furosemide"
            },
            {
                "label": "B.",
                "text": "Reduce furosemide dose to 40 mg orally"
            },
            {
                "label": "C.",
                "text": "Prescribe metolazone"
            },
            {
                "label": "D.",
                "text": "Continue current dose of furosemide IV"
            },
            {
                "label": "E.",
                "text": "Initiate mechanical ultrafiltration"
            }
        ],
        "correct_answer": "Continue current dose of furosemide IV",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with evidence of ongoing pulmonary edema should continue his current dose of furosemide. </p>\n<p><em>Play videos and click lower right hand corner buttons to expand viewing panes.</em></p>\n<p><br/></p>\n<p> <span class=\"fr-video fr-deletable fr-fvc fr-dvi fr-draggable\" contenteditable=\"false\"></span></p><div class=\"mediaplugin mediaplugin_videojs d-block\"><div style=\"max-width:400px;\"><div aria-label=\"Video Player\" class=\"video-js vjs-paused vjs-fluid id_videojs_68a28ac928efa_3-dimensions vjs-controls-enabled vjs-workinghover vjs-v8 vjs-user-active\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28ac928efa_3\" lang=\"en-gb\" role=\"region\" tabindex=\"-1\" title=\"Koratala\" translate=\"no\"><video class=\"vjs-tech\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28ac928efa_3_html5_api\" role=\"application\" tabindex=\"-1\" title=\"Koratala\"><source src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b2q17c_Koratala-Q1_Video_1_labeled.mp4\" type=\"video/mp4\"/>\n                https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b2q17c_Koratala-Q1_Video_1_labeled.mp4\n            </video><div aria-disabled=\"false\" class=\"vjs-poster vjs-hidden\"></div><div class=\"vjs-title-bar vjs-hidden\"><div class=\"vjs-title-bar-title\" id=\"vjs-title-bar-title-1513\"></div><div class=\"vjs-title-bar-description\" id=\"vjs-title-bar-description-1514\"></div></div><div aria-atomic=\"true\" aria-live=\"off\" class=\"vjs-text-track-display\" style=\"inset-inline: 50px;\" translate=\"yes\"><div style=\"position: absolute; inset: 0px; margin: 1.5%;\"></div></div><div class=\"vjs-loading-spinner\" dir=\"ltr\"><span class=\"vjs-control-text\">Video Player is loading.</span></div><button aria-disabled=\"false\" class=\"vjs-big-play-button\" title=\"Play Video\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play Video</span></button><div class=\"vjs-control-bar\" dir=\"ltr\"><button aria-disabled=\"false\" class=\"vjs-play-control vjs-control vjs-button\" title=\"Play\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play</span></button><button aria-disabled=\"false\" class=\"vjs-skip-backward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Backward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Backward</span></button><button aria-disabled=\"false\" class=\"vjs-skip-forward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Forward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Forward</span></button><div class=\"vjs-volume-panel vjs-control vjs-volume-panel-horizontal\"><button aria-disabled=\"false\" class=\"vjs-mute-control vjs-control vjs-button vjs-vol-3\" title=\"Mute\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Mute</span></button><div class=\"vjs-volume-control vjs-control vjs-volume-horizontal\"><div aria-label=\"Volume Level\" aria-live=\"polite\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"100\" aria-valuetext=\"100%\" class=\"vjs-volume-bar vjs-slider-bar vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-volume-tooltip\"></div></div><div class=\"vjs-volume-level\"><span class=\"vjs-control-text\"></span></div></div></div></div><div class=\"vjs-current-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Current Time </span><span class=\"vjs-current-time-display\" role=\"presentation\">0:00</span></div><div aria-hidden=\"true\" class=\"vjs-time-control vjs-time-divider\"><div><span>/</span></div></div><div class=\"vjs-duration vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Duration </span><span class=\"vjs-duration-display\" role=\"presentation\">0:08</span></div><div class=\"vjs-progress-control vjs-control\"><div aria-label=\"Progress Bar\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"0.00\" aria-valuetext=\"0:00 of 0:08\" class=\"vjs-progress-holder vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-load-progress\" style=\"width: 3.87%;\"><span class=\"vjs-control-text\"><span>Loaded</span>: <span class=\"vjs-control-text-loaded-percentage\">3.87%</span></span><div data-end=\"0.31\" data-start=\"0\" style=\"left: 0%; width: 100%;\"></div></div><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\"></div></div><div aria-hidden=\"true\" class=\"vjs-play-progress vjs-slider-bar\" style=\"width: 0%;\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\" style=\"right: 0px;\">0:00</div></div></div></div><div class=\"vjs-live-control vjs-control vjs-hidden\"><div aria-live=\"off\" class=\"vjs-live-display\"><span class=\"vjs-control-text\">Stream Type </span>LIVE</div></div><button aria-disabled=\"false\" class=\"vjs-seek-to-live-control vjs-control\" title=\"Seek to live, currently behind live\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Seek to live, currently behind live</span><span aria-hidden=\"true\" class=\"vjs-seek-to-live-text\">LIVE</span></button><div class=\"vjs-remaining-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Remaining Time </span><span aria-hidden=\"true\">-</span><span class=\"vjs-remaining-time-display\" role=\"presentation\">0:08</span></div><div class=\"vjs-custom-control-spacer vjs-spacer\"> </div><div class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-control vjs-button\"><div class=\"vjs-playback-rate-value\" id=\"vjs-playback-rate-value-label-id_videojs_68a28ac928efa_3_component_1758\">1x</div><button aria-describedby=\"vjs-playback-rate-value-label-id_videojs_68a28ac928efa_3_component_1758\" aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Playback Rate\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Playback Rate</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\" role=\"menu\"><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">2x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.25x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1x</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li></ul></div></div><div class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Chapters\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Chapters</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li class=\"vjs-menu-title\" tabindex=\"-1\">Chapters</li></ul></div></div><div class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Descriptions\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Descriptions</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">descriptions off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Subtitles\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Subtitles</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-disabled=\"false\" class=\"vjs-menu-item vjs-texttrack-settings\" role=\"menuitem\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles settings</span><span aria-live=\"polite\" class=\"vjs-control-text\">, opens subtitles settings dialog</span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Audio Track\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Audio Track</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"></ul></div></div><button aria-disabled=\"false\" class=\"vjs-picture-in-picture-control vjs-control vjs-button\" title=\"Picture-in-Picture\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Picture-in-Picture</span></button><button aria-disabled=\"false\" class=\"vjs-fullscreen-control vjs-control vjs-button\" title=\"Fullscreen\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Fullscreen</span></button></div><div aria-describedby=\"id_videojs_68a28ac928efa_3_component_2059_description\" aria-hidden=\"true\" aria-label=\"Modal Window\" aria-live=\"polite\" class=\"vjs-error-display vjs-modal-dialog vjs-hidden\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28ac928efa_3_component_2059_description\">This is a modal window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"></div></div><div aria-describedby=\"id_videojs_68a28ac928efa_3_component_2065_description\" aria-hidden=\"true\" aria-label=\"Caption Settings Dialog\" aria-live=\"polite\" class=\"vjs-modal-dialog vjs-hidden vjs-text-track-settings\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28ac928efa_3_component_2065_description\">Beginning of dialog window. Escape will cancel and close the window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"><div class=\"vjs-track-settings-colors\"><fieldset class=\"vjs-fg vjs-track-setting\"><legend id=\"captions-text-legend-id_videojs_68a28ac928efa_3_component_2065\">Text</legend><span class=\"vjs-text-color\"><label class=\"vjs-label\" for=\"vjs_select_2092\" id=\"captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065\">Color</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065\" id=\"vjs_select_2092\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-White\" id=\"captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-Black\" id=\"captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-Red\" id=\"captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-Green\" id=\"captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-Blue\" id=\"captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-Yellow\" id=\"captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-Magenta\" id=\"captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-Cyan\" id=\"captions-foreground-color-id_videojs_68a28ac928efa_3_component_2065-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-text-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_2097\" id=\"captions-foreground-opacity-id_videojs_68a28ac928efa_3_component_2065\">Opacity</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-opacity-id_videojs_68a28ac928efa_3_component_2065\" id=\"vjs_select_2097\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-opacity-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-opacity-id_videojs_68a28ac928efa_3_component_2065-Opaque\" id=\"captions-foreground-opacity-id_videojs_68a28ac928efa_3_component_2065-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-opacity-id_videojs_68a28ac928efa_3_component_2065 captions-foreground-opacity-id_videojs_68a28ac928efa_3_component_2065-SemiTransparent\" id=\"captions-foreground-opacity-id_videojs_68a28ac928efa_3_component_2065-SemiTransparent\" value=\"0.5\">Semi-Transparent</option></select></span></fieldset><fieldset class=\"vjs-bg vjs-track-setting\"><legend id=\"captions-background-id_videojs_68a28ac928efa_3_component_2065\">Text Background</legend><span class=\"vjs-bg-color\"><label class=\"vjs-label\" for=\"vjs_select_2107\" id=\"captions-background-color-id_videojs_68a28ac928efa_3_component_2065\">Color</label><select aria-labelledby=\"captions-background-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065\" id=\"vjs_select_2107\"><option aria-labelledby=\"captions-background-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065-Black\" id=\"captions-background-color-id_videojs_68a28ac928efa_3_component_2065-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065-White\" id=\"captions-background-color-id_videojs_68a28ac928efa_3_component_2065-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065-Red\" id=\"captions-background-color-id_videojs_68a28ac928efa_3_component_2065-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065-Green\" id=\"captions-background-color-id_videojs_68a28ac928efa_3_component_2065-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065-Blue\" id=\"captions-background-color-id_videojs_68a28ac928efa_3_component_2065-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065-Yellow\" id=\"captions-background-color-id_videojs_68a28ac928efa_3_component_2065-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065-Magenta\" id=\"captions-background-color-id_videojs_68a28ac928efa_3_component_2065-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065 captions-background-color-id_videojs_68a28ac928efa_3_component_2065-Cyan\" id=\"captions-background-color-id_videojs_68a28ac928efa_3_component_2065-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-bg-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_2112\" id=\"captions-background-opacity-id_videojs_68a28ac928efa_3_component_2065\">Opacity</label><select aria-labelledby=\"captions-background-id_videojs_68a28ac928efa_3_component_2065 captions-background-opacity-id_videojs_68a28ac928efa_3_component_2065\" id=\"vjs_select_2112\"><option aria-labelledby=\"captions-background-id_videojs_68a28ac928efa_3_component_2065 captions-background-opacity-id_videojs_68a28ac928efa_3_component_2065 captions-background-opacity-id_videojs_68a28ac928efa_3_component_2065-Opaque\" id=\"captions-background-opacity-id_videojs_68a28ac928efa_3_component_2065-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928efa_3_component_2065 captions-background-opacity-id_videojs_68a28ac928efa_3_component_2065 captions-background-opacity-id_videojs_68a28ac928efa_3_component_2065-SemiTransparent\" id=\"captions-background-opacity-id_videojs_68a28ac928efa_3_component_2065-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928efa_3_component_2065 captions-background-opacity-id_videojs_68a28ac928efa_3_component_2065 captions-background-opacity-id_videojs_68a28ac928efa_3_component_2065-Transparent\" id=\"captions-background-opacity-id_videojs_68a28ac928efa_3_component_2065-Transparent\" value=\"0\">Transparent</option></select></span></fieldset><fieldset class=\"vjs-window vjs-track-setting\"><legend id=\"captions-window-id_videojs_68a28ac928efa_3_component_2065\">Caption Area Background</legend><span class=\"vjs-window-color\"><label class=\"vjs-label\" for=\"vjs_select_2122\" id=\"captions-window-color-id_videojs_68a28ac928efa_3_component_2065\">Color</label><select aria-labelledby=\"captions-window-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065\" id=\"vjs_select_2122\"><option aria-labelledby=\"captions-window-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065-Black\" id=\"captions-window-color-id_videojs_68a28ac928efa_3_component_2065-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065-White\" id=\"captions-window-color-id_videojs_68a28ac928efa_3_component_2065-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065-Red\" id=\"captions-window-color-id_videojs_68a28ac928efa_3_component_2065-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065-Green\" id=\"captions-window-color-id_videojs_68a28ac928efa_3_component_2065-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065-Blue\" id=\"captions-window-color-id_videojs_68a28ac928efa_3_component_2065-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065-Yellow\" id=\"captions-window-color-id_videojs_68a28ac928efa_3_component_2065-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065-Magenta\" id=\"captions-window-color-id_videojs_68a28ac928efa_3_component_2065-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065 captions-window-color-id_videojs_68a28ac928efa_3_component_2065-Cyan\" id=\"captions-window-color-id_videojs_68a28ac928efa_3_component_2065-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-window-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_2127\" id=\"captions-window-opacity-id_videojs_68a28ac928efa_3_component_2065\">Opacity</label><select aria-labelledby=\"captions-window-id_videojs_68a28ac928efa_3_component_2065 captions-window-opacity-id_videojs_68a28ac928efa_3_component_2065\" id=\"vjs_select_2127\"><option aria-labelledby=\"captions-window-id_videojs_68a28ac928efa_3_component_2065 captions-window-opacity-id_videojs_68a28ac928efa_3_component_2065 captions-window-opacity-id_videojs_68a28ac928efa_3_component_2065-Transparent\" id=\"captions-window-opacity-id_videojs_68a28ac928efa_3_component_2065-Transparent\" value=\"0\">Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928efa_3_component_2065 captions-window-opacity-id_videojs_68a28ac928efa_3_component_2065 captions-window-opacity-id_videojs_68a28ac928efa_3_component_2065-SemiTransparent\" id=\"captions-window-opacity-id_videojs_68a28ac928efa_3_component_2065-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928efa_3_component_2065 captions-window-opacity-id_videojs_68a28ac928efa_3_component_2065 captions-window-opacity-id_videojs_68a28ac928efa_3_component_2065-Opaque\" id=\"captions-window-opacity-id_videojs_68a28ac928efa_3_component_2065-Opaque\" value=\"1\">Opaque</option></select></span></fieldset></div><div class=\"vjs-track-settings-font\"><fieldset class=\"vjs-font-percent vjs-track-setting\"><legend id=\"captions-font-size-id_videojs_68a28ac928efa_3_component_2065\">Font Size</legend><select aria-labelledby=\"captions-font-size-id_videojs_68a28ac928efa_3_component_2065\" id=\"vjs_select_2142\"><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2143-50\" id=\"vjs-track-option-2143-50\" value=\"0.50\">50%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2144-75\" id=\"vjs-track-option-2144-75\" value=\"0.75\">75%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2145-100\" id=\"vjs-track-option-2145-100\" value=\"1.00\">100%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2146-125\" id=\"vjs-track-option-2146-125\" value=\"1.25\">125%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2147-150\" id=\"vjs-track-option-2147-150\" value=\"1.50\">150%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2148-175\" id=\"vjs-track-option-2148-175\" value=\"1.75\">175%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2149-200\" id=\"vjs-track-option-2149-200\" value=\"2.00\">200%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2150-300\" id=\"vjs-track-option-2150-300\" value=\"3.00\">300%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2151-400\" id=\"vjs-track-option-2151-400\" value=\"4.00\">400%</option></select></fieldset><fieldset class=\"vjs-edge-style vjs-track-setting\"><legend id=\"captions-edge-style-id_videojs_68a28ac928efa_3_component_2065\">Text Edge Style</legend><select aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928efa_3_component_2065\" id=\"vjs_select_2161\"><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2162-None\" id=\"vjs-track-option-2162-None\" value=\"none\">None</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2163-Raised\" id=\"vjs-track-option-2163-Raised\" value=\"raised\">Raised</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2164-Depressed\" id=\"vjs-track-option-2164-Depressed\" value=\"depressed\">Depressed</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2165-Uniform\" id=\"vjs-track-option-2165-Uniform\" value=\"uniform\">Uniform</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2166-Dropshadow\" id=\"vjs-track-option-2166-Dropshadow\" value=\"dropshadow\">Drop shadow</option></select></fieldset><fieldset class=\"vjs-font-family vjs-track-setting\"><legend id=\"captions-font-family-id_videojs_68a28ac928efa_3_component_2065\">Font Family</legend><select aria-labelledby=\"captions-font-family-id_videojs_68a28ac928efa_3_component_2065\" id=\"vjs_select_2176\"><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2177-ProportionalSansSerif\" id=\"vjs-track-option-2177-ProportionalSansSerif\" value=\"proportionalSansSerif\">Proportional Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2178-MonospaceSansSerif\" id=\"vjs-track-option-2178-MonospaceSansSerif\" value=\"monospaceSansSerif\">Monospace Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2179-ProportionalSerif\" id=\"vjs-track-option-2179-ProportionalSerif\" value=\"proportionalSerif\">Proportional Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2180-MonospaceSerif\" id=\"vjs-track-option-2180-MonospaceSerif\" value=\"monospaceSerif\">Monospace Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2181-Casual\" id=\"vjs-track-option-2181-Casual\" value=\"casual\">Casual</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2182-Script\" id=\"vjs-track-option-2182-Script\" value=\"script\">Script</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928efa_3_component_2065 vjs-track-option-2183-SmallCaps\" id=\"vjs-track-option-2183-SmallCaps\" value=\"small-caps\">Small Caps</option></select></fieldset></div><div class=\"vjs-track-settings-controls\"><button aria-disabled=\"false\" class=\"vjs-default-button\" title=\"restore all settings to the default values\" type=\"button\">Reset</button><button aria-disabled=\"false\" class=\"vjs-done-button\" title=\"restore all settings to the default values\" type=\"button\">Done</button></div></div><button aria-disabled=\"false\" class=\"vjs-close-button vjs-control vjs-button\" title=\"Close Modal Dialog\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Close Modal Dialog</span></button><p class=\"vjs-control-text\">End of dialog window.</p></div></div></div></div><em> </em><p></p>\n<p> <span class=\"fr-video fr-deletable fr-fvc fr-dvi fr-draggable\" contenteditable=\"false\"></span></p><div class=\"mediaplugin mediaplugin_videojs d-block\"><div style=\"max-width:400px;\"><div aria-label=\"Video Player\" class=\"video-js vjs-paused vjs-fluid id_videojs_68a28ac928f80_4-dimensions vjs-controls-enabled vjs-workinghover vjs-v8 vjs-user-active\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28ac928f80_4\" lang=\"en-gb\" role=\"region\" tabindex=\"-1\" title=\"Koratala\" translate=\"no\"><video class=\"vjs-tech\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28ac928f80_4_html5_api\" role=\"application\" tabindex=\"-1\" title=\"Koratala\"><source src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b2q17d_Koratala-Q1_Video_2_labeled.mp4\" type=\"video/mp4\"/>\n                https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b2q17d_Koratala-Q1_Video_2_labeled.mp4\n            </video><div aria-disabled=\"false\" class=\"vjs-poster vjs-hidden\"></div><div class=\"vjs-title-bar vjs-hidden\"><div class=\"vjs-title-bar-title\" id=\"vjs-title-bar-title-2248\"></div><div class=\"vjs-title-bar-description\" id=\"vjs-title-bar-description-2249\"></div></div><div aria-atomic=\"true\" aria-live=\"off\" class=\"vjs-text-track-display\" style=\"inset-inline: 50px;\" translate=\"yes\"><div style=\"position: absolute; inset: 0px; margin: 1.5%;\"></div></div><div class=\"vjs-loading-spinner\" dir=\"ltr\"><span class=\"vjs-control-text\">Video Player is loading.</span></div><button aria-disabled=\"false\" class=\"vjs-big-play-button\" title=\"Play Video\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play Video</span></button><div class=\"vjs-control-bar\" dir=\"ltr\"><button aria-disabled=\"false\" class=\"vjs-play-control vjs-control vjs-button\" title=\"Play\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play</span></button><button aria-disabled=\"false\" class=\"vjs-skip-backward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Backward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Backward</span></button><button aria-disabled=\"false\" class=\"vjs-skip-forward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Forward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Forward</span></button><div class=\"vjs-volume-panel vjs-control vjs-volume-panel-horizontal\"><button aria-disabled=\"false\" class=\"vjs-mute-control vjs-control vjs-button vjs-vol-3\" title=\"Mute\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Mute</span></button><div class=\"vjs-volume-control vjs-control vjs-volume-horizontal\"><div aria-label=\"Volume Level\" aria-live=\"polite\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"100\" aria-valuetext=\"100%\" class=\"vjs-volume-bar vjs-slider-bar vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-volume-tooltip\"></div></div><div class=\"vjs-volume-level\"><span class=\"vjs-control-text\"></span></div></div></div></div><div class=\"vjs-current-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Current Time </span><span class=\"vjs-current-time-display\" role=\"presentation\">0:00</span></div><div aria-hidden=\"true\" class=\"vjs-time-control vjs-time-divider\"><div><span>/</span></div></div><div class=\"vjs-duration vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Duration </span><span class=\"vjs-duration-display\" role=\"presentation\">0:08</span></div><div class=\"vjs-progress-control vjs-control\"><div aria-label=\"Progress Bar\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"0.00\" aria-valuetext=\"0:00 of 0:08\" class=\"vjs-progress-holder vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-load-progress\" style=\"width: 0%;\"><span class=\"vjs-control-text\"><span>Loaded</span>: <span class=\"vjs-control-text-loaded-percentage\">0.00%</span></span><div data-end=\"0\" data-start=\"0\" style=\"left: 0%; width: 0%;\"></div></div><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\"></div></div><div aria-hidden=\"true\" class=\"vjs-play-progress vjs-slider-bar\" style=\"width: 0%;\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\" style=\"right: 0px;\">0:00</div></div></div></div><div class=\"vjs-live-control vjs-control vjs-hidden\"><div aria-live=\"off\" class=\"vjs-live-display\"><span class=\"vjs-control-text\">Stream Type </span>LIVE</div></div><button aria-disabled=\"false\" class=\"vjs-seek-to-live-control vjs-control\" title=\"Seek to live, currently behind live\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Seek to live, currently behind live</span><span aria-hidden=\"true\" class=\"vjs-seek-to-live-text\">LIVE</span></button><div class=\"vjs-remaining-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Remaining Time </span><span aria-hidden=\"true\">-</span><span class=\"vjs-remaining-time-display\" role=\"presentation\">0:08</span></div><div class=\"vjs-custom-control-spacer vjs-spacer\"> </div><div class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-control vjs-button\"><div class=\"vjs-playback-rate-value\" id=\"vjs-playback-rate-value-label-id_videojs_68a28ac928f80_4_component_2493\">1x</div><button aria-describedby=\"vjs-playback-rate-value-label-id_videojs_68a28ac928f80_4_component_2493\" aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Playback Rate\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Playback Rate</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\" role=\"menu\"><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">2x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.25x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1x</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li></ul></div></div><div class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Chapters\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Chapters</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li class=\"vjs-menu-title\" tabindex=\"-1\">Chapters</li></ul></div></div><div class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Descriptions\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Descriptions</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">descriptions off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Subtitles\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Subtitles</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-disabled=\"false\" class=\"vjs-menu-item vjs-texttrack-settings\" role=\"menuitem\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles settings</span><span aria-live=\"polite\" class=\"vjs-control-text\">, opens subtitles settings dialog</span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Audio Track\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Audio Track</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"></ul></div></div><button aria-disabled=\"false\" class=\"vjs-picture-in-picture-control vjs-control vjs-button\" title=\"Picture-in-Picture\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Picture-in-Picture</span></button><button aria-disabled=\"false\" class=\"vjs-fullscreen-control vjs-control vjs-button\" title=\"Fullscreen\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Fullscreen</span></button></div><div aria-describedby=\"id_videojs_68a28ac928f80_4_component_2794_description\" aria-hidden=\"true\" aria-label=\"Modal Window\" aria-live=\"polite\" class=\"vjs-error-display vjs-modal-dialog vjs-hidden\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28ac928f80_4_component_2794_description\">This is a modal window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"></div></div><div aria-describedby=\"id_videojs_68a28ac928f80_4_component_2800_description\" aria-hidden=\"true\" aria-label=\"Caption Settings Dialog\" aria-live=\"polite\" class=\"vjs-modal-dialog vjs-hidden vjs-text-track-settings\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28ac928f80_4_component_2800_description\">Beginning of dialog window. Escape will cancel and close the window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"><div class=\"vjs-track-settings-colors\"><fieldset class=\"vjs-fg vjs-track-setting\"><legend id=\"captions-text-legend-id_videojs_68a28ac928f80_4_component_2800\">Text</legend><span class=\"vjs-text-color\"><label class=\"vjs-label\" for=\"vjs_select_2827\" id=\"captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800\">Color</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800\" id=\"vjs_select_2827\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-White\" id=\"captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-Black\" id=\"captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-Red\" id=\"captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-Green\" id=\"captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-Blue\" id=\"captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-Yellow\" id=\"captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-Magenta\" id=\"captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-Cyan\" id=\"captions-foreground-color-id_videojs_68a28ac928f80_4_component_2800-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-text-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_2832\" id=\"captions-foreground-opacity-id_videojs_68a28ac928f80_4_component_2800\">Opacity</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-opacity-id_videojs_68a28ac928f80_4_component_2800\" id=\"vjs_select_2832\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-opacity-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-opacity-id_videojs_68a28ac928f80_4_component_2800-Opaque\" id=\"captions-foreground-opacity-id_videojs_68a28ac928f80_4_component_2800-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-opacity-id_videojs_68a28ac928f80_4_component_2800 captions-foreground-opacity-id_videojs_68a28ac928f80_4_component_2800-SemiTransparent\" id=\"captions-foreground-opacity-id_videojs_68a28ac928f80_4_component_2800-SemiTransparent\" value=\"0.5\">Semi-Transparent</option></select></span></fieldset><fieldset class=\"vjs-bg vjs-track-setting\"><legend id=\"captions-background-id_videojs_68a28ac928f80_4_component_2800\">Text Background</legend><span class=\"vjs-bg-color\"><label class=\"vjs-label\" for=\"vjs_select_2842\" id=\"captions-background-color-id_videojs_68a28ac928f80_4_component_2800\">Color</label><select aria-labelledby=\"captions-background-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800\" id=\"vjs_select_2842\"><option aria-labelledby=\"captions-background-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800-Black\" id=\"captions-background-color-id_videojs_68a28ac928f80_4_component_2800-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800-White\" id=\"captions-background-color-id_videojs_68a28ac928f80_4_component_2800-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800-Red\" id=\"captions-background-color-id_videojs_68a28ac928f80_4_component_2800-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800-Green\" id=\"captions-background-color-id_videojs_68a28ac928f80_4_component_2800-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800-Blue\" id=\"captions-background-color-id_videojs_68a28ac928f80_4_component_2800-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800-Yellow\" id=\"captions-background-color-id_videojs_68a28ac928f80_4_component_2800-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800-Magenta\" id=\"captions-background-color-id_videojs_68a28ac928f80_4_component_2800-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800 captions-background-color-id_videojs_68a28ac928f80_4_component_2800-Cyan\" id=\"captions-background-color-id_videojs_68a28ac928f80_4_component_2800-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-bg-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_2847\" id=\"captions-background-opacity-id_videojs_68a28ac928f80_4_component_2800\">Opacity</label><select aria-labelledby=\"captions-background-id_videojs_68a28ac928f80_4_component_2800 captions-background-opacity-id_videojs_68a28ac928f80_4_component_2800\" id=\"vjs_select_2847\"><option aria-labelledby=\"captions-background-id_videojs_68a28ac928f80_4_component_2800 captions-background-opacity-id_videojs_68a28ac928f80_4_component_2800 captions-background-opacity-id_videojs_68a28ac928f80_4_component_2800-Opaque\" id=\"captions-background-opacity-id_videojs_68a28ac928f80_4_component_2800-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928f80_4_component_2800 captions-background-opacity-id_videojs_68a28ac928f80_4_component_2800 captions-background-opacity-id_videojs_68a28ac928f80_4_component_2800-SemiTransparent\" id=\"captions-background-opacity-id_videojs_68a28ac928f80_4_component_2800-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-background-id_videojs_68a28ac928f80_4_component_2800 captions-background-opacity-id_videojs_68a28ac928f80_4_component_2800 captions-background-opacity-id_videojs_68a28ac928f80_4_component_2800-Transparent\" id=\"captions-background-opacity-id_videojs_68a28ac928f80_4_component_2800-Transparent\" value=\"0\">Transparent</option></select></span></fieldset><fieldset class=\"vjs-window vjs-track-setting\"><legend id=\"captions-window-id_videojs_68a28ac928f80_4_component_2800\">Caption Area Background</legend><span class=\"vjs-window-color\"><label class=\"vjs-label\" for=\"vjs_select_2857\" id=\"captions-window-color-id_videojs_68a28ac928f80_4_component_2800\">Color</label><select aria-labelledby=\"captions-window-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800\" id=\"vjs_select_2857\"><option aria-labelledby=\"captions-window-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800-Black\" id=\"captions-window-color-id_videojs_68a28ac928f80_4_component_2800-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800-White\" id=\"captions-window-color-id_videojs_68a28ac928f80_4_component_2800-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800-Red\" id=\"captions-window-color-id_videojs_68a28ac928f80_4_component_2800-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800-Green\" id=\"captions-window-color-id_videojs_68a28ac928f80_4_component_2800-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800-Blue\" id=\"captions-window-color-id_videojs_68a28ac928f80_4_component_2800-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800-Yellow\" id=\"captions-window-color-id_videojs_68a28ac928f80_4_component_2800-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800-Magenta\" id=\"captions-window-color-id_videojs_68a28ac928f80_4_component_2800-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800 captions-window-color-id_videojs_68a28ac928f80_4_component_2800-Cyan\" id=\"captions-window-color-id_videojs_68a28ac928f80_4_component_2800-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-window-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_2862\" id=\"captions-window-opacity-id_videojs_68a28ac928f80_4_component_2800\">Opacity</label><select aria-labelledby=\"captions-window-id_videojs_68a28ac928f80_4_component_2800 captions-window-opacity-id_videojs_68a28ac928f80_4_component_2800\" id=\"vjs_select_2862\"><option aria-labelledby=\"captions-window-id_videojs_68a28ac928f80_4_component_2800 captions-window-opacity-id_videojs_68a28ac928f80_4_component_2800 captions-window-opacity-id_videojs_68a28ac928f80_4_component_2800-Transparent\" id=\"captions-window-opacity-id_videojs_68a28ac928f80_4_component_2800-Transparent\" value=\"0\">Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928f80_4_component_2800 captions-window-opacity-id_videojs_68a28ac928f80_4_component_2800 captions-window-opacity-id_videojs_68a28ac928f80_4_component_2800-SemiTransparent\" id=\"captions-window-opacity-id_videojs_68a28ac928f80_4_component_2800-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28ac928f80_4_component_2800 captions-window-opacity-id_videojs_68a28ac928f80_4_component_2800 captions-window-opacity-id_videojs_68a28ac928f80_4_component_2800-Opaque\" id=\"captions-window-opacity-id_videojs_68a28ac928f80_4_component_2800-Opaque\" value=\"1\">Opaque</option></select></span></fieldset></div><div class=\"vjs-track-settings-font\"><fieldset class=\"vjs-font-percent vjs-track-setting\"><legend id=\"captions-font-size-id_videojs_68a28ac928f80_4_component_2800\">Font Size</legend><select aria-labelledby=\"captions-font-size-id_videojs_68a28ac928f80_4_component_2800\" id=\"vjs_select_2877\"><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2878-50\" id=\"vjs-track-option-2878-50\" value=\"0.50\">50%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2879-75\" id=\"vjs-track-option-2879-75\" value=\"0.75\">75%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2880-100\" id=\"vjs-track-option-2880-100\" value=\"1.00\">100%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2881-125\" id=\"vjs-track-option-2881-125\" value=\"1.25\">125%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2882-150\" id=\"vjs-track-option-2882-150\" value=\"1.50\">150%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2883-175\" id=\"vjs-track-option-2883-175\" value=\"1.75\">175%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2884-200\" id=\"vjs-track-option-2884-200\" value=\"2.00\">200%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2885-300\" id=\"vjs-track-option-2885-300\" value=\"3.00\">300%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2886-400\" id=\"vjs-track-option-2886-400\" value=\"4.00\">400%</option></select></fieldset><fieldset class=\"vjs-edge-style vjs-track-setting\"><legend id=\"captions-edge-style-id_videojs_68a28ac928f80_4_component_2800\">Text Edge Style</legend><select aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928f80_4_component_2800\" id=\"vjs_select_2896\"><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2897-None\" id=\"vjs-track-option-2897-None\" value=\"none\">None</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2898-Raised\" id=\"vjs-track-option-2898-Raised\" value=\"raised\">Raised</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2899-Depressed\" id=\"vjs-track-option-2899-Depressed\" value=\"depressed\">Depressed</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2900-Uniform\" id=\"vjs-track-option-2900-Uniform\" value=\"uniform\">Uniform</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2901-Dropshadow\" id=\"vjs-track-option-2901-Dropshadow\" value=\"dropshadow\">Drop shadow</option></select></fieldset><fieldset class=\"vjs-font-family vjs-track-setting\"><legend id=\"captions-font-family-id_videojs_68a28ac928f80_4_component_2800\">Font Family</legend><select aria-labelledby=\"captions-font-family-id_videojs_68a28ac928f80_4_component_2800\" id=\"vjs_select_2911\"><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2912-ProportionalSansSerif\" id=\"vjs-track-option-2912-ProportionalSansSerif\" value=\"proportionalSansSerif\">Proportional Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2913-MonospaceSansSerif\" id=\"vjs-track-option-2913-MonospaceSansSerif\" value=\"monospaceSansSerif\">Monospace Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2914-ProportionalSerif\" id=\"vjs-track-option-2914-ProportionalSerif\" value=\"proportionalSerif\">Proportional Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2915-MonospaceSerif\" id=\"vjs-track-option-2915-MonospaceSerif\" value=\"monospaceSerif\">Monospace Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2916-Casual\" id=\"vjs-track-option-2916-Casual\" value=\"casual\">Casual</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2917-Script\" id=\"vjs-track-option-2917-Script\" value=\"script\">Script</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ac928f80_4_component_2800 vjs-track-option-2918-SmallCaps\" id=\"vjs-track-option-2918-SmallCaps\" value=\"small-caps\">Small Caps</option></select></fieldset></div><div class=\"vjs-track-settings-controls\"><button aria-disabled=\"false\" class=\"vjs-default-button\" title=\"restore all settings to the default values\" type=\"button\">Reset</button><button aria-disabled=\"false\" class=\"vjs-done-button\" title=\"restore all settings to the default values\" type=\"button\">Done</button></div></div><button aria-disabled=\"false\" class=\"vjs-close-button vjs-control vjs-button\" title=\"Close Modal Dialog\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Close Modal Dialog</span></button><p class=\"vjs-control-text\">End of dialog window.</p></div></div></div></div><em> </em><p></p>\n<p><em>Images courtesy of Abhilash Koratala, MD, FASN, Medical College of Wisconsin</em></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The POCUS images demonstrate B-lines in the dependent lung zones, which indicate increased extravascular lung water, and A-lines (normal horizontal artifacts) in the upper anterior zones. This pattern is consistent with improving congestion, as the chest radiograph at presentation showed diffuse bilateral opacities (analogous to diffuse B-lines on US). The IVC is ~2 cm wide with minimal respiratory variation, which suggests high right atrial pressure in a spontaneously breathing patient. In summary, it can be inferred from the POCUS findings that the patient is not completely decongested despite resolution of symptoms.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">It is well recognized that in patients hospitalized for decompensated heart failure, persistent hemodynamic congestion (which can be detected by POCUS) at discharge portends worse outcomes despite clinical improvement. On the other hand, worsening kidney function (generally defined as ≥0.3 mg/dL rise in serum creatinine from baseline) has not been shown to be associated with worse outcomes in patients with good response to diuretics. Diuretic response constitutes adequate urine output to achieve negative fluid balance, defined as at least &gt;0.35 kg weight loss per 40 mg furosemide equivalent over 4 days in one study.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this case, the patient is symptomatically improved with good diuretic response but has residual congestion. Therefore, it is advisable to continue decongestive therapy regardless of the rise in creatinine level, which is most likely hemodynamically-mediated.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Withholding or reducing the dose of diuretic is not justified because of persistent congestion. Conversely, escalating the diuretic dose or starting ultrafiltration are also not indicated, as the patient is responding appropriately to current management. Additionally, metolazone would worsen his hypokalemia. </p>Lastly, caution must be exercised when interpreting the IVC ultrasound in patients with pulmonary hypertension, as the IVC may be chronically dilated; aiming for a small, collapsible IVC may lead to impaired cardiac output\n</div>",
        "references": [
            "Platz E, Campbell RT, Claggett B, et al. Lung ultrasound in acute heart failure: Prevalence of pulmonary congestion and short- and long-term outcomes.JACC Heart Fail7(10): 849–858, 2019",
            "Rivas-Lasarte M, Álvarez-García J, Fernández-Martínez J, et al. Lung ultrasound-guided treatment in ambulatory patients with heart failure: A randomized controlled clinical trial (LUS-HF study).Eur J Heart Fail21(12): 1605–1613, 2019",
            "Koratala A, Ronco C, Kazory A. Diagnosis of fluid overload: From conventional to contemporary concepts.Cardiorenal Med12(4): 141–154, 2022",
            "Mullens W, Damman K, Testani JM, et al. Evaluation of kidney function throughout the heart failure trajectory: A position statement from the Heart Failure Association of the European Society of Cardiology.Eur J Heart Fail22(4): 584–603, 2020",
            "Emmens JE, Ter Maaten JM, Matsue Y, et al. Worsening renal function in acute heart failure in the context of diuretic response.Eur J Heart Fail24(2): 365–374, 2022"
        ]
    },
    "54": {
        "question": "<div class=\"qtext\"><p>A 54-year-old woman with a history of alcoholic cirrhosis is admitted to the hospital for AKI. Serum creatinine level at presentation was 1.8 mg/dL, increased from a baseline of 0.6 mg/dL (reference range, 0.5–1.1). She was prescribed albumin at a dose of 1 g/kg/day IV. Two days later, serum creatinine level increased to 2.3 mg/dL and the patient became oliguric. </p>\n<p>On examination, BP is 118/56 mm Hg, and heart rate is 98/min. The patient is in no acute distress, and her lungs are clear to auscultation. The highest point of jugular venous pulsation is approximately 5 cm above the sternal angle. Her abdomen is distended, soft, and has a fluid wave, and there is 2+ bilateral pitting pedal edema. </p>\n<p>A spot urine sodium is &lt;20 mEq/dL. A kidney ultrasound is negative for hydronephrosis.</p>\n<p>A point-of-care US (POCUS) of the inferior vena cava (IVC) and suprapubic regions are shown below.</p>\n<p><em>Play video and click lower right hand corner button to expand viewing pane.</em></p>\n<p>\n</p>\n<p> <span class=\"fr-video fr-deletable fr-fvc fr-dvi fr-draggable\" contenteditable=\"false\"></span></p><div class=\"mediaplugin mediaplugin_videojs d-block\"><div style=\"max-width:400px;\"><div aria-label=\"Video Player\" class=\"video-js vjs-paused vjs-fluid id_videojs_68a28ace7629c_1-dimensions vjs-controls-enabled vjs-workinghover vjs-v8 vjs-user-active\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28ace7629c_1\" lang=\"en-gb\" role=\"region\" tabindex=\"-1\" title=\"Koratala\" translate=\"no\"><video class=\"vjs-tech\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28ace7629c_1_html5_api\" role=\"application\" tabindex=\"-1\" title=\"Koratala\"><source src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b2q18a_Koratala-Q2_video.mp4\" type=\"video/mp4\"/>\n            https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b2q18a_Koratala-Q2_video.mp4\n        </video><div aria-disabled=\"false\" class=\"vjs-poster vjs-hidden\"></div><div class=\"vjs-title-bar vjs-hidden\"><div class=\"vjs-title-bar-title\" id=\"vjs-title-bar-title-27\"></div><div class=\"vjs-title-bar-description\" id=\"vjs-title-bar-description-28\"></div></div><div aria-atomic=\"true\" aria-live=\"off\" class=\"vjs-text-track-display\" translate=\"yes\"><div style=\"position: absolute; inset: 0px; margin: 1.5%;\"></div></div><div class=\"vjs-loading-spinner\" dir=\"ltr\"><span class=\"vjs-control-text\">Video Player is loading.</span></div><button aria-disabled=\"false\" class=\"vjs-big-play-button\" title=\"Play Video\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play Video</span></button><div class=\"vjs-control-bar\" dir=\"ltr\"><button aria-disabled=\"false\" class=\"vjs-play-control vjs-control vjs-button\" title=\"Play\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play</span></button><button aria-disabled=\"false\" class=\"vjs-skip-backward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Backward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Backward</span></button><button aria-disabled=\"false\" class=\"vjs-skip-forward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Forward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Forward</span></button><div class=\"vjs-volume-panel vjs-control vjs-volume-panel-horizontal\"><button aria-disabled=\"false\" class=\"vjs-mute-control vjs-control vjs-button vjs-vol-3\" title=\"Mute\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Mute</span></button><div class=\"vjs-volume-control vjs-control vjs-volume-horizontal\"><div aria-label=\"Volume Level\" aria-live=\"polite\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"100\" aria-valuetext=\"100%\" class=\"vjs-volume-bar vjs-slider-bar vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-volume-tooltip\"></div></div><div class=\"vjs-volume-level\"><span class=\"vjs-control-text\"></span></div></div></div></div><div class=\"vjs-current-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Current Time </span><span class=\"vjs-current-time-display\" role=\"presentation\">0:00</span></div><div aria-hidden=\"true\" class=\"vjs-time-control vjs-time-divider\"><div><span>/</span></div></div><div class=\"vjs-duration vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Duration </span><span class=\"vjs-duration-display\" role=\"presentation\">0:08</span></div><div class=\"vjs-progress-control vjs-control\"><div aria-label=\"Progress Bar\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"0.00\" aria-valuetext=\"0:00 of 0:08\" class=\"vjs-progress-holder vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-load-progress\" style=\"width: 31.11%;\"><span class=\"vjs-control-text\"><span>Loaded</span>: <span class=\"vjs-control-text-loaded-percentage\">31.11%</span></span><div data-end=\"2.495\" data-start=\"0\" style=\"left: 0%; width: 100%;\"></div></div><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\"></div></div><div aria-hidden=\"true\" class=\"vjs-play-progress vjs-slider-bar\" style=\"width: 0%;\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\" style=\"right: 0px;\">0:00</div></div></div></div><div class=\"vjs-live-control vjs-control vjs-hidden\"><div aria-live=\"off\" class=\"vjs-live-display\"><span class=\"vjs-control-text\">Stream Type </span>LIVE</div></div><button aria-disabled=\"false\" class=\"vjs-seek-to-live-control vjs-control\" title=\"Seek to live, currently behind live\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Seek to live, currently behind live</span><span aria-hidden=\"true\" class=\"vjs-seek-to-live-text\">LIVE</span></button><div class=\"vjs-remaining-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Remaining Time </span><span aria-hidden=\"true\">-</span><span class=\"vjs-remaining-time-display\" role=\"presentation\">0:08</span></div><div class=\"vjs-custom-control-spacer vjs-spacer\"> </div><div class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-control vjs-button\"><div class=\"vjs-playback-rate-value\" id=\"vjs-playback-rate-value-label-id_videojs_68a28ace7629c_1_component_285\">1x</div><button aria-describedby=\"vjs-playback-rate-value-label-id_videojs_68a28ace7629c_1_component_285\" aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Playback Rate\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Playback Rate</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\" role=\"menu\"><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">2x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.25x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1x</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li></ul></div></div><div class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Chapters\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Chapters</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li class=\"vjs-menu-title\" tabindex=\"-1\">Chapters</li></ul></div></div><div class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Descriptions\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Descriptions</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">descriptions off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Subtitles\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Subtitles</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-disabled=\"false\" class=\"vjs-menu-item vjs-texttrack-settings\" role=\"menuitem\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles settings</span><span aria-live=\"polite\" class=\"vjs-control-text\">, opens subtitles settings dialog</span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Audio Track\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Audio Track</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"></ul></div></div><button aria-disabled=\"false\" class=\"vjs-picture-in-picture-control vjs-control vjs-button\" title=\"Picture-in-Picture\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Picture-in-Picture</span></button><button aria-disabled=\"false\" class=\"vjs-fullscreen-control vjs-control vjs-button\" title=\"Fullscreen\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Fullscreen</span></button></div><div aria-describedby=\"id_videojs_68a28ace7629c_1_component_589_description\" aria-hidden=\"true\" aria-label=\"Modal Window\" aria-live=\"polite\" class=\"vjs-error-display vjs-modal-dialog vjs-hidden\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28ace7629c_1_component_589_description\">This is a modal window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"></div></div><div aria-describedby=\"id_videojs_68a28ace7629c_1_component_595_description\" aria-hidden=\"true\" aria-label=\"Caption Settings Dialog\" aria-live=\"polite\" class=\"vjs-modal-dialog vjs-hidden vjs-text-track-settings\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28ace7629c_1_component_595_description\">Beginning of dialog window. Escape will cancel and close the window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"><div class=\"vjs-track-settings-colors\"><fieldset class=\"vjs-fg vjs-track-setting\"><legend id=\"captions-text-legend-id_videojs_68a28ace7629c_1_component_595\">Text</legend><span class=\"vjs-text-color\"><label class=\"vjs-label\" for=\"vjs_select_622\" id=\"captions-foreground-color-id_videojs_68a28ace7629c_1_component_595\">Color</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595\" id=\"vjs_select_622\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-White\" id=\"captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-Black\" id=\"captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-Red\" id=\"captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-Green\" id=\"captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-Blue\" id=\"captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-Yellow\" id=\"captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-Magenta\" id=\"captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595 captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-Cyan\" id=\"captions-foreground-color-id_videojs_68a28ace7629c_1_component_595-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-text-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_627\" id=\"captions-foreground-opacity-id_videojs_68a28ace7629c_1_component_595\">Opacity</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28ace7629c_1_component_595 captions-foreground-opacity-id_videojs_68a28ace7629c_1_component_595\" id=\"vjs_select_627\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace7629c_1_component_595 captions-foreground-opacity-id_videojs_68a28ace7629c_1_component_595 captions-foreground-opacity-id_videojs_68a28ace7629c_1_component_595-Opaque\" id=\"captions-foreground-opacity-id_videojs_68a28ace7629c_1_component_595-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace7629c_1_component_595 captions-foreground-opacity-id_videojs_68a28ace7629c_1_component_595 captions-foreground-opacity-id_videojs_68a28ace7629c_1_component_595-SemiTransparent\" id=\"captions-foreground-opacity-id_videojs_68a28ace7629c_1_component_595-SemiTransparent\" value=\"0.5\">Semi-Transparent</option></select></span></fieldset><fieldset class=\"vjs-bg vjs-track-setting\"><legend id=\"captions-background-id_videojs_68a28ace7629c_1_component_595\">Text Background</legend><span class=\"vjs-bg-color\"><label class=\"vjs-label\" for=\"vjs_select_637\" id=\"captions-background-color-id_videojs_68a28ace7629c_1_component_595\">Color</label><select aria-labelledby=\"captions-background-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595\" id=\"vjs_select_637\"><option aria-labelledby=\"captions-background-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595-Black\" id=\"captions-background-color-id_videojs_68a28ace7629c_1_component_595-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595-White\" id=\"captions-background-color-id_videojs_68a28ace7629c_1_component_595-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595-Red\" id=\"captions-background-color-id_videojs_68a28ace7629c_1_component_595-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595-Green\" id=\"captions-background-color-id_videojs_68a28ace7629c_1_component_595-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595-Blue\" id=\"captions-background-color-id_videojs_68a28ace7629c_1_component_595-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595-Yellow\" id=\"captions-background-color-id_videojs_68a28ace7629c_1_component_595-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595-Magenta\" id=\"captions-background-color-id_videojs_68a28ace7629c_1_component_595-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595 captions-background-color-id_videojs_68a28ace7629c_1_component_595-Cyan\" id=\"captions-background-color-id_videojs_68a28ace7629c_1_component_595-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-bg-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_642\" id=\"captions-background-opacity-id_videojs_68a28ace7629c_1_component_595\">Opacity</label><select aria-labelledby=\"captions-background-id_videojs_68a28ace7629c_1_component_595 captions-background-opacity-id_videojs_68a28ace7629c_1_component_595\" id=\"vjs_select_642\"><option aria-labelledby=\"captions-background-id_videojs_68a28ace7629c_1_component_595 captions-background-opacity-id_videojs_68a28ace7629c_1_component_595 captions-background-opacity-id_videojs_68a28ace7629c_1_component_595-Opaque\" id=\"captions-background-opacity-id_videojs_68a28ace7629c_1_component_595-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace7629c_1_component_595 captions-background-opacity-id_videojs_68a28ace7629c_1_component_595 captions-background-opacity-id_videojs_68a28ace7629c_1_component_595-SemiTransparent\" id=\"captions-background-opacity-id_videojs_68a28ace7629c_1_component_595-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace7629c_1_component_595 captions-background-opacity-id_videojs_68a28ace7629c_1_component_595 captions-background-opacity-id_videojs_68a28ace7629c_1_component_595-Transparent\" id=\"captions-background-opacity-id_videojs_68a28ace7629c_1_component_595-Transparent\" value=\"0\">Transparent</option></select></span></fieldset><fieldset class=\"vjs-window vjs-track-setting\"><legend id=\"captions-window-id_videojs_68a28ace7629c_1_component_595\">Caption Area Background</legend><span class=\"vjs-window-color\"><label class=\"vjs-label\" for=\"vjs_select_652\" id=\"captions-window-color-id_videojs_68a28ace7629c_1_component_595\">Color</label><select aria-labelledby=\"captions-window-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595\" id=\"vjs_select_652\"><option aria-labelledby=\"captions-window-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595-Black\" id=\"captions-window-color-id_videojs_68a28ace7629c_1_component_595-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595-White\" id=\"captions-window-color-id_videojs_68a28ace7629c_1_component_595-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595-Red\" id=\"captions-window-color-id_videojs_68a28ace7629c_1_component_595-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595-Green\" id=\"captions-window-color-id_videojs_68a28ace7629c_1_component_595-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595-Blue\" id=\"captions-window-color-id_videojs_68a28ace7629c_1_component_595-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595-Yellow\" id=\"captions-window-color-id_videojs_68a28ace7629c_1_component_595-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595-Magenta\" id=\"captions-window-color-id_videojs_68a28ace7629c_1_component_595-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595 captions-window-color-id_videojs_68a28ace7629c_1_component_595-Cyan\" id=\"captions-window-color-id_videojs_68a28ace7629c_1_component_595-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-window-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_657\" id=\"captions-window-opacity-id_videojs_68a28ace7629c_1_component_595\">Opacity</label><select aria-labelledby=\"captions-window-id_videojs_68a28ace7629c_1_component_595 captions-window-opacity-id_videojs_68a28ace7629c_1_component_595\" id=\"vjs_select_657\"><option aria-labelledby=\"captions-window-id_videojs_68a28ace7629c_1_component_595 captions-window-opacity-id_videojs_68a28ace7629c_1_component_595 captions-window-opacity-id_videojs_68a28ace7629c_1_component_595-Transparent\" id=\"captions-window-opacity-id_videojs_68a28ace7629c_1_component_595-Transparent\" value=\"0\">Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace7629c_1_component_595 captions-window-opacity-id_videojs_68a28ace7629c_1_component_595 captions-window-opacity-id_videojs_68a28ace7629c_1_component_595-SemiTransparent\" id=\"captions-window-opacity-id_videojs_68a28ace7629c_1_component_595-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace7629c_1_component_595 captions-window-opacity-id_videojs_68a28ace7629c_1_component_595 captions-window-opacity-id_videojs_68a28ace7629c_1_component_595-Opaque\" id=\"captions-window-opacity-id_videojs_68a28ace7629c_1_component_595-Opaque\" value=\"1\">Opaque</option></select></span></fieldset></div><div class=\"vjs-track-settings-font\"><fieldset class=\"vjs-font-percent vjs-track-setting\"><legend id=\"captions-font-size-id_videojs_68a28ace7629c_1_component_595\">Font Size</legend><select aria-labelledby=\"captions-font-size-id_videojs_68a28ace7629c_1_component_595\" id=\"vjs_select_672\"><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-673-50\" id=\"vjs-track-option-673-50\" value=\"0.50\">50%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-674-75\" id=\"vjs-track-option-674-75\" value=\"0.75\">75%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-675-100\" id=\"vjs-track-option-675-100\" value=\"1.00\">100%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-676-125\" id=\"vjs-track-option-676-125\" value=\"1.25\">125%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-677-150\" id=\"vjs-track-option-677-150\" value=\"1.50\">150%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-678-175\" id=\"vjs-track-option-678-175\" value=\"1.75\">175%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-679-200\" id=\"vjs-track-option-679-200\" value=\"2.00\">200%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-680-300\" id=\"vjs-track-option-680-300\" value=\"3.00\">300%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-681-400\" id=\"vjs-track-option-681-400\" value=\"4.00\">400%</option></select></fieldset><fieldset class=\"vjs-edge-style vjs-track-setting\"><legend id=\"captions-edge-style-id_videojs_68a28ace7629c_1_component_595\">Text Edge Style</legend><select aria-labelledby=\"captions-edge-style-id_videojs_68a28ace7629c_1_component_595\" id=\"vjs_select_691\"><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-692-None\" id=\"vjs-track-option-692-None\" value=\"none\">None</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-693-Raised\" id=\"vjs-track-option-693-Raised\" value=\"raised\">Raised</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-694-Depressed\" id=\"vjs-track-option-694-Depressed\" value=\"depressed\">Depressed</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-695-Uniform\" id=\"vjs-track-option-695-Uniform\" value=\"uniform\">Uniform</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-696-Dropshadow\" id=\"vjs-track-option-696-Dropshadow\" value=\"dropshadow\">Drop shadow</option></select></fieldset><fieldset class=\"vjs-font-family vjs-track-setting\"><legend id=\"captions-font-family-id_videojs_68a28ace7629c_1_component_595\">Font Family</legend><select aria-labelledby=\"captions-font-family-id_videojs_68a28ace7629c_1_component_595\" id=\"vjs_select_706\"><option aria-labelledby=\"captions-font-family-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-707-ProportionalSansSerif\" id=\"vjs-track-option-707-ProportionalSansSerif\" value=\"proportionalSansSerif\">Proportional Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-708-MonospaceSansSerif\" id=\"vjs-track-option-708-MonospaceSansSerif\" value=\"monospaceSansSerif\">Monospace Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-709-ProportionalSerif\" id=\"vjs-track-option-709-ProportionalSerif\" value=\"proportionalSerif\">Proportional Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-710-MonospaceSerif\" id=\"vjs-track-option-710-MonospaceSerif\" value=\"monospaceSerif\">Monospace Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-711-Casual\" id=\"vjs-track-option-711-Casual\" value=\"casual\">Casual</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-712-Script\" id=\"vjs-track-option-712-Script\" value=\"script\">Script</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ace7629c_1_component_595 vjs-track-option-713-SmallCaps\" id=\"vjs-track-option-713-SmallCaps\" value=\"small-caps\">Small Caps</option></select></fieldset></div><div class=\"vjs-track-settings-controls\"><button aria-disabled=\"false\" class=\"vjs-default-button\" title=\"restore all settings to the default values\" type=\"button\">Reset</button><button aria-disabled=\"false\" class=\"vjs-done-button\" title=\"restore all settings to the default values\" type=\"button\">Done</button></div></div><button aria-disabled=\"false\" class=\"vjs-close-button vjs-control vjs-button\" title=\"Close Modal Dialog\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Close Modal Dialog</span></button><p class=\"vjs-control-text\">End of dialog window.</p></div></div></div></div><em> </em><p></p>\n<p><em>Image courtesy of Abhilash Koratala, MD, FASN, Medical College of Wisconsin</em></p>\n<p><strong>Which ONE of the following is the MOST APPROPRIATE next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Perform large-volume paracentesis"
            },
            {
                "label": "B.",
                "text": "Insert indwelling urinary catheter"
            },
            {
                "label": "C.",
                "text": "Administer isotonic saline IV bolus"
            },
            {
                "label": "D.",
                "text": "Prescribe norepinephrine"
            },
            {
                "label": "E.",
                "text": "Initiate hemodialysis"
            }
        ],
        "correct_answer": "Perform large-volume paracentesis",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with evidence of significant ascites and elevated intra-abdominal pressure (IAP) on POCUS, large volume paracentesis should be performed.</p>\n<p><em>Play video and click lower right hand corner button to expand viewing pane.</em></p>\n<p><br/></p>\n<p> <span class=\"fr-video fr-deletable fr-fvc fr-dvi fr-draggable\" contenteditable=\"false\"></span></p><div class=\"mediaplugin mediaplugin_videojs d-block\"><div style=\"max-width:400px;\"><div aria-label=\"Video Player\" class=\"video-js vjs-paused vjs-fluid id_videojs_68a28ace76474_2-dimensions vjs-controls-enabled vjs-workinghover vjs-v8 vjs-user-active\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28ace76474_2\" lang=\"en-gb\" role=\"region\" tabindex=\"-1\" title=\"Koratala\" translate=\"no\"><video class=\"vjs-tech\" data-setup-lazy='{\"language\": \"en-GB\", \"fluid\": true, \"playbackRates\": [0.5, 0.75, 1, 1.25, 1.5, 1.75, 2], \"userActions\": {\"hotkeys\": true}}' id=\"id_videojs_68a28ace76474_2_html5_api\" role=\"application\" tabindex=\"-1\" title=\"Koratala\"><source src=\"https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b2q18b_Koratala-Q2_video_labeled.mp4\" type=\"video/mp4\"/>\n                https://education.asn-online.org/file.php/1/Quiz_Question_Images/ksapv9m1b2q18b_Koratala-Q2_video_labeled.mp4</video><div aria-disabled=\"false\" class=\"vjs-poster vjs-hidden\"></div><div class=\"vjs-title-bar vjs-hidden\"><div class=\"vjs-title-bar-title\" id=\"vjs-title-bar-title-778\"></div><div class=\"vjs-title-bar-description\" id=\"vjs-title-bar-description-779\"></div></div><div aria-atomic=\"true\" aria-live=\"off\" class=\"vjs-text-track-display\" style=\"inset-inline: 50px;\" translate=\"yes\"><div style=\"position: absolute; inset: 0px; margin: 1.5%;\"></div></div><div class=\"vjs-loading-spinner\" dir=\"ltr\"><span class=\"vjs-control-text\">Video Player is loading.</span></div><button aria-disabled=\"false\" class=\"vjs-big-play-button\" title=\"Play Video\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play Video</span></button><div class=\"vjs-control-bar\" dir=\"ltr\"><button aria-disabled=\"false\" class=\"vjs-play-control vjs-control vjs-button\" title=\"Play\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Play</span></button><button aria-disabled=\"false\" class=\"vjs-skip-backward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Backward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Backward</span></button><button aria-disabled=\"false\" class=\"vjs-skip-forward-undefined vjs-control vjs-button vjs-hidden\" title=\"Skip Forward\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Skip Forward</span></button><div class=\"vjs-volume-panel vjs-control vjs-volume-panel-horizontal\"><button aria-disabled=\"false\" class=\"vjs-mute-control vjs-control vjs-button vjs-vol-3\" title=\"Mute\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Mute</span></button><div class=\"vjs-volume-control vjs-control vjs-volume-horizontal\"><div aria-label=\"Volume Level\" aria-live=\"polite\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"100\" aria-valuetext=\"100%\" class=\"vjs-volume-bar vjs-slider-bar vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-volume-tooltip\"></div></div><div class=\"vjs-volume-level\"><span class=\"vjs-control-text\"></span></div></div></div></div><div class=\"vjs-current-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Current Time </span><span class=\"vjs-current-time-display\" role=\"presentation\">0:00</span></div><div aria-hidden=\"true\" class=\"vjs-time-control vjs-time-divider\"><div><span>/</span></div></div><div class=\"vjs-duration vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Duration </span><span class=\"vjs-duration-display\" role=\"presentation\">0:08</span></div><div class=\"vjs-progress-control vjs-control\"><div aria-label=\"Progress Bar\" aria-valuemax=\"100\" aria-valuemin=\"0\" aria-valuenow=\"0.00\" aria-valuetext=\"0:00 of 0:08\" class=\"vjs-progress-holder vjs-slider vjs-slider-horizontal\" role=\"slider\" tabindex=\"0\"><div class=\"vjs-load-progress\" style=\"width: 4.51%;\"><span class=\"vjs-control-text\"><span>Loaded</span>: <span class=\"vjs-control-text-loaded-percentage\">4.51%</span></span><div data-end=\"0.362\" data-start=\"0\" style=\"left: 0%; width: 100%;\"></div></div><div class=\"vjs-mouse-display\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\"></div></div><div aria-hidden=\"true\" class=\"vjs-play-progress vjs-slider-bar\" style=\"width: 0%;\"><div aria-hidden=\"true\" class=\"vjs-time-tooltip\" style=\"right: 0px;\">0:00</div></div></div></div><div class=\"vjs-live-control vjs-control vjs-hidden\"><div aria-live=\"off\" class=\"vjs-live-display\"><span class=\"vjs-control-text\">Stream Type </span>LIVE</div></div><button aria-disabled=\"false\" class=\"vjs-seek-to-live-control vjs-control\" title=\"Seek to live, currently behind live\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Seek to live, currently behind live</span><span aria-hidden=\"true\" class=\"vjs-seek-to-live-text\">LIVE</span></button><div class=\"vjs-remaining-time vjs-time-control vjs-control\"><span class=\"vjs-control-text\" role=\"presentation\">Remaining Time </span><span aria-hidden=\"true\">-</span><span class=\"vjs-remaining-time-display\" role=\"presentation\">0:08</span></div><div class=\"vjs-custom-control-spacer vjs-spacer\"> </div><div class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-control vjs-button\"><div class=\"vjs-playback-rate-value\" id=\"vjs-playback-rate-value-label-id_videojs_68a28ace76474_2_component_1023\">1x</div><button aria-describedby=\"vjs-playback-rate-value-label-id_videojs_68a28ace76474_2_component_1023\" aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-playback-rate vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Playback Rate\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Playback Rate</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\" role=\"menu\"><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">2x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1.25x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">1x</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.75x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li><li aria-checked=\"false\" aria-disabled=\"false\" class=\"vjs-menu-item\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">0.5x</span><span aria-live=\"polite\" class=\"vjs-control-text\"></span></li></ul></div></div><div class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-chapters-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Chapters\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Chapters</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li class=\"vjs-menu-title\" tabindex=\"-1\">Chapters</li></ul></div></div><div class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-descriptions-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Descriptions\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Descriptions</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">descriptions off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-subs-caps-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Subtitles\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Subtitles</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"><li aria-disabled=\"false\" class=\"vjs-menu-item vjs-texttrack-settings\" role=\"menuitem\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles settings</span><span aria-live=\"polite\" class=\"vjs-control-text\">, opens subtitles settings dialog</span></li><li aria-checked=\"true\" aria-disabled=\"false\" class=\"vjs-menu-item vjs-selected\" role=\"menuitemradio\" tabindex=\"-1\"><span class=\"vjs-menu-item-text\">subtitles off</span><span aria-live=\"polite\" class=\"vjs-control-text\">, selected</span></li></ul></div></div><div class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-control vjs-button vjs-hidden\"><button aria-disabled=\"false\" aria-expanded=\"false\" aria-haspopup=\"true\" class=\"vjs-audio-button vjs-menu-button vjs-menu-button-popup vjs-button\" title=\"Audio Track\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Audio Track</span></button><div class=\"vjs-menu\"><ul class=\"vjs-menu-content\"></ul></div></div><button aria-disabled=\"false\" class=\"vjs-picture-in-picture-control vjs-control vjs-button\" title=\"Picture-in-Picture\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Picture-in-Picture</span></button><button aria-disabled=\"false\" class=\"vjs-fullscreen-control vjs-control vjs-button\" title=\"Fullscreen\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Fullscreen</span></button></div><div aria-describedby=\"id_videojs_68a28ace76474_2_component_1324_description\" aria-hidden=\"true\" aria-label=\"Modal Window\" aria-live=\"polite\" class=\"vjs-error-display vjs-modal-dialog vjs-hidden\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28ace76474_2_component_1324_description\">This is a modal window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"></div></div><div aria-describedby=\"id_videojs_68a28ace76474_2_component_1330_description\" aria-hidden=\"true\" aria-label=\"Caption Settings Dialog\" aria-live=\"polite\" class=\"vjs-modal-dialog vjs-hidden vjs-text-track-settings\" role=\"dialog\" tabindex=\"-1\"><p class=\"vjs-modal-dialog-description vjs-control-text\" id=\"id_videojs_68a28ace76474_2_component_1330_description\">Beginning of dialog window. Escape will cancel and close the window.</p><div class=\"vjs-modal-dialog-content\" role=\"document\"><div class=\"vjs-track-settings-colors\"><fieldset class=\"vjs-fg vjs-track-setting\"><legend id=\"captions-text-legend-id_videojs_68a28ace76474_2_component_1330\">Text</legend><span class=\"vjs-text-color\"><label class=\"vjs-label\" for=\"vjs_select_1357\" id=\"captions-foreground-color-id_videojs_68a28ace76474_2_component_1330\">Color</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330\" id=\"vjs_select_1357\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-White\" id=\"captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-Black\" id=\"captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-Red\" id=\"captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-Green\" id=\"captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-Blue\" id=\"captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-Yellow\" id=\"captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-Magenta\" id=\"captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330 captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-Cyan\" id=\"captions-foreground-color-id_videojs_68a28ace76474_2_component_1330-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-text-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_1362\" id=\"captions-foreground-opacity-id_videojs_68a28ace76474_2_component_1330\">Opacity</label><select aria-labelledby=\"captions-text-legend-id_videojs_68a28ace76474_2_component_1330 captions-foreground-opacity-id_videojs_68a28ace76474_2_component_1330\" id=\"vjs_select_1362\"><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace76474_2_component_1330 captions-foreground-opacity-id_videojs_68a28ace76474_2_component_1330 captions-foreground-opacity-id_videojs_68a28ace76474_2_component_1330-Opaque\" id=\"captions-foreground-opacity-id_videojs_68a28ace76474_2_component_1330-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-text-legend-id_videojs_68a28ace76474_2_component_1330 captions-foreground-opacity-id_videojs_68a28ace76474_2_component_1330 captions-foreground-opacity-id_videojs_68a28ace76474_2_component_1330-SemiTransparent\" id=\"captions-foreground-opacity-id_videojs_68a28ace76474_2_component_1330-SemiTransparent\" value=\"0.5\">Semi-Transparent</option></select></span></fieldset><fieldset class=\"vjs-bg vjs-track-setting\"><legend id=\"captions-background-id_videojs_68a28ace76474_2_component_1330\">Text Background</legend><span class=\"vjs-bg-color\"><label class=\"vjs-label\" for=\"vjs_select_1372\" id=\"captions-background-color-id_videojs_68a28ace76474_2_component_1330\">Color</label><select aria-labelledby=\"captions-background-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330\" id=\"vjs_select_1372\"><option aria-labelledby=\"captions-background-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330-Black\" id=\"captions-background-color-id_videojs_68a28ace76474_2_component_1330-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330-White\" id=\"captions-background-color-id_videojs_68a28ace76474_2_component_1330-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330-Red\" id=\"captions-background-color-id_videojs_68a28ace76474_2_component_1330-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330-Green\" id=\"captions-background-color-id_videojs_68a28ace76474_2_component_1330-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330-Blue\" id=\"captions-background-color-id_videojs_68a28ace76474_2_component_1330-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330-Yellow\" id=\"captions-background-color-id_videojs_68a28ace76474_2_component_1330-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330-Magenta\" id=\"captions-background-color-id_videojs_68a28ace76474_2_component_1330-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330 captions-background-color-id_videojs_68a28ace76474_2_component_1330-Cyan\" id=\"captions-background-color-id_videojs_68a28ace76474_2_component_1330-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-bg-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_1377\" id=\"captions-background-opacity-id_videojs_68a28ace76474_2_component_1330\">Opacity</label><select aria-labelledby=\"captions-background-id_videojs_68a28ace76474_2_component_1330 captions-background-opacity-id_videojs_68a28ace76474_2_component_1330\" id=\"vjs_select_1377\"><option aria-labelledby=\"captions-background-id_videojs_68a28ace76474_2_component_1330 captions-background-opacity-id_videojs_68a28ace76474_2_component_1330 captions-background-opacity-id_videojs_68a28ace76474_2_component_1330-Opaque\" id=\"captions-background-opacity-id_videojs_68a28ace76474_2_component_1330-Opaque\" value=\"1\">Opaque</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace76474_2_component_1330 captions-background-opacity-id_videojs_68a28ace76474_2_component_1330 captions-background-opacity-id_videojs_68a28ace76474_2_component_1330-SemiTransparent\" id=\"captions-background-opacity-id_videojs_68a28ace76474_2_component_1330-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-background-id_videojs_68a28ace76474_2_component_1330 captions-background-opacity-id_videojs_68a28ace76474_2_component_1330 captions-background-opacity-id_videojs_68a28ace76474_2_component_1330-Transparent\" id=\"captions-background-opacity-id_videojs_68a28ace76474_2_component_1330-Transparent\" value=\"0\">Transparent</option></select></span></fieldset><fieldset class=\"vjs-window vjs-track-setting\"><legend id=\"captions-window-id_videojs_68a28ace76474_2_component_1330\">Caption Area Background</legend><span class=\"vjs-window-color\"><label class=\"vjs-label\" for=\"vjs_select_1387\" id=\"captions-window-color-id_videojs_68a28ace76474_2_component_1330\">Color</label><select aria-labelledby=\"captions-window-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330\" id=\"vjs_select_1387\"><option aria-labelledby=\"captions-window-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330-Black\" id=\"captions-window-color-id_videojs_68a28ace76474_2_component_1330-Black\" value=\"#000\">Black</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330-White\" id=\"captions-window-color-id_videojs_68a28ace76474_2_component_1330-White\" value=\"#FFF\">White</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330-Red\" id=\"captions-window-color-id_videojs_68a28ace76474_2_component_1330-Red\" value=\"#F00\">Red</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330-Green\" id=\"captions-window-color-id_videojs_68a28ace76474_2_component_1330-Green\" value=\"#0F0\">Green</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330-Blue\" id=\"captions-window-color-id_videojs_68a28ace76474_2_component_1330-Blue\" value=\"#00F\">Blue</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330-Yellow\" id=\"captions-window-color-id_videojs_68a28ace76474_2_component_1330-Yellow\" value=\"#FF0\">Yellow</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330-Magenta\" id=\"captions-window-color-id_videojs_68a28ace76474_2_component_1330-Magenta\" value=\"#F0F\">Magenta</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330 captions-window-color-id_videojs_68a28ace76474_2_component_1330-Cyan\" id=\"captions-window-color-id_videojs_68a28ace76474_2_component_1330-Cyan\" value=\"#0FF\">Cyan</option></select></span><span class=\"vjs-window-opacity vjs-opacity\"><label class=\"vjs-label\" for=\"vjs_select_1392\" id=\"captions-window-opacity-id_videojs_68a28ace76474_2_component_1330\">Opacity</label><select aria-labelledby=\"captions-window-id_videojs_68a28ace76474_2_component_1330 captions-window-opacity-id_videojs_68a28ace76474_2_component_1330\" id=\"vjs_select_1392\"><option aria-labelledby=\"captions-window-id_videojs_68a28ace76474_2_component_1330 captions-window-opacity-id_videojs_68a28ace76474_2_component_1330 captions-window-opacity-id_videojs_68a28ace76474_2_component_1330-Transparent\" id=\"captions-window-opacity-id_videojs_68a28ace76474_2_component_1330-Transparent\" value=\"0\">Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace76474_2_component_1330 captions-window-opacity-id_videojs_68a28ace76474_2_component_1330 captions-window-opacity-id_videojs_68a28ace76474_2_component_1330-SemiTransparent\" id=\"captions-window-opacity-id_videojs_68a28ace76474_2_component_1330-SemiTransparent\" value=\"0.5\">Semi-Transparent</option><option aria-labelledby=\"captions-window-id_videojs_68a28ace76474_2_component_1330 captions-window-opacity-id_videojs_68a28ace76474_2_component_1330 captions-window-opacity-id_videojs_68a28ace76474_2_component_1330-Opaque\" id=\"captions-window-opacity-id_videojs_68a28ace76474_2_component_1330-Opaque\" value=\"1\">Opaque</option></select></span></fieldset></div><div class=\"vjs-track-settings-font\"><fieldset class=\"vjs-font-percent vjs-track-setting\"><legend id=\"captions-font-size-id_videojs_68a28ace76474_2_component_1330\">Font Size</legend><select aria-labelledby=\"captions-font-size-id_videojs_68a28ace76474_2_component_1330\" id=\"vjs_select_1407\"><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1408-50\" id=\"vjs-track-option-1408-50\" value=\"0.50\">50%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1409-75\" id=\"vjs-track-option-1409-75\" value=\"0.75\">75%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1410-100\" id=\"vjs-track-option-1410-100\" value=\"1.00\">100%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1411-125\" id=\"vjs-track-option-1411-125\" value=\"1.25\">125%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1412-150\" id=\"vjs-track-option-1412-150\" value=\"1.50\">150%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1413-175\" id=\"vjs-track-option-1413-175\" value=\"1.75\">175%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1414-200\" id=\"vjs-track-option-1414-200\" value=\"2.00\">200%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1415-300\" id=\"vjs-track-option-1415-300\" value=\"3.00\">300%</option><option aria-labelledby=\"captions-font-size-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1416-400\" id=\"vjs-track-option-1416-400\" value=\"4.00\">400%</option></select></fieldset><fieldset class=\"vjs-edge-style vjs-track-setting\"><legend id=\"captions-edge-style-id_videojs_68a28ace76474_2_component_1330\">Text Edge Style</legend><select aria-labelledby=\"captions-edge-style-id_videojs_68a28ace76474_2_component_1330\" id=\"vjs_select_1426\"><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1427-None\" id=\"vjs-track-option-1427-None\" value=\"none\">None</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1428-Raised\" id=\"vjs-track-option-1428-Raised\" value=\"raised\">Raised</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1429-Depressed\" id=\"vjs-track-option-1429-Depressed\" value=\"depressed\">Depressed</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1430-Uniform\" id=\"vjs-track-option-1430-Uniform\" value=\"uniform\">Uniform</option><option aria-labelledby=\"captions-edge-style-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1431-Dropshadow\" id=\"vjs-track-option-1431-Dropshadow\" value=\"dropshadow\">Drop shadow</option></select></fieldset><fieldset class=\"vjs-font-family vjs-track-setting\"><legend id=\"captions-font-family-id_videojs_68a28ace76474_2_component_1330\">Font Family</legend><select aria-labelledby=\"captions-font-family-id_videojs_68a28ace76474_2_component_1330\" id=\"vjs_select_1441\"><option aria-labelledby=\"captions-font-family-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1442-ProportionalSansSerif\" id=\"vjs-track-option-1442-ProportionalSansSerif\" value=\"proportionalSansSerif\">Proportional Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1443-MonospaceSansSerif\" id=\"vjs-track-option-1443-MonospaceSansSerif\" value=\"monospaceSansSerif\">Monospace Sans-Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1444-ProportionalSerif\" id=\"vjs-track-option-1444-ProportionalSerif\" value=\"proportionalSerif\">Proportional Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1445-MonospaceSerif\" id=\"vjs-track-option-1445-MonospaceSerif\" value=\"monospaceSerif\">Monospace Serif</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1446-Casual\" id=\"vjs-track-option-1446-Casual\" value=\"casual\">Casual</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1447-Script\" id=\"vjs-track-option-1447-Script\" value=\"script\">Script</option><option aria-labelledby=\"captions-font-family-id_videojs_68a28ace76474_2_component_1330 vjs-track-option-1448-SmallCaps\" id=\"vjs-track-option-1448-SmallCaps\" value=\"small-caps\">Small Caps</option></select></fieldset></div><div class=\"vjs-track-settings-controls\"><button aria-disabled=\"false\" class=\"vjs-default-button\" title=\"restore all settings to the default values\" type=\"button\">Reset</button><button aria-disabled=\"false\" class=\"vjs-done-button\" title=\"restore all settings to the default values\" type=\"button\">Done</button></div></div><button aria-disabled=\"false\" class=\"vjs-close-button vjs-control vjs-button\" title=\"Close Modal Dialog\" type=\"button\"><span aria-hidden=\"true\" class=\"vjs-icon-placeholder\"></span><span aria-live=\"polite\" class=\"vjs-control-text\">Close Modal Dialog</span></button><p class=\"vjs-control-text\">End of dialog window.</p></div></div></div></div><em> </em><p></p>\n<p><em>Image courtesy of Abhilash Koratala, MD, FASN, Medical College of Wisconsin</em></p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">POCUS images demonstrate ascites extending from the subdiaphragmatic region to the pelvis, which is the likely cause of abdominal distension. Her IVC is &lt;0.5 cm in the maximal diameter with complete inspiratory collapse, which implies very low right atrial pressure (RAP) when interpreted in isolation. However, because the highest point of jugular venous pulsation is ~5 cm above the sternal angle, the total RAP is ~7 mm Hg, which is mildly elevated. The significant ascites, coupled with the elevated RAP, suggest elevated IAP. Therefore, the most appropriate next step is to measure IAP via bladder transducer, if available, and perform therapeutic paracentesis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">It is well known that IVC diameter does not reliably reflect RAP in states of intraabdominal hypertension (IAH). IAH is defined as IAP &gt;12 mm Hg and can cause extrinsic compression of the renal veins and kidney parenchyma, leading to elevated renal venous and parenchymal pressures and decreased kidney perfusion. Observational data suggest that reducing IAP is associated with improvement in kidney function. Of note, the urine sodium may be low in IAH, volume depletion, and hepatorenal syndrome, making its utility limited in patients with cirrhosis and AKI. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although an indwelling urinary catheter may be useful to transduce bladder pressure, which is a surrogate for IAP, POCUS images do not demonstrate urinary retention. The anechoic area in the suprapubic area is ill defined with floating bowel loops, indicating ascites, which should be managed with large-volume paracentesis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Administration of IV fluids is not indicated, as the estimated RAP is not low. Moreover, this patient’s kidney function has worsened despite albumin therapy, which makes volume depletion unlikely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Norepinephrine would raise this patient’s MAP and has been shown to improve or reverse hepatorenal syndrome. Renal replacement therapy may be required if her kidney function worsens and she develops life-threatening electrolyte abnormalities or pulmonary edema. However, paracentesis would address a potentially reversible cause of AKI and should be attempted first. </p>\n</div>",
        "references": [
            "Millington SJ. Ultrasound assessment of the inferior vena cava for fluid responsiveness: Easy, fun, but unlikely to be helpful.Can J Anaesth66(6): 633–638, 2019",
            "Bauman Z, Coba V, Gassner M, et al. Inferior vena cava collapsibility loses correlation with internal jugular vein collapsibility during increased thoracic or intra-abdominal pressure.J Ultrasound18(4): 343–348, 2015",
            "Adebayo D, Morabito V, Davenport A, et al. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy.Kidney Int87(3): 509–515, 2015",
            "Griffin BR, Liu KD, Teixeira JP. Critical care nephrology: Core curriculum 2020.Am JKidney Dis75(3): 435–452, 2020",
            "Koratala A, Reisinger N. Point of care ultrasound in cirrhosis-associated acute kidney injury: Beyond inferior vena cava.Kidney3603(11): 1965–1968, 2022"
        ]
    },
    "55": {
        "question": "<div class=\"qtext\"><p>A 52-year-old woman presents to the nephrology clinic for evaluation of hypertension. Three years ago, she presented to the emergency department with a transient ischemic attack (TIA), and her BP at the time was 190/100 mm Hg. Symptoms resolved with antihypertensive therapy, and she was discharged on an oral antihypertensive regimen. Recently, her systolic BP both in the office and with home monitoring has ranged from 140 to 150 mm Hg. Today, she describes periodic headaches and an intermittent “whooshing” noise in her ears. She has no edema, joint pain, or rashes. Her parents both have hypertension. Her medications include chlorthalidone, amlodipine, and carvedilol.</p>\n<p>On examination, BP is 148/84 mm Hg in her right arm and 144/84 mm Hg in her left. Her pulses are symmetrical and of normal rate. She has a right carotid bruit. There are no abdominal or renal arterial bruits. The remainder of the physical examination is normal.</p>\n<p>Her serum basic metabolic panel is within reference ranges. She has had four serum chemistry panels over the last 3 years without abnormalities except episodic mild hypokalemia.</p>\n<p><strong>Which ONE of the following is the most appropriate next step in management of this patient’s hypertension?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Measure urine metanephrine and catecholamine levels"
            },
            {
                "label": "B.",
                "text": "Measure serum\nrenin and aldosterone levels"
            },
            {
                "label": "C.",
                "text": "Prescribe\nspironolactone"
            },
            {
                "label": "D.",
                "text": "Perform CT angiography"
            },
            {
                "label": "E.",
                "text": "Perform bilateral adrenal vein sampling for aldosterone"
            }
        ],
        "correct_answer": "Perform CT angiography",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with a history suggesting fibromuscular dysplasia (FMD), CT angiography (CTA) is the most appropriate next step in management. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Per the US Registry for Fibromuscular Dysplasia, the mean age at diagnosis is 52 years. Other symptoms suggesting FMD include hypertension, headache, and pulsatile tinnitus, which are seen in 72%, 60%, and 27% of patients, respectively. Additionally, a carotid bruit, due to FMD in the extra-cranial carotid, is found in 75% of patients who undergo carotid imaging. Carotid bruits and headaches both correlate with tinnitus. Patients with FMD are at risk for TIAs. Per the First International Consensus on the Diagnosis and Management of FMD, the imaging test of choice is CTA. CTA is preferred to magnetic resonance angiography due to better spatial resolution and its ability to better visualize small calcifications, allowing for more accurate differentiation between FMD and atherosclerotic renal artery disease.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although hyperaldosteronism and pheochromocytoma are well-known causes of secondary hypertension, they do not explain this patient’s presentation and FMD. Although headaches are particularly common in pheochromocytomas, tinnitus is not typically described. Furthermore, patients with pheochromocytoma often present with tachycardia and/or excessive sweating, both of which are absent in this case. Consequently, measuring urine metanephrines and catecholamines is unlikely to be revealing. Similarly, although primary aldosteronism is an under-recognized cause of hypertension, this patient’s presentation is more consistent with FMD. Measurement by serum or selective renal artery testing would likely show increases in both renin and aldosterone, attributable to renal artery stenosis. Although hypokalemia may be a consequence of hyperaldosteronism, this is only seen in a minority of patients (estimated 9%–37%) and is not sensitive for diagnosis. In this case, episodic hypokalemia could be a result of thiazide diuretic use. Treatments for primary aldosteronism, such as spironolactone, may be effective but would be inferior to potentially curable management by renal artery stenting or surgery.</p>\n</div>",
        "references": [
            "Olin JW, Froehlich J, Gu X, et al. The United States Registry for Fibromuscular Dysplasia. Results in the first 447 patients.Circulation125(25): 3182–3190, 2012",
            "Dicks AB, Gornik HL, Gu X, et al. Association of fibromuscular dysplasia and pulsatile tinnitus: A report of the US Registry for Fibromuscular Dysplasia.J Am Heart Assoc10(17): e021962, 2021",
            "Gornik HL, Persu A, Adlam D, et al. First international consensus on the diagnosis and management of fibromuscular dysplasia.J Hypertens37(2): 229–252, 2019",
            "Garcia-Carbonero R, Matute Teresa F, Mercader-Cidoncha E, et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas.Clin Transl Oncol23(10): 1995–2019, 2021",
            "Brown JM, Siddiqui M, Calhoun DA, et al. The unrecognized prevalence of primary aldosteronism: A cross-sectional study.Ann Intern Med173(1): 10–20, 2020"
        ]
    },
    "56": {
        "question": "<div class=\"qtext\"><p>A 60-year-old-man with ESRD due to ADPKD, status post deceased donor kidney transplant 1 year ago, presents to establish care with a nephrologist after a recent move out of state. He has not been seen by a nephrologist for 5 months, and today reports ongoing headaches and malaise. The headaches are bilateral and not associated with vision changes. He denies recent infections, night sweats, or pruritis. He has no daytime sleepiness. He has a 10-pack-year smoking history, but a CT scan of his chest done as part of his original transplant evaluation was without evidence of lung disease or nodules. His immunosuppressive regimen is tacrolimus, mycophenolate mofetil, and prednisone. During chart review, his RBC indices were found to be elevated at his most recent transplant nephrology appointments, 5 and 6 months ago.</p>\n<p>On examination, BP is 124/76 mm Hg, heart rate is 60/min, and oxygen saturation is 99% while breathing room air. He has a normal cardiopulmonary examination. He does not have edema. His face is plethoric. </p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Result</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">WBC count</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3400/µL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4000–11,000</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Hemoglobin</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">18.6 g/dL (pre-transplant, 11.8)</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">14–18</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Platelet count</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">170,000/µL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">150,000–450,000</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Tacrolimus, whole blood trough</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">7.7 ng/mL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">5–10 (&gt;3 months after transplant)</td>\n</tr>\n</tbody>\n</table>\n<p>Evaluation for the V617F or other mutations in the <em>JAK2</em> gene for the diagnosis of polycythemia vera is negative.</p>\n<p><strong>Which ONE of the following is the next best step in diagnosis or management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "CT  scan of the chest and abdomen"
            },
            {
                "label": "B.",
                "text": "Lisinopril"
            },
            {
                "label": "C.",
                "text": "Phlebotomy"
            },
            {
                "label": "D.",
                "text": "Low-dose aspirin"
            },
            {
                "label": "E.",
                "text": "Bone marrow biopsy"
            }
        ],
        "correct_answer": "Lisinopril",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Prescribing lisinopril is the best management strategy in this patient with post-transplant erythrocytosis (PTE).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">PTE is defined as a hemoglobin &gt;17 g/dL or a hematocrit &gt;51% for &gt;6 months after transplantation in a patient who had a normal hematocrit previously. It has been reported to occur in 8%–15% of kidney transplant recipients.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Risk factors for PTE include male sex, diabetes, retention of native kidneys, and transplant renal artery stenosis. ADPKD is also a risk factor for PTE, as seen in this case. PTE must be distinguished from other causes of erythrocytosis, including hypoxemic lung disease, sleep apnea, heart failure, and malignancy. Secondary causes of erythrocytosis, including renal artery stenosis and renal cell carcinoma, should also be excluded. Myeloproliferative disorders should be ruled out by evaluating for <em>JAK2</em> gene mutations. </p>\n<p>Because erythropoietin (EPO) is produced by angiotensin II-sensitive peritubular fibroblasts in the renal interstitium, patients with PTE should be prescribed a moderate dose of ACEI or ARB as initial therapy. If after 4 weeks the hemoglobin remains &gt;17 g/dL, the dose of the drug may be titrated as tolerated. Typically, treatment is successful in &gt;90% of patients within 2–6 weeks.</p>\n<p>If ACEI/ARB therapy is not tolerated, then azathioprine or a mammalian target of rapamycin inhibitor such as sirolimus may be considered. In refractory cases, in whom secondary screening fails to identify a cause, periodic phlebotomy may be required. In this patient, phlebotomy could be considered if medical therapy were ineffective.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">If EPO levels are elevated, imaging should be considered to evaluate for malignancy. Although this patient was a smoker, his chest CT scan was normal before transplant, so he is unlikely to have chronic obstructive pulmonary disease or other pulmonary causes of erythrocytosis. Thus, a CT scan is not the next best step in management. If polycythemia worsened or progressed while receiving ACEI/ARB therapy for the most likely diagnosis of PTE, then further evaluation could be entertained.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Bone marrow biopsies are recommended in patients with clinical suspicion for polycythemia vera (PCV) or another hematologic malignancy, such as easy bleeding or bruising or pruritis. As this patient has no evidence of PCV-associated genetic mutations and does not report other symptoms associated with PCV, a bone marrow biopsy would not be indicated. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients with untreated PTE may develop thrombotic complications, which should be treated with anticoagulation. However, prophylactic anticoagulation or antiplatelet therapy, including low-dose aspirin, is not recommended. Additionally, treatment with ACEI and resolution of PTE would make the development of thrombosis very unlikely and is thus the optimal therapy. </p>\n</div>",
        "references": [
            "Razeghi E, Kaboli A, Pezeshki ML, et al. Risk factors of erythrocytosis post renal transplantation.Saudi J Kidney Dis Transpl. 19(4): 559–563, 2008",
            "Vlahakos DV, Marathias KP, Agroyannis B, et al. Posttransplant erythrocytosis.Kidney Int63(4): 1187–1194, 2003",
            "Kirimis E. Post-transplant erythrocytosis.Proc UCLA Health23, 2019"
        ]
    },
    "57": {
        "question": "<div class=\"qtext\"><p>A 47-year-old woman receiving HD through a forearm radiocephalic arteriovenous fistula (AVF) is evaluated in the dialysis unit for abnormal laboratory results. She has achieved her target weight without difficulty and completes all treatments. Her HD prescription is 3 hours with a blood flow rate of 400 mL/min and a dialysate flow rate of 600 mL/min. She reports no changes to her diet or her medication, although she says she ate a large meal in a restaurant the day before her monthly blood draw.</p>\n<p>On examination, BP is 147/68 mm Hg, heart rate is 73/min, and temperature is 37.2°C. She has a forearm AVF that has a thrill and is markedly pulsatile. There is no redness or warmth. Physical examination is otherwise unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>One Month Ago (Pre-Dialysis)</strong> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Current (Pre-Dialysis)</strong> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong> \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.1 mEq/L \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.7\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                60 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                80 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Kt/V \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.36\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.0\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &gt;1.2\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urea reduction ratio (URR)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                77%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                60%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &gt;65%\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the best next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "AVF angiography"
            },
            {
                "label": "B.",
                "text": "Increase dialysis time to 4 hours"
            },
            {
                "label": "C.",
                "text": "Dietary education"
            },
            {
                "label": "D.",
                "text": "Increase blood flow rate to 500 mL/min"
            },
            {
                "label": "E.",
                "text": "Repeat laboratory data in 2 weeks"
            }
        ],
        "correct_answer": "AVF angiography",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with evidence of AVF recirculation, the best next step in management is angiogram of her AVF (fistulagram), with possible angioplasty. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Recirculation is a common cause of decreased clearance in patients receiving HD. Recirculation happens when the blood flow in the vascular access is lower than the flow in the circuit. In this instance, some of the “clean” blood returned by the venous line gets pulled back into the dialyzer through the arterial line, leading to decreased efficiency. This process can arise from outflow or inflow stenosis. The increased pulsatility of the AVF on examination suggests an outflow obstruction. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Recirculation can be calculated using various methods, most commonly the urea-based method. In this method, ultrafiltration is turned off approximately 30 minutes after the initiation of HD. Blood samples are obtained from arterial (A) and venous (V) lines. The blood flow is then reduced to 50 mL/min, and a third systemic (S) blood sample is obtained from the arterial blood line after 30 seconds. Urea concentration in each of the three samples is then measured. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The percent recirculation can then be calculated using the following formula:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">% recirculation = ([S – A] ÷ [S – V]) × 100%</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">where S, A, and V refer to the concentration of solute in the systemic blood, pre-dialyzer arterial line, and post-dialyzer venous line, respectively. Some modern dialysis machines allow calculation of recirculation during treatment using thermodilution techniques. Recirculation of &gt;10% in an AVF or arteriovenous graft is considered abnormal and warrants further investigation. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Increasing treatment time may be needed if recirculation is ruled out and the vascular access has no pathology. However, this would not be the next best step, especially given the findings of increased pulsatility on AV access examination, which suggest an outflow obstruction that may be amenable to correction. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Increasing blood flow to 500 mL/min might improve clearance, but is unlikely to help significantly in the presence of outflow obstruction and recirculation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Dietician referral may be useful for patients with significant potassium or phosphorus intake but would not address inadequate dialytic clearance. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Repeating laboratory measurements in 2 weeks would not address the outflow obstruction in this patient’s dialysis access, which will likely require intervention. Additionally, failure to act could result in worsening clearance and hyperkalemia.</p>\n</div>",
        "references": [
            "Dinwiddie LC, Ball L, Brouwer D, et al. What nephrologists need to know about vascular access cannulation.Semin Dial26(3): 315–322, 2013",
            "Coyne DW, Delmez J, Spence G, et al. Impaired delivery of hemodialysis prescriptions: An analysis of causes and an approach to evaluation.J Am Soc Nephrol8(8): 1315–1318, 1997"
        ]
    },
    "58": {
        "question": "<div class=\"qtext\"><p>A 77-year-old man is evaluated in the hospital infusion clinic after receiving his first dose of rituximab as part of induction therapy for renal-limited microscopic polyangiitis (MPA). His past medical history includes hypertension and hyperlipidemia. His serum creatinine level has been stable at 1.7 mg/dL (reference range, 0.7–1.3), and a pretreatment screening chest x-ray was normal. His current medications include prednisone, trimethoprim-sulfamethoxazole, atorvastatin, and lisinopril.</p>\n<p>On arrival to the infusion center, he was afebrile, with a BP of 127/74 mm Hg, heart rate of 77/min, and oxygen saturation of 98% while breathing room air. He was pretreated with acetaminophen, chlorpheniramine, and methylprednisolone per infusion center protocol. Rituximab was initiated per protocol at 50 mg/h.</p>\n<p>One hour later, the patient develops low-grade fever, headache, chills, nausea, and mild dyspnea with chest tightness. His examination is notable for a BP of 110/60 mm Hg, heart rate of 104/min, respiratory rate of 24/min, temperature of 38°C, and oxygen saturation of 98% while breathing room air. There is no wheezing, rash, or urticaria.</p>\n<p>Rituximab is stopped, and the patient is monitored. Symptoms resolve after 1 hour.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Administer epinephrine IM"
            },
            {
                "label": "B.",
                "text": "Resume rituximab at decreased rate"
            },
            {
                "label": "C.",
                "text": "Increase prednisone dose"
            },
            {
                "label": "D.",
                "text": "Discontinue trimethoprim-sulfamethoxazole"
            },
            {
                "label": "E.",
                "text": "Change rituximab to avacopan"
            }
        ],
        "correct_answer": "Resume rituximab at decreased rate",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with a standard infusion reaction (SIR) to rituximab should resume the drug at a lower dose and infusion rate.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient manifested a grade 2 SIR to rituximab. The incidence of infusion reactions associated with rituximab is at least 50%. The most common infusion reaction is likely due to interactions between rituximab and the CD20 antigen on lymphocytes that triggers cytokine release, causing a constellation of flu-like symptoms that occur most commonly during the initial 30–120 minutes of the infusion and usually resolve within 3 hours. These symptoms include fever, chills, flushing, pruritus, headache, rash, dyspnea, chest discomfort, nausea, and weakness. The incidence of infusion reactions is highest with the first<sup> </sup>dose (77%) and deceases with subsequent doses (30% with the fourth dose and 14% with the eighth dose). Pre-medication with acetaminophen, an antihistamine, and methylprednisolone may attenuate the severity of the infusion reaction symptoms.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients who develop mild to moderate SIRs usually respond well to temporary cessation of rituximab until symptom resolution, followed by resuming the infusion at 50% of the initial rate. Additional doses of acetaminophen and antihistamine may be helpful. If well tolerated, the infusion rate can be gradually increased.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Anaphylaxis, mediated by mast cells and basophils, is uncommon but well described with rituximab. Patients may develop urticaria, wheezing, tachycardia, hypotension, and respiratory distress. Prompt recognition and treatment are critically important. The rituximab should be stopped, and anaphylaxis should be treated with epinephrine IM, bronchodilators, H1 histamine blockers, supplemental oxygen, and volume resuscitation. The patient should not be re-exposed to rituximab without evaluation by an allergy specialist skilled in desensitization. Desensitization is not necessary for this patient, who did not manifest compelling evidence of anaphylaxis. Sometimes, if severe SIR is difficult to distinguish from anaphylaxis, a tryptase level can help discriminate between these diagnoses and guide future treatment approaches.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There is no rationale for increasing the dose of prednisone in this case.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Trimethoprim-sulfamethoxazole was previously well tolerated and is not known to exacerbate rituximab-associated SIRs; it should be continued for <em>Pneumocystis</em> prophylaxis.</p>\n</div>",
        "references": [
            "Onrust S, Lamb H, Barman-Balfour J. Rituximab.Drugs58(1): 79–88, 1999",
            "Thietart S, Karras A, Jean-Francois A, et al. Evaluation of rituximab for induction and maintenance therapy in patients 75 years or older with antineutrophil cytoplasmic antibody-associated vasculitis. JAMA Network Open 5(7): 1–14, 2022",
            "Leandro M. Rituximab: Principles of use and adverse effects in rheumatoid arthritis.In:UpToDate, edited by St. Clair E, accessed February 15, 2023",
            "LaCasce A, Castells M, Burstein H, et al. Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy. In:UpToDate, edited by Drews R, Adkinson N, accessed February 15, 2023"
        ]
    },
    "59": {
        "question": "<div class=\"qtext\"><p>A 28-year-old woman is referred to the nephrology clinic to evaluate for secondary causes of hypertension. She has a past medical history of obesity and was diagnosed 3 months ago with hypertension by her primary care physician. She has no family history of hypertension. Her medications include lisinopril and metoprolol, and she does not take NSAIDs or other non-prescription medications. Since her last visit, she has intentionally lost 9 kg. </p>\n<p>Her BP is 122/75 mm Hg, and her heart rate is 65/min. The remainder of her examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 25%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Four Months Ago </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Current</strong> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong> \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.7 mEq/L \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.9\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                28 mEq/L \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                26\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.8 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.0\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Thyroid-stimulating hormone\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.54 μU/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–4.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Cortisol, plasma, 8 a.m</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10.2 μg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5–25 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Renin activity, plasma\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                27 ng/mL/hr\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.3–2.5 (normal diet, supine)\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Aldosterone\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><br/></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8 ng/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                ≤10 ng/dL\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST LIKELY cause of her laboratory abnormalities?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Primary aldosteronism"
            },
            {
                "label": "B.",
                "text": "Fibromuscular dysplasia"
            },
            {
                "label": "C.",
                "text": "Metoprolol"
            },
            {
                "label": "D.",
                "text": "Juxtaglomerular cell tumor"
            },
            {
                "label": "E.",
                "text": "Lisinopril"
            }
        ],
        "correct_answer": "Lisinopril",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of her laboratory abnormalities is lisinopril. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">ACEIs and ARBs increase plasma renin activity (PRA) through negative feedback and decrease plasma aldosterone concentration by inhibiting angiotensin II activity. Thus, these agents lower the aldosterone-to-renin ratio (ARR). It is important to understand the effect of commonly prescribed antihypertensives and other medications on the ARR. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">β-Blockers, such as metoprolol, directly suppress the release of renin from the juxtaglomerular apparatus, in contrast to the increase seen here.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Primary aldosteronism is associated with high aldosterone levels and low plasma renin activity. This patient presented with the opposite biochemical findings, which are inconsistent with this diagnosis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Benign tumors of the juxtaglomerular apparatus, also known as reninomas, are an extremely rare cause of secondary hypertension most frequently seen in the second and third decade of life with a slight female predominance. The typical presentation is uncontrolled hypertension with hypokalemia. Symptoms include polydipsia, polyuria, myalgias, and headaches. Typically, both renin and aldosterone levels are elevated. This diagnosis could be excluded in this case by discontinuing lisinopril and reassessing plasma renin activity after a washout period of several weeks. Again, reninoma is less likely in the absence of hypokalemia and hyperaldosteronism. The elevation in serum bicarbonate in this patient is likely attributable to obesity, evidenced by the improvement with weight loss.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Fibromuscular dysplasia (FMD) is a non-atherosclerotic cause of renovascular hypertension, usually diagnosed in young or middle-aged women. As with juxtaglomerular cell tumors, FMD would typically cause increases in both renin and aldosterone and could be evaluated by renal artery imaging if PRA remained elevated after stopping lisinopril. FMD would be a less likely cause of elevated PRA than lisinopril use in this patient.</p>\n</div>",
        "references": [
            "Lyons DF, Kem DC, Brown RD, et al. Single dose captopril as a diagnostic test for primary aldosteronism.J Clin Endocrinol Metab57(5): 892–896, 1983",
            "Krishnan A, Jacob J, Patel T. Juxtaglomerular cell tumor in a young male presenting with new onset congestive heart failure.Urol Case Rep31: 101189, 2020",
            "Nunes I, Santos T, Tavares J, et al. Secondary hypertension due to a juxtaglomerular cell tumor.J Am Soc Hypertens12(9): 637–640, 2018",
            "Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes.Arch Intern Med153(18): 2125–2129, 1993"
        ]
    },
    "60": {
        "question": "<div class=\"qtext\"><p>A 45-year-old man of Ghanian descent presents for evaluation of CKD. He has a history of hypertension that was diagnosed at age 25, recently diagnosed type 2 diabetes, and sub-nephrotic range proteinuria. His current medications include lisinopril, empagliflozin, metformin, and hydrochlorothiazide. </p>\n<p>On examination, BP is 150/95 mm Hg and heart rate is 75/min. His oxygen saturation is 97% while breathing room air. His examination is otherwise unremarkable.</p>\n<p>His creatinine level was 1.5 mg/dL 6 months ago and 2.5 mg/dL currently (reference range, 0.7–1.3). His hemoglobin A1<sub>c</sub> is 6.5% (reference range, 4.0–5.6). A urine protein-to-creatinine ratio is 3 mg/mg (reference range, &lt;0.2), which has not improved despite titration of lisinopril. </p>\n<p>A urine sediment is bland, and evaluation for autoimmune disorders and infectious diseases is negative. Kidney US is normal. </p>\n<p>The patient undergoes kidney biopsy, which reveals solidified and disappearing glomerulosclerosis with thyroidization-type tubular atrophy, but without significant vascular changes.</p>\n<br/><strong>Which ONE of the following is the most likely diagnosis?</strong><br/></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Hypertensive nephropathy"
            },
            {
                "label": "B.",
                "text": "Diabetic kidney disease"
            },
            {
                "label": "C.",
                "text": "Apolipoprotein L1 (APOL-1) nephropathy"
            },
            {
                "label": "D.",
                "text": "Thin basement membrane nephropathy"
            },
            {
                "label": "E.",
                "text": "Membranous nephropathy"
            }
        ],
        "correct_answer": "Apolipoprotein L1 (APOL-1) nephropathy",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient most likely has high-risk genotype apolipoprotein L1 (APO-L1) disease. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The gene encoding APO-L1 is one of six members of the <em>APO-L1</em> gene family located on chromosome 22. There are two known high-risk variants, G1 and G2, each of which involves two amino acid substitutions or deletions, respectively. The wild-type G0 allele confers no increased risk of kidney disease. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Each person inherits two copies of the <em>APO-L1</em> gene. If a person inherits two high-risk variants, the lifetime risk of kidney disease increases by 3- to 4-fold. Patients with one <em>APO-L1</em> risk allele may have a small increase in risk. There are some hypotheses as to how <em>APO-L1</em> high-risk variants affect the kidneys. These include a pore function of APO-L1, which increases cell membrane permeability to ions and causes cellular injury, mitochondrial dysfunction, and protein accumulation in the endoplasmic reticulum, leading to toxicity, autophagy, and apoptosis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">These variants provide enhanced protection against trypanosome subspecies and arose in humans in sub-Saharan Africa several thousand years ago. Approximately 13% of African Americans carry a high-risk genotype, and a substantial fraction will develop APO-L1 kidney disease. More than 50% carry at least one risk allele. <em>APO-L1</em> risk variants are not limited to African Americans; variants may also be found in any patient with descent from sub-Saharan Africa. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Pathology shows lesions in the spectrum of focal segmental glomerulosclerosis and solidified (global) glomerulosclerosis, sometimes with pronounced vascular and interstitial changes. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\"><em>APO-L1</em> risk variants increase the risk of hypertension-related kidney disease by 7- to 11-fold and may have some influence on CKD progression in patients with diabetes and proteinuric kidney disease. This patient has well-controlled diabetes, and biopsy findings are not consistent with diabetic or hypertensive nephropathy. Similarly, histopathologic findings are also inconsistent with membranous nephropathy or thin basement membrane disease, the latter of which typically presents with hematuria without albuminuria.</p>\n</div>",
        "references": [
            "Dummer PD, Limou S, Rosenberg AZ, et al. APOL1 kidney disease risk variants: An evolving landscape.Semin Nephrol35(3): 222–236, 2015",
            "Friedman DJ, Pollak MR. APOL1 nephropathy: From genetics to clinical applications.Clin J Am Soc Nephrol16(2): 294–303, 2021",
            "Freedman BI, Limou S, Ma L, et al. APOL1-associated nephropathy: A key contributor to racial disparities in CKD.Am J Kidney Dis72(5 Suppl 1): S8–S16, 2018"
        ]
    },
    "61": {
        "question": "<div class=\"qtext\"><p>A 50-year-old man with a past medical history of poorly-controlled type 2 diabetes and hyperlipidemia presents to his outpatient physician for evaluation of leg edema. Ten days ago, he developed an ulcer on his right hallux after wearing poorly fitting shoes; an urgent care provider prescribed a 7-day course of cephalexin, which he completed. Five days ago, he noticed that his socks were leaving skin imprints, and his feet started feeling “tight.” He denies urinary symptoms. His medications include aspirin, metformin, losartan, and atorvastatin. He has been taking ibuprofen 400 mg intermittently over the last week because of foot pain.</p>\n<p>On examination, his BP is 153/72 mm Hg. Cardiopulmonary examination is normal. He has 1+ pitting edema in his legs up to the shins. Examination of the right hallux reveals a 3-cm ulcer with purulent discharge; probing of the wound reveals a depth of 0.25 cm without extension to deeper tissues.  </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>\n                    Serum\n                </strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.7 mg/dL (baseline, 1.5)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Hemoglobin A1<sub>C</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.2%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.0–5.6</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Creatine kinase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                92 IU/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                55–170 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  C3\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                27 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                100–233\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  C4\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                37 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–48\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><strong>\n                    Urine</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Blood\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3+\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Protein\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2+ (previously negative)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Leukocyte esterase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Positive</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urine microscopy reveals 1–5 WBCs/HPF and 10–20 RBCs/HPF, about half of which are dysmorphic.</p>\n<p><strong>Which ONE of the following is the MOST appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe clindamycin"
            },
            {
                "label": "B.",
                "text": "Prescribe empagliflozin"
            },
            {
                "label": "C.",
                "text": "Discontinue atorvastatin"
            },
            {
                "label": "D.",
                "text": "Prescribe spironolactone"
            },
            {
                "label": "E.",
                "text": "Prescribe methylprednisolone"
            }
        ],
        "correct_answer": "Prescribe clindamycin",
        "abim_content_category": "Glomerular and Vascular Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step in management for this patient with suspected infection-related glomerulonephritis (IRGN) is to start antibiotics with activity against methicillin-resistant <em>Staphylococcus aureus</em> (MRSA). </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient has most likely developed IRGN. The findings of AKI, hypertension, hematuria, proteinuria, low C3, and edema are all consistent with nephritic syndrome. His wound’s failure to respond to cephalexin suggests infection with MRSA. In contrast to classic post-streptococcal glomerulonephritis, where kidney manifestations occur after resolution of the infection, IRGN may present contemporaneously with the infection. The next step in management is to change to antibiotics with appropriate coverage to eradicate the infection; clindamycin has activity against community-acquired MRSA. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Prescribing a sodium-glucose cotransporter-2 inhibitor such as empagliflozin would be inappropriate for managing AKI with nephritic features. Empagliflozin would be appropriate for management of CKD caused by type 2 diabetes, which is not suggested by the acute onset of symptoms, hematuria, or proteinuria.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Discontinuing atorvastatin would not be appropriate given the normal creatine kinase level, which would not support a diagnosis of pigment-related nephropathy. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Spironolactone would not be an appropriate choice for treating glomerulonephritis. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Methylprednisolone administration would not be the next best step in managing IRGN, as corticosteroids would not treat the underlying causative infection and have not been shown to improve outcomes in IRGN.</p>\n</div>",
        "references": [
            "Khalighi MA, Chang A. Infection-related glomerulonephritis.Glomerular Dis1: 82–91, 2021",
            "Nasr S, Radhakrishnan J, D’Agati V. Bacterial infection-related glomerulonephritis in adults.Kidney Int5: 792–803, 2013",
            "Rodríguez-Iturbe B, Burdmann EA, Barsoum RS. Glomerular diseases associated with infection.Comprehensive Clin Nephrol662–674, 2010",
            "Khalighi MA, Al-Rabadi L, Chalasani M, et al. Staphylococcal infection-related glomerulonephritis with cryoglobulinemic features.Kidney Int Rep3(5): 1128–1134, 2018"
        ]
    },
    "62": {
        "question": "<div class=\"qtext\"><p>A 53-year-old woman with ESRD due to hypertension presents to nephrology clinic for follow-up 6 months after a deceased donor kidney transplant. Her calculated panel of reactive antibodies (PRA) was 26% at the time of transplant and she received induction therapy with basiliximab. Her transplant surgery was uncomplicated, and she has had an unremarkable post-transplant course.</p>\n<p>Her medications include tacrolimus, mycophenolate, prednisone, nifedipine, and trimethoprim-sulfamethoxazole.</p>\n<p>Her physical examination is unremarkable.</p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Four Weeks Ago</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Current</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">BUN</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">48 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Creatinine </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.1 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.4 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.5–1.1</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Tacrolimus, whole blood trough</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">6.5 ng/mL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">6.9 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">5.0–10.0 (3–6 months post transplant)</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Donor-derived cell-free DNA</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.1%</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.2%</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Not applicable</td>\n</tr>\n</tbody>\n</table>\n<p>An allograft biopsy reveals severe intimal arteritis with interstitial inflammation and tubulitis.</p>\n<p><strong>Which ONE of the following is the most appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Plasma exchange and bortezomib"
            },
            {
                "label": "B.",
                "text": "Plasma exchange and thymoglobulin"
            },
            {
                "label": "C.",
                "text": "Methylprednisolone and thymoglobulin"
            },
            {
                "label": "D.",
                "text": "Methylprednisolone and IV immunoglobulin"
            },
            {
                "label": "E.",
                "text": "Rituximab and plasma exchange"
            }
        ],
        "correct_answer": "Methylprednisolone and thymoglobulin",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this kidney transplant recipient with AKI, a rising level of donor-derived cell-free DNA, and biopsy findings consistent with Banff grade IIB (severe) acute T-cell-mediated rejection, the most appropriate next step in management is the administration of methylprednisolone and T-cell-depleting therapies with rabbit anti-thymocyte globulin (thymoglobulin).</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Glucocorticoids and thymoglobulin are recommended in the treatment of Banff II and III lesions. Outcomes with thymoglobulin are superior to those with steroids alone.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Plasmapheresis, plasma exchange, and IV immunoglobulin (IVIG) with or without rituximab are commonly used strategies for treating antibody-mediated rejection. There are no data to support their use in patients with cell-mediated rejection.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Bortezomib is a chemotherapeutic approved for the treatment of multiple myeloma; it inhibits the proteosome, leading to plasma cell apoptosis. Small studies have shown mixed results in patients with antibody-mediated rejection when combined with plasma exchange and IVIG. It would not be expected to be useful in a patient with cell-mediated rejection.</p>\n</div>",
        "references": [
            "Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection.Am J Transplant20(9): 2318–2331, 2020",
            "Cooper JE. Evaluation and treatment of acute rejection in kidney allografts.Clin J Am Soc Nephrol15(3): 430–438, 2020"
        ]
    },
    "63": {
        "question": "<div class=\"qtext\"><p>A 63-year-old man with a past medical history of hypertension, coronary artery disease, type 2 diabetes, obstructive sleep apnea, and CKD stage G3a/A3 presents to nephrology clinic for management of hypertension. Five months ago, ambulatory BP monitoring (ABPM) showed uncontrolled hypertension, and spironolactone was added to his medication regimen. His current BP medications include carvedilol, losartan, chlorthalidone, and spironolactone, in addition to atorvastatin, aspirin, metformin, and dulaglutide. He reports adherence to all medications but mentions that he does not use his continuous positive airway pressure (CPAP) device consistently. </p>\n<p>His BP is 172/89 mm Hg, heart rate is 85/min, and he has a laterally displaced point of maximal impact on cardiac examination. A fundoscopic examination shows arteriovenous nicking. The remainder of his examination is unremarkable.</p>\n<p>A renal artery duplex Doppler US study performed 2 months ago showed no evidence of renal artery stenosis.</p>\n<strong>Which ONE of the following is the MOST appropriate next step in diagnosis or management?</strong><br/></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Order urinary screen for diuretics"
            },
            {
                "label": "B.",
                "text": "Request completion of a medication adherence questionnaire"
            },
            {
                "label": "C.",
                "text": "Measure plasma renin activity and serum aldosterone levels"
            },
            {
                "label": "D.",
                "text": "Prescribe amlodipine"
            },
            {
                "label": "E.",
                "text": "Refer for renal denervation"
            }
        ],
        "correct_answer": "Order urinary screen for diuretics",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with resistant hypertension, a urinary diuretic screen to confirm medication adherence is the next best step.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Medication nonadherence has been defined as taking &lt;80% of prescribed medication doses; nonadherence to antihypertensives has been associated with poor cardiovascular outcomes. Unfortunately, nonadherence is recognized by providers in &lt;50% of patients with evidence of nonadherence, such as this patient with inconsistent CPAP use and heart rate &gt;80/min despite reported adherence to carvedilol. The European Society of Hypertension recommends evaluating for nonadherence in patients suspected to have resistant hypertension or in those receiving at least two antihypertensive medications who do not have the expected physiologic response to medications. For these reasons, the International Society of Hypertension in the 2020 Global Hypertension Practice Guidelines recommended that the optimal means of diagnosing treatment nonadherence is by objective methods, such as reviewing pharmacy records, counting pills, measuring levels of a medication or its metabolite in urine or blood, or directly observing BP response to a drug. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Self-reported information like questionnaires has shown mixed results in determining adherence to medications. In this patient, who has already claimed adherence to medications, an objective marker of adherence is preferred.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Testing for primary aldosteronism should be done under controlled circumstances, including documentation of sitting or supine posture, ideally at 8:00 a.m. and while avoiding medications that can interfere with the results, notably mineralocorticoid receptor antagonists. In this patient, who is currently taking spironolactone, testing would not be diagnostic. If nonadherence were excluded, and it were safe to discontinue spironolactone for 4–8 weeks, testing for primary aldosteronism could be conducted.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Starting a new medication without assessing if the patient is adherent to current medications will increase polypharmacy and will not improve adherence. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although renal denervation has been shown to be a safe and efficacious procedure, it is expensive and operator-dependent, and the duration of its benefit remains unclear.</p>\n</div>",
        "references": [
            "Lane D, Lawson A, Burns A, et al. Nonadherence in hypertension: How to develop and implement chemical adherence testing.Hypertension79(1): 12–23, 2022",
            "Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines.Hypertension75(6): 1334–1357, 2020",
            "Gupta P, Patel P, Štrauch B, et al. Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence.Hypertension70(5): 1042–1048, 2017",
            "Meddings J, Kerr EA, Heisler M, et al. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: Still no better than a coin toss.BMC Health Services Res12:270, 2012",
            "Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence.Cochrane Database Syst Rev11: CD000011, 2014",
            "Gupta P, Patel P, Štrauch B, et al. Risk factors for nonadherence to antihypertensive treatment.Hypertension69(6): 1113–1120, 2017",
            "Gupta P, Patel P, Horne R, et al. How to screen for non-adherence to antihypertensive therapy.Curr Hypertens Rep18: 1–8, 2016",
            "Durand H, Hayes P, Morrissey EC, et al. Medication adherence among patients with apparent treatment-resistant hypertension: Systematic review and meta-analysis.J Hypertension35(12): 2346–2357, 2017"
        ]
    },
    "64": {
        "question": "<div class=\"qtext\"><p>A 54-year-old man is evaluated in the emergency department for several days of increasing somnolence, confusion, nausea, vomiting, and slurred speech. His past medical history is significant for uncontrolled type 2 diabetes with poor medication adherence, epilepsy, and CKD stage 4 attributed to diabetic nephropathy. His medications include insulin, phenytoin, lisinopril, and amlodipine. His wife reports that she has been directly observing his medication intake for the last 10 days. </p>\n<p>On physical examination, BP is 154/96 mm Hg, and heart rate is 86/min. The patient is alert but confused and oriented only to self. Ocular examination demonstrates horizontal nystagmus on lateral gaze. Upper extremities are tremulous when extended and dysmetria is noted on finger-to-nose testing. He has 3+ pitting edema in his lower extremities. </p>\n<p>Laboratory data obtained upon admission are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top; width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.9 mg/dL (baseline)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.8 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Aspartate aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                20 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Alanine aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                35 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin A1<sub>c</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;6%\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total phenytoin level\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9 ug/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Therapeutic: 10–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine drug screen\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Negative\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Urine protein-to-creatinine ratio\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4200 mg/mg\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;0.2\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Phenytoin toxicity is suspected.</p>\n<p><strong>Which ONE of the following best explains the mechanism of drug toxicity?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Increased drug distribution"
            },
            {
                "label": "B.",
                "text": "Increased drug absorption"
            },
            {
                "label": "C.",
                "text": "Decreased hepatic metabolism"
            },
            {
                "label": "D.",
                "text": "Decreased kidney filtration"
            },
            {
                "label": "E.",
                "text": "Decreased kidney secretion"
            }
        ],
        "correct_answer": "Increased drug distribution",
        "abim_content_category": "Pharmacology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with hypoalbuminemia from nephrotic syndrome, increased unbound drug distribution is the most likely cause of toxicity.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Phenytoin is a long-acting antiepileptic that inhibits voltage-gated sodium channels. Acute toxicity generally presents with signs of cerebellar dysfunction including horizontal nystagmus, dysmetria, slurred speech, hyperreflexia, and gait abnormalities. Severe symptoms include altered mentation, somnolence, or coma. This patient with nephrotic syndrome, likely attributable to long-standing uncontrolled diabetes, is exhibiting acute signs of phenytoin toxicity due to elevated unbound phenytoin levels. Phenytoin toxicity is a medical emergency requiring supportive care with gastric decontamination and possibly HD. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Drug distribution is significantly impacted in patients with both CKD and nephrotic syndrome because of decreased levels of plasma proteins, specifically albumin, and volume expansion due to sodium and water retention. Hypoalbuminemia leads to decreased plasma binding of drugs that are highly protein bound, with increased levels of free, unbound drug. Moreover, drug binding to plasma proteins may further be impeded by competitive binding of other compounds or other alterations in binding capacity. This patient with hypoalbuminemia and CKD would have an increased fraction of unbound phenytoin. Thus, his normal total phenytoin concentration likely underestimates his free phenytoin levels, which are sufficient to cause toxicity. Although the therapeutic range of free phenytoin remains unchanged, the therapeutic range for total phenytoin is &lt;10 µg/mL in patients with advanced CKD. In patients with hypoalbuminemia and CKD, free phenytoin levels should guide therapeutic decisions. If only total levels are available, the Winter-Tozer formula can estimate level of unbound phenytoin:</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Free phenytoin = (Total phenytoin) / (0.25 × albumin + 0.1)</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s unbound phenytoin level is &gt;16 ug/mL, which is supratherapeutic.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There is little evidence to suggest any influence of decreased kidney function on drug absorption from the gastrointestinal tract. Although a drug’s peak concentration and time to peak concentration are partially affected by CKD, the absolute bioavailability after PO versus IV administration is rarely different.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Phenytoin is primarily metabolized hepatically by the cytochrome P450 system, specifically the isozymes CYP2C9 and CYP2C19. Competitive inhibitors of cytochrome P450 (trimethoprim-sulfamethoxazole and fluconazole) can increase the risk of phenytoin toxicity. Patients with liver disease are also at increased risk for drug toxicity. In patients with CKD, the CYP isozyme activity is minimally affected. This patient with normal liver function would be expected to metabolize phenytoin appropriately. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">For any drug, kidney clearance may be estimated as glomerular filtration of unbound drug + tubular secretion – tubular reabsorption. The net clearance of drugs undergoing tubular secretion may be impaired in nephrotic syndrome or CKD, but only 1%–5% of free phenytoin is excreted unchanged in the urine. Thus, decreased kidney filtration or secretion would not play a major role in phenytoin toxicity.</p>\n</div>",
        "references": [
            "National Kidney Foundation.National Kidney Foundation Primer on Kidney Diseases. New York: Elsevier; 2022",
            "Robertson K, von Stempel CB, Arnold I When less is more: a case of phenytoin toxicity.BMJ Case Rep2013:bcr2012008023, 2013",
            "Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs.Neurology63(10 Suppl 4): S3–S8, 2004",
            "Iorga AB, Zane H.Phenytoin Toxicity[Review ofPhenytoin Toxicity]. Treasure Island, FL: StatPearls Publishing; 2022",
            "Richens A. Clinical pharmacokinetics of phenytoin.Clin Pharmacokinetics4(3): 153–169, 1979"
        ]
    },
    "65": {
        "question": "<div class=\"qtext\"><p>An 84-year-old woman is referred to the emergency department for abnormal laboratory data after a visit with her primary care physician. Three weeks ago, she was hospitalized with COVID-19, her third admission for an infectious illness in the last 2 years. At that time, her serum creatinine level was 6.4 mg/dL.</p>\n<p>Currently, serum creatinine level is 7.2 mg/dL (reference range, 0.5–1.1 mg/dL). Further evaluation reveals hematuria and proteinuria, and serologic evaluation reveals positive myeloperoxidase (MPO) and p-ANCA antibodies. She denies fever, arthralgias, rash, or lung symptoms. </p>\n<p>A kidney biopsy is obtained, which reveals 21/27 glomeruli globally sclerotic, 3 with cellular and 3 with fibrous crescents, as well as interstitial fibrosis and tubular atrophy of 85%–90%. IF is positive for 1–2+ fibrinogen staining in some glomeruli. EM reveals no electron-dense deposits.</p>\n<p><b>Which\n        ONE of the following is the MOST appropriate next step in management?</b>\n</p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Azathioprine"
            },
            {
                "label": "B.",
                "text": "Cyclophosphamide"
            },
            {
                "label": "C.",
                "text": "Rituximab"
            },
            {
                "label": "D.",
                "text": "Methylprednisolone"
            },
            {
                "label": "E.",
                "text": "Observation"
            }
        ],
        "correct_answer": "Observation",
        "abim_content_category": "Acute Kidney Disease and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with ANCA vasculitis and poor prognostic markers for renal recovery, observation is the most appropriate next step in management, with initiation of dialysis when appropriate. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although cyclophosphamide and rituximab accompanied by steroids are recommended induction agents for ANCA vasculitis, the risks and benefits of prescribing immunosuppression must be individualized. This elderly patient presented with evidence of significant chronicity and irreversible parenchymal damage, so exposure to potent immunosuppressive agents would increase the risk of serious infection while not providing much benefit in salvaging kidney function. Extra-renal manifestations of ANCA vasculitis, such as pulmonary hemorrhage, could alter the risk-benefit calculation in favor of immunosuppression.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Cyclophosphamide has long been a standard-of-care induction agent for the treatment of ANCA vasculitis. Its utility has primarily been confirmed by observational literature, including a landmark study published in 1992 demonstrating high rates of clinical improvement and even complete remission. The 2009 CYCLOPS trial showed no difference in outcomes between PO and IV cyclophosphamide, although cumulative dose was higher (but rates of relapse lower) in the PO group.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The RAVE trial demonstrated the non-inferiority of rituximab compared with cyclophosphamide, but patients such as this one were excluded due to the severity of illness. The RITUXVAS trial compared rituximab with cyclophosphamide and included patients with severe or dialysis-dependent disease, finding no difference, with the caveat that cyclophosphamide was also prescribed to patients in the rituximab arm during the first month of treatment.   </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although pulse-dose methylprednisolone is commonly used to induce remission in patients with ANCA vasculitis, as with cyclophosphamide and rituximab, the risks likely outweigh the benefits in this patient with significant chronicity on biopsy and numerous recent hospitalizations for infections.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Azathioprine is commonly used as maintenance therapy for ANCA vasculitis but is not first-line therapy for induction.  </p>\n</div>",
        "references": [
            "Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: An analysis of 158 patients.Ann Intern Med116(6): 488–498, 1992",
            "Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up.Ann Rheum Dis71(6): 955–960, 2012",
            "Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis.N Engl J Med363(3): 221–232, 2010",
            "Raffray L, Guillevin L. Rituximab treatment of ANCA-associated vasculitis.Expert Opin Biol Ther20(8): 899–910, 2020"
        ]
    },
    "66": {
        "question": "<div class=\"qtext\"><p>A 62-year-old man with a past medical history of type 2 diabetes, hypertension, and ESRD status post failed kidney transplant is evaluated during dialysis. He reports chest pain and back pain that started abruptly 30 minutes into his HD session. He has no dyspnea. Last week, he transferred from a different HD unit, where he had been dialyzing for the past year without difficulty through a radiocephalic arteriovenous fistula. His ultrafiltration target is 7 mL/kg/hour. No other patients in the unit have similar symptoms. The filter and tubing appear normal without discoloration. HD is stopped, and his symptoms improve. His medication regimen has not been recently changed, and he remains on low-dose prednisone for his failed kidney transplant.</p>\n<p>On examination, BP is 140/65 mm Hg, heart rate is 85/min, respiratory rate is 16/min, and temperature is 37.8°C. His cardiopulmonary examination is unremarkable, with no wheezing noted. </p>\n<p>Recent laboratory parameters are within normal limits.</p>\n<p><strong>Which ONE of the following is the most likely cause of the patient’s symptoms?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Type A dialyzer reaction"
            },
            {
                "label": "B.",
                "text": "Bacterial endotoxin"
            },
            {
                "label": "C.",
                "text": "Type B dialyzer reaction"
            },
            {
                "label": "D.",
                "text": "Acute hemolysis"
            },
            {
                "label": "E.",
                "text": "Air embolism"
            }
        ],
        "correct_answer": "Type B dialyzer reaction",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient is most likely experiencing a type B dialyzer reaction.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Type B dialyzer reactions are believed to be caused by dialysis membrane-mediated complement activation, followed by neutrophil activation and sequestration in the pulmonary circulation. Symptoms include chest pain, back pain, shortness of breath, and tachycardia, typically starting 15–30 minutes after treatment initiation. Dialyzer membranes that are less biocompatible, such as cellulose (cuprophane) membranes, are more likely to lead to type B reactions, whereas polyacrylonitrile membranes are very unlikely to induce type B reactions. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">A type A dialyzer reaction is an anaphylactoid reaction that is more severe than a type B reaction and typically occurs within minutes of starting HD. It presents with dyspnea, angioedema, and urticaria. Patients with type A reactions should have dialysis terminated immediately, without returning the blood to the patient.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute hemolysis can occur because of kinked dialysis lines or contamination of the dialysate water with chloramines. Hemolysis will usually cause a “port wine” appearance in the venous lines and can occasionally be seen in multiple patients in a unit if the etiology is contaminated supplies.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Bacterial endotoxin from inadequate water purification is unlikely, as other patients in the dialysis unit are asymptomatic. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Air embolisms during HD can cause chest pain and shortness of breath but are seen almost exclusively in patients with central venous catheters.</p>\n</div>",
        "references": [
            "Daugirdas JT.Handbook of Dialysis. Philadelphia, Wolters Kluwer Medical; 2023",
            "Chen DP, Flythe JE. Dialysis‐associated allergic reactions during continuous renal replacement therapy and hemodialysis: A case report.Hemodialysis Int24(1)E5–E9, 2019",
            "Mukaya JE, et al. Allergic reaction to polysulphone membrane dialyser masquerading as infection.Case Rep2015(1): bcr2014208591, 2015"
        ]
    },
    "67": {
        "question": "<div class=\"qtext\"><p>A 56-year-old man with ESRD due to diabetic nephropathy presents to nephrology clinic for a routine visit 5 months after receiving a deceased donor kidney transplant. His post-transplant course has been unremarkable, with immediate graft function and no episodes of rejection or opportunistic infections. His immunosuppressive regimen consists of tacrolimus, mycophenolate mofetil, and prednisone. He received induction with basiliximab. </p>\n<p>He reports feeling well and denies changes to appetite, dysuria, gross hematuria, pain over the allograft site, or fever. He has not had any procedures, illnesses, or medication changes over the last 2 months. </p>\n<p>On physical examination, he is afebrile, with BP 126/72 mm Hg without orthostatic symptoms and a heart rate of 84/min. The kidney allograft site is non-tender to palpation, and there are no abdominal bruits, peripheral edema, or skin rashes. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Result</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6,700/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12.3 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14–18\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Platelet count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                149,000/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                150,000–450,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                141 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.0 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Chloride\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                101 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                22 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.9 mg/dL (nadir 1.2)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Tacrolimus, whole blood trough\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                7 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                5.0–10.0 (3–6 months post transplantation)\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis is negative for protein but positive for 5–6 WBC/HPF and 2–3 RBC/HPF. </p>\n<p>US of the allograft shows mild dilation of the renal pelvis with normal calyces.</p>\n<p><strong>Which ONE of the following is the MOST likely diagnosis?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "BK virus\nnephropathy"
            },
            {
                "label": "B.",
                "text": "Obstructive uropathy"
            },
            {
                "label": "C.",
                "text": "Acute tubular necrosis"
            },
            {
                "label": "D.",
                "text": "Recurrent diabetic nephropathy"
            },
            {
                "label": "E.",
                "text": "Calcineurin inhibitor toxicity"
            }
        ],
        "correct_answer": "BK virus\nnephropathy",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with asymptomatic elevation of creatinine 2–6 months after kidney transplant likely has BK nephropathy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">BK polyomavirus is a small DNA virus that establishes lifelong, latent infection in the renal tubular and uroepithelial cells in most of the population. However, in states of compromised immunity, it can reactivate and lead to nephropathy. Among kidney transplant recipients, this reactivation may be subclinical or may manifest with AKI and ureteral strictures and is a risk factor for premature allograft loss. Although the risk of BK nephropathy is highest in the first 2–6 months after transplant, it may develop years later. Although the prevalence of asymptomatic viruria and viremia may be as high as 25%–30%, overt BK nephropathy is only diagnosed in up to 10% of kidney transplant recipients. In hematopoietic stem cell transplant recipients, hemorrhagic cystitis is the most commonly reported manifestation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The urinalysis in BK virus nephropathy is variable and may show pyuria, hematuria, or no abnormal findings. Urine cytology may reveal BK-infected cells, called decoy cells due to their resemblance to renal carcinoma cells. Kidney biopsy with specific immunostaining using an antibody against the related SV40 virus is confirmatory. The main treatment strategy includes reducing overall immunosuppression. There are no specific antiviral treatments with proven efficacy for BK nephropathy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although obstruction is a common cause of kidney dysfunction after transplant, the lack of significant hydronephrosis is reassuring. Mild pelvicaliectasis is a common finding after transplant and is not diagnostic for obstructive uropathy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acute tubular necrosis is unlikely to occur in the absence of known nephrotoxins or acute illness and with normal hemodynamics. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although recurrent diabetic nephropathy is a common long-term finding in allograft biopsies, it is not expected to present as AKI early after transplantation. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Tacrolimus nephrotoxicity is unlikely in the setting of a normal trough level.</p>\n</div>",
        "references": [
            "Manzano Sánchez D, Jimeno García L, Manzano Sánchez D, et al. Renal function impairment in kidney transplantation: Importance of early BK virus detection.Transplant Proc51(2): 350–352, 2019",
            "Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal transplant recipients.N Engl J Med347(7): 488–496, 2002",
            "Kerbauy KN, Kerbauy MN, Bautzer V, et al. Severe hemorrhagic cystitis caused by the BK polyomavirus is associated with decreased survival post-allogeneic hematopoietic stem cell transplantation.Transpl Infect Dis21(5): e13101, 2019",
            "Johnston O, Jaswal D, Gill J, et al. Treatment of polyomavirus infection in kidney transplant recipients: A systematic review.Transplantation89(9): 1057–1070, 2010"
        ]
    },
    "68": {
        "question": "<div class=\"qtext\"><p>A 63-year-old man with a past medical history of CKD stage 3, hypertension, and type 2 diabetes presents to the emergency department for altered mental status. He was recently prescribed gabapentin for peripheral neuropathy, and the dose has been titrated to 100 mg thrice daily. His other medications include amlodipine, empagliflozin, and lisinopril. </p>\n<p>On his initial examination, BP is 143/90 mm Hg, heart rate is 70/min, respiratory rate is 16/min, and oxygen saturation is 96% while breathing room air. Fifteen minutes later, his BP is 190/70 mm Hg, heart rate is 47/min, respiratory rate is 8/min, and oxygen saturation is 92% while breathing room air. The patient is minimally responsive during the examination and intermittently twitches. Pupils are pinpoint.  </p>\n<p>Laboratory studies are unremarkable. </p>\n<p>A CT scan of the head is remarkable for a large, heterogeneous mass with midline shift concerning for a glioblastoma. There is no evidence of white matter edema in the parieto-occipital regions.</p>\n<p>Neurology and neurosurgery are consulted.</p>\n<p><strong>Which ONE of the following is the next BEST step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Discontinue gabapentin"
            },
            {
                "label": "B.",
                "text": "Prescribe morphine"
            },
            {
                "label": "C.",
                "text": "Prescribe atropine"
            },
            {
                "label": "D.",
                "text": "Prescribe nicardipine"
            },
            {
                "label": "E.",
                "text": "Prescribe mannitol"
            }
        ],
        "correct_answer": "Prescribe mannitol",
        "abim_content_category": "Hypertension",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In this patient with a space-occupying brain lesion and evidence of increased intracranial pressure (ICP), mannitol should be administered. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The Cushing reflex, seen in patients with increased ICP, is defined by bradycardia, irregular respiratory patterns, and BP variability with widened pulse pressure. The underlying mechanism is likely due to a rise in ICP that is greater than the cerebral perfusion pressure, leading to compression of the cerebral arteries and cerebral ischemia. Additionally, the increased ICP can trigger compensatory responses that lead to an increase in sympathetic and parasympathetic flow. The sympathetic outflow leads to arteriolar vasoconstriction and a rise in mean arterial pressure, and the parasympathetic outflow leads to reflex bradycardia. Respiratory changes are believed to be due to compression of the brainstem respiratory center. The vital sign instability likely represents brainstem herniation, and the prognosis for this patient is poor. Clinicians must have a high index of suspicion for cerebral edema and emergently lower ICP. The best next step in this situation would be to administer mannitol IV in an attempt to decompress the brain. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Gabapentin can cause sedation, myotonic jerks, and altered mental status when administered in large or frequent doses in patients with CKD. Although this patient recently started gabapentin, the vital sign instability would not be typical of gabapentin toxicity. Furthermore, the dosing is reasonable for this patient’s eGFR.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Although the pain associated with a headache may be a potent driver of increased BP, administering an IV analgesic would not address the underlying cause of this patient’s deterioration or directly address increased ICP.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Atropine would increase this patient’s heart rate but would not address the underlying cause of bradycardia and increased ICP attributable to cerebral mass effect.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiologic entity characterized by headaches, confusion, visual disturbances, seizures, and posterior white matter edema in the parieto-occipital regions. The cause is thought to be loss of autoregulation and endothelial dysfunction in the setting of elevated BP. This patient instead has a mass and vital sign instability consistent with the Cushing reflex. In this setting, acutely lowering his BP may compromise cerebral perfusion and would not be the next best step in management.</p>\n</div>",
        "references": [
            "Dinallo S, Waseem M.Cushing Reflex.Treasure Island, FL: StatPearls Publishing; 2022",
            "Blum RA, Comstock TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function.Clin Pharmacol Ther56(2): 154–159, 1994",
            "Long D, Koyfman A, Long B. The thunderclap headache: Approach and management in the emergency department.J Emerg Med56(6): 633–641, 2019",
            "Lin AL, Avila EK. Neurologic emergencies in the cancer patient: Diagnosis and management.J Intensive Care Med32(2): 99–115, 2017",
            "Aiyagari V, Gorelick PB. Management of blood pressure for acute and recurrent stroke.Stroke40(6): 2251–2256, 2009",
            "Lamy C, Oppenheim C, Méder JF, Mas JL. Neuroimaging in posterior reversible encephalopathy syndrome.J Neuroimaging14(2): 89, 2004"
        ]
    },
    "69": {
        "question": "<div class=\"qtext\"><p>A 48-year-old woman with a history of ESRD status post kidney transplant presents to the emergency department with 2 weeks of intermittent fevers, diarrhea, fatigue, and body aches. </p>\n<p>She is currently 8 months status post deceased donor kidney transplantation. The kidney allograft functioned immediately. She received anti-thymocyte globulin for induction. Because of positive donor hepatitis C status, the patient was prescribed 12 weeks of glecaprevir/pibrentasvir after transplant and achieved sustained virologic response. Valganciclovir and trimethoprim-sulfamethoxazole were prescribed for 6 months after transplant. Her current immunosuppressive regimen consists of tacrolimus, mycophenolate, and prednisone.</p>\n<p>Her course has been uncomplicated until the last few weeks, at which time she developed persistent fevers and diarrhea (3-6 loose stools per day). </p>\n<p>On examination, BP is 108/68 mm Hg, heart rate is 96/min, and temperature is 37.8°C. She is ill-appearing but in no distress. Her allograft is nontender, and the rest of her examination is unremarkable.</p>\n<p>Pretransplant serologic data from the donor and recipient are shown below:</p><table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Donor</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Recipient</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                CMV IgG\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                +\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<b><p>–</p></b>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                EBV IgG\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                +\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                +\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hepatitis B virus (HBV) surface antigen (HBsAg)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>–</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>–</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                HBV surface antibody (HBsAb)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>–</p>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                +\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                HBV core antibody (HBcAb)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>–</p></td><td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"><p>–</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hepatitis C virus (HCV) core antibody\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                +\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>–</p>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                HCV nucleic acid test (NAT)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                +\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<p>–</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>Current laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<strong> </strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.0/µL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Hemoglobin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.8 g/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                12–16\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Serum\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.3 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                17 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                24 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.1 mg/dL (baseline, 1.0)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Alanine aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                76 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Aspartate aminotransferase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                82 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10–40\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Total bilirubin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.1 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.3–1.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">  Alkaline phosphatase\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                128 U/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30–120\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis reveals no protein, RBCs, or WBCs.</p>\n<p><strong>Which ONE of the following is the MOST likely cause of this patient’s symptoms and laboratory abnormalities?  </strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Cytomegalovirus"
            },
            {
                "label": "B.",
                "text": "Pneumocystis jirovecii"
            },
            {
                "label": "C.",
                "text": "Mycophenolate"
            },
            {
                "label": "D.",
                "text": "Hepatitis C"
            },
            {
                "label": "E.",
                "text": "Serum sickness"
            }
        ],
        "correct_answer": "Cytomegalovirus",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient most likely has primary cytomegalovirus (CMV) infection. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">She exhibits classical signs and symptoms of CMV infection, including fever, fatigue, and leukopenia. Additionally, her diarrhea suggests CMV colitis, and the abnormal liver function tests suggest the possibility of CMV hepatitis. Donor-positive/recipient-negative serostatus (pre-transplant CMV IgG) is an important risk factor for CMV infection, in addition to lymphocyte-depleting induction therapy such as anti-thymocyte globulin (ATG). CMV most commonly develops in the first 12 months following transplantation. This patient received standard prophylaxis with valganciclovir for 6 months after transplant. Patients are at increased risk for development of CMV infection in the months following discontinuation of antiviral prophylaxis.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The patient received prophylaxis against <em>Pneumocystis jirovecii</em> for 6 months with trimethoprim-sulfamethoxazole, but this was discontinued 2 months before presentation. <em>Pneumocystis</em> infection typically presents with signs and symptoms of pneumonia. This patient has symptoms more consistent with CMV infection rather than the typical pulmonary symptoms expected with <em>Pneumocystis</em>. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mycophenolate is a commonly used medication for maintenance immunosuppression. Its side effects include both gastrointestinal (e.g., diarrhea, nausea) and hematologic (e.g., leukopenia, anemia) manifestations. Although this patient does have diarrhea and cytopenias, mycophenolate is much less likely to cause the fever and liver function abnormalities observed in this patient. Additionally, the timing of symptom onset is more consistent with CMV infection than mycophenolate toxicity.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">There is an increasing utilization of kidney transplants from donors testing positive for hepatitis C. This patient, who received a kidney from a donor with positive HCV NAT, was appropriately treated with direct-acting antiviral therapy (glecaprevir/pibrentasvir), leading to a sustained virologic response. Although active HCV infection may cause abnormal liver function tests, recurrence of hepatitis C would be very unlikely after treatment and would be less likely to cause the other symptoms reported by this patient. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Patients may develop serum sickness, a type III hypersensitivity reaction, following exposure to ATG, particularly in patients with prior exposure to ATG or other rabbit antigens. Typical manifestations include fever, rash, joint pain, and jaw pain, which commonly manifest 1–2 weeks after exposure. This patient was exposed to ATG 8 months earlier, and the timing and clinical presentation are more consistent with CMV infection.</p>\n</div>",
        "references": [
            "Humar A, Limaye A, Blumberg E, et al. Extended valganciclovir porphylaxis in D+R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: Two-year results of the IMPACT study.Transplantation90(12): 1427-1431, 2010",
            "Reischig T, Vlas T, Kacer M, et al. A randomized trial of valganciclovir prophylaxis versus preemitive therapy in kidney transplant recipients. J AM Soc Nephrol 34 (5): 920–934, 2023",
            "Raval AD, Kistler K, Tang Y, et al. Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: A systematic literature review of real-world evidence.Transpl Infect Dis23(2): e13483, 2021"
        ]
    },
    "70": {
        "question": "<div class=\"qtext\"><p>A 33-year-old male transplant recipient presents to the nephrology clinic to discuss infertility. He was diagnosed with IgA nephropathy at age 24, which progressed to ESRD over 3 years. He received PD for 6 months and subsequently received a living-related kidney transplant at age 28. Basiliximab was given for induction immunosuppression, and he has been maintained on sirolimus, mycophenolate mofetil, and prednisone. He has not had any significant complications following transplant, and serum creatinine level has remained stable at 0.8 mg/dL (reference range, 0.7–1.3) without proteinuria. </p>\n<p>The patient and his partner have been attempting to conceive a child for the last 3 years without success. He successfully fathered a child with his current partner prior to starting PD, but they have been unsuccessful following transplantation. A urologic evaluation revealed reduced total sperm count and motility.</p>\n<p><strong>Which ONE of the following is the BEST next step to diagnose or manage this patient’s infertility?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Change mycophenolate to azathioprine"
            },
            {
                "label": "B.",
                "text": "Taper prednisone"
            },
            {
                "label": "C.",
                "text": "Change sirolimus to tacrolimus"
            },
            {
                "label": "D.",
                "text": "Prescribe testosterone"
            },
            {
                "label": "E.",
                "text": "Evaluate for adrenal insufficiency"
            }
        ],
        "correct_answer": "Change sirolimus to tacrolimus",
        "abim_content_category": "Kidney Transplantation",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with secondary male infertility should have his immunosuppressive regimen changed from sirolimus to tacrolimus. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Sirolimus, an inhibitor of the mammalian target of rapamycin (mTORi), is an effective immunosuppressant agent used in kidney transplantation. It has several important side effects, including the potential to impair spermatogenesis, leading to a reduction in total sperm count and decreased pregnancy rates. Conversely, tacrolimus does not appear to significantly impact spermatogenesis. Converting from an mTORi-based regimen to tacrolimus may improve total sperm count, although reversibility after mTORi withdrawal is not certain, and male patients receiving mTORi should be counseled about this potential side effect.  </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mycophenolate is a teratogenic medication, associated with first trimester miscarriage and fetal birth defects. Women who intend to become pregnant should stop mycophenolate and typically are converted to azathioprine, which can be safely used in pregnancy. Although some have advocated that men receiving mycophenolate should use barrier contraception precautions, there is currently no evidence that paternal exposure to mycophenolate increases the risk of fetal birth defects or male infertility. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Low-dose prednisone is not likely to cause male infertility. As such, weaning prednisone is not likely to improve spermatogenesis and could risk rejection of the allograft.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Testosterone therapy is not expected to improve total sperm count and may reduce spermatogenesis by decreasing follicle-stimulating hormone production.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acquired adrenal insufficiency due to chronic steroid exposure is an unlikely cause of male infertility and is less likely to cause reduced sperm count than mTORi exposure.</p>\n</div>",
        "references": [
            "Zuber J, Anglicheau D, Elie C, et al. Sirolimus may reduce fertility in male renal transplant recipients.Am J Transplant8(7): 1471–1479, 2008",
            "Huyghe E, Aziri A, Nohra J, et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: An overview.Transplant Int20(4): 305–311, 2007",
            "Midtvedt K, Bergan S, Asberg A. Exposure to mycophenolate and fatherhood.Transplantation101(7): e214–e217, 2017"
        ]
    },
    "71": {
        "question": "<div class=\"qtext\"><p>A 70-year-old woman with a past medical history of CKD stage 3b and idiopathic interstitial lung disease presents to the nephrology clinic for routine follow-up. She reports the gradual development of edema over the last 3 months. She notes a good appetite without nausea or vomiting. Her lung function is at baseline, and she sees her pulmonologist regularly. She has begun a low-protein diet (0.5 mg/kg/day), as she has read that this approach can protect her kidneys from further decline. At her last visit 1 year ago, her weight was 65 kg.</p>\n<p>On examination, her BP is 100/68 mm Hg, and weight is 65 kg. Her pulmonary examination is notable for fine crackles throughout all lung fields. She has trace edema to the mid-shins bilaterally. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>One Year Ago</strong> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Current</strong> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\">\n<strong>Reference Range</strong> \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Potassium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.1 mEq/L \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.4 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Total CO<sub>2</sub> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                22 mEq/L \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                26 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                BUN \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                50 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                41\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.8 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.3\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Calcium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                9.4 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Phosphorus \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4.8 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Albumin\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.8 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.8\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.5\n            </td>\n</tr>\n</tbody>\n</table>\n<p>Urinalysis is negative for protein, blood, or leukocyte esterase.</p>\n<p><strong>Which ONE of the following is the most appropriate next step in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Decrease carbohydrate intake to 130 g/day"
            },
            {
                "label": "B.",
                "text": "Decrease phosphorus intake to 800 mg/day"
            },
            {
                "label": "C.",
                "text": "Decrease potassium intake to 3000 mg/day"
            },
            {
                "label": "D.",
                "text": "Increase protein intake to 50 g/day"
            },
            {
                "label": "E.",
                "text": "Decrease sodium intake to 2000 mg/day"
            }
        ],
        "correct_answer": "Increase protein intake to 50 g/day",
        "abim_content_category": "Chronic Kidney Disease",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with evidence of protein energy wasting (PEW) should be counseled to increase her protein intake to 0.8 g/kg/day, or approximately 50 g/day.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">An estimated 20%–25% of patients with early to moderate CKD will develop PEW, with increased prevalence as kidney disease progresses. Clues include a patient with stable or decreased weight with a net loss in lean muscle mass. PEW can occur in the setting of hypercatabolic states and proinflammatory cytokines. Low appetite, uremic toxicity, and gastroparesis can also contribute to low protein intake, as can social and physical inability to achieve adequate nutrition. In patients with non-nephrotic CKD, protein intake should be similar to that of healthy adults as recommended by KDIGO. Protein intake may be limited to &lt;0.8 g/kg/day only in patients with CKD stage G4 and G5 with appropriate education (grade 2b recommendation). To date, there is no convincing evidence that long-term protein restriction delays the progression of CKD. In the largest randomized controlled trial conducted, the MDRD study, there was no difference in GFR decline between patient cohorts randomized to a protein intake of 1.3 g/kg/day versus 0.58 g/kg/day after 2.2 years.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">As this patient has normal BP without diabetes, no proteinuria, and normal serum electrolytes, there is currently no evidence to support a diet low in carbohydrates, potassium, sodium, or phosphorus.</p>\n</div>",
        "references": [
            "Kovesdy C, Kople J, Kalantar-Zadeh K. Management of protein-energy wasting in non-dialysis-dependent chronic kidney disease: Reconciling low protein intake with nutritional therapy.Am J Clin Nutr97(6): 1163–1177, 2013",
            "KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease. Summary of Recommendation Statements.Kidney IntSuppl3(1): 5–14, 2013",
            "National Kidney Foundation. Clinical practice guidelines for nutrition in chronic renal failure.Am J Kidney Dis.35(6 Suppl 2): S17–S104, 2000"
        ]
    },
    "72": {
        "question": "<div class=\"qtext\"><p>A 58-year-old man with a past medical history of chronic myeloid leukemia presents to the hospital for new-onset weakness. He denies nausea and vomiting but reports poor oral intake for the last 3 days. Three weeks ago, he saw his primary care physician, and his laboratory studies were unchanged from his baseline.</p>\n<p>Repeat laboratory data are as follows: </p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Value</strong> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\">\n<strong>Reference Range</strong> \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                WBC count\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                310,000/µL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                4000–11,000\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Blasts\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                25%\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0%\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                Serum\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Potassium \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.8 mEq/L \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Total CO<sub>2</sub> \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                26 mEq/L \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Creatinine \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.3 mg/dL (baseline) \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.7–1.3 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Uric acid\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                6.5 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–7.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                  Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5 mg/dL \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the most likely cause of his abnormal potassium value?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Poor oral intake"
            },
            {
                "label": "B.",
                "text": "Intracellular shift"
            },
            {
                "label": "C.",
                "text": "Leukocytosis"
            },
            {
                "label": "D.",
                "text": "Tumor genesis syndrome"
            },
            {
                "label": "E.",
                "text": "Renal potassium wasting"
            }
        ],
        "correct_answer": "Leukocytosis",
        "abim_content_category": "Acid-Base and Potassium Disorders",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The most likely cause of this patient’s low potassium value on laboratory testing is leukocytosis and does not represent true hypokalemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Profound leukocytosis may be associated with both hypokalemia and hyperkalemia. High potassium values can represent true hyperkalemia, such as in tumor lysis syndrome, or pseudohyperkalemia, due to the lysis of WBC in vitro after sample collection, prolonged incubation times, and tourniquet use, causing cell lysis of fragile leukemic cell membranes. These findings are classically seen in patients with chronic lymphocytic leukemia. Pseudohypokalemia in the setting of leukocytosis is thought to be related to the high metabolic activity of leukocytes in vitro, especially with prolonged incubation time, and may be seen in patients with acute and chronic myeloid leukemia. The key to diagnosing spurious potassium values is a normal arterial or venous blood gas or plasma potassium level drawn at the same time as the serum sample. Given clinical suspicion, treatment of these entities should not be undertaken until a true electrolyte abnormality is confirmed, although it may be prudent to obtain an EKG until true potassium disorders are excluded. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s oral intake has been poor only for a few days, with normal laboratory data a few weeks ago, making low oral intake an unlikely cause of hypokalemia.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Tumor genesis syndrome, or the rapid growth of tumor cells, may lead to true hypokalemia and hypophosphatemia, as the growing cells utilize serum substrate in their division and growth. The normal serum phosphorus level makes this diagnosis less likely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Metabolic alkalosis may lead to hypokalemia, as cells exchange hydrogen for potassium ions across the cell membrane in response to the high serum pH. This effect causes an intracellular shift of potassium, with resulting hypokalemia. However, this patient's metabolic alkalosis is mild and unlikely to cause significant cell shifts. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Renal potassium wasting may cause hypokalemia. A variety of mechanisms have been postulated to cause renal potassium wasting in the setting of leukemia, including increased lysozyme activity causing proximal tubule cell damage and paraneoplastic renin activity by the leukemic cells. These patients typically exhibit renal magnesium wasting as well, so the normal serum magnesium level makes this diagnosis less likely.</p>\n</div>",
        "references": [
            "El Shamy O, Rein J, Kattamanchi S, et al. Reverse pseudohyperkalemia is more than leukocytosis: A retrospective study.Clin Kidney J14(5): 1443–1449, 2021",
            "Rifkin S. Pseudohyperkalemia in patients with chronic lymphocytic leukemia.Int J Nephrol2011: 759749, 2011",
            "Chothia M, Davids M. Pseudohypokalaemia and pseudohypoxaemia in a patient with acute myeloid leukaemia.Afr J Nephrol23(1): 15–18, 2020",
            "Santoriello D, Andal L, Cox R, et al. Lysozyme-induced nephropathy.Kidney Int Rep2(1): 84–88, 2017",
            "Filippatos TD, Milionis HJ, Elisaf MS. Alterations in electrolyte equilibrium in patients with acute leukemia.Eur J Haematol75(6): 449–460, 2005"
        ]
    },
    "73": {
        "question": "<div class=\"qtext\"><p>A 66-year-old man with a history of hypertension and diffuse large B cell lymphoma (DLBCL) presents to the oncology clinic for routine follow-up. He was recently diagnosed with a recurrence of his DLBCL and received the first cycle of rituximab, gemcitabine, carboplatin, and dexamethasone 3 days ago without incident. He feels well, without shortness of breath, chest pain, or edema. He notes slightly decreased urine output since beginning treatment. His vital signs are all within acceptable limits, including a BP of 132/75 mm Hg.</p>\n<p>The results of his laboratory tests prompt admission to the hospital, where he is administered 0.9% saline IV at a rate of 150 mL/hour, and prescribed rasburicase. His urine output is 600 mL after 6 hours of therapy. He has tingling in his fingers and around his mouth. </p>\n<p>Laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Admission</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>After 6 Hours</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 25%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Potassium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">5.2 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">5.7 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.5–5.0 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">22 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">16</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28  </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">BUN</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">50 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">63 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8–20 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Creatinine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.5 mg/dL (baseline, 1.1)</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.9</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7–1.3   </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Calcium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">7.4 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">6.2 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">8.6–10.2 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Phosphorus</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">10.2 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">12.5 </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.0–4.5 </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Lactate dehydrogenase</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2600 U/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">2500</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">80–225</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Uric acid</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">21 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">14</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">3.0–7.0</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the next BEST STEP in management?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Initiate renal replacement therapy"
            },
            {
                "label": "B.",
                "text": "Increase the rate of IV fluid administration"
            },
            {
                "label": "C.",
                "text": "Change IV fluid from 0.9% saline to isotonic sodium bicarbonate"
            },
            {
                "label": "D.",
                "text": "Prescribe sevelamer"
            },
            {
                "label": "E.",
                "text": "Prescribe allopurinol"
            }
        ],
        "correct_answer": "Initiate renal replacement therapy",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">In the setting of tumor lysis syndrome (TLS) with AKI, severe hyperphosphatemia, and symptomatic hypocalcemia, the next best step in therapy is to initiate renal replacement therapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">TLS occurs due to tumor cell breakdown, typically following cytotoxic therapy, releasing intracellular contents such as potassium, phosphorus, and nucleic acids, which are metabolized to uric acid. The AKI that occurs in TLS is thought to result from acute uric acid and calcium phosphate precipitation in the renal parenchyma. The advent of rasburicase to lower uric acid levels has helped to reduce the incidence of AKI in TLS. Additional conservative management with IV fluids is often adequate to treat mild TLS. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Mild hyperphosphatemia may be treated with dietary phosphate restriction and oral phosphate binders, but patients with severe hyperphosphatemia and/or associated symptomatic hypocalcemia may require renal replacement therapy. Because of the burden of phosphate production in TLS, daily HD is often required and results in significant rebound hyperphosphatemia. CRRT effectively removes phosphorus without rebound and may be preferred in some settings. Either modality would also help to reduce uric acid levels.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Increasing the rate of IV fluid administration would not address hyperphosphatemia or symptomatic hypocalcemia, and the patient already has robust urine output at the current infusion rate. Although alkalinization of the urine has been used for both prevention and treatment of TLS due to hyperuricemia, the use of bicarbonate-containing IV solutions has fallen out of favor as it may increase the risk of calcium phosphate precipitation.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Allopurinol, a xanthine oxidase inhibitor, is sometimes added as an adjunct for uric acid lowering in established TLS, but this patient’s uric acid level is responding to rasburicase. Allopurinol is likely unnecessary to treat hyperuricemia and would not address the severe hyperphosphatemia and hypocalcemia.</p>\n</div>",
        "references": [
            "Cairo MS, Bishop M. Tumour lysis syndrome: New therapeutic strategies and classification.Br J Haematol127(1): 3–11, 2004",
            "Jones GL, Will A, Jackson GH, et al. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology.Br J Haematol169(5): 661–671, 2015",
            "Sakarcan A, Quigley R. Hyperphosphatemia in tumor lysis syndrome: The role of hemodialysis and continuous veno-venous hemofiltration.Pediatr Nephrol8(3): 351–353, 1994",
            "Pichette V, Leblanc M, Bonnardeaux A, et al. High dialysate flow rate continuous arteriovenous hemodialysis: A new approach for the treatment of acute renal failure and tumor lysis syndrome.Am J Kidney Dis23(4): 591–596, 1994"
        ]
    },
    "74": {
        "question": "<div class=\"qtext\"><p>A 56-year-old man with a history of controlled type 2 diabetes presents to the clinic with fatigue and easy bruising and is subsequently diagnosed with acute lymphoblastic leukemia (ALL). His planned chemotherapy includes high-dose methotrexate with prophylactic dose (10 mg/m<sup>2</sup>) leucovorin rescue. His only medications are metformin and atorvastatin, and he does not take over-the-counter medications.</p>\n<p>On examination, his BP is 123/76 mm Hg. He has scattered purpura and ecchymoses but otherwise appears well and is in no distress. </p>\n<p>His baseline laboratory data are as follows:</p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Value</strong></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 30%;\"><strong>Reference Range</strong></td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Serum</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Sodium</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">141 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">136–145</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Total CO<sub>2</sub></td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">25 mEq/L</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">23–28</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Creatinine </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.9 mg/dL</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">0.7–1.3</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">Urine</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\"> </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Albumin-to-creatinine ratio</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">53 mg/g</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">&lt;30</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   Specific gravity</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.020</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">1.002–1.030</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">   pH</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">6.0</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">4.5–8.0</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which intervention will MOST likely reduce the risk of methotrexate toxicity?</strong></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Prescribe glucarpidase"
            },
            {
                "label": "B.",
                "text": "Increase leucovorin dose to 100 mg/m2"
            },
            {
                "label": "C.",
                "text": "Prescribe acetazolamide"
            },
            {
                "label": "D.",
                "text": "Reduce methotrexate dose"
            },
            {
                "label": "E.",
                "text": "Prescribe sodium bicarbonate IV"
            }
        ],
        "correct_answer": "Prescribe sodium bicarbonate IV",
        "abim_content_category": "Acute Kidney Injury and ICU Nephrology",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The next best step to reduce the risk of methotrexate (MTX)-induced AKI in this patient is to alkalinize the urine with isotonic sodium bicarbonate IV.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">High-dose MTX therapy (&gt;500 mg/m<sup>2</sup>) remains an important component of regimens targeting a variety of cancers, including ALL, but confers an increased risk of kidney toxicity. MTX causes damage when it precipitates in the renal tubules. Increasing the solubility of MTX and its metabolites in urine is critical to preventing AKI. IV fluids are administered to increase urinary flow and decrease luminal MTX concentration. Because MTX is more soluble in basic urine, isotonic sodium bicarbonate should be administered to achieve a urine pH of at least 7.0 prior to initiation of therapy and maintained throughout therapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Leucovorin is used to “rescue” patients from the toxicity of high-dose MTX, including gastrointestinal toxicity and myelosuppression. Leucovorin dosing is increased if a patient receiving MTX develops AKI, but there would be no reason to increase to high-dose leucovorin at this time.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Glucarpidase is a recombinant carboxypeptidase enzyme, which can metabolize antifolates such as methrotrexate to inactive metabolites. It can be used to treat MTX toxicity, but it is not indicated for prophylactic use, as it would interfere with MTX therapy.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Acetazolamide is a carbonic anhydrase inhibitor that increases the excretion of bicarbonate and increases urine pH. Although this action would be beneficial to improve MTX solubility in the urine, the use of acetazolamide with high-dose MTX has not been widely studied, and IV sodium bicarbonate remains preferred.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The dose of MTX may be reduced for patients with significantly impaired kidney function at baseline or who have experienced toxicity in the past. This patient has no indication for a reduced dose of MTX.</p>\n</div>",
        "references": [
            "Howard SC, McCormick J, Pui C-H, et al. Preventing and managing toxicities of high-dose methotrexate.Oncologist21(12): 1471–1482, 2016",
            "Amitai I, Rozovski U, El-Saleh R, et al. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.Hematol Oncol38(4): 584–588, 2020",
            "Shamash J, Earl H, Souhami R. Acetazolamide for alkalinisation of urine in patients receiving high-dose methotrexate.Cancer Chemother Pharmacol28(2): 150–151, 1991",
            "Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention/therapy.Semin Nephrol30(6): 570–581, 2010"
        ]
    },
    "75": {
        "question": "<div class=\"qtext\"><p>A 62-year-old woman with a history of hypertension, hypothyroidism, and osteoporosis presents to clinic with headaches, dizziness, and nausea. Her symptoms have progressively worsened over the last 3 weeks. She has taken ibuprofen and acetaminophen for her headaches with minimal improvement. Prior to this episode, she had been feeling well other than occasional heartburn that resolved with over-the-counter antacids. Her medications include hydrochlorothiazide, levothyroxine, cholecalciferol, and calcium carbonate. Her only recent medication change has been an increase in her levothyroxine dose. </p>\n<p>On examination, BP is 100/65 mm Hg, and heart rate is 108/min. Her weight is 52 kg. She has dry mucous membranes and tachycardia with a regular rhythm. The remainder of the examination is unremarkable.</p>\n<p>Laboratory data are as follows: </p>\n<table style=\"border: 1px solid black; cellpadding: 1px 1px 1px 5px; cellspacing: 0; border-collapse: collapse; width: 75%;\">\n<tbody>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<strong>Value</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;width: 40%;\">\n<strong>Reference Range</strong>\n</td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Serum</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Sodium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                144 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                136–145 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Potassium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.9 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.5–5.0 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Chloride \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                98–106 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Total CO<sub>2</sub>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                40 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                23–28  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      BUN\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                68 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8–20 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Creatinine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.4 mg/dL (baseline, 1.0)\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–1.1\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Glucose\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                88 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                70–99, fasting  \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                14.2 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8.6–10.2 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Magnesium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.8 mEq/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.6–2.6\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Phosphorus\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                2.9 mg/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                3.0–4.5\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      PTH, intact\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                8 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                10­–65 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      25-Hydroxyvitamin D\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                34 ng/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                30‒60\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      1,25-Dihydroxyvitamin D\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                55 pg/mL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                15–60\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Thyroid-stimulating hormone\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.4 mU/L\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.5–4.0\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Free thyroxine\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                1.5 ng/dL\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                0.8–1.8\n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n<strong>Urine, 24-hour</strong>\n</td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                 \n            </td>\n</tr>\n<tr>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                      Calcium\n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                75 mg \n            </td>\n<td style=\"border: 1px solid black; padding: 1px 5px 1px 5px; vertical-align: top;\">\n                &lt;250\n            </td>\n</tr>\n</tbody>\n</table>\n<p><strong>Which ONE of the following is the MOST likely cause of this patient’s hypercalcemia?</strong></p><p></p></div>",
        "choices": [
            {
                "label": "A.",
                "text": "Primary hyperparathyroidism"
            },
            {
                "label": "B.",
                "text": "Familial hypocalciuric hypercalcemia"
            },
            {
                "label": "C.",
                "text": "Vitamin D toxicity"
            },
            {
                "label": "D.",
                "text": "Hyperthyroidism"
            },
            {
                "label": "E.",
                "text": "Milk-alkali syndrome"
            }
        ],
        "correct_answer": "Milk-alkali syndrome",
        "abim_content_category": "Calcium, Phosphorus, and Magnesium Disorders and Stones",
        "explanation_html": "<div class=\"cs-collapsible-content\">\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient with hypercalcemia, metabolic alkalosis, and AKI most likely has milk-alkali or calcium-alkali syndrome. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Milk-alkali syndrome was first described in the early 1900s when the “Sippy regimen” for peptic ulcer disease was introduced. Patients were prescribed large amounts of milk, cream, sodium bicarbonate, and magnesium oxide. With the advent of new pharmacologic treatments for peptic ulcer disease, milk-alkali syndrome became a very rare phenomenon. However, increasing numbers of cases have been reported due to use of over-the-counter calcium supplements for prevention and treatment of osteoporosis in postmenopausal women. Some have advocated renaming this constellation of findings “calcium-alkali syndrome” to reflect the most likely origin of this disorder in modern clinical practice.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Milk-alkali syndrome is the third leading cause of hypercalcemia among hospitalized patients. It requires co-ingestion of large amounts of elemental calcium and absorbable alkali. This typically results from significant ingestion of calcium carbonate (&gt;4 g/day) and is worsened in settings of volume depletion. In milk-alkali syndrome, renal calcium absorption is increased, with relative hypocalciuria (usually &lt;100 mg/day). Phosphorus levels are often low due to the phosphate-binding properties of calcium carbonate. Thiazide diuretic, NSAID, and ACEI use are associated with milk-alkali syndrome. </p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">The intact PTH level is appropriately suppressed in the setting of hypercalcemia, making primary hyperparathyroidism unlikely.</p>\n<p>Although familial hypocalciuric hypercalcemia is one of the few causes of hypercalcemia that results in a low urinary calcium excretion as seen in this case, the intact PTH would be elevated rather than low-normal as in this case, and hypercalcemia is typically mild.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">Normal values for 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels make vitamin D toxicity unlikely.</p>\n<p dir=\"ltr\" style=\"margin-bottom: 15px;\">This patient’s levothyroxine dose was recently increased, but her free thyroxine level remains in the normal range, making hyperthyroidism an unlikely cause of her hypercalcemia</p>\n</div>",
        "references": [
            "Patel AM, Goldfarb S: Got calcium? Welcome to the calcium-alkali syndrome. J Am Soc Nephrol21(9): 1440‒1443, 2010",
            "Medarov BI: Milk-alkali syndrome.Mayo Clic Proc84(3): 261‒267, 2009",
            "Wang M, Cho C, Gray C, et al: Milk-alkali syndrome: a ‘quick ease’ or a ‘long-lasting problem.’Endocrinol Diabetes Metab Case Rep2020:EDM20-0028, 2020",
            "Patel AM, Adeseun GA, Goldfarb S: Calcium-alkali syndrome in the modern era.Nutrients5(12): 4880‒4893, 2013"
        ]
    }
}